CARMAT
2018 Registration document
Including Annual Financial Report
GENERAL REMARKS

In this registration document, the terms “CARMAT” or the “Company” shall mean the company, CARMAT.

This registration document contains information on the Company’s objectives and its avenues for development. This information is sometimes identified by the use of the future or the conditional, and terms that refer to the future, such as “consider”, “envisage”, “think”, “have as an objective”, “expect”, “intend”, “must”, “aspire”, “estimate”, “believe”, “wish”, “can” or, where appropriate, the negative form of these verbs, or any other variation or similar terminology.

The reader’s attention is drawn to the fact that these objectives and avenues for development depend on circumstances or events which may or may not occur.

These objectives and avenues for development are not historical data and must not be interpreted as guarantees that the events and data set out will occur, that the hypotheses will be verified or that the objectives will be achieved.

By their very nature, the objectives and avenues for development in this registration document could be affected by known and unknown risks, or by uncertainties linked specifically to the very nature of clinical trials, the regulatory, economic, financial and competitive environment or by other factors which could lead to the Company’s future results, performance and achievements being significantly different from the objectives that have been formulated or suggested here.

In particular, these factors may include the factors set out in Chapter 2, “Risk Factors”, of this registration document. It is therefore possible that these objectives and avenues for development may not be achieved, and the statements or information in this registration document may turn out to be erroneous. As such, the Company will under no circumstances be required to provide updates, subject, that is, to the applicable regulations and in particular the General Regulations for the French Financial Markets Authority (AMF).

This registration document also contains information relating to the Company’s activity, as well as the market and industry in which it operates. This information specifically comes from studies carried out by internal and external sources (analysts’ reports, specialist studies, sector publications and any other information published by market research companies, public bodies and corporations and learned societies).

The Company considers that this information presents a faithful picture of the market and the industry in which it operates, and that it faithfully reflects its competitive position. However, although this information is considered to be reliable, it has not been verified by an independent expert, and the Company cannot guarantee that a third party using different methods to gather, analyze or calculate data on the markets would obtain the same results.

Investors are invited to consider carefully the risk factors described in Chapter 2, “Risk Factors”, in this registration document. If some or all of the risks materialize, this could have a negative impact on the Company’s activity, its position, its financial performance or its objectives.

In addition, other risks, not currently identified or considered as non-significant by the Company, could have the same negative effect.

Drawings, images, graphics and photographs used in this document are purely for illustration purposes, and shall in no case constitute a commitment of any kind on the part of CARMAT. The reproduction in any form of any part of this document is strictly prohibited.

To assist the reader’s understanding, this registration document has a glossary attached. Words identified by an asterisk “*” when they first appear can be found in this glossary. A summary of references used in the document and their sources is provided at the end of the document.

This registration document (document de référence) was filed with the Financial Markets Authority (AMF) on March 12, 2019 in accordance with Article 212-13 of the General Regulations of the Authority. It may be used in connection with a financing operation if it is supplemented by a securities note signed by the Financial Markets Authority. This document has been drawn up by the issuer and liability is borne by its signatories.
# CONTENT

**MESSAGE FROM THE CHAIRMAN AND FROM THE CEO** ...........................................................................................................  4

**MISSION AND VISION** .................................................................................................................................................  6

**CARMAT PROFILE** .........................................................................................................................................................  8

**HISTORY OF THE COMPANY** ........................................................................................................................................ 10

**CARMAT AND ITS SHAREHOLDERS** ............................................................................................................................... 12

<table>
<thead>
<tr>
<th>1 DESCRIPTION OF ACTIVITIES</th>
<th>3 FINANCIAL INFORMATIONS *</th>
<th>5 INFORMATION ON THE COMPANY AND ITS CAPITAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>p.15</td>
<td>p. 69</td>
<td>p. 117</td>
</tr>
<tr>
<td>1.1 Heart failure.............. p.16</td>
<td>3.1 Notes on activity in the 2017 reporting period............. p.70</td>
<td>5.1 Legal structure ................ p.118</td>
</tr>
<tr>
<td>1.2 Markets and actors present p.21</td>
<td>3.2 Financial statements as at December 31, 2017 ............... p.78</td>
<td>5.2 Share capital * .................. p.118</td>
</tr>
<tr>
<td>1.3 The first self-regulated bioprosthetic artificial heart p.26</td>
<td>3.3 Auditors’ report on the annual financial statements ........ p.93</td>
<td>5.3 Major shareholders * .......... p.132</td>
</tr>
<tr>
<td>1.4 Going on the market process .................. p.31</td>
<td>4 CORPORATE GOVERNANCE p.95</td>
<td>5.4 Memorandum and articles of association ......................... p.134</td>
</tr>
<tr>
<td>1.5 Strategy of the Company .................. p.38</td>
<td>4.1 Composition of the Company’s administrative and management bodies * ..................... p.96</td>
<td>5.5 Particulars of the legal affairs of the Company in the financial period * ........................ p.148</td>
</tr>
<tr>
<td>2 RISKS FACTORS *</td>
<td>4.2 Conflicts of interest in the governing, management and supervisory bodies and the executive board ................... p.102</td>
<td>5.6 Regulated agreements........ p.150</td>
</tr>
<tr>
<td>p.47</td>
<td>4.3 Specialized committees .... p.102</td>
<td>6 SUPPLEMENTARY INFORMATION p.153</td>
</tr>
<tr>
<td>2.1 Risks relating to the market in which the Company operates ......................... p.48</td>
<td>4.4 Statement on corporate governance * ......................... p.104</td>
<td>6.1 Author of the registration document * ......................... p.154</td>
</tr>
<tr>
<td>2.2 Risks relating to the Company’s activity ............................................................. p.50</td>
<td>4.5 Compensation and benefits of directors and management * .................. p.108</td>
<td>6.2 Statutory auditors * .................. p.154</td>
</tr>
<tr>
<td>2.3 Regulatory and legal risks .....p.56</td>
<td>4.6 Staff and organization * ...... p.114</td>
<td>6.3 Information from third parties, declarations by experts and declarations of interest ........ p.155</td>
</tr>
<tr>
<td>2.4 Insurance and cover for risks ................................................................. p.60</td>
<td></td>
<td>6.4 Publicly accessible documents ......................................... p.155</td>
</tr>
<tr>
<td>2.5 Financial risks .................. p.61</td>
<td></td>
<td>6.5 Information on holdings ...... p.156</td>
</tr>
<tr>
<td>2.6 Risks relating to the Company’s organization ........................................... p.66</td>
<td></td>
<td>6.6 Recent events ........................................ p.156</td>
</tr>
<tr>
<td>2.7 Special circumstances and disputes ......................................................... p.68</td>
<td></td>
<td>6.7 Cross-reference tables ........ p.157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.8 Glossary............................ p.160</td>
</tr>
</tbody>
</table>

Items forming part of the Annual Financial Report are clearly identified in the table of contents by the symbol *.

Items forming part of the Corporate Governance Report are available within the 4.1, 5.6, 5.2.6 and 4.4.3 paragraphs.
Q&A WITH THE CHAIRMAN
JEAN-PIERRE GARNIER

You have just joined CARMAT as new Chairman: what were your motivations and what are your goals?

First of all, I was delighted to discover, from the first day at CARMAT, a team of professionals passionate about their profession. The emotional nature of the total artificial heart CARMAT - we are still talking about an alternative to the human heart - makes it very easy to focus on this project. It was also one of the reasons why I accepted my mission. I would like to stress, however, that my main motivation lies in the technological advance offered by this bioprosthesis for patients with heart failure who have no other alternatives, and whose life-threatening condition is actually compromised in the short term. In fact, apart from cardiac transplantation, an act unfortunately reserved, for reasons of lack of obvious graft, to a tiny part of patients, there is currently no reliable solution in the long term.

I believe that, from my experience, I can contribute to the definition and implementation of the market access strategy for this unique product, in order to make it available to the greatest number of patients and to make CARMAT a leading company in the field of biventricular assistance.

You are an expert in the pharmaceutical world. How do you plan to transfer your know-how to the field of medical technologies in which CARMAT operates?

I have spent my entire career in the pharmaceutical industry in positions of very high responsibility, including that of Chairman of the pharmaceutical group GlaxoSmithKline (GSK) from 2000 to 2008 or the Swiss biopharmaceutical company Actelion, acquired by Johnson & Johnson in 2017. I am therefore very familiar with the issues facing healthcare companies when marketing their products. The medtech sector shares many similarities with the pharmaceutical world, in particular by the very innovative, often first-in-class nature of the treatments developed.

This is precisely the case of CARMAT, whose therapy currently has no equivalent, in terms of performance and service to the patient, in the market. I am therefore particularly excited to share in the Board of Directors my vision of CARMAT as a commercial company. Naturally, my ambition is to increase its reputation also across the Atlantic, the US market being the one that offers the most potential for the development and adoption of breakthrough medical innovations.

How do you see the future close to society?

Before talking about the future, we must talk about the present. And from this point of view, I am impressed by the concentration of talent within a company of this size. If I refer to the major groups I managed, and the financial means they have, this is a feat almost impossible to reproduce in France!

A company of about 170 employees that brings together medical skills, know-how from aeronautics, mechanics, electronics, production, clinic ... it’s just incredible. CARMAT remains a start-up, an SME, which has managed to create not only a unique product in the world, but it has contributed to the emergence of an ecosystem, composed of specialized subcontractors, which did not exist in France previously, at least in the healthcare area.

The crucial issue for CARMAT will, in my opinion, be its transformation into a commercial and industrial company, to continue to play this role of French pioneer and to show a way not only in the French medtech, but especially in the innovation in health in the broad sense. I am convinced that thanks to the collective work - that of talented employees, ambitious management and a visionary Board of Directors - we can make CARMAT the true French success story and a global player in medtech.
What lessons do you draw from the year 2018?

In 2018, our project has seen a clear increase in power on all levels. First, thanks to the internationalization of the pivotal study, we were able to achieve a very satisfactory recruitment rate, which allowed us to finalize the inclusion of the 10 patients in the first cohort in summer. Since then, we have seen that the prosthesis has perfectly fulfilled its mission according to its specifications, and 70% of implanted patients have achieved the primary goal of survival at 6 months with the bioprosthesis, or a successful heart transplant. This last point related to the transplantation is extremely interesting because it allows the use of our bioprosthesis not only in definitive therapy (DT - Destination Therapy), but also as a bridge to the transplantation awaiting a transplant, which widens the potential market targeted by CARMAT. The 3 cases of successful transplants and the retreat that is now available on these patients show that, from a surgical point of view, there is no technical obstacle to this operation in clinical routine. In addition, the bioprosthesis even contributes to improving the health status of patients, as in the case of the first transplanted patient who suffered from comorbidities preventing immediate transplantation and who could be treated during the 8 months of support with the bioprosthesis, thus making him re-eligible for the reception of a natural heart.

The second key advance is the launch of prosthesis production in our automated site in Bois-d’Arcy which, thanks to its production capacity and very high standard production processes, will meet our needs in the commercial phase. The necessary settings, following the implementation of some corrective actions on the technical aspects of production, are in progress and we should have the first prostheses from this production site in April.

Finally, I am delighted by the evolution of our governance with the arrival of Jean-Pierre Garnier as Chairman of the Board of Directors, Pascale d’Arbonneau as Chief Financial Officer and Thierry Dupoux as Senior Director of Quality Assurance. I am convinced that thanks to their sharp international profiles and past experiences, our project will experience a new phase of success.

What are your goals for 2019?

Our goals are clear and realistic. As soon as the new prostheses are available, we will resume implantations in all the active centers as well as in additional clinical centers in two new European countries, in order to complete the recruitment of patients of the 2nd cohort as soon as possible. In parallel, we intend to finalize and submit during the year the CE marking technical file that will be subsequently completed with all the data from the pivotal study. This should allow us to file the CE marking application in early 2020.

In the meantime, we will continue to automate and make reliable the production process and structure the commercial launch plan for our bioprosthesis in Europe. Clinical development in the United States represents another major strategic focus and, given a constructive dialogue with the Food & Drug Administration (FDA), we hope to receive approval to initiate a clinical feasibility study in 2019. To carry it out, we intend to rely on hospital centers of high quality and notoriety with a strong experience in mechanical circulatory assistance.

If we take into account the quality of the intermediate data of the pivotal study, our progress in the process of industrialization and the interest of the international medical community for our project, CARMAT is now in a particularly favorable position to finalize the clinical development phase. The company will be able to rely on its optimized financial resources and strengthened by a loan of € 30 million from the European Investment Bank * to address more concretely and effectively marketing phase.

*: Loan granted under conditions
MISSION AND VISION

CARMAT, with its artificial heart, is dedicated to providing doctors with innovative technologies to save lives and improve the quality of life of patients with terminal heart failure. Ultimately, the company aims to become the No. 1 alternative to heart transplantation. CARMAT relies on the commitment of its teams and the support of its shareholders.

CARMAT aims to meet a major public health challenge related to cardiovascular diseases, heart failure, the leading cause of death in the world. More specifically, CARMAT aims to provide a lasting solution to the treatment of terminal heart failure, a disease for which there are very few effective options today, mainly cardiac transplantation.

Heart failure is a progressive disease that affects 20 million patients in Europe and the United States. Of this population, tens of thousands of people are terminally ill. The number of human grafts available is only 4,000 to 5,000 per year. The artificial heart CARMAT is intended to offer a permanent solution to these patients who are facing a therapeutic impasse.

MARKET

A fast-growing, high-potential market with more than 200,000 patients suffering from terminal biventricular heart failure each year.

CARMAT PROSTHESIS

The first physiological cardiac bioprosthesis aimed at becoming a credible therapeutic and economic alternative to cardiac transplantation.

An innovative leading position with strong intellectual property and significant barriers to entry thanks to Prof. Carpentier’s scientific leadership and the technological excellence of Airbus Group.

Biomaterials based on pericardium
- Bovine pericardium or ePTFE are the only components in contact with blood.
- Pericardial valves.
Approved portable system: The implanted patient must be able to return home

A team of 90 people as of December 31, 2018, consisting of 31 women and 59 men and comprising 2 doctors, 53 engineers, and 8 graduate technicians

In addition of Stéphane Piat, a board of directors of 10 directors, including 5 independent and 2 internationally recognized experts in cardiology

Stéphane Piat, as General Manager, has to support the commercial strategy of CARMAT to address the market

Board members as at December 31, 2018 (Anne-Pascale Guédon missing on the picture)

In December 2018, the European Investment Bank granted CARMAT a loan of € 30.0 million (under conditions) as part of the Juncker Support Plan for innovative companies.
CARMAT PROFILE

Founded in 2008, after more than 15 years of research, CARMAT develops a total artificial heart, orthotopic *, bioprosthetic *, self-regulating and implantable, as well as its power supply system and its control and remote diagnosis systems.

The name CARMAT originated from the meeting in the early 1990s between Professor Alain Carpentier and Jean-Luc Lagardère, then Chairman of Matra Defense (Airbus Group). The resulting rapprochement resulted in a very active cooperation starting in 1993 with the aim of designing a bioprosthetic artificial heart.

This unique partnership combines:

- the experience of more than 30 years of Professor Alain Carpentier, father of modern valvular heart surgery. Professor Carpentier has developed treatments for biological tissues of animal origin, which have enabled him to design the most widely used biological valves in the world (Carpentier-Edwards® valves). He has also developed the technics of restorative surgery and mitral annuloplasty used today all over the world, on the principle that a device must always be associated with a reproducible procedure; and

- Matra Defense’s (Airbus Group) expertise on embedded systems and their constraints (reliability, severe environments, mass and volume) enabling engineers to work on the concept using simulations, modeling, testing.

The Company’s goal is to address a global public health need that is the treatment of advanced heart failure. It is a severe, progressive, and often fatal disease that is constantly increasing in developed countries.

The CARMAT bioprosthetic artificial heart project aims to offer a long-term therapeutic solution to patients with advanced biventricular heart failure who are not eligible for transplantation and who have exhausted all treatment options and to whom no satisfactory solution is currently proposed.

To date, the artificial heart CARMAT highlights 3 major technical achievements, leading to undeniable competitive advantages compared to other medical devices on the market:

- The only artificial heart project whose surfaces in contact with blood are made of biologically compatible materials to reduce thromboembolic risks;

- The first intelligent artificial heart project that would provide an immediate and automatic response to the patient’s metabolic needs;

- Special attention to patients’ quality of life, with the development of light external equipment and quiet operation.
CARMAT is aiming for CE marking to be able to market its prosthesis over the next few years in Europe. To this end, CARMAT submits for analysis and review to a certification body, DEKRA, the elements of a dossier comprising a technical part and a clinical part. The clinical part of the dossier will include the clinical results obtained during the preclinical trials, the feasibility study of 4 patients finalized in early 2016 and the ongoing pivotal study started in August 2016.

As a reminder, the pivotal study aims to validate the safety, efficiency and performance of the system and will contribute to the CE marking filing process. The objective of the Company is to implant around 20 patients and to demonstrate the survival of these patients over a 6-month horizon.

In addition to obtaining the CE marking, industrial and commercial development will generate additional financial needs: financing of day-to-day operations and R & D during the initial commercial launch phase, working capital requirements related to the development of sales, investment to increase production capacity and automate production processes. To date, the Company estimates that these additional requirements could reach € 100 million. Additional funds will be required, beyond the use of the available balance of the Kepler equity lines and the financing obtained in December 2018 from the EIB.

Beyond the domain of artificial heart bioprosthetic, the Company also intends in the future to develop new applications of its know-how in the cardiovascular field. However, it does not plan to devote resources to these potential applications until the artificial heart project is completed.

**SCOPE OF ACTIVITY**

<table>
<thead>
<tr>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EUROPEAN MARKET ACCESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of the implantations for the pivotal study (cohort 2)</td>
<td>Obtaining CE marking</td>
<td>Obtaining financing for innovation in some European countries</td>
</tr>
<tr>
<td>Filing of the technical dossier for CE marking</td>
<td>Discussions with the main European agencies to obtain funding for innovation</td>
<td></td>
</tr>
<tr>
<td><strong>US MARKET ACCESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning of implantations in the United States as part of a feasibility study (EFS)</td>
<td>Continuation of the feasibility study (EFS) in the United States</td>
<td>Start of the pivotal study in the United States</td>
</tr>
<tr>
<td><strong>COMMERCIAL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketing preparation</td>
<td>Commercial launch in EMEA</td>
<td>Commercial development in EMEA</td>
</tr>
<tr>
<td><strong>INDUSTRIAL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased production at the Bois d’Arcy plant</td>
<td>Continued optimization of the supply chain</td>
<td></td>
</tr>
<tr>
<td>Improvement of production processes and standardization</td>
<td>Continuous improvement of processes and production capacity</td>
<td></td>
</tr>
<tr>
<td>Strengthening the supplier network</td>
<td>Continuation of development of logistics functions</td>
<td></td>
</tr>
<tr>
<td>Development of logistics functions</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRODUCT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement and reliability of the product for CE marking</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPANY TRANSFORMATION &amp; FINANCING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industrial and commercial transformation of the Company, upgrade of the organization, operation and information systems / Preparation of new funding stages</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source CARMAT – Provisional project schedule
HISTORY OF THE COMPANY

2008

Creation of CARMAT by Matra Défense (Airbus Group), Truffle Capital and Professor Alain Carpentier

2009

Completion of modeling and optimization work on the artificial heart (900 grams) in readiness for the assembly and implantation phase for the preclinical trials

Appointment of Marcello Conviti as chief executive officer of CARMAT

2010

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

2011

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

2012

Approval from the CPP (patient protection committee*)

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

2013

Capital increase in the amount of €29.3 million (issue premium included)

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

Approval from the CPP (patient protection committee*)

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

Approval from the CPP (patient protection committee*)

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

Approval from the CPP (patient protection committee*)

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

Approval from the CPP (patient protection committee*)

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart

CARMAT presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery

Approval from the CPP (patient protection committee*)

CARMAT granted the status of “Innovation Enterprise” by Bpifrance for Mutual Funds for Investment in Innovation (FCPI)

Capital increase of €16 million, including issue premium, on the occasion of CARMAT’s flotation on Euronext’s Alternext market in Paris

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille

CARMAT obtains authorization from the ANSM to conduct a feasibility study in France involving four patients

Further elements added to the ANSM file, notably the results of the implants on animals and the intermediate results on the durability tests

CARMAT is a winner at the European Mediscience Awards in the Best Technology category

Capital increase in the amount of €29.3 million (issue premium included)

Conclusion of an agreement with Edwards Lifesciences, the world leader in the cardiac valves sector and hemodynamic monitoring, for the use of Carpentier-Edwards biological cardiac valves in the CARMAT bioprosthetic artificial heart
CARMAT receives €5 million in research tax credits (CIR) for the year 2012, in line with the Company’s 2013 financing plan.

Authorization received to recommence feasibility trials on the CARMAT bioprosthetic heart.

CARMAT secures its future funding, reaching the 5th milestone of its agreement with Bpifrance and receiving €5.3 million.

CARMAT puts in place a new flexible equity financing arrangement with Kepler Cheuvreux, a mechanism enabling CARMAT to raise over €11 million over the year.

The patient receiving an implant of the CARMAT bioprosthetic heart at Nantes Teaching Hospital on August 5, 2014 went home and benefited from the prosthesis for almost nine months before he died.

In December 2018, CARMAT was granted a conditional loan of 30 million euros by the European Investment Bank (EIB).

Resumption in May 2017 of the trials corresponding to the pivotal study (after approval of the ANSM in France) and enlargement in Europe (Kazakhstan and Czech Republic) of this pivotal study. Discussion also initiated in the United States with the FDA.

In November 2016, the feasibility study relating to four patients being completed, the experience gained allows CARMAT to start work on preparation of the pivotal study, after both ANSM and the CPP authorizations.

In December 2017, CARMAT received more than €50 million following the completion of a fundraising exercise open to the public, a transaction carried out notably with the support of two historic shareholders (Pierre Bastid and Antonino Ligresti).

Stéphane Piat replaces Marcello Conviti as chief executive officer to define and support CARMAT’s commercial strategy to address the market.

At the end of August, the first implantation under the pivotal study is carried out. However, the patient concerned died at the end of November, the analyses performed showing no involvement of the CARMAT prosthesis in the patient’s death.

At the end of April, CARMAT raise €50 million though a private placement, with the support in particular of certain historical shareholders and also with the arrival of new investors.

The Bois d’Arcy plant is certified and commissioned.

A third implantation of the CARMAT heart is carried out on April 8 by the cardiac surgery department at the Georges Pompidou European Hospital.

A fourth implantation of the CARMAT heart is carried out on December 22 by the team at La Pitié Salpêtrière on a patient suffering from severe biventricular failure.

Finalization, with positive results, of the first part (cohort 1 of 10 patients) of the pivotal study. Beginning of the implantations of cohort 2.

In December 2014, CARMAT secures its future funding, reaching the 5th milestone of its agreement with Bpifrance and receiving €5.3 million.

CARMAT receives €5 million in research tax credits (CIR) for the year 2012, in line with the Company’s 2013 financing plan.

A third implantation of the CARMAT bioprosthetic heart is carried out on August 5, 2014 at Nantes Teaching Hospital.

The patient receiving an implant of the CARMAT bioprosthetic heart at Nantes Teaching Hospital on August 5, 2014 went home and benefited from the prosthesis for almost nine months before he died.

CARMAT receives €5 million in research tax credits (CIR) for the year 2012, in line with the Company’s 2013 financing plan.
CARMAT AND ITS SHAREHOLDERS

SHAREHOLDERS AS AT DECEMBER 31, 2018
(to the knowledge of the Company)

<table>
<thead>
<tr>
<th>Public</th>
<th>46.1% (4,278,514 shares)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matra Défense (Airbus Group)</td>
<td>14.4% (1,333,798 shares)</td>
</tr>
<tr>
<td>Air Liquide</td>
<td>0.8% (76,982 shares)</td>
</tr>
<tr>
<td>Therabel Pharma</td>
<td>1.4% (125,000 shares)</td>
</tr>
<tr>
<td>Santé Holding SRL</td>
<td>7.4% (688,881 shares)</td>
</tr>
<tr>
<td>Truffle Capital</td>
<td>3.8% (356,024 shares)</td>
</tr>
<tr>
<td>Pr Alain Carpentier &amp; His Association</td>
<td>7.1% (663,583 shares)</td>
</tr>
<tr>
<td>Loshas</td>
<td>13.9% (1,291,959 shares)</td>
</tr>
<tr>
<td>Cornovum</td>
<td>5.0% (458,715 shares)</td>
</tr>
</tbody>
</table>

ANALYSTS’ COVERAGE

<table>
<thead>
<tr>
<th>Broker / Analyst</th>
<th>Opinion</th>
<th>Target share price</th>
<th>Opinion’s date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilbert Dupont</td>
<td>Buy</td>
<td>€35.00</td>
<td>February 13, 2019</td>
</tr>
<tr>
<td>Portzamparc</td>
<td>Reinforce</td>
<td>€26.50</td>
<td>February 14, 2019</td>
</tr>
<tr>
<td>Invest Securities</td>
<td>Neutral</td>
<td>€29.00</td>
<td>January 16, 2019</td>
</tr>
<tr>
<td>Edison</td>
<td>- *</td>
<td>€83.89</td>
<td>October 26, 2018</td>
</tr>
</tbody>
</table>

*: Edison does not give any recommendation but only an evaluation of the company.
### INFORMATION ON THE CARMAT SHARE

<table>
<thead>
<tr>
<th>Market</th>
<th>Number of shares outstanding (December 31, 2018)</th>
<th>Mnemonic &amp; ISIN code</th>
<th>Share price &amp; market capitalization (December 31, 2018)</th>
<th>Average liquidity (12 months during 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euronext Growth</td>
<td>9,275,919</td>
<td>ALCAR FR0010907956</td>
<td>€23.50 / share</td>
<td>8,299 shares / day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>€218.0 m</td>
<td></td>
</tr>
</tbody>
</table>

### CONTACTS

<table>
<thead>
<tr>
<th>Chairman</th>
<th>Chief executive officer</th>
<th>Chief financial officer and Head of investor relations</th>
<th>Head office</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Pierre Garnier</td>
<td>Stéphane Piat</td>
<td>Pascale d'Arbonneau</td>
<td>36, avenue de l'Europe Vélizy- Villacoublay</td>
<td><a href="http://www.carmatsa.com">www.carmatsa.com</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>+ 33 1 39 45 64 50</td>
<td><a href="mailto:contact@carmatsa.com">contact@carmatsa.com</a></td>
</tr>
</tbody>
</table>
1

DESCRIPTION OF ACTIVITIES
Heart failure occurs when the myocardium (cardiac muscle) can no longer carry out its essential function as a blood “pump” and provide a sufficient cardiac output to satisfy the metabolic needs of the organism. When the failure reaches the left ventricle, we talk of left ventricular failure; when it reaches the right ventricle, we talk of right ventricular failure; when the failure reaches both ventricles, the left and the right, we talk of congestive or biventricular heart failure.

The main cause is coronary disease* (particularly myocardial infarction*), for about 2/3 of systolic heart failure cases. High blood pressure* is estimated to be an important contributing factor in many cases.

- In a heart attack, a plaque of lipids or a blood clot forms in one of the arteries of the heart, which are called coronary arteries, and the flow is interrupted. The part of the cardiac muscle that does not receive any blood is no longer oxygennated (ischemia*). It dies and is replaced by scar tissue. If this damaged part is important, the cardiac muscle weakens and the heart tends to expand; this secondary expansion, due to the increase in pressure within the heart, will in turn damage the healthy part of the heart and the heart failure will worsen over time.

- In high blood pressure (HBP), the resistance to blood flow increases in the arteries. The heart must fight against this resistance. As with all muscle subjected to an increased effort, it will first of all increase in size (hypertrophy*). If HBP is not correctly treated, the heart can dilate; its contractile force will progressively weaken and heart failure will develop. This heart failure is frequently aggravated by the tendency of hypertensive hearts to have cardiac arrests.

The left ventricle is the most frequently affected ventricle. Right ventricular failure is usually due to right ventricular pressure overload, i.e. pulmonary arterial hypertension.

But the principal cause of pulmonary hypertension is, in fact, left heart failure. That is why heart failure frequently progresses from the left ventricle to the right ventricle.

Up to 30% of patients whose left heart failure is treated with a left ventricular assist device develop right heart failure.

The most frequent complications are the following:

- irregular heart beat: the heart must pump faster to ensure the same flow rate despite its expansion; a serious ventricular arrhythmia can then develop which may go so far as a cardiac arrest;
- thromboembolic accidents (formation of clots): when a clot reaches the brain, it leads to a stroke*, with dramatic and often disabling consequences; and
- renal failure, the kidney being an organ very sensitive to variations in pressure caused by an inadequate cardiac pump.

Being a progressive disease, the prognosis is poor: less than 50% survival 5 years after the diagnosis, more than 40% of deaths within a year following initial hospitalization.

Practitioners distinguish the severity of failure or extent of the handicap using the NYHA (New York Heart Association) classification which is based on symptoms and includes 4 classes.

---

**References**


A shift to class III is a determining factor⁹:

- for the patient: it marks the passage between a virtually normal life and a considerably reduced activity, very often involving a loss of autonomy;
- clinically this means more aggressive therapies, a dependence on drugs, and, with class IV, the start of repeated hospitalizations;
- for society, this represents an explosion of the costs,

particularly due to hospitalizations: a class IV patient costs the community up to 15 times more than a class II patient¹⁰.

Class III and class IV patients represent between 20 and 35% of the total, with class IV reaching up to 5% of heart failures.

¹⁰ Kulbertus HE et al. What has long medical treatment to offer and what does it cost. Eur Heart J 1997 (suppl F) 26-28. Les patients en classe III et IV représentent entre 20 et 35% du total, la classe IV pouvant atteindre 5% des insuffisances cardiaques.

### 1.1.2 EPIDEMIOLOGY, PREVALENCE AND INCIDENCE

The prevalence* of heart failure is rising sharply in developed countries.

The prevalence of heart failure can be estimated at 1–2% in the western world and the incidence approaches 5–10 per 1 000 persons per year¹¹.

In Europe, the disease affects approximately 2% of the general population¹²,¹³ i.e. approximately 15 million Europeans¹⁴,¹⁵. The prevalence increases greatly with age. A French epidemiological study has shown that it can affect nearly 12% of patients over the age of 60¹⁶.

In the United States, over 5.8 million people were suffering from heart failure in 2012, with an annual incidence* of over 550,000 new patients annually. According to a new study published by an American Heart Association working group in May 2013, the prevalence of heart failure in the United States should increase by 46% between 2010 and 2030¹⁷, bringing the affected population to over 8 million people.

In addition, end-stage chronic heart failure with altered ejection fraction *, focused market for CARMAT, would affect 4.1 million people in Europe and the United States¹⁸,¹⁹ (people under 75).

This progression of the epidemiology is linked to the aging of the population, but also, in the case of advanced heart failure, to the improved survival after a myocardial infarction and to the progress made in the medicinal treatments, such as betablockers* and diuretics* ²⁰ or coronary stents.

The paradox is that the availability of these new medications or new technologies has enabled more effective treatment of acute coronary syndromes and considerably increased patient survival after an infarction which is the strongest predictor of left systolic dysfunction and the risk of heart failure: patients no longer die immediately but are treated long term, during which time the disease

---

**NYHA**

<table>
<thead>
<tr>
<th>NYHA</th>
<th>Class I</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>No symptoms</td>
<td>Tiredness, palpitations, shortness of breath after a sustained effort</td>
<td>Symptoms and discomfort on the least effort</td>
<td>Symptomatic even at rest</td>
</tr>
<tr>
<td>Activity</td>
<td>No limitation</td>
<td>Modest limitation</td>
<td>Marked reduction</td>
<td>Inability for all activity, permanently confined to bed</td>
</tr>
</tbody>
</table>


¹⁰ Kulbertus HE et al. What has long medical treatment to offer and what does it cost. Eur Heart J 1997 (suppl F) 26-28. Les patients en classe III et IV représentent entre 20 et 35% du total, la classe IV pouvant atteindre 5% des insuffisances cardiaques.


DESCRIPTION OF ACTIVITIES

continues to develop. Consequently, the total number of people living with a compromised heart function and with clinical heart failure will increase considerably in the coming decades. This evolution also leads to a population of older heart failure patients, suffering from various comorbidities, and thus even less susceptible to have access to transplants. Out of the 8.5 million American people suffering from heart failure predicted by the AHA by 2030, only 2.5 million of these will be under 65 years old.

1.1.3 ECONOMIC CHALLENGE

Heart failure constitutes a real public health challenge which is set to increase: in Western countries, the cost of heart failure is now one of the largest of all chronic diseases.

According to the most recent study from the American Heart Association working group published in May 2013, the total cost of heart failure which was 31 billion dollars in the United States in 2012 is estimated to be 70 billion by 2030. The direct costs (medical costs) of patient treatment is expected to increase by 250% between 2012 and 2030. Taking account of all the direct costs from resulting co-morbidities, the cost will explode to 160 billion dollars in 2030.

Moreover, this study points out that 80% of the medical expenses are attributable to the hospitalizations.

There are no recent studies dealing with the cost of heart failure on a European level. As an example, the direct cost of advanced chronic heart failure in France was in the region of 1.5 billion euros (3.3 billion euros for the long-term condition class which combines serious cardiovascular diseases - ALD 5 in 2009, only for the general National Health Insurance system) and was reported to affect over 730,000 people in 2011 (a 9% increase compared to the previous year).

In a statement released on May 7, 2010 on the occasion of the European Heart Failure Awareness Day, the French Society of Cardiology and the French Federation of Cardiology recalled some figures. In France there are more than 100,000 new cases a year. 10% of these patients were hospitalized, the average length of hospitalization exceeding ten days and the rate of re-admission within six months being 20%. In 2008, heart failure was the main diagnosis for 195,800 hospital stays in France for which the daily cost of a hospital stay in cardiology intensive care was over 2,000 euros.

Overall, heart failure represents between 2 and 2.5% of the total expenditure on health care in Western countries, with costs linked to hospitalization alone representing more than 70% of the total cost of the disease. Due to repeated hospitalizations, class IV chronic heart failure represents between 61% and 92% of the total cost of heart failure.

1.1.4 AVAILABLE TREATMENTS

It should be noted that this disease is incurable in the chronic phase and that current treatments aim solely at reducing the symptoms. Treatments evolve as the disease progresses.

MEDICATIONS

In classes I and II, treatment is essentially drug-based and, depending on the severity and symptoms, combines:

- anticoagulants and anti-platelet aggregation medication to prevent the formation of blood clots;
- angiotensin-converting enzyme inhibitors to reduce vascular resistance;
- betablockers which reduce the cardiac rhythm and output to decrease blood pressure;
- diuretics to remove excess fluids and, in this way, lighten the burden on the heart to prevent pulmonary edema;
- vasodilators which relax the blood vessels to increase the flow of blood and oxygen to the heart without increasing its workload;
- etc.

The complexity of treatment and the need for frequent
DESCRIPTION OF ACTIVITIES

adjustments leads to low patient compliance: 40% of patients do not take their treatment correctly after 3 months 27. 

DEVICES

From class III, surgical options and the implantation of supporting medical devices are considered, such as:

- mono- or biventricular pacemakers to prevent arrhythmias;
- implantable defibrillators to treat ventricular tachycardia and prevent sudden death;
- left ventricular reconstruction;
- restrictive mitral annuloplasty;
- mechanical circulatory support systems, implantable or not, and artificial hearts.

For the most part, these options pursue the objective of recovering the heart’s natural function. For example, biventricular pacemakers aim to reeducate the ventricles by synchronizing their contractions.

Restrictive mitral annuloplasty aims to reeducate the left ventricle by affecting its geometry. However, if these approaches temporarily relieve some patients, they face important difficulties in selecting patients 28 or technical implementation 29, which restrict their adoption and do not prevent the progression of the disease.

Finally, the use of stem cells to regenerate damaged heart muscle is a promising avenue of research, but remains very controversial 30, in particular due to difficulties in collection or generation, then in administration (a large number of cells “die” during the injection) and the lack to date of a clinical demonstration of long-term regeneration of the myocardium.

The mechanical circulatory support systems are the devices which could be considered as the closest, in function and indication, to the CARMAT artificial heart project. Their characteristics and evolution are detailed in Paragraph 1.2.2. « Technologies and market players ». However, in contrast to artificial hearts which replace both ventricles, the diseased heart is left in place and can continue to degrade.

Positive inotropes* are generally introduced at the most advanced stage of the disease. These are drugs, administered intravenously in the hospital setting, which increase the contractility of the cardiac muscle and that allow, at least temporarily, critical situations of low cardiac output in episodes of acute decompensated heart failure* or cardiogenic shock* to be resolved. Dependence on inotropes marks the terminal phase of heart failure with a mean survival of 3 and a half months 31.

TRANSPLANTATION

Indeed, in the end-stage form of the disease, the only treatment possible is the replacement of the diseased ventricles by the transplantation* of a healthy heart, i.e. the heart of a donor.

Professor Christian Bernard performed the first heart transplant in South Africa on December 3, 1967. The first transplant patients, with few exceptions, did not survive more than a few weeks after the operation, notably due to rejection (reaction of the host against the transplant which it considered as a foreign biological body). Several important advances have allowed the improvement of patient survival:

- the preservation of donor hearts thanks to refrigeration, allowing the removal at a distance from the place of transplantation;
- endomyocardial biopsy allowing the early diagnosis of rejection: a probe is introduced, under X-ray control and under local anesthesia, into a large vein and pushed until it is in the right ventricle, permitting a small piece to be sampled which is then analyzed under a microscope;
- finally, and above all, the arrival of ciclosporin, an immunosuppressant* the therapeutic use of which offered great hopes in organ transplantation from the early 1980s by preventing acute rejection.

Today, heart transplant survival is slightly higher than 50% at 10 years 32. Survival after one year has progressed from 76% to 87% over the past 20 years 33.

The hopes founded on this treatment continue to face major problems that limit its mainstreaming.

The first reason can be found in the very strict eligibility criteria both for the harvesting of the organ and for the transplant. Notably, the donor 34 must, in principle, be under the age of 61 years, brain dead, not a carrier of

certain viruses such as HIV or hepatitis B and C, not be a drug addict or have a cancer and, of course, not be suffering from heart disease. This therefore limits the possibility of donation mainly to trauma deaths (in particular road accidents, which are constantly decreasing). Only 435 hearts were therefore harvested in France in 2012 and 397 were implanted.

In France, 41% of donors were over 60 years old in 2011 compared to 22% in 2007, which explains why not all of the transplants harvested can be used.

Considering this shortage of organs, the eligibility criteria of the recipient are even stricter in order to ensure the greatest chance of success with each transplant. Blood groups must be identical, weight and size equivalent. Irreversible pulmonary hypertension, an active infection or a cancer are formal contraindications. Other relative contraindications are also taken into account such as diabetes, advanced lung or liver disease, renal impairment and morbid obesity etc. A psychological assessment is considered to ensure that the patient understands and undertakes to adhere to complex life-long medical treatment. Patients with psychiatric disorders, or addicted to alcohol or drugs are not considered.

Age of the patient, which must be usually below 65 years, even if there is no legislation in this area, is a particularly discriminating criterion. The organs are therefore reserved for the youngest patients, while the vast majority of chronic heart failure patients are over 60 years or suffering from comorbidities making them ineligible.

Furthermore, post-transplant survival decreases significantly with age. Only 80% of patients over 60 years are still alive after one month, and 67% after one year.

In this way, the number of transplants has been stable or declining in all developed countries for over ten years, while the prevalence of heart failure has considerably increased.

Heart transplant waiting lists therefore do not reflect treatment needs, but simply the number of patients satisfying all the eligibility criteria, particularly age. The low diffusion of heart transplantation as treatment of choice for end-stage heart failure is shown in the following table where we can see the small number of patients who could expect to benefit.

The limitations of transplantation also emerge in the difficulties in treating transplant patients and complications - either the transplant itself or complications caused by the immunosuppression. So, 5 years after a heart transplant, 95% of patients suffer from hypertension, 81% from hyperlipidemia, and 32% from diabetes. Furthermore, 25% to 50% develop coronary disease of the graft, and 33% suffer from chronic renal failure.

A heart transplant is a heavy treatment at a very high price. The Milliman Institute has published a detailed report on the estimated cost of organ transplants in the United States. In terms of heart transplantation, its 2014 conclusions show a cost of 1,242,200 dollars, including 30 pre-transplantation days and 180 post-transplantation days.

It is difficult to make international comparisons in view of the very different health funding systems and figures available covering different pre- and post-implantation periods.

<table>
<thead>
<tr>
<th></th>
<th>France</th>
<th>United States</th>
<th>Germany ****</th>
<th>UK *****</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transplantations</td>
<td>450 *</td>
<td>3,244 **</td>
<td>312</td>
<td>177</td>
</tr>
<tr>
<td>Patients on waiting list</td>
<td>364 *****</td>
<td>3,782 ***</td>
<td>703</td>
<td>246</td>
</tr>
</tbody>
</table>

* : 2018 - Agence de la biomédecine (Biomedicine Agency)
** : 2017 - UNOS
*** : As at January 17, 2019
**** : 2018 - EuroTransplant
****** : 2017 – NHS Organ Donation Annual Report

35 Agence de la biomédecine - Synthèse nationale de prélèvement et de greffe 2012 et annexe au bilan 2012.
1.2 MARKETS AND ACTORS PRESENT

1.2.1 ADDRESSABLE MARKET FIGURES

CARMAT intends to market an artificial bioprosthetic valve for patients in NYHA classification end stage class IV heart failure which is either chronic or ischemic heart disease (of which «acute myocardial infarction» is only a sub-group), in a the Bridge To Transplant indication, i.e. pending transplantation (refer to paragraph 1.2.2 «Technologies and market players ») and/or for the Destination Therapy (final treatment).

The figures below refer to the indication for destination therapy.

Chronic heart failure affects approximately 15 million European patients 39 and 5 million patients in the United States 40, i.e. a total of approximately 20.8 million patients in this geographical area.

Referring to the indications obtained by similar devices, this artificial bioprosthetic heart could be indicated for patients suffering from acute or chronic end stage heart failure under 70 years old who cannot be transplanted, without obvious indication like cancer, reducing their life expectancy to less than 6 months.

Considering that:

- 2.3% of these patients will reach the end stage of the disease annually - involving the first hospitalisation - i.e. a population of approximately 478,400 patients 41;
- 38% of this population is under 70 years old, i.e. a population involving approximately 182,000 patients 42, 43;
- around 5,000 eligible patients are transplanted per year; and
- the anatomical compatibility of the CARMAT heart for men and women is 86% and 14% respectively (with a weighting of 80/20 between men and women), it should be noted that the available clinical data indicate that these compatibility rates will increase in the near future;

there are therefore approximately 126,700 potential patients in Europe and the United States for the indication class IV end stage chronic heart failure.

40 Heart Disease and Stroke Statistics – 2010 Update at a glance – American Heart Association and American Stroke Association.
43 Heart Disease and Stroke Statistics – 2010 Update at a glance – American Heart Association and American Stroke Association.

1.2.2 TECHNOLOGIES AND MARKET PLAYERS

Heart transplantation, especially in light of the lack of organs, cannot fulfill the needs of patients in class IV end-stage heart failure (refer to Paragraph 1.1.4 « Available Treatments »). Alternative medical devices exist, – often grouped under the term mechanical assisted circulatory support (MCS: Mechanically Circulatory Support).

The principal market players are Thoratec® and Heartware® in the field of ventricular assistance, and Syncardia in the field of artificial hearts.

These devices are indicated in two main cases:

- pending transplantation (BTT: Bridge to Transplant)

The device is implanted temporarily until an organ is available or until the patient’s condition improves sufficiently to tolerate the operation. Given the thromboembolic or infectious complications of the available devices, they were, until recently, used mostly for this short-term indication. However, they are limited by cost – the cost of the implantation of the device adding to the cost of the transplant;

- definitive treatment (DT: Destination Therapy)

This indication was, until recently, reserved for patients who were ineligible for a transplant, or who did not wish to have a transplant. However, under the pressure of a fast increasing prevalence and the shortage of organs, numerous patients temporarily implanted actually become destination therapy patients.

The aim of Destination Therapy is to offer a system
providing a real quality of life to the patient, i.e. a reasonable autonomy and a return home, and even a professional or social life, which is accompanied by an increase of at least 2 NYHA classes, without major complications.

Furthermore, since the first approval of this indication for the HeartMate®II by the FDA in 2010 and the Syncardia obtaining a status as a device for compassionate use for first line destination treatment in the United States in March 2012 (refer to paragraph 2.3.2.2 Total orthotopic artificial hearts), this indication has increased considerably in North America and also in other European countries such as Germany.

The devices can then be distinguished into two categories:

(N.B.: The following information concerning the other devices has been taken exclusively from public sources such as websites of the companies cited, publicly accessible presentations for investors or referenced scientific publications. Readers are encouraged to conduct their own research in order to form their own opinions. CARMAT accepts no liability concerning the accuracy of this information.)

VENTRICULAR ASSISTANCE DEVICES 44

These devices are often and incorrectly referred to by the media as artificial hearts.

However, as their name indicates, they are implanted in parallel to the native heart, to assist it by supplementing its flow to meet the metabolic needs, but do not replace it. The historical leader in this category is the Thoratec® company with the HeartMate III® - the HeartWare® company is its main competition.

Thoratec® announced that it exceeded 18,000 implants for its HeartMate II® in 2014 (i.e. scarcely 5 years after its approval by the FDA for the destination treatment indication) and it was on this basis particularly that in the middle of 2015 this Company was acquired by Saint Jude Medical, based on a value of 3.3 billion dollars. In October 2015, the Company announced that it had obtained the CE mark for its product HeartMate III®.

More recently, in April 2016, the Abbott Group and Saint Jude Medical announced their merger, thus valuing Saint Jude Medical at approximately $ 25.0 billion. The new group created as a result of this merger is positioned as a global leader in medical devices, with applications in the cardiac field, diabetes treatment, or vision disorders.

The products of Thoratec®, entity now belonging to the Abbott Group, can theoretically assist the left (Left Ventricular Assist Device – LVAD) or right (Right Ventricular Assist Device – RVAD) ventricle or both ventricles. In the latter case, they are called biventricular assist devices (BiVAD). To date, however, there are no implantable devices approved for the right ventricle or biventricular application, all the devices having been designed for the left ventricle.

Nevertheless, the wider diffusion of these left ventricular assist devices has led to an increase in the need for biventricular assistance 45. Indeed, the development of a right heart failure is a major complication of left ventricular assist devices. 20% of patients implanted with the HeartMate II® develop right heart failure 46. The indication to add a right ventricular assistance device involves up to 37% of cases depending on the study 47, 48, 49, 50.

Assessment methods are being developed for this risk to identify patients liable to benefit from early stage biventricular assistance as it has also been shown that early implantation results in a very significant improvement in survival compared to later implantation 51, 52, 53. This could contribute to an increase in the use of biventricular devices, such as the one from CARMAT, as a first-line treatment.

These non-pulsating devices, such as the HVAD® by HeartWare® are designed to supplement the cardiac function and not as a substitute for it. They consequently have limitations in terms of their flow rate. The flow rate of the centrifugal pumps of these left ventricular assist devices

47 Potapov EV et al. Tricuspid incompetence and geometry of the right ventricle as predictors of right ventricular function after implantation of a left ventricular assist device. J Heart Lung Transplant 2008 ; 27 : 1275-81.
51 Fitzpatrick JR et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008 ; 27:1286-92.
52 Fitzpatrick JR et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg 2009 ; 137:971-977.
53 Takeda K et al. Outcome of unplanned right ventricular assist device support for severe right heart failure after implantable Left Ventricular Assist Device insertion. J Heart Lung Transplant 2014 ; 33(2):141-8.
is determined by the specific geometry of each device, the speed of rotation of the pumps in turns per minute, and the difference in pressure between the entry into the pump (ventricular pressure) and the ejection from the pump (aortic pressure).

The right ventricle is very different from the left ventricle. The blood pressures are significantly lower in the right side of the heart. On the left side, the blood needs to reach all the organs, the brain at the highest point, the extremities of the limbs, at the furthest. On the right side, it is «sufficient» to send the blood to the neighboring lungs for reoxygenation. The actual design of a left ventricular assist device with a centrifugal pump and the constant flow rate would have to be significantly modified to adapt it to assist the right ventricular.

To our knowledge, only one manufacturer of implantable left ventricular assist devices with a centrifugal pump, meaning the HeartWare® company, has expressed an intention to seek authorization for a right ventricular assist device 54. This company was acquired by Medtronic in August 2016, for a total valuation of $ 1.0 billion.

A few constant flow rate centrifugal pump left ventricular assistance devices have been tested experimentally for biventricular assistance 55, 56. Very few publications exist on the subject. All indicate that the design for the left side of the heart is a major flaw: currently «The right pump, in a circuit of normal pulmonary pressure, would pump more volume than the left and would result in pulmonary edema.»

« TOTAL » ORTHOTOPIC ARTIFICIAL HEARTS (TOTAL ARTIFICIAL HEART: TAH)

Like a heart transplant procedure, orthotopic «total» artificial hearts replace both failing ventricles, by implanting in their place (orthotopic replacement) two ventricular volumes and a system that ensures a blood flow. The CARMAT bioprosthetic artificial heart project belongs to this category.

The only total artificial heart currently on the market in Europe and the United States belongs to the eponymous private equity company Syncardia 57. After facing financial difficulties («Chapter 11»), the company received in September 2016 the support of the private equity fund Versa Capital Management, which could relaunch this company in a peiran way.

The Syncardia® device was designed in the 1970s and implanted for the first time in 1982 – under the name Jarvik 7. The patient survived for 112 days. In 1985, a patient reached the transplantation stage for the first time after surviving for 9 days with the artificial heart. In 1990, the FDA closed the Symbion, Inc. company which held the rights for Jarvik 7 and stopped the ongoing clinical study (IDE*) – because of breach of its regulations. The technology was taken up again by an Arizona University Centre under the name CardioWest™. A new clinical study started again in 1992 in the United States and lasted 10 years. This led to FDA approval in 2004 for a bridge to transplantation indication and the CE mark in 2005. Meanwhile, a new privately funded company, Syncardia Systems, Inc., was created in 2001 to prepare for and then proceed to marketing 58. Syncardia announced the 1000th implantation of its artificial heart in February 2012, which is 19 years after the first implant in December, 1982.

So, it is an artificial heart whose design dates back more than 40 years. Its functioning is based on a pneumatic actuation. The internal polyurethane diaphragms are activated by the compressed air, generated by a compressor, which is itself powered electrically. Four mechanical valves are used in each device. Two percutaneous plastic tubes approximately 2 metres long (7 feet) connect the device to the external compressor, the portable version of which, the Freedom™ portable driver, weighs 6.12 kg (13.5 pounds) excluding carrying accessories such as the backpack or sling bag, for 3 hours independent operation 59.

CARMAT can only welcome the regulatory, financial and commercial success of the market players. Indeed, they maintain the attention of the scientific and financial communities, highlighting the expected advantages of CARMAT’s innovations and preparing the route.

The orthotopic total heart is also the most dynamic area of research on the market, confirming the important need for this type of device and the leadership of CARMAT in this field.

54 Site internet HeartWare® HeartWare International 2013 Fourth Quarter and Year-End Results Conference Call - Thursday, February 27, 2014.
Compared to a transplant, the respective advantages and disadvantages of the current systems are summarized in the following table:

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Transplantation</th>
<th>Assist systems and Artificial hearts</th>
</tr>
</thead>
<tbody>
<tr>
<td>- State of the art in terms of destination treatment</td>
<td>- Immediate availability</td>
<td></td>
</tr>
<tr>
<td>- Normal physical activity possible</td>
<td>- Planned procedure</td>
<td>- Good level of physical activity</td>
</tr>
<tr>
<td>- Good long term prognosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disadvantages</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Lack of donors and organs</td>
<td>- Dependency on the device</td>
<td></td>
</tr>
<tr>
<td>- Risk of rejection</td>
<td>- Operational independence dependent on a continuous electrical supply</td>
<td></td>
</tr>
<tr>
<td>- The transplant is exposed to diseases</td>
<td>- Infection of the percutaneous wire(s)</td>
<td></td>
</tr>
<tr>
<td>- Risk of coronary diseases in the transplant</td>
<td>- Risks of anticoagulation</td>
<td></td>
</tr>
<tr>
<td>- Risk of immunosuppression</td>
<td>- Severe hemorrhage</td>
<td></td>
</tr>
<tr>
<td>- Renal impairment</td>
<td>- CVA</td>
<td></td>
</tr>
<tr>
<td>- Neoplasia (cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Susceptibility to infections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dependency on the device</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Operational independence dependent on a continuous electrical supply</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Infection of the percutaneous wire(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Risks of anticoagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Severe hemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- CVA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regarding assist devices:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Serious cardiac arrhythmias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Aortic regurgitation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Pump thrombosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Thanks to the use of breakthrough technologies, such as biological or hemocompatible materials to limit the risks linked to anticoagulation, or fuel cells to increase patient’s autonomy and quality of life, CARMAT aims to appreciably reduce the majority of these disadvantages and to offer a real alternative to transplantation.

---

Thus, facing its main market competitors, whether they are positioned on the market of total orthotopic artificial hearts or ventricular assistance devices, CARMAT has significant advantages:

**DESCRIPTION OF ACTIVITIES**

<table>
<thead>
<tr>
<th>Total orthotopic artificial heart</th>
<th>Total orthotopic artificial heart</th>
<th>Ventricular assistance devices</th>
<th>Ventricular assistance devices</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARMAT</strong></td>
<td><strong>SYNCARDIA</strong></td>
<td><strong>THORATEC</strong></td>
<td><strong>HEARTWARE</strong></td>
</tr>
</tbody>
</table>

**Corporate information**
- Listed company
- € 53 million last fund raising in December 2017
- « Chapter 11 » procedure in 2016
- Support of the private equity fund Versa Capital Management in September 2016
- Acquired by Saint Jude Medical in 2015 for $3.3 billion, Saint Jude Medical acquired by Abbott in 2016 for $25.0 billion
- Acquired by Medtronic in 2016 for $1.0 billion

**Market access**
- Pending
- Pivotal study ongoing process
- Bridge to Transplant approval: 2004 (USA) and 1999 (CE marking)
- Study for destination Therapy: Pending
- Bridge to Transplant approval: 2017 (USA)
- Destination Therapy approval: 2015 (CE marking) and 2018 (USA)
- Bridge to Transplant approval: November 2012
- Study for destination Therapy: September 2017

**Technology**
- Bioprosthetic artificial heart, biocompatible, autoregulated
- Artificial heart, with pneumatic technology designed in the 70’s (Jarvik 7)
- Ventricular assistance device, with centrifugal rotary pump
- Ventricular assistance device, with centrifugal pump

**Avantages / Drawbacks**
- Biocompatibility of materials used, minimizing the risk of vascular accidents or hemorrhages
- Self-regulation of the system, according to the patient’s physiological needs
- Operation facilitating the quality of life of the patient
- Relatively high risks of thrombosis, hemorphages or infections due to the use of non-biocompatible materials in contact with patients’ blood (use of anticoagulants)
- System that may be relevant as a temporary solution.
- Risks of thrombosis due to the use of non-biocompatible materials in contact with patients’ blood (use of anticoagulants)
- Risk of right ventricular failure
- Fixed operating speed, not adapted to the needs of the patient. Renal and hepatic complications in a medium term
- Complications related to the maintenance of the native heart (regurgitation of the aortic valve, ventricular arrhythmias, ...)

Visual of the prosthesis
1.3 THE FIRST SELF-REGULATED BIOPROTHETIC ARTIFICIAL HEART

1.3.1 POSITIONING ON THE MARKET

The artificial heart CARMAT is intended to offer a permanent solution to patients with terminal heart failure who are facing a therapeutic stalemate due to the lack of human grafts.

The innovations carried by the artificial heart CARMAT aim initially to meet the needs inadequately covered by existing technologies: hemocompatibility, pulsatility and quality of life.

Depending on the benefits demonstrated in terms of lifetime, the artificial heart CARMAT could then address patients with better prognosis. Eventually, it could become the No. 1 alternative to heart transplantation.

CARMAT will propose a price that will ultimately allow the healthcare system to be effective in relation to the sustained costs for the solutions used today.
1.3.2 DESCRIPTION OF THE CARMAT PROSTHESIS

As presented on the previous page, the system consists of:

- an implantable part, the bioprosthetic artificial heart, as such;
- patient systems allowing the return home;
- a hospital system allowing complete configuration of the prosthesis and patient monitoring.

THE PROSTHESIS

The implantable parts include the prosthetic heart and the connection to the power supply, either by battery or by the mains.

The prosthesis reproduces the operation of the natural heart by using hydraulic actuation, an actuation liquid serving as an intermediary for deploying a blood-throbbing membrane. The cardiac rhythm is broken down into two periods, diastole* when the ventricles fill up with blood, and systole* when the blood is pumped into the great vessels and organs.

The prosthesis comprises two ventricular cavities, one on the right and one on the left, each separated by a flexible hybrid membrane into two volumes, one for blood, one for the actuation liquid. The movement of this membrane reproduces the viscoelastic nature of the cardiac muscle and acts in the same way on the blood, pumping it when it contracts.

A motor-pump group - consisting of two miniature pumps - moves the actuation liquid to the ventricles thus generating systole or by reversing the direction of rotation, towards the external pouch during diastole.

An electronic device integrated to the prosthesis regulates the flow according to patients’ needs using information given by sensors and processed by a microprocessor.

A flexible external pouch contains the actuation liquid and beats at cardiac rhythm.
DESCRIPTIO N of A ctivitiES

THE ELECTRICAL CONNECTION

The transfer of electrical energy from the monitoring console or portable batteries to the prosthesis will be percutaneous for the early clinical trials. This solution has the merit of being proven as it is used by the majority of implantable ventricular assistance systems currently available.

The percutaneous cable, however, is a possible cause of infection. Compared to the various solutions considered to date, the most promising one appears to be positioning an implantable connector that will offer the potential to treat potential infections, an additional differentiation point. This solution will be incorporated in the near future, pending the implementation of completely implantable solutions.

THE HOSPITAL MONITORING CONSOLE

The hospital monitoring console (CSH) – which is already available – is only used in implantation centres by certified medical staff. It allows the medical team to pilot the prosthesis during implantation, and to assume the follow up during periodic control visits, and it also allows the downloading while functioning of new functions or versions of the prosthesis’s softwares, like for example, the software that allows automatic adaptation to the patient’s metabolic needs.

The console can import the monitoring data from the patient’s systems and, in the long run, it could interface with the doctor’s computer to receive and analyze data transmitted by remote transmission. It offers surgeons detailed functions for the analysis of the prosthesis’ functioning and of the physiological parameters measured.

THE PATIENT SYSTEM

The systems that the patient takes home contribute significantly to their quality of life as they give them the mobility and autonomy essential for a life close to normal.

• The first portable system weighing 3 kg (including bag) provided over 5 hours of independent operational life - (at a fixed flow rate of 6 litres per minute) - with Lithium-Ion batteries and offered good mobility. However, autonomy in the true sense of the term is not limited to 5 hours, since the patient may carry extra previously-charged batteries, or connect directly to a power outlet where possible.

• The second generation portable power supply, which is subject to fuel cell research, aims to give patients autonomy of more than 12 hours, with a weight of less than 3 kg. The use of a fuel cell should be a first in the medical field. It should provide an original solution integrating the production of hydrogen on demand and optimizing patient security while being ergonomic.

Other additional accessories such as a battery charger, connection materials to the home electricity supply, carrying bags or belts or materials to protect the system when showering are also intended. All the elements of the system intended for the patients aim to allow them to feel safe, to have a good quality of life at home and to ensure their mobility for the requirements of everyday life.

1.3.3 INNOVATIONS AND COMPETING ADVANTAGES

To date, the artificial heart CARMAT highlights 3 major technical achievements, leading to undeniable competitive advantages compared to other medical devices on the market:

• The only artificial heart project where surfaces in contact with the blood are made of biologically compatible material to reduce thromboembolic risks;

• The first intelligent artificial heart project that would provide an immediate and automatic response to the patient’s metabolic needs;

• Special attention to patients’ quality of life, with the development of light external equipments and quiet operation.

To the knowledge of CARMAT, no existing or planned device includes or foresees the use of biological material, nor self-regulation by means of multiple embedded sensors. These two characteristics constitute the key of the technological breakthrough CARMAT intends to offer to patients.
HEMOCOMPATIBILITY

All the implants and assist or organ substitution devices in contact with blood pose the major problem of their hemocompatibility: they must not cause the destruction of red blood cells* (hemolysis*) or activate the coagulation cascade*, thus favoring the formation of a clot blocking a blood vessel which can cause a pulmonary embolism* or a stroke.

The causes of these problems are based around two points:

- hemodynamics, respecting the blood flow, which should prevent stasis (abnormal stagnation and accumulation of blood) or « shearing » of red blood cells (shear stress). This issue also covers the aspect related to the necessary variability required by a device intended to supplement or replace the original functioning of the natural heart. The organ must ensure a non-continuous flow of blood according to the activity of the individual. This essential constraint is now covered by the pulsed effect of the CARMAT prosthesis;
- the surface condition and toxicity of the materials in direct contact with the blood. These materials may be of a varied chemical nature, but their surface condition must be either perfectly smooth and water-repellent so as not to cause any adherence, or else of a microporous structure so as to guarantee satisfactory adherence of proteicin* biological tissues.

The CARMAT bioprosthetic artificial heart project contributes original solutions to overcoming this major obstacle by developing a type of blood flow pulsatile actuation which is compatible with physiological blood pressure, thanks to the optimized design of ventricular cavities and the use of microporous biological and synthetic biomaterials which allow by hypothesis a continuous proteinic* coverage, adhering to all surfaces in direct contact with the blood.

Research into non-thrombogenic materials which are essential for the final performance of the system has been a goal which many companies have pursued without success, particularly in ventricular assistance.

The CARMAT artificial bioprosthetic heart project has followed on from the hemocompatibility principles demonstrated in the research carried out on the Carpentier-Edwards biological valves designed by Professor Alain Carpentier, which have proven clinical experience of 30 years, having been implanted in over a million patients with implantation times of over 25 years **, **. These biological valves, unlike mechanical valves, allow the considerable reduction, or even elimination in certain cases, of the anticoagulant treatment, which is especially restrictive for the patient.

An agreement with an initial term of one year, automatically renewable for one year at a time, was entered into on November 5, 2010 between CARMAT and Edwards Lifesciences, the world leader in the heart valves sector and in hemodynamic monitoring, for the use and supply of Carpentier-Edwards biological heart valves® for the CARMAT bioprosthetic artificial heart project.

Four Carpentier-Edwards pericardial valves realized with bovine pericardium are incorporated into each CARMAT bioprosthetic artificial heart. The surfaces in contact with blood of the atrial connection interfaces are also covered by treated bovine pericardium. The face in contact with the blood of the biosynthetic membranes loaded in the ventricle to put the blood in movement is also covered with bovine pericardium, the cavity is covered by micro-porous synthetic hemocompatible material. This will mean that all the components coming into contact with the blood are in micro-porous hemocompatible or biological materials, setting them apart from other artificial heart projects which specifically use mechanical valves.

---


Source CARMAT – Hemocompatible materials
DESCRIPTION OF ACTIVITIES

AUTO REGULATION

To improve patients’ quality of life, the CARMAT bioprosthetic artificial heart project was designed to permanently analyze the hemodynamic situation of the patient and to adapt thereto in real time.

Thus, for example, if a patient climbs the stairs the cardiac output of the artificial heart will increase as a natural heart would do. If they lie down to sleep, the heart will slow down to ensure a comfortable sleep.

The output of the artificial heart is therefore pulsatile*, in the same way as a natural heart, and its hemodynamic operation is based on Starling’s law which governs the functioning of the human heart. In accordance with this law, changes in heart rate occur principally from variations in venous return (pre-load) but are also sensitive to the influence of arterial pressures (after-load).

The artificial heart also simulates the reactions of the natural heart to stimuli from the nervous system particularly in maintaining aortic pressure in order to permanently ensure satisfactory perfusion of organs, especially the cerebral arteries.

Unlike other research projects on bioprosthetic artificial hearts that offer little or no adaptation to the needs of the patient, the medical self-regulation of the CARMAT bioprosthesis aims to reproduce the physiological functioning by implementing:

- an original algorithm allowing replication of the visco-elastic characteristics of the cardiac muscle which changes shape under the effect of pressure depending on its initial elongation, respecting Starling’s law;
- an algorithm simulating cardiac function in response to peripheral resistance modifications, which themselves are dependent on the nervous system. The analysis of aortic pressure allows the beat rate to be corrected.

OTHER COMPETING ADVANTAGES

Miniaturization:

In the absence of embedded self-regulation, the other artificial heart projects bypass the problem of adjustment by the use of external control consoles, or by the use of portable extracorporeal devices. These bulky devices, often reserved for hospital doctors, do not allow an acceptable quality of life for the patient.

Taking advantage of progress made in the miniaturization of electronics, the trend among research projects today is to design hearts which integrate the command and adaptation systems as much as possible. But the intrathoracic space is limited. This integration is often realized at the expense of the ejection volume, which requires the artificial acceleration of the beat rate to provide a physiological blood flow.

The shape of the CARMAT artificial bioprosthetic heart has been completely optimised to the anatomy of the thorax in order to fit the largest number of patients, at the same time maintaining a physiological ejection fraction using all of the space available around the volumes reserved for blood.

This anatomical shape has been studied taking several criteria into account, such as its total volume, its ventricular volume, its interfaces with the aorta*, the pulmonary artery* and the atria.

Respecting the obligation of as large a ventricular volume as possible to avoid continuous operation at high frequency, while conserving a very significant reliability of onboard elements, has required significant miniaturization efforts for all the sub-assemblies involved in its activation: motor pump unit, control electronics and sensors.

An advanced virtual 3D implantation system has therefore been developed, based on a sophisticated three-dimensional simulation, which allows, in a completely non-invasive manner, the removal of the natural heart and grafting of the prosthesis to check its anatomical compatibility with a given patient.

An implantable device can only be a valid therapeutic solution if the implantation is simple and reproducible. Under
the supervision of Professor Carpentier, the CARMAT teams have therefore worked in tight collaboration with several surgeons, anesthesiologists, perfusionists and nursing personnel of the operating theater to design and develop a procedure that all cardiac surgery teams can perform in good conditions, even in cases of emergency.

Notably an original interface with the patient’s atria was developed, interface which allows the surgeon to have much more room to work, and a better subsequent alignment of the prosthesis. Consequently, the procedure is considerably easier and faster. Indeed, the implantation time must be as short as possible to limit the neurological risks of a prolonged extracorporeal circulation.

Once this interface is sutured to the atria, the prosthesis can simply be clicked into place. The cover of this interface consists of a hybrid material of which the side in contact with the blood is made of bovine pericardia to respect the hemocompatibility philosophy of the prosthesis.

The Company is also working to lighten the portable system, currently weighing 3 kilograms, to improve usage comfort for the patient.

Power supply and independent operation:

Experiences of ventricular assistance have been revelatory in terms of showing the current limits of portable electrical energy technology. These systems use rechargeable batteries with different technologies (Nickel metal Hydride, Lithium-ion...). The autonomy on offer is in the region of just 4 to 6 hours, thus forcing the patient’s life into a rhythm that is both restrictive. Progress is being made every year, but this does not enable any major improvements to be anticipated in the short term. For this reason, this mode of power will be adopted for the first versions of the system intended for patients.

CARMAT is continuing its technology watch in this area in order to offer patients increased mobility, of the order of ten hours or more, in future versions of its prosthesis.

1.4 GOING ON THE MARKET PROCESS

The process of placing the bioprosthetic artificial heart CARMAT on the market is based on the results obtained during a phase of preparation of the clinical trials, which consisted in studying, designing and manufacturing human implantable cardiac artificial heart systems CARMAT, and to carry out all the tests and validations required to obtain an authorization for clinical trials by the ANSM in France or by the regulatory authorities of other countries.

CARMAT is currently pursuing the last two phases of the process of placing the prosthesis on the market:

- a phase of clinical trials in progress, including a feasibility test, which was finalized in early 2016, and a pivotal study, which was initiated in mid-2016, after endorsement by the Patient Protection Committee (CPP) and the French National Medicines and Health Products Safety Agency (ANSM);
- A phase of obtaining the CE marking which aims to complete the in vitro and clinical validations for the submission of the CE marking dossier and which also integrates the industrialization of manufacturing processes. This third phase takes place in parallel with the clinical trials and allows the company to complete its preparation for the marketing of the product.
1.4.1 PREPARATION OF THE CLINICAL TRIALS

The phase of preparation of the clinical trials, now finalized, took place in 3 stages:

- Study and detailed design of the system and its subassemblies.
- The development of the various subsets as well as their qualifications and the integration of the system. During this phase the Company successfully conducted a very broad preclinical testing program:
  - Biocompatibility tests
  - Test bench tests: functional tests, software tests, environmental tests, validation and verification tests of the integration process, endurance tests.
  - Ex vivo tests and in vivo tests (implantations on animals)
- The manufacture of systems for preclinical testing purposes and the commencement of clinical trials.

BIOCOMPATIBILITY TESTS

It is reminded that the prosthesis uses hybrid materials forming the ventricular cavity and suture flanges. These materials constitute one of the original features of the CARMAT system. As well as proving their long-term in vitro physicochemical stability, the Company has chosen during the preparation phase to demonstrate their good long-term implantation properties on the basis of their calcification resistance and excellent hemocompatibility.

The demonstration of the biocompatibility of the material used by CARMAT in direct contact with biological tissue is very promising and has been published in a scientific journal.

CARMAT has limited the materials interfacing with blood to bovine pericardium and expanded PTFE, which are known for their biocompatibility. As the inlets and outlets, the ventricles have been designed to optimize the blood flow through the device and so minimize contacts and the risks of thrombosis.

TESTS ON TEST SYSTEMS

All of the test-bench experiments were conducted with constant attention paid to ensuring that every constraint of every component of the system is taken into account with the view of improving the overall quality of the device. CARMAT’s testing strategy was to specify the critical components of its device in order to study them separately and then to bring these components together and to test the
overall system to obtain a sufficiently high level of confidence for its device. Thus, the Company set up a general test program for its device and specified the sub-components: motor-pump units, hybrid membrane and pouch, sensors, electronics and software according several test categories (functional tests, software tests or endurance tests). All these tests and verifications have been successfully passed.

**TESTS EX VIVO AND IN VIVO**

Since 2010, the Company has carried out 23 ex vivo and in vivo implantations in order to confirm anatomical compatibility, to develop ancillary implantation instruments, to develop the surgical procedure and train teams.

Despite the limitations of the animal model for the CARMAT artificial heart project, implantation on animals was an indispensable procedural training tool. CARMAT therefore carried out between the end of 2011 and the date of this registration document the implantation of prostheses on about sixty animals.

During these tests with a duration of up to 10 days, the prosthesis operated most of the time at its maximum flow rate (9 liters / minute), without the use of anticoagulants and without dysfunction or stopping and the post-mortem examinations did not detected the presence of blood clots in the device and in the organs of the animal. The results were published in the European Journal of Cardiothoracic Surgery (European Journal of Cardiothoracic Surgery).

### 1.4.2 CLINICAL VALIDATION FEASIBILITY STUDY

In 2013, CARMAT obtained authorization from ANSM and the favorable opinion of the Patient Protection Committee (CPP) to start the feasibility study. Its objective was to verify the safety and the exploration of the main performances of the prosthesis. This study was approved by the ANSM for 4 patients in France.

The indication concerned patients whose disease had progressed at a very advanced stage and whose life-course prognosis was initiated in the short term. Under these particular conditions, a clinical follow-up of 30 days or more after implantation of the artificial heart was considered as encouraging. Success criteria included survival at 30 days.

The following table summarizes the results of the feasibility study. Details of the first two cases were published in the medical journal «The Lancet» ⁶⁴.

<table>
<thead>
<tr>
<th>Transplantation date</th>
<th>Hospital</th>
<th>Characteristics and monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 December 18, 2013</td>
<td>Georges-Pompidou European Hospital in Paris</td>
<td>Male of 76 years. Support 74 days in the hospital, died following a functional drift of the prosthesis.</td>
</tr>
<tr>
<td>2 August 5, 2014</td>
<td>Laennec Hospital of the University in Nantes</td>
<td>Male of 68 years. Exceptional recovery; Returned home for 4 months. Support 270 days; Died due to a functional drift of the prosthesis</td>
</tr>
<tr>
<td>3 April 8, 2015</td>
<td>Georges-Pompidou European Hospital in Paris</td>
<td>Male of 74 years. Support 254 days; Returned home for 4 months. Died during hospitalization due to respiratory and renal failure.</td>
</tr>
<tr>
<td>4 December 22, 2015</td>
<td>La Pitié Salpêtrière Hospital in Paris</td>
<td>Male of 56 years. Support 20 days; Died during his resuscitation.</td>
</tr>
</tbody>
</table>

DESCRIPTIO N OF ACTIVITIES

The test was voluntarily suspended by CARMAT during the analysis phases of the prostheses of patients 1 and 2. These analyzes resulted in an improvement in the selection and the validation of components of the prosthesis.

At the beginning of 2016, the feasibility study was completed with the 4th implantation. The primary endpoint (survival at 30 days) was reached in 75%. At the end of this process, the CARMAT system has accumulated a clinical experience of 21 months of operation, enabling the Company to initiate further clinical validation with the introduction of the pivotal study in mid-2016, after both approval of the ANSM and the CPP.

PIVOTAL STUDY

On August 29, 2016, with the approval of both ANSM and CPP, CARMAT announced the first implantation of its artificial heart bioprosthetic as part of the pivotal study. The aim is to validate the safety, efficiency and performance of the system and to contribute to the filing process in order to obtain the CE marking.

In view of the satisfactory results of the feasibility study, the protocol of the pivotal study may include patients with better prognosis, which would increase and accelerate recruitment.

The pivotal study initiated by CARMAT mid-2016 was suspended after the death of the first patient implanted in this pivotal study, ie the fifth patient implanted in total benefiting from the CARMAT prosthesis. The Company confirmed then that the prosthesis functioned correctly during its use by the first patient in the pivotal study. The death of this patient was linked to the interruption of the power supply of the system, following a mishandling of the batteries by the patient who caused the stopping of the prosthesis. Thus, CARMAT Support-Training teams actively worked on this postoperative follow-up aspect in order to enhance the safety of future patients.

On May 2, 2017, the ANSM (French National Agency for the Safety of Medicines and Health Products) gave CARMAT permission to resume its pivotal study in France. This decision follows the positive outcome of the analyses and actions requested by the regulator.

The setting up of an international multicenter study is part of good clinical practices and ensures a global basis for a product which is not intended to be limited to the domestic market. It reinforces the ability of CARMAT to put in place a multicenter pivotal study and to establish an international base of trained cardiac surgeons upstream of commercialization.

CARMAT wishes to extend the participation in its pivotal study to other European centers, and has already identified centers in Europe who have confirmed their interest in participating in the pivotal study, in particular important centers, in both volume and in renown in the field of circulatory support.

The extension of the clinical investigation plan to these international centers requires an effort from the Company in terms of locating all the documentation intended for the doctors and the patients and the establishment of local clinical resources and requires the obtaining of the regulatory authorization to conduct the clinical trials in each of the centers, in particular the authorization of the local ethics committees.

During the 2017 year, CARMAT stepped up its efforts to open the pivotal study to other countries in the European zone. These efforts have resulted in the obtaining of the authorization to implement implantations in Kazakhstan and the Czech Republic, in leading and internationally recognized centers (Astana National Research Center for Cardiac Surgery and Prague Institute of Clinical and Experimental Medicine respectively).

The Company announced on October 19, 2017 the realization of the first international implantation of the artificial bioprosthetic heart carried out at the National Research Center for Cardiac Surgery (Astana, Kazakhstan), then on November 27, 2017 the realization of a second implantation performed at the Institute for Clinical and Experimental Medicine (IKEM) (Prague, Czech Republic), both in accordance with the protocol of the pivotal study approved by the ANSM and in accordance with local authorizations.

More recently, CARMAT announced it has received the approval to perform implants of its total artificial heart in patients at the Heart Center of the Rigshospitalet hospital, Copenhagen, Denmark.

The Heart Center of the Rigshospitalet is an internationally recognized center for the diagnosis and treatment of all types of heart diseases. It has developed a strong expertise in treating advanced heart failure and has participated in front-line clinical studies with innovative medical therapies and devices in this field. The study will be conducted by Professor Finn Gustafsson, a leading heart failure and transplantation cardiologist whose research focuses on the use of invasive hemodynamics in patients.

Finally, CARMAT is being discussed with two other European Union members to obtain permission to implant its artificial heart as part of its pivotal study.

A total of between 20 and 30 patients should be implanted with the CARMAT artificial heart to provide the clinical validation required to submit a file for the CE mark.

In addition, positive discussion with the US Food and Drug Administration («FDA») continued to evaluate clinical development opportunities in the United States for the launch of a clinical trial in 2019. The objective of the Company would be to conduct a preliminary feasibility study. The Company
has surrounded itself with US consultants in order to assist it in its efforts.

**COMMUNICATION OF THE CLINICAL STUDY RESULTS**

CARMAT plans to communicate on the overall progress of the CE marking or on the completion of significant milestones in the pivotal study. In accordance with good clinical practice and subject to regulatory requirements or special circumstances, CARMAT will not communicate individually on patient implantations and their health status.

Thus, CARMAT presented in January 2019 the intermediate results of the first part of the pivotal study. The interim analysis included the 10 patients in the first cohort of the pivotal study, the first patient of whom was recruited in August 2016 and the last in July 2018. In total, the pivotal study foresees the inclusion of 20 patients, patients with terminal biventricular heart failure.

70% of patients in this first cohort achieved the primary objective of the study corresponding to 6 months of survival with the prosthesis or a successful heart transplant in the months following the implantation of the CARMAT device. By way of comparison, this rate was only 50% during the feasibility study.

The data collected from patients who achieved the primary objective of the study reconfirm the biocompatibility of the CARMAT prosthesis, already proven in the feasibility study, including its good safety profile, never reached by other technologies, with no stroke, no gastrointestinal bleeding and no percutaneous cable infection. In addition, these patients required only mild anticoagulant therapy.

Refer to the table below to assess the results obtained at this stage by CARMAT (Cohort 1) compared to other therapies:

<table>
<thead>
<tr>
<th></th>
<th>Survival rate at 6 months</th>
<th>Stroke</th>
<th>Bleeding / Reintervention</th>
<th>Gastrointestinal bleeding</th>
<th>Percutaneous cable-related infection</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARMAT prosthesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Faisability study</td>
<td>50 %</td>
<td>0 %</td>
<td>75 %</td>
<td>0 %</td>
<td>0 %</td>
</tr>
<tr>
<td><strong>CARMAT prosthesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal study Cohort 1</td>
<td>70 %</td>
<td>0 %</td>
<td>40 %</td>
<td>0 %</td>
<td>0 %</td>
</tr>
<tr>
<td><strong>SynCardia</strong></td>
<td>54 % - 62 %</td>
<td>23 %</td>
<td>41 %</td>
<td>20 %</td>
<td>22 %</td>
</tr>
<tr>
<td><strong>BIVAD</strong></td>
<td>46 % - 68 %</td>
<td>7 %</td>
<td>na</td>
<td>7 %</td>
<td>7 %</td>
</tr>
</tbody>
</table>

** : Lavee J et al, J Heart Lung Transplant 2018; 37; 1399-1402

In addition, the intermediate results of the pivotal study showed that cardiac transplantation is possible after implantation of the CARMAT prosthesis (3 successful operations, 100% success) and secondly that the surgery time relative to the implantation of the CARMAT device evolves very favorably with the experiment (about 5 hours to date).
1.4.3 CE MARKING

This phase, prior to the placing on the market of the prosthesis, aims to validate its compliance with European regulatory requirements. It is a process of analysis and validation by a notified body of a file prepared by CARMAT and containing all the elements of conception, production, quality and clinical effectiveness of the prosthesis.

The actions linked to this phase take place in parallel with the pivotal study and include in particular:

- The submission of the various modules constituting the technical marking dossier to the DEKRA notified body responsible for their evaluation;
- Continued endurance testing of systems;
- The location of the documentation - regulatory as intended for users - with a view to extending clinical trials, CE marking and later commercialization outside France.

During 2018 year, the technical teams have made considerable progress in setting up the file for obtaining CE marking, which is a necessary precondition for marketing the bioprosthesis.

Most of the modules were submitted in 2018, and all modules will be audited by the notified body in 2019. The finalization of the modules of the pivotal study is planned for 2019 and the evaluation and submission of the clinical module in 2020.

1.4.4 PROVISIONAL PROJECT SCHEDULE

CARMAT made in 2018 very positive moves among which:

- Clinically: The finalization of cohort 1 (10 patients) of the pivotal study, for which it communicated in January 2019 positive results. 70% of patients in this cohort achieved the primary objective of the study, which was 6 months of survival with the prosthesis or a successful heart transplant within 6 months of device implantation. In addition, the data collected from patients who achieved the primary objective reconfirm the biocompatibility of the CARMAT prosthesis, and in particular its good safety profile, never reached by other technologies.
At the industrial level: The certification of its new Bois d’Arcy production site, and the transfer of most of the production from the historical Vélizy site to that of Bois d’Arcy. Eventually, this new site will produce several hundred prostheses annually. In addition, CARMAT continued in 2018 its actions to make the production process more reliable.

With regard to market access: The further preparation of the submission of its CE marking technical file, which is scheduled for 2019; and further the continuation of a positive dialogue with the FDA (Food & Drug Administration - USA) to obtain the authorization to start a clinical trial (EFS - Early Feasibility Study) in the USA.

In terms of the transformation of CARMAT into a manufacturing and commercial company: strengthening the Company’s information systems, continuing the preparation of the commercial launch, and strengthening the management team, in the areas of Quality and Finance.

Given these advances, the CARMAT project schedule is updated as follows.

The reader is invited to refer to Chapter 2. « Risk Factors », for an informed appreciation of this timetable, as well as to the Company’s regular press releases on the progress of the project.

### SCOPE OF ACTIVITY

#### 2019

**EUROPEAN MARKET ACCESS**
- Continuation of the implantations for the pivotal study (cohort 2)
- Filing of the technical dossier for CE marking

**US MARKET ACCESS**
- Beginning of implantations in the United States as part of a feasibility study (EFS)

**COMMERCIAL**
- Marketing preparation

**INDUSTRIAL**
- Increased production at the Bois d’Arcy plant
- Improvement of production processes and standardization
- Strengthening the supplier network
- Development of logistics functions

**PRODUCT**
- Improvement and reliability of the product for CE marking

**COMPANY TRANSFORMATION & FINANCING**
- Industrial and commercial transformation of the Company, upgrade of the organization, operation and information systems / Preparation of new funding stages

#### 2020

**EUROPEAN MARKET ACCESS**
- Obtaining CE marking
- Discussions with the main European agencies to obtain funding for innovation

**US MARKET ACCESS**
- Continuation of the feasibility study (EFS) in the United States

**COMMERCIAL**
- Commercial launch in EMEA

**INDUSTRIAL**
- Continued optimization of the supply chain
- Continuous improvement of processes and production capacity
- Continuation of development of logistics functions

**PRODUCT**
- Improvement and reliability of the product for CE marking

**COMPANY TRANSFORMATION & FINANCING**
- Industrial and commercial transformation of the Company, upgrade of the organization, operation and information systems / Preparation of new funding stages

#### 2021

**EUROPEAN MARKET ACCESS**
- Obtaining financing for innovation in some European countries

**US MARKET ACCESS**
- Start of the pivotal study in the United States

**COMMERCIAL**
- Commercial development in EMEA

**INDUSTRIAL**
- Continuous improvement of processes and production capacity

**PRODUCT**
- Improvement and reliability of the product for CE marking

**COMPANY TRANSFORMATION & FINANCING**
- Industrial and commercial transformation of the Company, upgrade of the organization, operation and information systems / Preparation of new funding stages

Source CARMAT – Provisional project schedule
1.5 STRATEGY OF THE COMPANY

1.5.1 REGULATORY STRATEGY

FRENCH AND EUROPEAN CONTEXT

The CARMAT heart is an active implantable medical device (AIMD) and, as such, must satisfy the Key Requirements of directives 90/385/EEC and 93/42/EEC to obtain the CE marking.

It is a very rigorous process of which CARMAT has already successfully passed the first step thanks to the ISO 13485-9001 certification in July, 2011. The annual audits of re-certification have also been successfully passed, the latest in July 2017.

The key requirements mentioned in various directives applicable to medical devices are as follows:

- the medical devices must not compromise the clinical state or the security of the patient;
- additionally, they must not present risks for the people who implant them, or for third parties;
- these devices are required to meet the performance determined by the manufacturer;
- they must be designed such that they can resist storage and transportation conditions.

These requirements are described in rather general terms in order to cover a large range of technologies. The manufacturer must review each key regulation in order to determine if it applies to the device, then identify the harmonized European standard that allows compliance with that key regulation to be shown. The requirement to comply with the key regulations must be the manufacturer’s priority in order to ensure that all the necessary measures have been taken so that the device does not compromise the safety and health of the patients, the user and, if required, other people, once installed, maintained and used correctly, depending on the planned use, it being understood that any risks linked to its use constitute acceptable risks with regard to the benefit brought to the patient and compatible with a high level of protection of health and safety.

Compliance with key regulations must be considered both as an objective (compliance with safety and health), and as a means of obtaining the objective. According to the European directives, each stage of the CE marking process must take into account, in addition to the considerations of security and planned usage of the device, other aspects such as the design or properties related to the construction, protection against radiation, mechanical, thermal or electrical risks, or function measurements or even labeling.

CE marking via the declaration of CE compliance is based on a complete audit of the quality assurance system with an assessment of all the Company’s processes and focusing on activities linked to the product. An exhaustive technical file must then be prepared, consisting of, in addition to the design elements, the risk management file and all the verification and validation data – in particular the results of clinical trials. The Company will then have to be audited by an independent notified body which will confirm the technical file and all of the product and organization related processes at CARMAT and if necessary at its sub-contractors. Once this audit has been successfully passed, CARMAT will be able to obtain the CE marking, which authorizes the commercialization of the product throughout the European community. Certain member states have put in place additional conditions concerning, for example, the registration or notification of market introduction.

If the clinical studies are successful and subject to no difficulties particularly in continuing the studies or the patient recruitment rate, the full CE mark file for the model artificial bio-prosthetic heart will be submitted to the notified body. So, the validation process by the notified body takes, in general, from six weeks to a few months. This process is summarized in the illustration below (refer to Paragraph 2.2 « Risks Relating to the Company’s Activity » and 2.3 « Regulatory and Legal Risks », for the risks associated in particular with clinical trials and CE marking).

AMERICAN REGULATIONS

The marketing of the CARMAT heart in the United States of America is subject to obtaining approval (PMA: Premarket Approval) awarded by the American Health Authority (FDA: Food & Drug Administration). Before submitting a PMA application to the FDA, CARMAT will be required to supplement the existing clinical file with new preclinical tests and data from a new multicenter clinical study performed on a larger population (refer to Paragraph 2.2.4 « Risks Connected With Clinical Studies in the United States »). Carrying out this study in the United States is itself subject to obtaining authorization (IDE : Investigational Device Exemption) from the FDA, based in particular on all of the pre-clinical data (technical studies, animal studies, etc.) required by the sponsor and clinical data collected in other countries.
In October 2013, the FDA published a guidance document «Early Feasibility Studies». This approach to feasibility studies was designed to acquire initial clinical knowledge when additional non-clinical testing methods are not available or are not sufficient to initiate a pivotal study. These studies may be initiated before the design of the device is finalized and may be justified on the basis of less evidence than for other types of clinical studies. This is the approach chosen by CARMAT.

In August 2018, CARMAT submitted to the FDA (Food & Drug Administration in the United States) an application for authorization to start a feasibility study (EFS - Easy Feasibility Study). CARMAT is working on this issue with the FDA teams and is conducting the necessary preclinical tests in parallel. CARMAT hopes to start the EFS by the end of 2019.

This cautious strategy would allow the integration of certain clinical data acquired in Europe into the FDA file (the aim is that the majority of the European centers selected for the pivotal study would be approved by the FDA).

1.5.2 MARKETING STRATEGY

The Company will be able to market its product throughout Europe once it has been granted CE marking, subject to applying the national systems covering the cost of the device (refer to Paragraph 2.3.4 « Risks connected with changes in reimbursement policies for medical devices »). The Company considers that the absence of reimbursement is not synonymous with the absence of sales or revenue. Hospitals in some countries have their own budgets to finance innovation and pre-reimbursement financing exists in many countries (NUB in Germany or Forfait Innovation in France, etc.).

The Company currently plans to proceed with this commercialization through a direct sales force in the principal European countries, and a distribution network in the countries deemed less strategic, at least during the initial phase.

This choice stems from two factors:

- rigorous selection of the indications and the need for technical and clinical support for each implantation. This support is provided primarily by the Company in the training and launch phase;
- a concentric approach strategy to the market involving focusing initially on the center of the target, i.e. the active heart transplantation centers (at least 20 cardiac transplants per year) followed by the less active centers, then the centres with teams dedicated to heart failure (surgery and cardiology) but who are not...
approved for transplantation and finally, if the local regulations permit, all cardiac surgery centers.

This approach should allow incremental investment. In view of the very small number of transplants, the number of truly active cardiac transplantation centres, i.e. those which use their approval and carry out a sufficient volume of transplants to maintain available trained teams, is very low and less than around ten in each major country. For example, less than 10 centers in France and Germany perform more than 20 transplants per year.

The Company therefore considers that, to cover this target consisting only of centers of excellence, a direct sales force is the most appropriate response in the initial phases of commercial development (a 3- to 5-year period post-commercial launch in Europe). In the longer term, when the Company has built up a solid clinical and medical-economic database and has confirmed the adoption of the therapy by the implantation centers, it may turn its efforts to educating referral centers in order to expand recruitment and promote growth.

The development of a commercial approach to the American market is premature at this stage.

With regard to the politics of fixing the price, the price objective of the CARMAT bioprosthetic artificial heart project remains in line with current practices of reimbursement for available devices. For example, a left mono-ventricular implantable assist device is, today, reimbursed between €60,000 and €110,000 (excluding taxes) in Europe (approximately €90,000 excluding taxes in France 65). Being a system that consists of an implantable part, but also external parts and associated pre- and post-operational services, the adjustment variables are many and could allow the adaptation to volume and reimbursement conditions specific to each center or each market.

The reimbursement procedures are many and different for each country. Therefore, the sales force will initially consist of profiles with a strong clinical background to ensure the training and adoption of the device by the medical-surgical community and the collection of medical-economic data. The Company could partner with local reimbursement experts to optimize and accelerate support.

It is in this perspective that CARMAT announced on September 1, 2016 the arrival of Stéphane Piat as chief executive officer, replacing Marcello Conviti. With his experience in the commercialization of medical devices, particularly at Johnson & Johnson Cordis or Abbott, Stéphane Piat intends to implement this strategy.

65 Liste des Produits et Prestations remboursables – LPP (ameli.fr) : regulated price per unit for the HeartMate II® is € 87 565.

1.5.3 INDUSTRIAL STRATEGY

CHOICE OF INTEGRATION MODEL

The Company designs or specifies all of the elements making up the CARMAT artificial heart project, including its external elements as well as all the ancillary tools, packaging, systems and methods intended for the validation (test benches) and production of components, sub-assemblies and systems (clean room). It has also developed strong intellectual property rights concerning all of these elements. Nevertheless, considering the very high number of specialties and expertise involved in each component and sub-assembly of the system, it was impossible to develop and especially to produce them all internally.

The Company has therefore adopted a model of integration: it designs and specifies, but entrusts the manufacturing of most of the elements to specialized subcontractors, recognized in their domain of activity and selected following rigorous consultation - elements that are then integrated into the Company’s clean room.

CARMAT integrates the components and sub-assemblies provided by manufacturers of very different sizes, methods and areas of expertise. Thus the Company has dozens of manufacturers of elements or service providers linked to the implantable part of the CARMAT system.

The challenge for a company such as CARMAT involves federating these companies with different origins and methods (some are large sub-contracting groups in the space industry and others are very small specialist companies) with common strict processes as are required by the medical technologies field and regulatory authorities. This coordination relates to technical aspects, logistics and in particular, quality. Great efforts have been made by the Company to validate and qualify these suppliers, so that each one of them conforms to the very high level of quality standards required by the active implantable medical device domain.

CARMAT’s mode of operation, its methods, and its integration process are therefore identical to those of a large group in the management of a project as complex as that of the bioprosthetic artificial heart. The creation of this network constitutes an accomplishment in its own right, and creates value for CARMAT as well as for all industry in France.

In parallel, the Company actively continues a strategy of developing a secondary source of supplies, in particular...
the transformation of critical raw materials or the supply of key components. To initiate a second source involves the selection of a new supplier, help in producing the first parts, then qualifying them while ensuring that each part comes from a source that is strictly identical to those coming from another source, including the documentation which comes with them to satisfy traceability. It is important work but vital to reduce the dependency of the Company with regards to their suppliers and to anticipate the industrialization phase.

The Company is continually adapting to the challenges of industrialization and production of prostheses in larger quantities with controlled, correctly managed quality.

**INTERNALIZED PRODUCTION AND PRODUCTION CAPABILITIES**

In contrast, the Company has kept and retained the production of the biosynthetic elements of the prosthesis (ventricular biomembrane, ventricular coverings and atrial connection interfaces) internal, protected by numerous patents and by industrial secrets.

Vélizy CARMAT’s clean room has two distinct areas, one is ISO class 5 used for the manufacturing and sterilization of biosynthetic and ventricular internal elements, the other is ISO class 7 where other elements, essentially outsourced, are assembled around the sterile «heart of the heart». The manufacturing, integration and sterilization of the prosthesis are also performed in this controlled environment by specialized and highly qualified personnel.

2017 year was marked by the construction of a new dedicated site to manufacture up to 500 units per year, site that was opened and certified in 2018. This site, with an area of 1,600 m², located in Bois d’Arcy in the immediate suburbs of Paris, has a 270 m² clean room complying with ISO 7 standards. Most of the production has already been transferred from Vélizy to Bois d’Arcy in 2018, and it is expected that this transfer will be finalized in the first quarter of 2019.

On the industrial front, the Company is also continuing its efforts to secure supply, improve information systems, adapt production processes for components and equipment, and improve the reliability of the production process. The goal is to achieve better replicability, and to increase quality and production capacity.

**MAIN PARTNERS**

In connection with Bpifrance financing (refer to Paragraph 3.110 « Important Contracts »), the bioprosthetic artificial heart project is based around CARMAT as leader, with four other partners in complementary research and development areas, thereby allowing the participation in the development of a high-technology sector in the field of medical devices:

- **Dedienne Santé** is an SME specializing in the design, manufacture, market introduction and distribution of surgical implants, mainly in the orthopedic domain. For the bioprosthetic artificial heart project, Dedienne Santé did use biocompatible PEEK to develop the assemblies which make up the structural parts of the prosthesis;

- **Iréis** (formerly called HEF R&D) is a subsidiary of the HEF group which specializes in surface engineering and has invented many tri-biological or anti-corrosion surface treatments and coatings since 1953. In connection with the total artificial heart project, Iréis performs the qualification of the motor-pump unit, which is a critical part of the prosthesis;

- **PaxiTech** is a technological spin-off of the CEA created in September 2003, whose objective is to produce and market portable fuel cells and fuel cell components, regardless of their power range. In connection with the bioprosthetic artificial heart project, PaxiTech developed a fuel cell which would eventually be used as a source of portable external energy. After having developed a first promising prototype with the company PaxiTech, CARMAT evaluates the feasibility of the industrial development of such a product with Air Liquide. The challenge would be to offer implanted patients increased mobility of at least ten hours without having to connect to the home network;

- with strong experience of almost 50 years (the company was created in 1959), **Vignal Artru Industries** (Pack’Aero group) is a specialist SME in the production of high precision mechanical micro-systems. In connection with the bioprosthetic artificial heart project, VAI produces the «motor-pump unit» (MPU) assemblies, made up of two micro-pumps and a duct. VAI is in charge of integrating these units, the various characterization and running-in tests, as well as the receiving files of motor-pump unit assemblies.

During the fourth quarter of 2017, CARMAT signed a partnership agreement with AddUp, the Joint Venture specialized in 3D printing set up by the Michelin and Fives groups. The aim of this collaboration is to strengthen the industrial development of the CARMAT heart and contribute to increase the Company’s production capacity in preparation for the large scale production phase. To this effect, CARMAT and AddUp plan to use the possibilities offered by the technology of additive manufacturing to simplify and optimize the production of mechanical primary pieces.

Thanks to AddUp’s expertise, CARMAT will ultimately be able to provide surgeons and patients with a version of its artificial heart that incorporates all the technological benefits of 3D printing, and in particular:

- optimized anatomical interfaces leading to enhanced...
anatomical compatibility and surgical comfort;

- reduction in the number of components, thus better securing the device’s assembly.

### 1.5.4 INNOVATION AND R&D MANAGEMENT

**APPLICATION OF SKILLS**

CARMAT is a company, created ten years ago, but it already enjoys – thanks to its involvement with the bioprosthetic artificial heart project and thanks to its teams – an exceptional and unique dual expertise accumulated over more than 15 years of development and collaboration with the medical world and the world of space and aeronautics, in the application of biomaterials and advanced technologies in the field of bioprosthetic artificial hearts.

Over and above the contributions of the world of medicine and the world of space and aeronautics, the Company has also found ways of bringing together skills in areas that have never been in the habit of working together on so complex a project, each acquiring expertise belonging to these fields.

Emboldened by this unique capacity for creating synergies between skills from industry and from the medical world, CARMAT’s future ambition, in addition to the field of the bioprosthetic artificial heart, is to tackle the development of new applications of its know-how in the cardiovascular domain. Original simple devices derived from research already carried out by CARMAT and the patents that it holds, in particular with regard to hemocompatible biomaterials, could also be developed. Products derived from patents which have already been submitted - particularly in the field of digital simulation and ancillary implantation materials – may also result in commercial marketing or sale of rights. Original services could also be commercialized.

However, the Company does not foresee devoting resources to these potential applications while the artificial heart project is not successfully completed. The Company continues an aggressive protection policy of its intellectual property and ensures a permanent technological watch of technologies and methods corresponding to its areas of activity.
INTELLECTUAL PROPERTY

Patents and other intellectual property rights are of fundamental importance in the medical devices sector. CARMAT regularly files patent applications to protect its innovations.

**Patents:**

CARMAT’s portfolio of patents is made up of 12 patents held in the name of the Company, classified in two categories: firstly, patents associated with the architecture of the bioprosthetic artificial heart project and secondly, patents linked to the hemocompatible materials and sub-assemblies of the prosthesis.

Details of these patents are set out below:

<table>
<thead>
<tr>
<th>Title</th>
<th>Geographical area</th>
<th>Submission / publication no.</th>
<th>Date of Submission</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>« Independent ventricular chamber implantable cardiac prosthesis »</td>
<td>France</td>
<td>FR9812941, FR2784585</td>
<td>October 15, 1998</td>
<td>Expiring on October 15, 2018</td>
</tr>
<tr>
<td>« One-piece heart prosthesis implantable in an anatomical position »</td>
<td>France</td>
<td>FR0605333, FR2902345</td>
<td>June 15, 2006</td>
<td>Expiring on June 15, 2026</td>
</tr>
<tr>
<td>« Implantable one-piece heart prosthesis »</td>
<td>France</td>
<td>FR200800184, FR2926223</td>
<td>January 14, 2008</td>
<td>Expiring on January 14, 2028</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP09290009.1, EP2078533</td>
<td>January 07, 2009</td>
<td>Expiring on January 07, 2029</td>
</tr>
<tr>
<td></td>
<td>International</td>
<td>PCT/FR2009/000008, WO2009/112662</td>
<td>January 07, 2009</td>
<td>Published on September 17, 2009</td>
</tr>
<tr>
<td>« Composite hemocompatible material and the process through which this is obtained »</td>
<td>France</td>
<td>FR0511430, FR2892939</td>
<td>November 10, 2005</td>
<td>Expiring on November 10, 2025</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP06291857.2, EP178515</td>
<td>October 25, 2006</td>
<td>Expiring October 25, 2026</td>
</tr>
<tr>
<td>« Reduced radial volume rotatory volumetric pump »</td>
<td>France</td>
<td>FR0604206, FR2900988</td>
<td>May 12, 2006</td>
<td>Expiring on May 12, 2026</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP7290571.4, EP1855005</td>
<td>May 07, 2007</td>
<td>Expiring on May 07, 2027</td>
</tr>
<tr>
<td>Title</td>
<td>Geographical area</td>
<td>Submission / publication no.</td>
<td>Date of Submission</td>
<td>Status</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>« Rapid connection device between a totally implantable cardiac prosthesis and natural atria »</td>
<td>France</td>
<td>FR0605331 FR2902343</td>
<td>June 15, 2006</td>
<td>Granted on September 05, 2008 Expiring on June 15, 2026</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP07290723.1 EP1867350</td>
<td>June 11, 2007</td>
<td>Granted on September 24, 2008 Expiring on June 11, 2027</td>
</tr>
<tr>
<td>« Connection device between a cardiac prosthesis and natural atria »</td>
<td>France</td>
<td>FR0605332 FR2902344</td>
<td>June 15, 2006</td>
<td>Granted on September 05, 2008 Expiring on June 15, 2026</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP07290724.9 EP1867351</td>
<td>June 11, 2007</td>
<td>Granted on September 24, 2008 Expiring on June 11, 2027</td>
</tr>
<tr>
<td>« Process for producing a hemocompatible item with a complex configuration and item thereby obtained »</td>
<td>France</td>
<td>FR0703339 FR2915803</td>
<td>May 10, 2007</td>
<td>Granted on June 04, 2010 Expiring on May 10, 2027</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP08290405.3 EP1992369</td>
<td>April 28, 2008</td>
<td>Granted on May 06, 2015 Expiring on April 28, 2028</td>
</tr>
<tr>
<td>« Process for obtaining a composite hemocompatible material and material obtained »</td>
<td>France</td>
<td>FR10001724 FR2959134</td>
<td>April 22, 2010</td>
<td>Granted on July 13, 2012 Expiring on April 22, 2030</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP11161291.7 EP2380608</td>
<td>April 06, 2011</td>
<td>Granted on September 12, 2012 Expiring on April 06, 2031</td>
</tr>
<tr>
<td></td>
<td>International</td>
<td>PCT/FR2011/050768 WO2011/131887</td>
<td>April 06, 2011</td>
<td>Published on October 27, 2011</td>
</tr>
<tr>
<td>« Process to ensure the connection of an anatomical duct »</td>
<td>France</td>
<td>FR1152364 FR2972919</td>
<td>March 22, 2011</td>
<td>Granted on July 04, 2014 Expiring on March 22, 2031</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP12158011.2 EP2502577</td>
<td>March 05, 2012</td>
<td>Granted on November 02, 2016 Expiring on March 05, 2032</td>
</tr>
<tr>
<td></td>
<td>International</td>
<td>PCT/FR2012/050449 WO2012/127145</td>
<td>March 05, 2012</td>
<td>Published on September 27, 2012</td>
</tr>
<tr>
<td>« Tissue endoprosthesis and the process through which this is produced »</td>
<td>France</td>
<td>FR1500457</td>
<td>March 10, 2015</td>
<td>Granted on March 24, 2017 Expiring on March 10, 2035</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP16159051.8</td>
<td>March 07, 2016</td>
<td>Published on September 14, 2016</td>
</tr>
<tr>
<td></td>
<td>International</td>
<td>PCT/FR2016/050525 WO2016/142617</td>
<td>March 07, 2016</td>
<td>Published on September 15, 2016</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>EP18179971.9</td>
<td>June 26, 2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>International</td>
<td>PCT/FR2018/051562</td>
<td>June 26, 2018</td>
<td></td>
</tr>
</tbody>
</table>
**Description of Activities**

- **Exclusive licence agreements:**

  **Exclusive licence contract with the Pierre et Marie Curie University**

  In the terms of an exclusive licence contract dated 17 June 1993, modified by amendment no. 1 of June 27, 1995 and by amendment no. 2 of November 12, 1997, the Pierre et Marie Curie University gave Matra Défense the rights to use patent no. 8800381 to plan studies and further development with a view to creating prototype artificial hearts implantable into human beings.

  Although initially it was Matra Défense which used the intellectual property rights thus granted, the benefit of this license was subsequently assumed by CARMAT, to which the Université Pierre et Marie Curie consented by way of an agreement duly signed by the Université Pierre et Marie Curie, Matra Défense, the Scientific Research Association of the Alain Carpentier Foundation and CARMAT. Under this agreement (i) the Université Pierre et Marie Curie expressly waived any benefit from all intellectual property rights linked to or resulting directly or indirectly from the work on the bioprosthetic artificial heart project and acknowledged that CARMAT was the sole owner of all the intellectual property rights that could have been attributed to the Université Pierre et Marie Curie; and (ii) in return, the Scientific Research Association of the Alain Carpentier Foundation granted at no cost, in its name and for its account and in the interest of Matra Défense, 400 CARMAT shares (equivalent to 10,000 CARMAT shares following the 25:1 stock split) to the benefit of the Université Pierre et Marie Curie.

  Patent No. 8800381 has now expired since 2008. However, the exclusive license agreement stipulates that it will be valid for five years from the date of the first marketing of the product implementing the patent claims for the European countries as well as other countries and will be tacitly renewable for two successive five-year periods, unless one or the other party cancels one year before each deadline.

- **Trade marks:**

  The Company has registered the « CARMAT » trademark in the following countries or geographical zones:

<table>
<thead>
<tr>
<th>Registration number</th>
<th>Statut</th>
<th>Date filed</th>
<th>Renewal date</th>
<th>Territories</th>
<th>Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>023184827</td>
<td>Recorded</td>
<td>Sept. 23, 2002</td>
<td>Sept. 23, 2022</td>
<td>France</td>
<td>9, 10, 42</td>
</tr>
<tr>
<td>007374821</td>
<td>Recorded</td>
<td>Oct. 29, 2008</td>
<td>Oct. 29, 2028</td>
<td>Community (European Union)</td>
<td>9, 10, 42</td>
</tr>
<tr>
<td>1022720</td>
<td>Recorded</td>
<td>June 19, 2009</td>
<td>June 19, 2019</td>
<td>International Designations: China, Japan, Switzerland, Russia</td>
<td>9, 10, 42</td>
</tr>
<tr>
<td>3663230</td>
<td>Recorded</td>
<td>January 07, 2009</td>
<td>August 04, 2019</td>
<td>United States (USA)</td>
<td>10, 42</td>
</tr>
<tr>
<td>1442665</td>
<td>Recorded</td>
<td>June 25, 2009</td>
<td>Sept. 27, 2026</td>
<td>Canada</td>
<td>10, 42</td>
</tr>
<tr>
<td>200911637</td>
<td>Recorded</td>
<td>June 24, 2009</td>
<td>June 24, 2019</td>
<td>South Africa</td>
<td>10</td>
</tr>
<tr>
<td>200911637</td>
<td>Recorded</td>
<td>June 24, 2009</td>
<td>June 24, 2019</td>
<td>South Africa</td>
<td>42</td>
</tr>
<tr>
<td>1838058</td>
<td>Recorded</td>
<td>July 09, 2009</td>
<td>July 09, 2019</td>
<td>India</td>
<td>10, 42</td>
</tr>
</tbody>
</table>
- Domain names:

The Company has filed the following domain names:

<table>
<thead>
<tr>
<th>Domain name</th>
<th>Date reserved</th>
<th>Renewal date</th>
</tr>
</thead>
<tbody>
<tr>
<td>carmatsas.com</td>
<td>October 29, 2008</td>
<td>October 29, 2028</td>
</tr>
<tr>
<td>carmatsas.fr</td>
<td>October 29, 2008</td>
<td>October 29, 2028</td>
</tr>
<tr>
<td>carmatsas.eu</td>
<td>October 29, 2008</td>
<td>October 31, 2028</td>
</tr>
<tr>
<td>carmat.tel</td>
<td>February 20, 2009</td>
<td>March 22, 2019</td>
</tr>
<tr>
<td>carmatsa.fr</td>
<td>April 29, 2010</td>
<td>April 29, 2021</td>
</tr>
<tr>
<td>carmatsa.com</td>
<td>April 29, 2010</td>
<td>April 30, 2021</td>
</tr>
<tr>
<td>carmatsa.eu</td>
<td>April 29, 2010</td>
<td>April 29, 2021</td>
</tr>
</tbody>
</table>
2

RISKS FACTORS
Caution:

Investors are invited to take into consideration all the information appearing in this Registration Document, including the risk factors described in this Chapter.

When preparing this registration document, the Company carried out a review of the risks which might have a significant unfavorable impact on its activity, its financial situation, its performance, its development or its prospects, and it considers that there are no other significant risks than those presented.

However, investors’ attention is drawn to the fact that other risks which are unknown or whose materialization is not considered, at the date of filing this registration document, as liable to have a significant unfavorable impact on its activity, its financial situation, its performance, its development or its prospects, might or may exist.

2.1 RISKS RELATING TO THE MARKET IN WHICH THE COMPANY OPERATES

2.1.1 RISKS RELATED TO MARKET SIZE

The Company’s bioprosthetic artificial heart aims in particular to be the destination therapy for patients with biventricular end-stage heart failure whose condition is life-threatening in the short term, who have exhausted all therapeutic alternatives and who do not have access to a heart transplant due to their age, comorbidities or the shortage of donor organs.

The scientific community agrees that the prevalence of this indication is increasing significantly due to population ageing and progress made in the treatment of myocardial infarction, which prevents many deaths in the short term, but which substantially increases the absolute number of people living with a compromised cardiac function and with a heart failure in the clinical sense.

However, progress that could be made in the area of prevention of certain risk factors of cardiovascular diseases in general (nicotinism, hypertension, obesity, etc.) or specific therapeutic breakthroughs in the field of heart failure could lead to a reduction in the prevalence of the disease in its advanced stage.

Moreover, the population targeted by the indication is heterogeneous and mostly elderly. It is possible that the Company’s bioprosthetic artificial heart may not obtain the indication or adoption by the medical and scientific community for the whole of the population currently targeted (about 0.5% of the total number of heart failure patients).

A significant reduction in the market to which the Company could propose its product, due to a reduction in the prevalence of the disease or a limitation of the indications, whether due to a decision by the regulatory authorities or due to a failure of the scientific community and healthcare professionals to adopt its bioprosthetic artificial heart, could have a significant, unfavorable impact on the Company’s activity, its financial situation, its performance, its development or its prospects.

2.1.2 RISKS RELATING TO COMPETITION

Potential competition to CARMAT comprises:

- on the one hand, total artificial hearts, whether on sale or still in development, and implantable biventricular assist devices (BIVADS) with a high potential to serve as substitutes for the heart developed by CARMAT;

- In this segment, only the Syncardia® player has a total artificial heart product currently marketed in Europe and the United States. After facing financial difficulties («Chapter 11»), the company received in September 2016 the support of the private equity fund Versa Capital Management, which could stimulate this competitor of CARMAT in a perennial way.

- on the other hand, and to a lesser degree, implantable right/left ventricular assist devices (RVAD/LVAD), which are less apt to serve as substitutes as they only support one ventricle.

- In this other segment, two main players are active:

  - the historical leader, Thoratec®, whose more than 18,000 products were implanted at the end of 2014,
and who was bought by mid-2015 by Saint Jude Medical on the basis of a valuation of $ 3.3 billion, even though HeartMate® products may have resulted in relatively high levels of complications including thrombosis. In April 2016, the Abbott Group and Saint Jude Medical announced their merger, valuing Saint Jude Medical at approximately $ 25.0 billion. The new group created as a result of this merger is positioned as a global leader in medical devices, with applications in the cardiac field, diabetes treatment, or vision disorders. Abbott announced in late August 2017 that it had received FDA approval for its HeartMate® 3 left ventricular support system (LVAD) for Bridge To Transplant indication, and in October 2018 for Destination Therapy. According to Abbott, this system offers a new option for physicians who manage patients with advanced heart failure requiring short-term hemodynamic support (awaiting transplant).

The system also provides new patients with new devices that embody the evolution of left ventricular assist (LVAD) therapy, such as improving blood flow in a pump that uses a complete magnetic levitation to reduce the trauma of blood passing through the system. However, this system is non-pulsatile and is limited to assistance from the left ventricle.

FDA approval for Bridge To Transplant indication of the HeartMate® 3 system was supported by a clinical study that showed a significant improvement in patients with heart failure, an 83% increase in walking distance, and an improvement of 68% of quality of life to six months. Patients receiving the HeartMate® 3 system also had a survival rate of 86% at six months. During the clinical study, according to Abbott, the HeartMate® 3 system did not have any presumed or established blood coagulation in the pump at six months.

The clinical study included more than 1,000 patients with Class IIIIB or IV heart failure in the New York Heart Association (NYHA). Patients were monitored for a six month short-term endpoint and continue to be monitored for a two-year long-term endpoint.

FDA approval for Destination Therapy of the HeartMate® 3 system was supported by a clinical study of 366 patients comparing survival of patients using HeartMate® 3 to patients using HeartMate® 2. The study showed a percentage 2-year survival (no stroke and no pump change) of 77.9% for HeartMate® 3 users compared to 56.4% for HeartMate® 2 users.

- HeartWare®, the main competitor of Thoratec®, with products such as HVAD®, designed to assist cardiac function but not to substitute for it. This company was acquired by Medtronic in August 2016, for a total valuation of $ 1.0 billion. This acquisition, through the financial support provided by Medtronic, among the world leaders in medical devices, reinforces HeartWare®’s ability to continue its activities and the development of new products competing with the CARMAT artificial heart.

As at the date hereof CARMAT is not currently aware of any existing device or project which involves or plans to involve the use of either biological materials or self-regulation via multiple integrated sensors. These two characteristics are at the core of the technological innovation that CARMAT intends to offer to patients.

Nevertheless, the medical devices market is highly competitive and rapidly evolving. In particular, the Company competes with very larger companies which possess greater industrial and commercial experience and superior resources. Consequently, the Company cannot warrant that its product will:

- obtain the necessary regulatory approvals and reach its intended markets faster than rival products;
- be competitive vis-à-vis other products that have been developed or are in development, which may prove to be cheaper, safer or more efficient;
- adapt rapidly enough to new technological developments and scientific advances;
- be accepted by medical establishments, physicians or patients in place of existing treatments, and;
- compete effectively with other products for treatment of the same pathologies.

Even if the Company’s product is marketed successfully, it may be slow to gain acceptance in the market, leaving the Company in a position where its revenues are insufficient to recoup the costs incurred. In order to ensure that its product is accepted by the market ahead of existing products, the Company will have to make significant efforts in terms of both marketing and capital investment. To date, the Company has not undertaken any significant marketing activity since its product is still in clinical development phase.

Lastly, the Company’s contracts with its employees do not contain non-competition clauses. The Company therefore does not enjoy the protection afforded by such clauses; however, it intends to maintain and develop a policy of securing staff loyalty by awarding interests in its share capital to its employees.

If all or part of the aforementioned risks materialized, this could have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development or its prospects.
2.1.3 RISKS OF COMMERCIAL FAILURE

To date, if the Company succeeds in obtaining CE marking in the European Union for the CARMAT bioprosthetic artificial heart and a product marketing authorization from the FDA in the United States enabling it to market its bioprosthetic artificial heart, it may take time to secure the backing of the medical community, especially cardiologists, cardiac surgeons and third-party payers. Whether or not the market accepts the bioprosthetic artificial heart quickly or not will depend in particular on the following factors:

- the medical profession’s perception of the therapeutic benefit of the bioprosthetic artificial heart;
- the medical profession’s and patients’ perception of the improvement in comfort and quality of life;
- the demonstration of product efficacy and safety;
- the number of establishments likely to carry out artificial heart implants;
- the process and the quality of training of cardiac surgeons in a new surgical technique;
- the cost of the treatment;
- the healthcare payment policies of governments and other third parties;
- the effective implementation of a scientific publicity strategy;
- the possible occurrence of adverse effects in its tests or in the clinical trials of its competitors, once the CE marking has been obtained;
- the support of recognized experts;
- the willingness of targeted patients to try a new product; and
- the willingness of professionals to prescribe the product.

Poor market penetration resulting from any one of these factors could have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development and its prospects.

2.1.4 RISKS RELATING TO THE ACHIEVEMENT OF NON ORGANIC GROWTH

The Company’s commercial activities will in the long term depend partly on its ability to constantly improve and expand its product offerings, and in particular systems relating to the power supply and remote diagnosis of the bioprosthesis, in order to meet constantly changing market requirements, face up to strong competitive and technological pressure and extend its geographic coverage.

To go on that way, the Company might therefore have to consider making selective acquisitions of new or complementary products or technologies. The execution of this strategy partly depends on the Company’s ability to identify attractive targets, to acquire them in satisfactory conditions and to integrate the acquired targets successfully into its operations or its technology.

Moreover, the acquisition of products, technologies, teams or companies, and the conclusion of other significant transactions could entail a significant cost burden for the Company. The Company could also have to finance such acquisitions by borrowing or by issuing securities, which could cause it to take financial risks, or have a dilutive impact for its shareholders.

The activity, financial situation, performance, development and prospects of the Company could be significantly affected by the materialization of one or more of these risks.

2.2 RISKS RELATING TO THE COMPANY’S ACTIVITY

2.2.1 RISKS OF DEPENDENCE ON A SINGLE PRODUCT, THE BIOPROSTHETIC ARTIFICIAL HEART, AND THE TECHNOLOGICAL APPROACH ADOPTED BY THE COMPANY

The Company remains dependent on the clinical development and commercial success of its bioprosthetic artificial heart. The development of this complex bioprosthesis, which the Company can not guarantee the outcome, required and still requires significant investments until its commercialization phase in terms of time and financial resources, as well as the involvement of highly qualified staff.
CARMAT’s future success and its capacity to generate revenue will thus depend on the technical and commercial success of this medical device, and specifically on a number of conjunctural factors, such as:

- the authorization and success of clinical trials necessary for obtaining CE marking for the CARMAT artificial heart in the European Union, being specified that if the results of these studies are not satisfactory or conclusive, the Company may have to choose between abandoning the program, resulting in the loss of the corresponding investment in time and money, or its continuation, without guarantee that the additional expenses thus incurred will lead to success;
- obtaining from the FDA an IDE (Investigational Device Exemption) allowing the conduct of a trial in the United States, necessary to obtain a PMA (Premarket Approval), a prelude to the placing on the US market, or in accordance with the provisions published in October 2013 by the FDA in its guidance document «Investigational Device Exemptions for Early Medical Feasibility Device Clinical Studies, including certain First in Human (FIH) Studies» (refer to paragraph 1.5.1 «Regulatory Strategy» of the Registration Document);
- the success of the commercial launch; and
- acceptance of the bioprosthetic artificial heart by the medical community, and more particularly by cardiologists and cardiac surgeons, as well as by third party payers (e.g. social security systems).

The regulatory barriers to the control, manufacture and marketing of the CARMAT bioprosthetic artificial heart are all stronger as this product constitutes a technological innovation. The combined use of biological materials and a system of self-regulation by means of multiple onboard sensors being unprecedented, the manufacture of a product meeting all the constraints that would be imposed presents a challenge as for its technical development that make it difficult to predict the timing and cost of product development as well as the subsequent requirements of regulatory authorities.

This product requires surgery and the assistance of a seasoned team of surgeon(s), anesthetist(s), perfusionist(s) and nursing staff (at the point of their training, see risk factor 2.2.6 in this registration document), the success of the implementation of the CARMAT bioprosthetic artificial heart also depends on the intervention of third parties that the Company can not control. Surgeons could use the CARMAT bioprosthetic artificial heart inappropriately. Misuse could undermine the Company’s image and could in some cases lead to legal action against it. All of these consequences could have adverse effects on the general business of the Company.

If CARMAT does not manage to finalize the clinical and commercial development of its bioprosthetic artificial heart, the Company’s activity, its financial situation, its performance, its development and its prospects could be significantly affected.

In the future, capitalizing on the expertise acquired within the framework of its bioprosthetic artificial heart project, CARMAT plans to develop new applications of its expertise in the cardiovascular field or apply this expertise and its intellectual property to other fields of application. However, the development of complementary projects could be delayed insofar as the artificial heart project is at present the Company’s priority. Moreover, CARMAT cannot rule out the possibility that it might not manage to have other products enabling it to reduce this dependence. Such a situation would also have a negative impact on its development and its prospects.

The realization of all or part of the aforementioned risks could have a material adverse effect on the Company’s business, financial position, results, development or prospects.

### 2.2.2 RISKS RELATING TO THE FUTURE RESULTS OF CLINICAL STUDIES

As part of its development, the Company will make use of numerous studies to confirm the safety and efficiency of its products. After the successful completion of the feasibility study in early 2016, the Company initiated the pivotal study protocol. The results of clinical studies are in any case uncertain. If the Company were unable to obtain positive results proving the therapeutic breakthrough represented by its products, the Company might not obtain the regulatory approvals required for their marketing. If such a risk were to materialize, the Company’s ability to win market share would be negatively affected in a significant manner, and this would have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development and its prospects.

If the Company is unable to satisfactorily complete the necessary clinical studies, including obtaining positive results and meeting the other requirements for obtaining a regulatory approval, it is possible that it may never generate revenues with its future products. It could also have to limit or abandon certain development programs.

Lastly, investors could misinterpret the clinical results that the Company might report to the market, partly because it would be hard to establish conclusions in relation to the primary objectives set within the framework of the clinical studies, and partly because the data and analyses provided could be complex to understand.

If one or more of these risks materialized, this could have
RISKS FACTORS

2.2.3 RISKS RELATING TO CLINICAL STUDIES IN EUROPE

To obtain the certificate allowing CE marking for its bio-prosthetic artificial heart, the Company will have to perform clinical studies on a significant number of patients in several centers in Europe. These studies and the publications of the results of these studies should make it possible to rapidly make the products developed by the Company known to important hospital centers and doctors recognized for their expertise in the area of transplantation and circulatory support. However, the quality and relevance of these studies depend on the Company’s ability to recruit the planned number of patients within a limited period of time so as to be able to publish the results rapidly. The remoteness or geographic distribution of clinical study centers could give rise to operational and logistic problems, which could cause additional costs and delays.

If the Company were unable to recruit the required number of patients, thereby causing delays in the clinical studies and in the publication of their results, this would postpone the recognition of the Company’s products and of its capacity for winning market share, which could have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development or its prospects.

Moreover, the Company depends and will depend on third-party CROs (Contract Research Organizations) to conduct its clinical studies. Although the Company counts on these organizations to provide a high-quality service relative to the Company’s clinical studies, it cannot control all aspects of their activities. If these third parties do not fulfill their contractual duties or obligations, or if they do not meet deadlines, if it is necessary to replace them or if the quality and accuracy of the clinical data that they collect are compromised, the clinical studies planned by the Company could be extended, delayed or canceled. Any extension, delay or cancelation would have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development or its prospects.

2.2.4 RISKS RELATING TO CLINICAL STUDIES IN THE UNITED STATES

As stipulated in paragraph 1.5.1 « Regulatory strategy », there are several ways in which the Company can access the American market, but these steps relating to design and setting up clinical studies are costly.

Although the Company has already initiated relations with American opinion leaders and specialists in regulatory matters, it has however never carried out clinical studies in the United States or under the authority of the FDA, and this could have a negative impact on the time and costs involved in such studies. No assurance can be given that the Company will be able to carry out the planned clinical studies in the United States profitably and within a reasonable time frame.

Furthermore, it is possible that the results of these studies will not be positive, that they will cost far more than expected, and that the HUD and/or PMA will never be granted. If one of these events occurred, it could have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development and its prospects.

2.2.5 OTHER SPECIFIC RISKS CONNECTED WITH CLINICAL TRIALS

The Company is currently in the phase of performing the pivot study required for CE marking. It currently initiate the steps required to obtain authorization for product marketing in the United States, in accordance with the procedures contained in paragraph 1.5.1 « Regulatory strategy ».

For this purpose CARMAT have to perform the industrial assembly of prostheses intended for clinical trials, with higher volumes than in the past.

In a context of validation of an innovative production process involving numerous subcontractors and the production transfer to the new Bois d’Arcy site, the planned deadlines may be extended even further for production of the prostheses required for these trials, and then in carrying out the trials themselves. Such a situation, if it occurred, could have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development and its prospects.

The disclosure of confidential information relating to the performance of clinical trials work in progress, and in particular the disclosure of information making it possible to...
identify, directly or indirectly, persons taking part in the trials (personal health data) could not only adversely affect the perceptions of the medical community and the general public regarding the CARMAT product and its prospects, and also expose the Company to a risk of legal action initiated by the persons in question and/or their families.

It should be noted that the Company could decide, or indeed the regulatory bodies could demand, that the Company suspend or put an end to the clinical trials if the patients were exposed to unexpected, serious risks. Deaths and other undesirable events might occur in connection with the trials, thus causing delays or interrupting the trials and thus preventing the Company from pursuing the development of its bioprosthetic artificial heart in the targeted indication or in other indications.

Clinical trials are costly. If the results of these trials are unsatisfactory or inconclusive, the Company may be required to choose between abandoning its program, resulting in the loss of the corresponding investment in time and money, or continuing, with no guarantee that the additional expenses incurred will lead to a successful outcome.

The Company’s inability to carry out and complete these clinical trials successfully could have a significant, unfavorable impact on its activity, its prospects, its financial situation, its performance and its development.

### 2.2.6 RISKS CONNECTED WITH A SLOWDOWN IN THE COMPANY’S EFFORTS TO TRAIN CARDIAC SURGEONS

In order to ensure the success of the Company’s marketing efforts, it is essential that a sufficient number of cardiac surgeons are trained by the Company and that they have at their disposal the necessary instructions to implant the bioprosthetic artificial heart.

The Company considers that its methods for training surgeons comply with the relevant legislation in the European Union countries in which it will initially market the bioprosthetic artificial heart, and with FDA regulations. However, these methods for training surgeons may be subject to specific local regulations governing relations between manufacturers of medical devices and health professionals. Thus in France, training programs are subject to the prior approval of the Ordre des Médecins (the French Order of Physicians*), issued at the request of the medical device manufacturer.

This training process could therefore turn out to be longer than predicted and thus affect growth in the Company’s sales. If the Company could not adequately train surgeons, the surgeons are at risk of carrying out inappropriate operations or surgical procedures that could delay or stop performance of the clinical trials, or even cause the death of patients.

This type of situation could undermine the image of the Company and possibly lead to legal proceedings being brought against it. Such situations would have unfavorable impacts on the widespread adoption of the bioprosthetic artificial heart and, more generally, on the Company’s activity, financial situation, performance, development and prospects.

### 2.2.7 RISKS RELATING TO THE ADOPTION OF THE CARMAT BIOPROSTHETIC ARTIFICIAL HEART BY CARDIAC SURGEONS, CARDIOLOGISTS, HEALTH CARE PROFESSIONALS, OPINION LEADERS AND PATIENTS

The Company believes that cardiac surgeons, cardiologists and other health professionals will only use its products on a large scale when they have become convinced, through clinical data or scientific publications, that its product offers benefits or is interesting alternative to existing products on the market. These same professionals may be reluctant to change their treatment practices or may reconsider the use of the Company’s bioprosthetic artificial heart. In addition, patients themselves will only be interested in the CARMAT bioprosthetic artificial heart if they perceive it as a factor in improving their comfort and quality of life compared to existing treatments.

The development of ventricular assist devices has given rise in recent years to a growing interest in miniature axial or centrifugal pumps with non-pulsatile flow. The CARMAT bioprosthetic artificial heart is intended for different indications and will offer features that these products do not have, such as the use of biological materials and sensors to ensure physiological pulsatile flow according to metabolic demand.

In addition, the lack of accuracy in the media coverage of the Company, including the eventual death of one or more patients, could negatively influence the immediate or term membership of patients with CARMAT bioprosthetic artificial heart. The occurrence of adverse effects on patients with CARMAT bioprosthetic artificial heart, but also on patients with other clinical trials involving artificial hearts, could lead to the requirement of additional regulatory conditions by the authorities, to a perception public
delays, delays in granting regulatory authorizations at the testing or approval stage, increased requirements for CE marking, or reduced demand for the product.

Failure of the Company to convince cardiac surgeons, cardiologists and other health professionals of the benefits and benefits of its products would result in poor market penetration that would have a material adverse effect on the Company, its business, its financial position, results, development or prospects.

If the Company was unable to convince cardiac surgeons, cardiologists, other healthcare professionals and patients of the benefits and advantages and the safety of its products, the result would be weak market penetration which would have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development or its prospects.

2.2.8 DEPENDENCE RISKS RELATING TO CURRENT AND FUTURE STRATEGIC PARTNERSHIPS AND COLLABORATIONS

As the Company is not involved in producing the various components of the bioprosthetic artificial heart, but rather assembles them in order to create and market this complex bioprosthesis itself, it could be dependent on these partners or other suppliers of raw materials, components, sub-assemblies or essential services.

In particular, the Company cannot control the amount or the timing of the resources which its existing or future partners and suppliers devote and will devote to the bioprosthetic artificial heart. It is possible that these partners or suppliers may not fulfill or may be unable to fulfill their obligations in line with the Company’s expectations. As a result, the Company could face development delays which could have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development and its prospects. To limit this risk, the Company carries out risk analysis initiatives in relation to the various subcontractors with a view to implementing replacement solutions where required, and intends to systematically introduce double-sourcing for the mass production phase.

Since its foundation, furthermore, CARMAT has always collaborated with renowned cardiac surgery teams. Three French centers have been selected and trained to participate in the first phase of human clinical trials: the Georges Pompidou European Hospital in Paris, the Marie Lannelongue Surgical Center in Le Plessis-Robinson and the Laennec Hospital, Nantes. 3 foreign centers are currently participating in the pivotal study.

The Company could become dependent on these first French transplantation centers and their cardiac surgery teams. This could slow down the general acceptance of the artificial heart and the transfer of surgical procedure and skills acquired during the first clinical trials to other transplantation centers and, as a result, could have negative consequences on the Company’s expansion and development.

However, if all or part of the aforementioned risks materialized, this could have a significant unfavorable impact on the Company’s activity, its financial situation, its performance, its development or its prospects.

2.2.9 RISKS CONNECTED WITH OUTSOURCING THE MANUFACTURE OF THE COMPONENTS OF THE BIOPROSTHETIC ARTIFICIAL HEART

The Company’s role is to assemble various components into the bioprosthetic artificial heart, the manufacture of numerous components being outsourced to different suppliers. The Company therefore depends on third parties for the manufacture of most of the components and sub-assemblies forming the bioprosthesis and its power and control systems (see Paragraph 1.5.3 « Industrial strategy »). CARMAT’s capacity to market its bioprosthetic artificial heart will partly depend on its capacity to obtain from its suppliers components that have been manufactured in strict compliance with the regulatory provisions and established protocols, in a profitable manner and in the quantities requested.

It is not possible for the Company to control the amount or the timetable of the resources which its suppliers will devote to manufacture of the components of the bioprosthetic artificial heart.

Problems might arise during the manufacturing process for various reasons, such as equipment failure, breach of specific protocols and procedures, or problems with the supply of raw materials.

Certain suppliers may not wish to make commitments beyond the pre-production phase due to specific regulatory or legal risks related to the field of active implantable medical devices.

If relations with its suppliers break down or deteriorate, the Company might find itself unable to form new relations with other suppliers under commercially acceptable
RISKS FACTORS

conditions, or even not find equivalent suppliers, which could adversely affect its ability to produce, develop and market its bioprosthetic artificial heart successfully.

If the Company were to change critical suppliers (biological cardiac valves, motor-driven pump unit, long-term implantable PEEK, implantable expanded PTFE, etc.) for its products, it would be asked to perform revalidation of the manufacturing process and procedures in accordance with the standards in force. Obtaining this new CE marking could be costly and time-consuming, and it could require the attention of the Company’s most qualified staff. If this new CE marking were to be refused, the Company could be forced to find an alternative supplier, which could delay the production, development and marketing of its products and increase their manufacturing costs.

Moreover, dependence on third-party manufacturers creates additional risks which the Company would not have had to face if it produced the components itself, namely:

- non-compliance of components manufactured by third parties with regulatory provisions and quality control;
- breach of agreements with the Company by third parties; and
- termination or non-renewal of these agreements for reasons outside the Company’s control.

If it turns out that products manufactured by third parties do not comply with regulatory provisions, sanctions could be imposed on the Company. These sanctions might include fines, injunctions, claims for damages, the refusal of regulatory authorities to allow it to carry out clinical trials or to grant it CE marking or any other authorization for marketing of its bioprosthetic artificial heart, delays in obtaining authorizations or the suspension or cancelation of authorizations, the revocation of licenses, the seizure or recall of its products, operational restrictions and criminal prosecutions.

These events could have a significant, unfavorable impact on the Company’s activity, its prospects, its financial situation, its performance and its development.

Although the Company has always sought to develop sources of procurement from several suppliers and sub-contractors so as to reduce the risks referred to above, CARMAT is still dependent on a single supplier for a number of materials and components.

Faced with the problem of recurring overloads faced by certain suppliers in the high-tech sector, CARMAT has already begun to identify secondary suppliers for the most critical parts of the prosthesis and external sub-assemblies, in order to ensure the reliability of supplies and thus ensure sufficient production capacity. This selection must be conducted in line with strict criteria for the quality, skills and production facilities of the suppliers. Consequently, CARMAT must undertake surplus production, validate the industrial processes and verify that the products obtained are identical to those from its first procurement source. In some cases, CARMAT will probably have to vertically integrate certain outsourced processes.

If the Company were to encounter difficulties in the procurement of these materials, biological products or electronic or electromechanical components, if new standards for the use of these materials were to come into force or if it were unable to keep to these sub-contracting agreements, enter into new agreements or obtain the materials or biological products needed to develop and manufacture its bioprosthetic artificial heart and electric power supply system in the future, its activity, its financial situation, its performance, its prospects and its development might be significantly impacted.

In time, during the marketing phase of the bioprosthetic artificial heart, the Company’s gross margin could be affected by fluctuations in the market prices of raw materials such as animal pericardium, expanded PTFE and other implantable polyurethanes and biological valves; these are hard to predict or control and could have an unfavorable impact on the Company’s activity, financial situation, performance, development and prospects.

2.2.10 RISKS RELATING TO INDUSTRIAL PROCESS DYSFUNCTION (SUCH AS NON-COMPLIANCE WITH MATERIOVIGILANCE AND PRODUCT TRACEABILITY)

The Company’s products are classified as medical devices and, as such, are subject to specific regulations in all the countries in which they are manufactured, tested or marketed. These regulations impose obligations regarding, in particular:

- design;
- product preclinical and clinical trials carried out on humans;
- product manufacturing, quality control and quality assurance;
- product labeling, including user manuals;
- product storage;
- product identification and traceability;
- data storage procedures; and
- supervision after products are put on the market and reporting of incidents related to the use of the products (deaths, serious injuries, dysfunctions, etc.).

These regulations apply to the Company as a manufacturer of these products.

At present, the Company depends on third-party
RISks fACTORS

companies to manufacture most of the components and sub-assemblies forming the bioprosthesis and its power and control systems, and this will no doubt continue to be the case in the future. The Company cannot guarantee that its suppliers or subcontractors comply or will comply with the applicable regulations. The notified body, during a certification or monitoring audit, or the regulatory authorities, during an inspection or on the occasion of any other regulatory process, could identify failures to comply with the applicable regulations or standards and request that this be remedied by carrying out corrective actions that could interrupt the manufacture and supply of the Company’s products.

The suspension, total stoppage or total or partial prohibition of the activities of the Company’s suppliers and subcontractors could adversely affect the Company’s reputation and have a significant unfavorable impact on the use or sale of the Company’s products.

The Company has established a quality system which is based on procedures aiming, among other things, to detect any nonconforming product internally or externally. This quality system has been certified by a third-party organization in accordance with the regulatory requirements of the applicable European Directive 93/42/EEC and the reference standards (ISO 9001 and ISO 13485). These procedures are included in a compliance defect management system with a view to:

- identifying and recording compliance defects relating to the products or the quality system;
- recording of all investigations and analyses relating to analysis of the causes of these compliance defects and the related risks;
- identifying and implementing corrections or corrective and preventive measures; and
- measuring the efficiency of the actions taken to correct the compliance defects.

The treatment of any incident reporting having consequences for the patients and/or users and/or third parties is defined by the regulations relating to materiovigilance which describes the procedures for reporting incidents to the competent authorities. The Company has an internal procedure for monitoring and analysis of incident reports received and, where applicable, for their reporting by the materiovigilance correspondent to the national regulatory authorities (e.g., the French national agency for medicine and healthcare product safety, ANSM).

Failure to comply with the compliance obligations may result in sanctions, including a refusal to grant CE marking, which may also have a negative impact on the assessment of the device in other non-European jurisdictions. After obtaining the CE marking, these deficiencies may also lead to the suspension or withdrawal of authorizations, seize or recall of products, restriction of use and criminal proceedings which may, individually, significantly increase the costs borne by the Company, to delay the development and commercialization of its bioprosthetic artificial heart and thus to have a significant adverse effect on its activity, its financial situation, its results, its development and its prospects.

Dysfunctions could nevertheless occur, and this could have an unfavorable impact on the Company’s activity, financial situation, performance, development and prospects.

2.3 REGULATORY AND LEGAL RISKS

2.3.1 RISKS RELATING TO REGULATIONS AND REGULATORY CHANGE

The control, manufacture and sale of the Company’s products are subject to obtaining and maintaining the necessary legal and regulatory authorizations and certifications for the marketing of medical devices. Indeed, the Company’s products are covered by strict and constantly changing regulations.

Compliance with this regulatory process may prove long and costly, and no guarantee can be given that the authorizations required for new products or changes to existing products will be obtained, or obtained within an acceptable period, or that an authorization will not be withdrawn in the future or be subjected to major post-marketing study requirements. Throughout the world, countries have adopted more demanding regulatory conditions than in the past, and this has increased or could increase the time and uncertainty involved in new product launches, and the clinical and regulatory costs involved in these launches. If certification or authorization for marketing the Company’s products were refused or removed or subjected to major post-marketing study requirements, their marketing could be delayed or prohibited in the countries in question, or the margins on sales of these products could be negatively affected by the increase in study costs, and each of these risks could have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development and its prospects.

The clinical and commercial development of the
Company’s bioprosthetic artificial heart requires everyday working relations with numerous doctors and healthcare professionals who have knowledge and experience essential for its development. These professionals contribute as researchers, consultants, instructors, inventors or speakers. New laws, regulations or other developments could limit the Company’s ability to maintain strong links with these professionals or prevent it from receiving their advice and contributions.

In Europe, the United States and in other countries, regulations could:

- delay and/or significantly increase the cost of developing, testing, manufacturing and marketing the Company’s bioprosthetic artificial heart;
- limit the pathologies for which CARMAT would be authorized to market its bioprosthetic artificial heart;
- impose new, more stringent requirements;
- suspend the authorization for the bioprosthetic artificial heart;
- require that clinical trials be halted.

The subsequent detection of previously unknown problems could result in fines, delays or suspensions of regulatory authorizations, product seizures or recalls, notifications of doctors or any other action in the field, restrictions concerning operation and/or legal action in the criminal court. Such a situation, if it occurred, could have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development or its prospects.

### 2.3.2 RISKS RELATING TO THE REGULATORY ENVIRONMENT IN EUROPE (CE MARKING)

The Company’s implantable bioprosthetic artificial heart, but also all the ancillary tools that accompany it and its monitoring consoles, come within the category of medical devices and are governed, in particular, by the provisions of Directive 93/42/EEC which harmonizes the conditions for the sale and free circulation of these products in the European Economic Area.

These products can be placed on the market only after obtaining the certificates permitting CE marking, valid for a period of five years. This CE marking attests the compliance of the medical device in question with the essential health and safety requirements stipulated by the applicable European directive and certifies that it has undergone the appropriate procedures for evaluation of its compliance.

The regulations on medical devices to which CARMAT is subject are complex and tend to become more and more strict. For the moment, it is the directive 90/385/EEC of June 20th, 1990, reviewed in the framework of the directive 2007/47/EEC of September 5th, 2007 regarding active medical devices for the countries of the European Union, which have been transposed in France in the Public Health Code, which define the requirements that must be met for medical devices to be CE marked. Similar laws and regulations in other countries around the world frame many aspects of medical devices, including:

- design, development and manufacture of products;
- product testing and clinical trials carried out on humans;
- product storage;
- product marketing, including advertising and promotion;
- approvals and market authorizations;
- procedures for storing data; and
- supervision after products are put on the market and reporting deaths.

The new regulation (EU) 2017/745, adopted by the European Parliament in April 2017, entered into force on May 26, 2017 and will replace directives 93/42/EEC and 2007/47/EEC after a period of 3 year transition (implemented May 26, 2020). In the year preceding the end of the transitional period, the Notified Bodies authorized to issue the certifications will no longer be able to issue certificates with reference to the old Directives and CARMAT could therefore have to establish if necessary a dossier compliant with the requirements of the new Regulation, which strengthens manufacturers’ obligations relating mainly to post-market monitoring. The direct or indirect costs associated with complying with current or future regulations, obligations or guidelines may be high. Nevertheless, since CARMAT’s product is still in the clinical evaluation phase, the company estimates that the additional costs related to compliance with the new regulation will be limited.

Furthermore, data from clinical trials can produce divergent interpretations, which could delay the obtaining of or restrict the scope of regulatory authorization, or force the Company to repeat trials in order for them to meet the regulator’s requirements. Changes to regulations during the development of the bioprosthetic artificial heart and its regulatory review can lead to delays or to the refusal of authorization.

Breach to comply with the compliance obligations may result in sanctions, including a refusal to grant CE marking, which may also have a negative impact on the assessment of the device in other non-European jurisdictions. After obtaining the CE marking, these deficiencies may also lead to the suspension or withdrawal of authorizations, seize or recall of products, restriction of use and criminal proceedings which may, individually, significantly...
increase the costs assumed by the Company, to delay the
development and commercialization of its bioprosthetic artificial heart and thus to have a significant adverse
effect on its activity, its financial situation, its results, its
development and its prospects.

2.3.3 RISKS RELATING TO THE REGULATORY ENVIRONMENT IN THE UNITED STATES

The US market is governed by the regulations established
by the FDA which regulate preclinical and clinical trials,
the manufacture, labeling, distribution and marketing of
medical equipment. The FDA has broad powers to prohi-
bit, isolate and seize medical devices that have been falsi-
fied or with labeling not meeting standards, to demand a
recall, repairs, a replacement or the reimbursement of
such devices, to refuse to grant a product marketing
authorization, to suspend studies in progress or to demand
export certificates from foreign governments.

The marketing of products such as those manufactured by
the Company in the United States market is subject to the
PMA procedure, which may be long, complex and costly
because it must be based on safety and efficiency data,
coming in particular from large-scale clinical trials, some-
times randomized where a similar product exists.

In the case of CE marking, the choice between the “Bridge
To Transplant” indication, i.e. waiting for a transplant, or
“Destination Therapy”, i.e. definitive treatment, is left
to the judgment of the medical personnel. In the United
States, the FDA demands a clinical safety and efficiency
study for each indication, starting with the shortest, i.e.
waiting for a transplant. No equivalent device (ventricular
assist device or artificial heart) has so far submitted an IDE
and then a PMA for the “destination therapy” indication
without having first obtained a PMA for the “waiting for
transplant” indication (see Paragraph 1.2.2 « Technologies
and market players »).

There is an alternative to the traditional IDE and PMA pro-
cess for compassionate indications (refer to section 1.5.1
« Regulatory Strategy »). CARMAT could also benefit from
the new provisions made public by the FDA in October
2013 within a guidance document « Investigational Device
Exemptions for Early Medical Feasibility Device Clinical
Studies, including certain First in Human (FIH) Studies »: A
study of feasibility (= EFS, Early Feasibility Study) can thus
be conducted on new medical devices, without prior clini-
cal experience, and in some cases could also be conduc-
ted with limited prior clinical experience; this is the case,
for example, of medical devices already used outside the
United States.

If the Company could not obtain a PMA, it would not be
able to market its products in the US market.

Even when products have received a PMA, the product
marketing authorizations granted by the FDA can be with-
drawn following failure to comply with regulatory stan-
dards or the occurrence of unexpected problems after the
authorization has been granted.

Such a situation, if it occurred, could have a significant
unfavorable impact on the Company, its activity, its finan-
cial situation, its performance, its development and its
prospects.

2.3.4 RISKS CONNECTED WITH CHANGES IN REIMBURSEMENT POLICIES FOR MEDICAL DEVICES

The Company’s capacity to generate revenues with the
bioprosthetic artificial heart and the associated systems
and services that it could develop, the degree of success
of these products and their performance, partly depend
on the conditions of compensation and reimbursement in
those countries where it plans to market its products.

Many patients will not be capable of paying themselves to
obtain access to a product that the Company could deve-
lop. The Company’s ability to obtain acceptable levels of
reimbursement from government authorities, private
health insurers and any other organization will therefore
have an impact on its capacity for marketing its products
successfully. Reimbursability affects customers’ choices
concerning the products that they buy and the prices that
they are prepared to pay. Reimbursement varies from one
country to another and can have a significant impact on
the acceptance of new products and services. The Com-
pany cannot be certain of obtaining an optimal reimburse-
ment in Europe, the United States or elsewhere for the
products that the Company has developed or might deve-
lop, and any reimbursement granted could be reduced or
canceled in the future.

In Europe, in the United States and in the other main mar-
kets in which the Company could sell its products, there
is constant economic, regulatory and political pressure
to limit the cost of procedures involving medical devices.
Third-party paying organizations are increasingly ques-
tioning the prices of medical devices, and many third-
party paying organizations could refuse to reimburse or
could increase the proportion paid by patients for certain
deVICES.
New legislative or administrative reforms to reimbursement systems in Europe, the United States or other countries which could substantially reduce the reimbursement of operations using the Company’s medical devices or which could refuse coverage for these operations, for example by price regulation, competitive pricing, coverage and payment policies, the comparative efficiency of therapies, technological assessments and managed healthcare systems, could have a significant unfavorable impact on the Company, its activity, its financial situation, its performance, its development or its prospects.

### 2.3.5 RISKS RELATING TO PROTECTION OF INTELLECTUAL PROPERTY RIGHTS

The Company is the owner of patents and a know-how that is specific to it, as well as other intellectual property rights (such as, in particular, copyright, marks and domain names).

It is important for the success of the Company’s activity that it is able to obtain, maintain and ensure respect for its patents and other intellectual property rights and thus protect its technologies against possible unlawful use by third parties.

Given the importance of patents in its industry, in 2008 the Company commissioned a study by a specialized firm to confirm its freedom to operate, both in the United States and in Europe, as to the corresponding US and European patents bearing claims on any device, system and method relating to the bioprosthetic artificial heart. According to the findings of the study, the relevant patents of the Company did not infringe on that date the US and European patents found in the research carried out.

An update of this study was commissioned by the Company in the fourth quarter of 2017, by researching and analyzing patent applications and patents filed with the European Patent Office (EPO) and the United States Patent Office (USPTO) bearing claims on any device, system and method pertaining to the bioprosthetic artificial heart that were made public after January 2008. The research firm in charge of this study concluded under the terms of this study that the CARMAT heart does not infringe on that date the US and European patents found in the research carried out.

Despite the efforts made by CARMAT to protect its technologies, its assets and its know-how, there is a risk regarding the validity and/or the value of the intellectual property rights pertaining thereto.

Indeed, the possibility cannot be excluded that:

- the Company’s granted patents and more generally its intellectual property rights may be disputed or invalidated at a subsequent stage or that the Company may not be able to enforce them;
- patents for which applications are being considered, including certain important patents in several jurisdictions, or any other claim to a deed pertaining to an intellectual property right, might ultimately not be granted;
- the extent of the protection conferred by a patent or an intellectual property deed might be insufficient to provide effective protection from competitors;
- the Company’s products will not infringe, or be accused of infringing, patents or other intellectual property rights belonging to third parties;
- third parties might claim rights over patents or other intellectual property rights that the Company owns directly or that it exploits.

It is precised that there is great disparity between the national legislations applicable in the various countries where the Company registers or protects its intellectual property rights.

Until now, no uniform global policy has emerged on the content of patents granted in the area of medical devices and the scope of the claims allowed.

Lastly, the protection and enforcement of the Company’s intellectual property rights will require legal action where necessary, the costs and contingencies of which may have an impact on the Company’s activities. In this sense, apart from the expenses that these legal actions entail, they could have the effect of diverting the management team from its priorities and reducing the Company’s profits.

If one of these factors concerning one of the patents or intellectual property rights occurs, it could have an unfavorable impact on the activity, prospects, financial situation, performance and development of the Company.
2.3.6 RISKS RELATING TO THE CONFIDENTIALITY OF THE COMPANY’S INFORMATION AND KNOW-HOW

The Company may be required to provide public or private bodies with sensitive proprietary information notably in order to conduct certain tests for the purposes of researching or validating its commercial projects. The Company also relies on its own technologies, methods, processes, know-how and data that are not patented and which it considers to be industrial and technical secrets. In both cases, their protection is specifically insured by confidentiality agreements between the Company and its employees, consultants and relevant third parties.

However, these agreements and other methods of protecting commercial and technical secrets are not always effective and cannot protect with any certainty the confidentiality of said industrial and technical information and secrets, because any breach of the aforementioned contractual agreements, including through disclosure to competitors, would potentially entail imminent damage for the Company without it having any really appropriate measure for obtaining compensation.

Furthermore, the dissemination, notably via the media or by third parties, of confidential or even non-confidential information concerning the Company or its activities, with or without its authorization, and the dissemination of false or inaccurate information by third parties could also have unfavorable consequences for the Company’s activity, financial situation, performance, development and prospects.

2.3.7 RISKS CONNECTED WITH PRODUCT LIABILITY

All cardiac surgery involves significant risks of serious complications that can have mortal consequences. The clinical trials and marketing of the bioprosthetic artificial heart involve a risk of incurring the manufacturer’s liability for defective goods. If CARMAT were faced with a liability claim for defective goods, and if it did not manage to defend that claim successfully, its liability could be significant.

As the Company has not entered the sales phase for the bioprosthetic artificial heart, it has not taken out insurance against liability for defective products. However, the Company has already taken out insurance policies in relation to the clinical trials phase as a result of which it possesses the level of insurance cover required under current regulations in France (in accordance with the French Public Health Code and the provisions arising from the Huriet Act of December 20, 1988) and in other countries. If necessary, it will take out other insurance policies as its clinical trials program is extended (see Paragraph 2.4 «Insurance and cover for risks» below).

However, the Company cannot guarantee that its insurance cover will be sufficient to meet liability suits that may be filed against it. If CARMAT were held liable and were unable to obtain and maintain appropriate insurance cover at an acceptable cost, or to protect itself in any way against liability suits arising out of defective goods, this would have a serious impact on the marketing of the bioprosthetic artificial heart and more generally it would damage the Company’s reputation, its activities, its financial situation, its performance, its development and its prospects.

2.4 INSURANCE AND COVER FOR RISKS

The Company has adopted a policy for covering the main insurable risks with cover limits that it considers compatible with the nature of its activity. The premiums paid by the Company for all insurance policies amounted to €110,889 for the 2018 reporting period, compared with €69,088 for the 2017 period.

As the Company has not entered the sales phase for the bioprosthetic artificial heart, it has not yet taken out insurance against liability for defective products.
2.5 FINANCIAL RISKS

2.5.1 HISTORY OF OPERATIONAL LOSSES – RISKS CONNECTED WITH FORECAST LOSSES

The Company was established in June 2008. As at December 31, 2018, accumulated losses stood at €187.5 million. This loss comes mainly from research costs and the costs of developing the CARMAT bioprosthetic artificial heart; such costs cannot be capitalized as intangible assets under French accounting rules.

The Company will incur further significant operational losses in the course of the next few years, particularly due to:

- the completion of research and clinical trials on the bioprosthetic artificial heart in Europe and then the United States in order to obtain sales authorizations;
- the extension of production capabilities of the bioprosthetic artificial heart CARMAT;
- costs connected with marketing the CARMAT bioprosthetic artificial heart;
- the expansion of its portfolio of products through the future implementation of projects to develop new breakthrough medical devices using skills and know-how developed by CARMAT for bioprosthetic artificial hearts; and
- payment of additional milestones, royalties or payments for licenses or partnerships.

As of the date of this registration document, the bioprosthetic artificial heart has not generated any operational revenue. The Company’s profitability will be dependent on the results of its clinical trials and on sales of the bioprosthetic artificial heart, which could be commenced once CE marking has been obtained. The Company considers that before revenues are generated from sales of the bioprosthetic artificial heart, its only sources of financing will come from funds raised on the Euronext Growth market in Paris, state grants, research tax credits (CIR), bank loans and, to a lesser extent, income from cash investments and current financial instruments, and that this will enable it to deal with short and medium term liquidity risks (see Paragraph 2.5.5 « Liquidity Risks »).

In addition to the funding provided in December 2017 for €52.9 million and the €30.0 million loan granted conditionally by the EIB in December 2018, additional financing, particularly in the form of new capital increases, will be required for the Company to be able to finance, in particular, the marketing of the artificial bioprosthetic heart (see paragraph 2.5.3 « Dilution risk connected with issuing shares giving immediate or future access to the Company’s capital »).

The increase in expenses, particularly in the event of a lack or suspension of revenue sources, could have a significant unfavorable impact on the Company’s business, financial situation, performance, development and its prospects.

2.5.2 UNRELIABLE CAPITAL RESOURCES AND UNRELIABLE ADDITIONAL FUNDING

The Company has made significant investments in research and development since it began its operations in 2008. The total cost of developing the bioprosthetic artificial heart (i.e. excluding expenses related to preparations for its marketing and industrial production) represents as of today a total amount of €229 million for the Company since it was founded.

The Company expects to have significant financing requirements in particular to prepare for and then begin marketing the bioprosthetic artificial heart once CE marking has been obtained. In particular, the Company will have to finance its current operations and research and development during the initial commercial launch phase, the working capital requirement related to sales development and investments intended to increase production capacity and automate production processes.

The future capital needs of CARMAT remain dependent on a number of factors, such as:

- higher costs and slower progress than expected for its program to develop the bioprosthetic artificial heart;
- higher costs and longer delays than expected in obtaining regulatory authorizations, including time required to conduct additional tests for the purpose of obtaining such authorizations or the preparation time for application dossiers submitted to regulatory bodies;
- higher costs and longer delays than expected in obtaining monies, such as reimbursements, for the Company’s devices and services from the relevant public or private bodies in European or other countries, including the time required to conduct additional tests for the purpose of obtaining such funding or the preparation
time for application dossiers submitted to the bodies concerned;
• the costs of preparing, lodging, defending and maintaining patents and other intellectual property rights;
• the ability of the Company to establish or maintain collaborative arrangements within the time frame contemplated;
• new opportunities to develop new promising products or acquire new technologies, products or companies or other activities; and
• the date of the commercial launch of the total heart of the Company, currently scheduled for 2020.

The Company estimates that based on its cash position, as at the end of 2018, all of its additional financial requirements until it can generate positive cash flows could be as high as €100 million in total (part of which may be covered by the line of Kepler equity financing, with a balance of €24.2 million as of December 31, 2017 and another part by the €30.0 million loan granted conditionally by the EIB in December 2018).

As a result, fundraising will be required, beyond using the available balance of Kepler equity lines and the EIB loan. The sizing and sequencing of these fundraising rounds will depend in particular on the progress of the pivotal study and the process of obtaining CE marking, and the date of obtaining the authorization to start an «Early Feasability Study» in the United States of America, but also market conditions.

The Company might fail to raise sufficient funds on favorable terms or fail to raise any funds at all when it needs to. If the necessary funds are not available, the Company may have to:
• delay or scale down its development or marketing program;
• cut staff;
• obtain funds through partnership agreements which could force it to give up rights over certain technologies, rights which it would not have given up in different circumstances;
• grant licenses on its technologies to partners or third parties or conclude collaboration agreements that might be less attractive than those which it would have been possible to obtain in different circumstances; or
• consider hiving off assets, or even approaching another company.

In addition, if the Company raises capital by issuing new shares, the participation of its shareholders could be diluted. Indebtedness financing, to the extent that it would be available, could also include restrictive conditions for the Company and its shareholders. In addition, seeking additional financing could distract management from its day-to-day operations, which could limit its ability to develop and market its product.

If one or more of these risks materialized, this could have a significant negative impact on the Company’s business, financial situation, performance, development and its prospects.

2.5.3 DILUTION RISK CONNECTED WITH ISSUING SECURITIES GIVING IMMEDIATE OR FUTURE ACCESS TO THE COMPANY’S CAPITAL

As mentioned in Paragraph 2.5.2 « Unreliable capital resources and unreliable additional funding » of this registration document, the Company could issue shares or new financial instruments giving access to its capital to finance its expansion, which may lead to a certain dilution for the shareholders of the Company.

In addition to the financing operations, since its creation the Company has also allocated or issued BCE warrants, BSA share subscription warrants, stock-options and preferential shares free of charges convertible in ordinary shares as part of its incentive policy for its executives and employees. The Company could in the future allocate or issue new instruments giving access to its capital to employees and/or consultants.

As at December 31, 2018, the exercise or the conversion of all securities giving access to capital would allow the subscription of 1,246,750 new ordinary shares representing 13.44% of the current issued share capital and 11.85% of share capital after issue of these new ordinary shares.

It should be noted that within this envelope, 366,000 new ordinary shares (29.36% of the dilution potential) are likely to result from the exercise of BSA Kepler, a financing tool put in place by the Company in September 2018.

The exercise or the conversion of the issued instruments giving access to capital and all new allocations or issuances would lead to a potential significant dilution for the shareholders.
If the Company were to breach the terms of its agreements with Bpifrance for subsidies and repayable advances totaling €31.6 million (see Paragraph 3.1.10 « Important contracts »), it might not receive the expected aid. (Balance to be collected by the Company as of December 31, 2018: €1,450,732)

If the Company were to breach the terms of its agreements with Bpifrance, it could also be required to repay the sums advanced. These situations could deprive the Company of the financial means to complete its research and development.

In the event that the Company does not meet the conditions set out in the €30.0 million loan agreement signed with the EIB in December 2018, CARMAT may not be able to benefit from one or more of the three 10.0 million euros tranches provided for in this contract. In addition, this contract provides, in certain situations, for a mandatory repayment of the amounts borrowed. These two configurations could deprive the Company of the significant financial resources needed to carry out its research and prepare for the commercialization phase of its prosthesis.

(See Chapter 3, paragraph 3.1.10 for the particular conditions of the EIB loan).

In addition, to finance its activities, the Company also opted to take the research tax credit («CIR») for the financial periods from 2009 to 2018. This mechanism involves offering a tax credit to enterprises which invest significantly in research and development.

Research expenditure eligible for the CIR specifically includes wages and salaries, services sub-contracted to approved research organizations (public or private) and intellectual property costs.

The CIR relating to the 2018 period was recorded under Income taxes in the income statement and appears under Other accounts receivable in the balance sheet. The income statement for the period from January 1, 2018 to December 31, 2018 shows a research tax credit of €1,983,916.

The Research Tax Credit is an important source of financing. It could be jeopardized by a change in regulations or by an objection from the tax authorities, even though the Company complies with the requirements concerning documentation and the eligibility of costs.

If one or more of these risks materialized, this could have a significant negative impact on the Company’s business, financial situation, performance, development and its prospects.
2.5.5 LIQUIDITY RISKS

In 2018, the Company consumed €40.5 million in cash. The Company finances its growth through equity increases.

In December 2018, the European Investment Bank (EIB) granted CARMAT a loan of €30.0 million. At the date of this registration document, the Company obtained a first tranche of €10.0 million in January 2019. The loan agreement provides that under certain conditions, the Company is obliged to repay the amounts borrowed, exposing CARMAT to a liquidity risk.

At the date of this registration document, the Company has no other bank debt than that resulting from the loan granted by the EIB.

Owing to its historic loss-making situation, which results from the fact that it is still in a development phase during which it is incurring expenditure on (mainly clinical) research and development without earning regular revenues, the Company faces a funding risk.

The board of directors has nevertheless assumed that the business is a going concern, having taken the following points in particular into account:

- cash and available cash instruments totaling €25,301,658 as at December 31, 2018;
- the payment of repayable advances (€1,450,732) still to be claimed between now and the end of the Bpifrance aid program signed in 2009, corresponding to milestone 7 (CE marking expected in 2020);
- the research tax credit of €2.0 million generated in the 2018 fiscal year period;
- the possibility of using the balance of the equity financing line set up in September 2018 with Kepler Cheuvreux, exercised on the initiative of the latter, subject in particular to certain price and liquidity assumptions, for a total amount, on which Kepler Cheuvreux is engaged under these same assumptions, of €24.2 million as of December 31, 2018;
- the €30.0 million loan granted by the EIB in December 2018.

The Company’s industrial and commercial development after it has obtained CE marking will give rise to further financial requirements: financing for ongoing operations and R&D during the initial commercial launch phase, need for working capital in relation to sales development, investment for the purpose of increasing production capacity and automating production processes. The Company currently estimates that these additional requirements could reach €100 million. Extra funds will need to be raised in addition to the exploitation of the remaining Kepler equity financing lines and EIB loan.

These funds will be needed in particular to:

- finance the training of additional surgical centers in addition to those trained for the clinical trials of the feasibility study;
- develop and run a direct or indirect sales force, and to provide technical and clinical support to implant centers and their patients;
- carry out clinical activities such as implant registries or comparative or medico-economic studies, upon request by regulatory authorities or voluntarily for marketing purposes;
- implement improvements to the systems or pursue activities necessary to secure the willingness of healthcare providers to pay for the bioprosthetic artificial heart, its external systems and ancillary services in various countries;
- to initiate and finalize a multi-center study (IDE) in the United States, in order to obtain from the FDA the authorization to market the prosthesis there;
- ramp up industrial production by developing automated production processes, securing alternative suppliers for critical supplies and by setting up additional production capacity.

The Company has carried out a specific review of its liquidity risk and considers that it is able to meet its deadlines.

2.5.6 EQUITY RISK

At the time of registration of this registration document, the Company has no shareholdings in third-party listed companies and is therefore not exposed to risks in relation to third-party shares.

The Company entered into a liquidity contract with an independent financial services provider, initially Dexia Securities France (now DSF Markets) in 2010 and subsequently Tradition Securities and Futures as of 2014, and today with Gilbert Dupont, the purpose of which is to improve the liquidity of transactions and regularize the CARMAT share price, without impeding the normal operation of the market and without misleading third parties. To this end the Company made an amount of €300,000 available to this service provider. Treasury shares acquired through the implementation of this liquidity agreement are recorded under financial assets at their purchase price.
Where appropriate, a valuation allowance is recorded with reference to the average official stock market price for the month preceding the end of the period (see Paragraph 3.2.2.4 « Supplementary information on balance sheet »).

2.5.7 RISK RELATED TO CHANGES IN THE STOCK PRICE AND MARKET VALUATION OF THE COMPANY

The share price of the Company is subject to the volatility of the financial markets and may be significantly affected by events such as changes in market conditions specific to the Company’s business sector, announcements by the Company, the realization or not, or the late performance by the Company of scientific or regulatory steps in the development of the total artificial heart project of CARMAT.

In recent years, the financial markets have also experienced significant variations that may not reflect the operational or financial performance of listed companies.

In this respect, the market price of the CARMAT share has changed a lot since its IPO in July 2010, as evidenced by the following graph.

Fluctuations in the stock markets, the economic situation or any failure or delay by the Company in achieving new scientific or regulatory milestones could have a material adverse effect on the Company’s share price and market valuation.

2.5.8 RISK OF SHARE PRICE VOLATILITY AND MARKET VALUATION OF THE COMPANY LINKED TO THE PROFILE OF THE PATIENTS AND PATHOLOGY TARGETED

CARMAT’s bioprosthetic heart project aims in particular to be the destination therapy for patients with biventricular end-stage heart failure (NYHA class IV - Intermacs classes 1-4), i.e. patients whose illness is at a very advanced stage and whose life expectancy is short. The current standard treatment for this pathology is heart transplantation.

In France, heart transplants have a one-month survival rate of 84.8% for «young» patients aged 18-60 and 79.3% for patients aged over 60. The one-year survival rate is 75.8% for the first category and 67% for the second (see paragraph 1.1.4 « Available treatments » - Transplantation and the 2013 annual report of the Biomedicine Agency referred to therein). This relative performance must also be appreciated with regard to the profile of the population eligible for transplantation, i.e. patients whose general health is good enough for the transplanted organs to have the best chance of success, given that they are in short supply. The patients in CARMAT’s current trials are not systematically eligible for transplants due to comorbidities or their age, and they are therefore even more fragile than patients who are eligible for or have received transplants.
At present, no treatment available or in clinical trials for the targeted pathology has a one-year survival rate of 100%. While the Company’s object is to put forward a credible alternative to heart transplantation and achieve a comparable or better survival rate, it does not hope to obtain a 100% survival rate over any period.

CARMAT presented in January 2019 the intermediate results of the first part of the pivotal study. The interim analysis included the 10 patients in the first cohort of the pivotal study, the first patient of whom was recruited in August 2016 and the last in July 2018. In total, the pivotal study foresees the inclusion of 20 patients, patients with terminal biventricular heart failure.

70% of patients in this first cohort achieved the primary objective of the study corresponding to 6 months of survival with the prosthesis or a successful heart transplant in the months following the implantation of the CARMAT device. By way of comparison, this rate was only 50% during the feasibility study.

Deaths during future clinical studies are to be expected and are an inherent factor in the profile of the targeted patients and pathology. Taken individually, one death will not jeopardize the project if the overall survival rate set down in the study protocols is achieved or exceeded. Nevertheless, any death that attracts negative coverage in the media in spite of the efforts – part reserve, part education – made by the Company, could have a significant unfavorable effect on the Company’s share price and market capitalization, as well as on its net assets and its ability to raise new capital.

2.5.9 RISKS RELATED TO FUTURE USE OF TAX LOSS CARRY FORWARDS

At December 31, 2018, after taking into account the net loss generated in the first half of the year, the Company has a carry forwards deficit of €221,385,242. To date, this deficit can be indefinitely carried forward to future profits. In France, for the years ended December 31, 2012 onwards, the allocation of these deficits is capped at 1 million euros, plus 50% of the fraction of profits exceeding this ceiling. The unused balance of the deficit can be carried forward to subsequent years, and is chargeable under the same conditions without limitation in time.

It can not be ruled out that future tax developments in the area of corporate taxation will call into question all or part of the allocation of these previous deficits to future profits or to limit it in time.

2.6 RISKS RELATING TO THE COMPANY’S ORGANIZATION

2.6.1 RISKS RELATING TO THE LACK OF SALES RESOURCES AND MEANS OF DISTRIBUTION

Given its stage of development, the Company still has only limited experience in the sales, marketing and distribution areas. In order to ensure the large-scale success of sales of the bioprosthetic artificial heart, the Company will have to adapt its organization, expand in global markets, set up a distribution network and recruit dedicated, qualified staff (especially to provide technical and clinical support for implant centers and their patients). It is in this perspective that CARMAT announced on September 1, 2016 the arrival of Stéphane Piat as chief executive officer, replacing Marcello Conviti. With his experience in the commercialization of medical devices, particularly at Johnson & Johnson Cordis or Abbott, Stéphane Piat intends to implement a strategy aimed at executing the commercialization through a direct sales force in the principal European countries, at least during the initial phase. In other countries such as the United States, indirect forms of distribution could be considered. The Company cannot nevertheless guarantee that it will be able to keep its distributors or sign new distribution agreements, nor that these distributors will devote the necessary resources to the commercial success of its products.

Moreover, the Company will have to provide training for doctors in the countries in which it wants to operate, and therefore have “ambassadors” and training centers (see Paragraph 1.5.2 « Marketing strategy »).

The Company might not be able to establish an appropriate structure or it could experience a delay in the organization of marketing and distribution resources, in the
recruitment and training of sales staff or in setting up its
distribution network.

Any of these events could have a significant unfavorable
impact on the Company's activity, its financial situation,
its performance, its development and its prospects.

2.6.2 RISKS RELATING TO THE
NEED TO KEEP, ATTRACT AND
RETAIN KEY PERSONNEL AND SCIENTIFIC
ADVISORS

The Company's success depends largely on the work and
expertise of the members of its board of directors and its
key scientific personnel, in particular Stéphane Piat, chief
executive, Dr. Piet Jansen, medical director, Éric Richez,
development director and Marc Grimmé, technical direc-
tor. To date the Company has not taken out any so-called
«key person» insurance (insurance policies to cover per-
manent incapacity/death) and the loss of their skills
would affect its capacity for attaining its goals. Although
the Company has for several years conducted manage-
ment and knowledge transfer programs, thereby creating
a know-how base which is not confined to specific indi-
viduals, the simultaneous departure of several important
employees from its executive management or its research
and development activities would significantly affect the
Company's capacity to attain its goals.

Furthermore, the Company will need to recruit highly qua-
lified staff in order to develop its activities as and when
it expands into areas which require supplementary skills
such as manufacturing, marketing, clinical support,
reimbursement and regulatory affairs.

The Company is competing with other companies,
research bodies and academic institutions in order to
recruit and retain highly qualified scientific, technical
and management personnel. As this competition is very
intense, the Company may not be able to attract or retain
key personnel in conditions that are acceptable from an
economic point of view.

Faced with this risk, the Company has established sys-
tems for motivating its personnel and strengthening its
loyalty, in the form of variable remuneration based on per-
formance and the allocation of securities giving access
to the Company's capital and preferential shares free of
charges convertible to ordinary shares, although there
is nothing to ensure that these systems will be sufficient
to enable the Company to retain or recruit the necessary
personnel. See section 5.2.1 « Share capital and security
classes » of this registration document.

The Company's inability to attract and retain this key per-
sonnel would prevent it from attaining its overall objec-
tives, and would thus have a significant unfavorable
impact on its activity, its financial situation, its perfor-
mance, its development and its prospects.

2.6.3 RISKS CONNECTED WITH
GROWTH MANAGEMENT

The Company expects to grow significantly and to extend
eventually its field of activity to designing and produ-
cing medical devices other than the bioprosthetic artifi-
cial heart. It will therefore need to adapt its organizational
structure and employ new skills, and it will therefore need
to recruit personnel and extend its operational capaci-
ties; this could place significant demands on its internal
resources.

To this end, the Company will have to:

• train, manage, motivate and hold on to a growing num-
ber of qualified staff and/or distributors;
• anticipate the expenses connected with this growth
and the associated financing needs;
• anticipate demand for its products and the revenues
they might generate; and
• increase the capacity of its existing operational, finan-
cial and management computer systems.

The Company's inability to manage growth or unexpected
difficulties encountered during its expansion could have
a significant unfavorable impact on its activity, its finan-
cial situation, its performance, its development and its
prospects.
2.7 SPECIAL CIRCUMSTANCES AND DISPUTES

There are no administrative, judicial or arbitration proceedings, including any proceedings the Company is aware of which are pending or which are being threatened, which are capable of having or which in the course of the last 12 months have had a significant impact on the financial situation or the profitability of the Company and/or group.
3

FINANCIAL INFORMATIONS
3.1 NOTES ON ACTIVITY IN THE 2018 REPORTING PERIOD

3.1.1 SELECTED FINANCIAL INFORMATIONS

The activity of the Company is exclusively focused on the research and development of an innovative product in the medical sector. No sales activities are envisaged in the immediate short term.

CHANGE IN THE COMPANY’S ACTIVITY IN THE COURSE OF THE REPORTING PERIOD

As the total artificial heart being developed by CARMAT is still in clinical development, the Company recorded no revenue in 2018.

The structure and increase in operating expenses, which totaled €43.5 million (+40% compared with 2017), reflect the achievement of strategic priorities of the Company, and notably:

- the continuation of the CE marking process undertaken with DEKRA, with the confirmation of the objective of submitting the technical dossier in 2019;
- the conduction of the pivotal study, with the positive results of the first cohort of 10 patients having been presented by CARMAT on January 15, 2019;
- the ramping up of industrial capacity of the Company with the certification of the new manufacturing site in Bois-d'Arcy, near Paris, and the transfer of the majority of production to that site during the year;
- the ongoing transformation of CARMAT into an industrial and commercial company, notably with the strengthening of its sales and marketing structure and the adaptation of its IT system.

Once other income statement items are taken into account, and notably reversals of operating provisions (other operating income) of €708.8 thousand, a financial loss of €944.8 thousand and Research Tax Credit of €2.0 million, CARMAT recorded a net loss of €41.7 million in 2018, compared with a net loss of €29.2 million in 2017.

Clinical development

The Company finalized the first part of the pivotal study (cohort 1 of 10 patients) and reported the results in January 2019. These are positive since 70% of patients in this first cohort achieved the primary objective of the study corresponding to 6 months of survival with the prosthesis or to a successful heart transplant within 6 months after implantation of the device.
The data collected from patients who achieved the primary objective of the study reconfirm the biocompatibility of the CARMAT prosthesis, already proven in the feasibility study, including its good safety profile, never reached by other technologies, with no stroke, no gastrointestinal bleeding and no percutaneous cable infection. In addition, these patients required only mild anticoagulant therapy.

Patient recruitment in the second part of the pivotal study started in accordance with the protocol in September 2018 in the international centers (Czech Republic, Kazakhstan and Denmark).

To date, the cumulative support time of the CARMAT heart in the context of the pivotal study reached 5 years in the 11 implanted patients. This cumulative experience shows the ability of CARMAT technology to provide a sustainable response to patients suffering from terminal biventricular heart failure, accompanied by a marked improvement in quality of life.

In addition, in 2018, CARMAT also submitted to the FDA (Food & Drug Administration, the United States health authority) an Investigational Device Exemption (IDE) file for a feasibility study (Early Feasibility Study - EFS). The dossier is on track and will have to be completed with biocompatibility tests on a number of prostheses in production, which allows CARMAT to consider, in the event of validation by the FDA, a start of implantations in patients by the end of 2019. The selection of clinical centers and the formation of scientific committees are under way.

- Industrial production and production

During the fiscal year, CARMAT commissioned and obtained certification for its new Bois d’Arcy production site. The transfer of production from the Vélizy site to the Bois d’Arcy site will be completely finalized in the first quarter of 2019.

Analysis of the data collected, representing more than 20 years of cumulative operation of the prosthesis between clinical study and reliability tests on test benches, has identified points of improvement to be made to the manufacturing process.

The implementation of these corrective actions necessitated a suspension of production and consequently of implantations during the 4th quarter of 2018. Production resumed at the beginning of 2019 and the new prostheses will be available as early as April 2019.

In the long term, several hundred prostheses can be produced annually on the Bois d’Arcy site.

- Market & sale development

In view of the commercial launch of the prosthesis in Europe (post-CE marking), CARMAT has also expanded its marketing and sales teams, which work together with the entire organization, to ensure an optimal commercial launch, in time Europe, then to the United States.

- Governance and management

During 2018, CARMAT expanded its governance and management with experienced profiles, corresponding to the internationalization of its project:

- appointment, in December 2018, of Jean-Pierre Garnier as the new Chairman of the Board of Directors: a scientist and business leader with a PhD in Pharmacology from Louis Pasteur University and an MBA from Stanford University, Jean-Pierre Garnier was notably President and CEO of pharmaceutical group GlaxoSmithKline (GSK) from 2000 to 2008 and Chairman of Actelion (Biotechnology) from 2011 to 2017.

- appointment of Pierre Bastid as an independent director.

- appointment of Thierry Dupoux as Senior Director of Quality and Pascale d’Arbonneau as Chief Financial Officer, both of whom have substantial experience – including international experience – in the Health sector.

STRENGTHENED FINANCIAL STRUCTURE

At December 31, 2018, the Company had a cash position of €25.3 million, versus €60.7 million at the end of 2017.

Furthermore, CARMAT is notably benefiting from:

- a contingent equity line subscribed to with Kepler Cheuvreux, within the framework of which it had, at December 31, 2018, access to an additional €24.2 million (which may be exercised depending on its requirements and on market conditions, until end-September 2020); and

- non-dilutive financing from the European Investment Bank (EIB) via a €30.0 million under conditions loan agreement signed on December 17, 2018. At the end of the 2018 financial year, CARMAT had not yet made use of this loan.

Given these elements, the Company is confident in its ability to successfully undertake its clinical development and prepare for the commercial phase.
3.1.2 INVESTMENTS MADE AND ENVISAGED

PRINCIPAL INVESTMENTS MADE IN THE LAST THREE FINANCIAL PERIODS

In the year ended December 31, 2018, the Company recorded capital expenditures of €2.3 million representing:

- property, plant and equipment of €2,176,599, mainly related to the finalization of the development of the new Bois d’Arcy production site;
- intangible assets of €116,700, representing the acquisition of licenses and computer software.

In the year ended December 31, 2017, the Company increased its capital expenditure in the sum of €3,558,636, representing:

- property, plant and equipment of €3,528,393, primarily for the purchase of measuring and control equipment and industrial tools, and linked to the ongoing development of the new Bois d’Arcy production site, for an amount of €2,760,389;
- intangible assets of €30,243, representing the acquisition of licenses and computer software.

In the year ended December 31, 2016, the Company incurred new capital expenditure in the sum of €1,096,157, representing:

- property, plant and equipment of €977,980, primarily for the purchase of measuring and control equipment and industrial tools, premises refurbishment and the acquisition of computer hardware;
- intangible assets of €118,177, representing the acquisition of licenses and computer software.

PRINCIPAL ASSETS UNDERWAY

Tangible fixed assets in progress at the end of the 2018 financial year amounted to €1.6 million and relate to the end of the development of the new Bois d’Arcy production site.

MAIN INVESTMENTS ENVISAGED

The main investments expected in the short term relate to production equipment to improve processes or streamline production.

3.1.3 PROGRESS MADE AND DIFFICULTIES ENCOUNTERED DURING THE REPORTING PERIOD

As a reminder, the analysis of the data collected, representing more than 20 years of cumulative operation of the prosthesis between clinical study and test bench reliability tests, has identified points of improvement to be made to the manufacturing process.

The implementation of these corrective actions necessitated a suspension of production and consequently of implantations during the 4th quarter of 2018. Production resumed at the beginning of 2019 and the new implantable prostheses will be available as early as April 2019.

3.1.4 ANTICIPATED DEVELOPMENTS, OUTLOOK AND SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

In accordance with its strategy, CARMAT is pursuing its clinical developments (pivotal study in Europe and ongoing discussions with the FDA for the start of an early feasibility study in the United States (see section 3.1.1).

The clinical data from the pivotal study will represent the last remaining element to be added to the CE marking dossier before it is submitted to the DEKRA certification body, which CARMAT plans to start in early 2020.

Obtaining CE marking would pave the way for the commercialization of the prosthesis in Europe.

On a financial level, at the end of January 2019, the Company drew the first tranche (€10 million) of the €30 million loan granted by the EIB in December 2018.

TRENDS SINCE THE YEAR END

There have been no significant changes to the financial or commercial situation since the financial year ended on December 31, 2018.

The Company devotes itself exclusively to the clinical trials required to advance the artificial bioprosthetic heart project and to prepare the CE marking application, with a view to marketing the product.
FINANCIAL INFORMATIONS

PROFIT FORECASTS OR ESTIMATES

The Company does not intend to make any profit forecasts or estimates.

3.1.5 STATEMENT OF RESULTS FOR THE PAST FIVE PERIODS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital at the end of the period</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share capital</td>
<td>371,036.76</td>
<td>360,661.76</td>
<td>241,277.76</td>
<td>183,117.40</td>
<td>175,200.80</td>
</tr>
<tr>
<td>Number of existing ordinary shares</td>
<td>9,275,919</td>
<td>9,016,544</td>
<td>6,031,944</td>
<td>4,577,935</td>
<td>4,380,020</td>
</tr>
<tr>
<td>Maximum number of future shares to be created</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- by conversion of bonds</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- by exercise of subscription rights</td>
<td>1,246,750</td>
<td>943,025</td>
<td>852,140</td>
<td>466,610</td>
<td>640,875</td>
</tr>
</tbody>
</table>

Opérations and results

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue excluding VAT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Profit before tax, profit sharing, depreciation and amortization, and increases in provisions</td>
<td>-42,784,848</td>
<td>-30,020,856</td>
<td>-25,378,370</td>
<td>-20,229,406</td>
<td>-19,975,189</td>
</tr>
<tr>
<td>Corporation taxes</td>
<td>1,983,916</td>
<td>2,334,690</td>
<td>2,817,116</td>
<td>3,148,534</td>
<td>2,209,185</td>
</tr>
<tr>
<td>Profit sharing for the period</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Profit after tax, profit sharing, depreciation and amortization and increases in provisions</td>
<td>-41,729,066</td>
<td>-29,227,910</td>
<td>-22,980,178</td>
<td>-17,545,761</td>
<td>-18,263,056</td>
</tr>
<tr>
<td>Distributed profit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Profit per share

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit after tax and profit sharing, but before depreciation and provisions</td>
<td>-4.40</td>
<td>-3.07</td>
<td>-3.74</td>
<td>-3.73</td>
<td>-4.06</td>
</tr>
<tr>
<td>Profit after tax, profit sharing, depreciation and amortization, and increases to provisions</td>
<td>-4.50</td>
<td>-3.34</td>
<td>-3.81</td>
<td>-3.83</td>
<td>-4.17</td>
</tr>
<tr>
<td>Dividend paid per share</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Staff

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Average workforce employed during the period</td>
<td>90</td>
<td>70</td>
<td>56</td>
<td>48</td>
<td>47</td>
</tr>
<tr>
<td>Wage bill for the period</td>
<td>6,819,510</td>
<td>5,220,243</td>
<td>4,371,200</td>
<td>4,069,741</td>
<td>3,792,937</td>
</tr>
<tr>
<td>Value of social benefits paid during the period</td>
<td>3,906,890</td>
<td>2,163,452</td>
<td>1,803,184</td>
<td>1,611,888</td>
<td>1,272,566</td>
</tr>
</tbody>
</table>

3.1.6 PROPOSED APPROPRIATION OF THE RESULT

We propose approval of the annual financial statements (balance sheet, income statement and annex) as presented.

These financial statements show a net loss of €41,729,066.

We propose appropriation of this loss to Losses carried forward, taking the balance of that item from €-145,751,009 to €-187,480,075.

3.1.7 PARTICULARS OF DIVIDENDS

In accordance with the provisions of Article 243 of the General Tax Code, it is recalled that no distribution of dividends has taken place for the last three fiscal years.

There are no plans to adopt a policy of paying dividends in the short term, taking into account the Company’s stage of development.
The Company performs its activities in premises that it leases on the basis of lease agreements concluded in accordance with market prices and conditions with companies which have no direct or indirect ties to Company directors. CARMAT does not own any real estate.

For the financial year in course at the date of this registration document, the Company considers that it has suitable premises that will be adequate for its projected growth and employees.

As a reminder, in fiscal year 2018, CARMAT commissioned and obtained certification for its new Bois d’Arcy production site. The transfer of production from the Vélizy site to the Bois d’Arcy site will be completely finalized in the first quarter of 2019.

It will allow manufacturing on a larger scale with a higher yield to meet the requirements of the clinical trials and the commercial launch.

In connection with search for non-thrombogenic* material, CARMAT decided to follow a path originally opened by Professor Alain Carpentier’s work on biological valves, which uses animal pericardium that has been chemically treated to render it inert and biologically stable, so that rejection by the body is avoided.

In designing and manufacturing the bioprosthetic artificial heart, the Company is therefore subject to chemical and biological risks, obliging it to put in place preventative and protective measures for the benefit of its operators and for waste management in line with current environmental and safety regulations governing the use, storage, handling and disposal of hazardous materials. The Company believes that it complies with these regulations.

In particular, the Company has entrusted two specialized subcontractors to manage its waste products. It undertakes an annual evaluation of the risks by work unit. This involves analyzing each hazardous situation, quantifying the risks by severity and occurrence and describing preventive measures. Generally, all operations in which there is the possibility of substance evaporation are performed under hoods or in chambers with activated carbon filters.
3.1.9 PARTICULARS OF PAYMENT PERIODS

PARTICULARS OF SUPPLIER PAYMENT PERIODS

In accordance with the provisions of Articles L.441-6-1 and D. 441-4 of the French Commercial Code, we bring your attention to the following details concerning supplier payment periods:

As at December 31, 2018, trade accounts payable totaled €3,281,077. A comparison of the figures from the financial statements is set out below:

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts payable and related payables shown under liabilities</td>
<td>7,615,547</td>
<td>5,825,388</td>
</tr>
<tr>
<td>Less: amounts receivable from suppliers shown under assets in balance sheet</td>
<td>0</td>
<td>-13,342</td>
</tr>
<tr>
<td>Less: accrued charges included under this heading</td>
<td>-4,334,470</td>
<td>-2,131,654</td>
</tr>
<tr>
<td>Liabilities related to fixed assets and similar liabilities</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Less: accrued charges included under this heading</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>3,281,077</strong></td>
<td><strong>3,680,392</strong></td>
</tr>
</tbody>
</table>

The breakdown of this amount by maturity date is shown below, based on the payment terms negotiated with suppliers:

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Due (including amounts receivable from suppliers)</td>
<td>404,414</td>
<td>606,658</td>
</tr>
<tr>
<td>Falling due on January 31</td>
<td>2,876,663</td>
<td>3,073,734</td>
</tr>
<tr>
<td>Falling due on February 28</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Falling due on or after March 31</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Detail of debts due at the end of the financial year:

**Article D.441 i.-1 °: Invoices received not settled on the closing date of the financial year whose term has expired**

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>0 day</th>
<th>1 to 30 days</th>
<th>31 to 60 days</th>
<th>61 to 90 days</th>
<th>&gt; 90 days</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(A) Late payment part</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>34</td>
</tr>
<tr>
<td>Number of invoices concerned</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total amount of invoices concerned (incl. VAT)</td>
<td>258,520</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Percentage of the total amount of purchases for the year (incl. VAT)</td>
<td>0.70%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**(B) Invoices excluded from (A) relating to disputed**

<table>
<thead>
<tr>
<th>Number of invoices concerned</th>
<th>1 invoice for an amount of €145,894 incl. VAT</th>
</tr>
</thead>
</table>

3.1.10 IMPORTANT CONTRACTS

The important contracts to which the Company is a party are as follows:

- a royalties agreement signed on June 24, 2008 and amended on February 5, 2010, between CARMAT, Professor Alain Carpentier and Matra Défense (an Airbus Group subsidiary): please refer to Paragraph 5.6 « Regulated agreements »;
- an exclusive license agreement with the Pierre and Marie Curie University relating to patent no 8800381: please refer to Paragraph 1.5.4 « Innovation and management of the R&D »;
- an exclusive license agreement with the Centre Technique des Industries Mécaniques relating to patent no
2760973: please refer to Paragraph 1.5.4 «Innovation and management of the R&D »;
• a framework aid agreement for the CARMAT Industrial Strategic Innovation (ISI) project and an agreement in support of the CARMAT project entered into on July 24, 2009 for a total sum granted by Bpifrance of €33 million ;
• a non-dilutive financing agreement concluded in December 2018 with the European Investment Bank for an amount of €30.0 million.

**FRAMEWORK AGREEMENT WITH BPIFRANCE**

**Initial conditions of the agreement**

On July 24, 2009, the Company signed a framework agreement with Bpifrance to secure aid for the CARMAT Industrial Strategic Innovation (ISI) project. Under the terms of the agreement, Bpifrance undertook to pay a total amount of €33.0 million, of which €18.5 million as subsidies and €14.5 million as refundable advances, payable upon achievement of the key milestones set out in the agreement, the last one being the achievement of CE marking.

The Company acts as project leader, thus receiving all of the refundable advances and €17.4 million in subsidies, i.e. €31.9 million, the remaining €1.1 million to be paid to the four partners in the project: Dedienne Santé, PaxiTech, Vignal Artru Industries (Pack’Aero Group) and Iréis (formerly HEF R&D).

Under the Bpifrance Innovation framework agreement, each of the partners has undertaken to provide the resources necessary to complete the development project for the bioprosthetic artificial heart and its components. In return, Bpifrance will pay its subsidies and repayable advances as certain phases and milestones described below are executed.

**Accounting and financial conditions**

The subsidies accrue to the Company as of right and so will not be repayable in the event of success of the project. Accordingly, they are accounted for in the «Subsidies » line of the income statement.

Repayable advances will have to be repaid by CARMAT according to the arrangement set out in the paragraphs below. Repayable advances are therefore accounted for on the liabilities side of the balance sheet under the « Other equity – Conditional advances » line.

The corresponding interest is shown on the liabilities side of the balance sheet under the «Sundry loans and financial debts » line.

By addendum to initial contract, signed in September 16, 2013, the Parties agreed to calculate the amount of the financial returns due by CARMAT based on thresholds of revenue generated by the products and services created by the project (reference products and services).

Threshold S1 (cumulative sales of reference products and services) is set at €38 million.

Threshold S2 (cumulative sales of reference products and services) is set at €2 billion.

If threshold S1 (as defined above) is reached, CARMAT will pay Bpifrance the following flat fees by June 30 of each year following the reference year:

<table>
<thead>
<tr>
<th>Year</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>€184,000</td>
</tr>
<tr>
<td>2</td>
<td>€368,000</td>
</tr>
<tr>
<td>3</td>
<td>€1,472,000</td>
</tr>
<tr>
<td>4</td>
<td>€2,784,000</td>
</tr>
<tr>
<td>5</td>
<td>€8,316,000</td>
</tr>
<tr>
<td>6</td>
<td>€11,300,000</td>
</tr>
</tbody>
</table>

The amounts will reimbursed as indicated above, based on CARMAT’s operating income from the project’s products, in light of the annual income statement.

If threshold S1 not be reached, CARMAT will not pay Bpifrance the amounts above.

From year 2 and for the remaining years, in case of a fall in sales exceeding 20% of the updated forecasts (in 2013), as defined in the table below, these amounts would be then capped.

In this scenario, CARMAT will generate new forecasts allowing it to draw up a new timetable for the reimbursements to Bpifrance.

Should sales of the reference products and services be in excess of the forecasts, the flat fees defined above will not be affected.

In any case, in the event that no reimbursement is due pursuant to this Article over a period of 10 years from payment of the last subsidy as set out in the agreement providing for a repayable advance, CARMAT will be released from any obligation to pay financial returns. Moreover, this agreement will be terminated ipso jure with no other formalities, provided that CARMAT has complied with all its obligations. CARMAT will be bound to pay specific fees as defined above, should threshold S1 be reached before this date, and until said date is reached.

If the advance payment has been reimbursed in accordance with the provisions above, CARMAT will pay Bpifrance during the year after the date said reimbursement is completed and provided sales of the reference products and services (excluding taxes) have reached at least €2 billion, 2.5% of the yearly revenue generated the previous year by sales of the Project’s products and
services.

The corresponding amounts will be payable on any generated sales, subject to a maximum financial return of €50 million at nominal value, if achieved before the end of 8 years.

**Amounts received and still to be received at December 31, 2018**

The Bpifrance agreements provides for the payment of a total of €17.4 million in grants, all of which was received at the end of the 2018 financial year.

It also provides for the payment of a total sum of €14.5 million for repayable advances, of which €1.5 million remains to be collected by the end of the program (after obtaining the CE marking).

**EUROPEAN INVESTMENT BANK (EIB) FINANCING AGREEMENT**

The financing agreement signed with the EIB allows CARMAT to borrow up to €30 million via three tranches of €10 million each.

Within the context of the positive interim results of the first part of the pivotal study, published by CARMAT on January 15, 2019 the Company carried out the drawdown on the first tranche of the EIB loan, i.e. €10 million, on January 31, 2019.

The drawdowns on the second and third tranches are subject to certain technical and financial milestones, including the successful execution of clinical trials and/or the raising of additional funds.

The amounts borrowed bear an average fixed interest rate of 8% for the first tranche, 8% for the second tranche and 5% for the third tranche. The reimbursement of each tranche will take place at the end of the loan period (bullet payment), i.e. five years from the date of the drawdown on this specific tranche.

The loan contract provides for certain information and operational commitments (such as limits on authorized debt, approval for external growth operations, etc.). Failure to comply with these conditions would give the EIB the right, if deemed necessary, to demand an early reimbursement of the loan.

The occurrence of certain changes in the shareholding structure or a change in management not approved beforehand by the EIB would also allow the latter, if deemed necessary following discussions with the Company, to demand an early reimbursement of the loan.

The loan is not secured. Any new Group subsidiary becoming material with respect to the financial contract would be personally liable for the Company. To date, CARMAT has no subsidiaries.

Furthermore, the Company has signed a royalty agreement with the EIB that provides for the payment to the latter of additional remuneration depending on the commercial performance of the Company. This agreement is valid for 13 years from the year during which the cumulative sales of CARMAT reach €500,000. The Company can decide to terminate the royalties contract at any time by paying a lump sum (net of any royalties already paid), which depends on the amount borrowed and the year during which the decision is taken.

Upon the occurrence of certain events (in particular should the EIB demand the early repayment of the loan or should a new shareholder reach 33% of the voting rights of CARMAT), the EIB could, if deemed necessary, demand from CARMAT an advance payment of royalties up to a certain percentage of the amount of the loan effectively used (this percentage would range from 100% of the borrowed amount if the event occurs during the first four years of the financial contract to 160% if the event occurs after the eleventh year).

**OTHER IMPORTANT CONTRACTS**

**Edwards Lifesciences**

An agreement with an initial term of one year, automatically renewable annually, was entered into in the final quarter of 2010 by CARMAT and Edwards Lifesciences, the world leader in the heart valves sector and in hemodynamic monitoring, for the use and supply of Carpentier-Edwards bioprosthetic heart valves for the CARMAT total artificial heart.

**Invibio Limited**

An agreement with a term of 12 years was concluded during the third quarter of 2012 between CARMAT and Invibio Limited, for the supply and use of PEEK-OPTIMA polymer materials®. This material is used by CARMAT owing to its biocompatibility characteristics, its certified long-term implantability and its mechanical properties. The structural sub-assemblies of the prosthesis are manufactured out of this material.
### 3.2 FINANCIAL STATEMENTS AS AT DECEMBER 31, 2018

#### 3.2.1 2018 ANNUAL STATEMENTS

**INCOME STATEMENT**

<table>
<thead>
<tr>
<th>Income statement</th>
<th>December 31, 2018 (in euros)</th>
<th>December 31, 2017 (in euros)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>France</strong></td>
<td>Total</td>
<td>Total</td>
</tr>
<tr>
<td><strong>OPERATING INCOME</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales of merchandise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales of finished goods</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales of finished services</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NET REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production left in stock</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed asset production</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subsidies (note 3.2.2.5)</strong></td>
<td>14,000</td>
<td>28,000</td>
</tr>
<tr>
<td><strong>Write-backs of amortization/depreciation and provisions, and transfers of expenditure</strong></td>
<td>708,481</td>
<td></td>
</tr>
<tr>
<td><strong>Other revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL OPERATING INCOME (I)</strong></td>
<td><strong>722,481</strong></td>
<td><strong>28,000</strong></td>
</tr>
<tr>
<td><strong>OPERATING EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of merchandise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in inventory (merchandise)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Purchases of raw materials and other supplies</strong></td>
<td>6,523,753</td>
<td>2,410,973</td>
</tr>
<tr>
<td>Change in inventory (raw materials and other supplies)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL OPERATING EXPENSES (II)</strong></td>
<td><strong>43,488,886</strong></td>
<td><strong>31,062,596</strong></td>
</tr>
<tr>
<td><strong>1 - OPERATING RESULT (I - II)</strong></td>
<td><strong>-42,766,405</strong></td>
<td><strong>-31,034,596</strong></td>
</tr>
<tr>
<td><strong>SHARES IN RESULTS OF JOINT OPERATIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profits allocated or loss transferred (III)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss or profit transferred (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FINANCIAL INCOME</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial income from equity interests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from other securities and fixed asset receivables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other interest receivable and similar income</td>
<td></td>
<td>707</td>
</tr>
<tr>
<td><strong>Write-backs of impairments and provisions, transfers of expenditure</strong></td>
<td>708,481</td>
<td></td>
</tr>
<tr>
<td><strong>Positive exchange differences</strong></td>
<td>41,149</td>
<td>73,797</td>
</tr>
<tr>
<td><strong>Net proceeds from sales of marketable securities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL (V)</strong></td>
<td>41,149</td>
<td>74,504</td>
</tr>
</tbody>
</table>
### FINANCIAL INFORMATIONS

#### Income statement

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>France</strong></td>
<td><strong>Export</strong></td>
<td><strong>Total</strong></td>
</tr>
<tr>
<td>Financial expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization/depreciation, impairments and provisions</td>
<td>937,512</td>
<td>503,724</td>
</tr>
<tr>
<td>Interest expenses and similar charges</td>
<td>48,425</td>
<td>43,143</td>
</tr>
<tr>
<td>Negative exchange differences</td>
<td>48,425</td>
<td>43,143</td>
</tr>
<tr>
<td>Net expenses from sales of marketable securities</td>
<td>985,937</td>
<td>546,867</td>
</tr>
<tr>
<td><strong>Total (VI)</strong></td>
<td>985,937</td>
<td>546,867</td>
</tr>
<tr>
<td><strong>2 - Financial result (V-VI)</strong></td>
<td>-944,788</td>
<td>-472,363</td>
</tr>
<tr>
<td><strong>3 - Earnings before interest and tax (I-II+III-IV+V-VI)</strong></td>
<td>-43,711,193</td>
<td>-31,506,958</td>
</tr>
<tr>
<td><strong>Extraordinary income (Note 3.2.2.5)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extraordinary income from management operations</td>
<td>60,198</td>
<td>59,740</td>
</tr>
<tr>
<td>Write-backs of impairments and provisions, transfers of expenditure</td>
<td>60,198</td>
<td>59,740</td>
</tr>
<tr>
<td><strong>Total (VII)</strong></td>
<td>60,198</td>
<td>59,740</td>
</tr>
<tr>
<td><strong>Extraordinary expenses (Note 3.2.2.5)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extraordinary expenses from management operations</td>
<td>3,424</td>
<td>9,869</td>
</tr>
<tr>
<td>Extraordinary expenses from capital operations</td>
<td>58,564</td>
<td>105,513</td>
</tr>
<tr>
<td>Amortization/depreciation, impairments and provisions</td>
<td>61,987</td>
<td>115,382</td>
</tr>
<tr>
<td><strong>Total (VIII)</strong></td>
<td>61,987</td>
<td>115,382</td>
</tr>
<tr>
<td><strong>4 - Extraordinary result (VII-VIII)</strong></td>
<td>-1,789</td>
<td>-55,642</td>
</tr>
<tr>
<td>Employee profit-sharing (IX)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income taxes (X) (Note 3.2.2.4)</td>
<td>-1,983,916</td>
<td>-2,334,690</td>
</tr>
<tr>
<td><strong>Total income (I+III+V+VII)</strong></td>
<td>823,829</td>
<td>162,244</td>
</tr>
<tr>
<td><strong>Total expenses (II+IV+VI+VIII+IX+X)</strong></td>
<td>42,552,895</td>
<td>29,390,154</td>
</tr>
<tr>
<td><strong>5 - Loss (total income – total expenses)</strong></td>
<td>-41,729,066</td>
<td>-29,227,910</td>
</tr>
</tbody>
</table>
## BALANCE SHEET

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(in euros)</strong></td>
<td>Gross</td>
<td>Net</td>
</tr>
<tr>
<td><strong>UNCALLED SHARE CAPITAL (TOTAL I)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible fixed assets (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Start-up costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Development costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Licenses, patents and similar rights</td>
<td>1,978,685</td>
<td>89,777</td>
</tr>
<tr>
<td>- Goodwill *</td>
<td></td>
<td>72,072</td>
</tr>
<tr>
<td>- Assets under construction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Advances and payments on account</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant and equipment (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Land</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Buildings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Technical plant, equipment and tooling</td>
<td>8,068,236</td>
<td>2,327,214</td>
</tr>
<tr>
<td>- Other property, plant and equipment</td>
<td>2,807,037</td>
<td>1,629,202</td>
</tr>
<tr>
<td>- Assets under construction</td>
<td>1,606,508</td>
<td>1,606,508</td>
</tr>
<tr>
<td>- Advances and payments on account</td>
<td>1,606,508</td>
<td>2,760,389</td>
</tr>
<tr>
<td>Financial assets ** (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Holdings accounted for on an equity basis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Other holdings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Other equity investments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Loans</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Other financial assets</td>
<td>485,877</td>
<td>485,877</td>
</tr>
<tr>
<td><strong>TOTAL II</strong></td>
<td>14,946,342</td>
<td>6,138,578</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stocks and work in progress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Raw materials, supplies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Work in progress – goods</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Work in progress – services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Semi-finished and finished products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Merchandise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advances and prepayments on orders</td>
<td>375,721</td>
<td>181,706</td>
</tr>
<tr>
<td>**Debtors *****</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Trade accounts receivable</td>
<td>4,579,872</td>
<td>3,825,641</td>
</tr>
<tr>
<td>- Other accounts receivable (note 3.2.2.4)</td>
<td></td>
<td>3,825,641</td>
</tr>
<tr>
<td>- Subscribed capital – called, not paid up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketable securities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash instruments (note 3.2.2.4)</td>
<td>25,301,658</td>
<td>60,722,988</td>
</tr>
<tr>
<td>Deferred charges *** (note 3.2.2.4)</td>
<td>433,318</td>
<td>367,492</td>
</tr>
<tr>
<td><strong>TOTAL III</strong></td>
<td>30,690,569</td>
<td>65,097,827</td>
</tr>
<tr>
<td><strong>ADJUSTMENT ACCOUNTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bond issuance costs to be amortized (IV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bond redemption premiums (V)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrealized foreign exchange losses (VI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRAND TOTAL (I+II+III+IV+V+VI)</strong></td>
<td>45,638,911</td>
<td>69,849,521</td>
</tr>
</tbody>
</table>

* including lease rights.
** of which less than one year.
*** of which more than one year.
## Liabilities

### EQUITY

- **Capital (of which, paid in: 371,037) (note 3.2.2.4)** 371,037 360,662
- **Issue, merger and acquisition premiums (notes 3.2.2.3 and 3.2.2.4)** 194,560,697 189,541,644
- **Excess of restated assets**
  - **Reserves**
    - Legal reserve
    - Statutory or contractual reserves
    - Regulatory reserves
    - Other reserves 29,840
  - **Losses brought forward** -145,751,009 -116,523,099
  - **Result for the period (profit or loss)** -41,729,066 -29,227,910
  - **Capital grants**
  - **Regulatory provisions**

### OTHER EQUITY

- **Proceeds of issues of participating stock**
- **Conditional advances (note 3.2.2.4)** 13,056,577 13,056,577

### PROVISIONS

- **Provisions for risks**
- **Provisions for charges (notes 3.2.2.4 and 3.2.2.5)** 991,440 983,135

### DEBTS *

- **Financial debts**
  - Convertible bonds
  - Other bonds
  - Loans from credit institutions
  - Bank overdrafts
  - Sundry loans and financial debts (note 3.2.2.4) 4,651,634 3,714,150
- **Advances and payments on account received for current orders**
  - Accounts payable (note 3.2.2.4)
    - Trade accounts payable and related payables 7,615,547 5,825,388
    - Tax and social liabilities 2,985,907 2,118,974
  - Liabilities secured to property and related liabilities (note 3.2.2.4)
  - Other debts (note 3.2.2.4) 46,544

### ADJUSTMENT ACCOUNTS

- **Deferred income * (note 3.2.2.4)**

### debts and deferred income of less than one year.

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital (of which, paid in: 371,037) (note 3.2.2.4)</td>
<td>371,037</td>
<td>360,662</td>
</tr>
<tr>
<td>Issue, merger and acquisition premiums (notes 3.2.2.3 and 3.2.2.4)</td>
<td>194,560,697</td>
<td>189,541,644</td>
</tr>
<tr>
<td>Total 1</td>
<td>7,481,498</td>
<td>44,151,297</td>
</tr>
<tr>
<td><strong>OTHER EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds of issues of participating stock</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total II</td>
<td>13,056,577</td>
<td>13,056,577</td>
</tr>
<tr>
<td><strong>PROVISIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provisions for risks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provisions for charges (notes 3.2.2.4 and 3.2.2.5)</td>
<td>991,440</td>
<td>983,135</td>
</tr>
<tr>
<td>Total III</td>
<td>991,440</td>
<td>983,135</td>
</tr>
<tr>
<td>**DEBTS *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial debts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Convertible bonds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Other bonds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Loans from credit institutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Bank overdrafts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Sundry loans and financial debts (note 3.2.2.4)</td>
<td>4,651,634</td>
<td>3,714,150</td>
</tr>
<tr>
<td>Advances and payments on account received for current orders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Trade accounts payable and related payables</td>
<td>7,615,547</td>
<td>5,825,388</td>
</tr>
<tr>
<td>- Tax and social liabilities</td>
<td>2,985,907</td>
<td>2,118,974</td>
</tr>
<tr>
<td>Liabilities secured to property and related liabilities (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other debts (note 3.2.2.4)</td>
<td>46,544</td>
<td></td>
</tr>
<tr>
<td>Adjustments accounts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred income * (note 3.2.2.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total IV</td>
<td>15,299,831</td>
<td>11,658,512</td>
</tr>
<tr>
<td>Unrealized foreign exchange gains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total V</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRAND TOTAL (I+II+III+IV+V)</strong></td>
<td>36,829,147</td>
<td>69,849,521</td>
</tr>
<tr>
<td>* debts and deferred income of less than one year.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## CASH FLOW STATEMENT

<table>
<thead>
<tr>
<th>Cash flow statement</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>(in euros)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net result</td>
<td>-41,729,066</td>
<td>-29,227,910</td>
</tr>
<tr>
<td>Amortization/depreciation and provisions</td>
<td>1,636,615</td>
<td>1,541,744</td>
</tr>
<tr>
<td>Write-backs of amortization/depreciation and provisions</td>
<td>-708,481</td>
<td>-42,847</td>
</tr>
<tr>
<td>Gains or losses on asset sales</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment subsidies transferred to income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other income and expenses with no impact on cash flow</td>
<td>937,484</td>
<td>501,650</td>
</tr>
<tr>
<td><strong>SELF-FINANCING CAPACITY</strong></td>
<td><strong>-39,863,448</strong></td>
<td><strong>-27,227,364</strong></td>
</tr>
<tr>
<td>Tax and social liabilities</td>
<td>866,933</td>
<td>512,352</td>
</tr>
<tr>
<td>Trade accounts payable</td>
<td>1,790,159</td>
<td>2,236,651</td>
</tr>
<tr>
<td>Other debts</td>
<td>46,544</td>
<td></td>
</tr>
<tr>
<td>Deferred income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stocks and work in progress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advances and prepayments on orders</td>
<td>-194,015</td>
<td>-166,561</td>
</tr>
<tr>
<td>Other accounts receivable</td>
<td>-754,231</td>
<td>402,667</td>
</tr>
<tr>
<td>Trade receivables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred charges</td>
<td>-65,826</td>
<td>-36,410</td>
</tr>
<tr>
<td><strong>CHANGES IN CASH POSITION (CHANGE IN WORKING CAPITAL)</strong></td>
<td><strong>1,689,564</strong></td>
<td><strong>2,948,699</strong></td>
</tr>
<tr>
<td><strong>CASH FLOW FROM OPERATIONS</strong></td>
<td><strong>-38,173,884</strong></td>
<td><strong>-24,278,664</strong></td>
</tr>
<tr>
<td>Acquisition of property, plant and equipment</td>
<td>-2,176,599</td>
<td>-3,528,393</td>
</tr>
<tr>
<td>Acquisition of intangible fixed assets</td>
<td>-116,780</td>
<td>-30,243</td>
</tr>
<tr>
<td>Acquisition of financial fixed assets</td>
<td>-13,335</td>
<td>-150,543</td>
</tr>
<tr>
<td>Proceeds from financial fixed asset disposals</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CASH FLOW FROM INVESTMENT OPERATIONS</strong></td>
<td><strong>-2,306,714</strong></td>
<td><strong>-3,709,179</strong></td>
</tr>
<tr>
<td>Increase in capital</td>
<td>10,375</td>
<td>119,384</td>
</tr>
<tr>
<td>ORA/BSA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Issue premium and reserves</td>
<td>5,048,893</td>
<td>57,418,100</td>
</tr>
<tr>
<td>Capitalization of current accounts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loans and conditional advances</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CASH FLOW FROM FINANCING OPERATIONS</strong></td>
<td><strong>5,059,268</strong></td>
<td><strong>57,547,484</strong></td>
</tr>
<tr>
<td><strong>CHANGE IN CASH AND CASH EQUIVALENTS</strong></td>
<td><strong>-36,421,330</strong></td>
<td><strong>29,559,640</strong></td>
</tr>
<tr>
<td>OPENING CASH AND CASH EQUIVALENTS (NOTE 3.2.2.4)</td>
<td>60,722,988</td>
<td>31,163,348</td>
</tr>
<tr>
<td>CLOSING CASH AND CASH EQUIVALENTS (NOTE 3.2.2.4)</td>
<td>25,301,658</td>
<td>60,722,988</td>
</tr>
</tbody>
</table>
3.2.2 ANNEX TO THE FINANCIAL STATEMENTS

Annex to the balance sheet for the year ended December 31, 2018, totaling €36,829,147, and to the income statement for the year ended December 31, 2018, presented in list form and showing zero revenue resulting in a loss of €41,729,066.

The financial year commenced on January 1, 2018 and ended on December 31, 2018, a duration of 12 months which is identical to that of the comparative period.

The notes and tables presented in the following are an integral part of the financial statements for the period ended on December 31, 2018 as approved by the board of directors on February 11, 2019. They are presented in euros unless otherwise stated.

3.2.2.1 FEATURES OF THE YEAR

The Company’s activity is devoted to the development of an artificial heart that responds to the challenges of terminal heart failure. The product is currently in the pivotal study phase following a protocol approved by the ANSM.

- Under the terms of the equity financing agreement signed with Kepler Cheuvreux on January 20, 2015, twenty-five subscriptions were made between January and December for a total of 242,000 stock warrants, enabling the capital to be increased by €9,680.00, by issuing 242,000 ordinary shares with a par value of €0.04, issued at an average unit price of €20.67, with an issue premium of €4,991,860.00. Taking into account the costs related to the capital increase of €112,672.33, which are deducted from the issue premium under the preferential accounting method, the net issue premium under this capital increase is €4,888,867.67.

- Two BCE exercises were executed between January and December for a total of 45 BCE 2009-2, increasing the capital by an amount of €45.00 by issuing 1,125 ordinary shares with a par value of €0.04, issued at a unit price of €8.00 per share, i.e. with an issue premium of €7.96 per share.

- A share subscription warrants (BSA) exercise was carried out between January and December for a total of 650 warrants, enabling the capital to be increased by an amount of €650.00, by issuing 16,250 ordinary shares with a par value of €0.04, issued at a unit price of €8.00 per share, i.e. with an issue premium of €7.96 per share.

All of the capital increases carried out during the year enabled the share capital to be increased by €10,375.00, through the creation of 259,375 new ordinary shares. The share capital of the company was thus been increased from €360,661.76 to €371,036.76. The total amount of issue premiums was increased from €189,541,644 to €194,560,697.

The Company maintains the option for the Research Tax Credit for the year 2018. The first option was exercised in respect of the 2009 calendar year and renewed each year until 2018. The Research Tax Credit for the year 2018 has been recorded in the income statement (€1,983,916) (see note 3.2.2.5 in the notes to the financial statements) and shown in the « Other receivables » line of the balance sheet.

The development of a new production site in Bois d’Arcy (Yvelines), initiated in 2017, was completed in fiscal year 2018. It ensures the ramp-up of production, in phase with the announced objectives of the pivotal study. At the end of the financial year, an amount of €2,923,007 was recorded under Technical Plant, Equipment and Industrial Tooling for site improvements.

The status of the project and the significant activities of the Company are detailed in section 3.1 « Comments on the Company’s business during the year » of this document.

3.2.2.2 SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

No event occurring after the end of the financial year is liable to alter the presentation or the valuation of the accounts as decided by the Board of Directors.

3.2.2.3 ACCOUNTING RULES AND METHODS

The valuation methods for this period have not been changed from those used in the previous financial year.

General principles and conventions

The accounts for the period have been prepared and presented in accordance with the accounting regulations and the principles laid down in Articles 120-1 et seq. of the
The basic valuation method for the items shown in the accounts is that of historical cost.

The general accounting conventions have been applied in accordance with the provisions of the French Commercial Code, the Accounting Decree of November 29, 1983 and the CRC regulations concerning the redrafting of the General Accounting Plan applicable as at the end of the period.

The general accounting conventions have been applied in accordance with the prudent person rule, on the basis of the following assumptions:
- the business is a going concern;
- the accounting methods are consistent from one year to the next;
- there is a clear cut-off between accounting periods.

The board of directors has assumed that the business is a going concern, having taken the following points in particular into account:
- the level of cash and cash equivalents available as of December 31, 2018, for a total amount of €25,301,658;
- the payment of repayable advances (€1,450,732) still to be collected by the end of the Bpifrance aid program signed in 2009, corresponding to key step 7;
- the possibility of using the flexible equity financing set up in September 2018 with Kepler Cheuvreux, whose balance at December 31, 2018 is equal to €24.2 million;
- the obtaining non-dilutive financing from the European Investment Bank (EIB) granted on December 17, 2018, which at December 31, 2018 amounted to €30.0 million.

The Company’s industrial and commercial development after it has obtained CE marking will give rise to further financial requirements: financing for ongoing operations and R&D during the initial commercial launch phase, need for working capital in relation to sales development, investment for the purpose of increasing production capacity and automating production processes. The Company currently estimates that these additional requirements could reach €100 million. Further fundraising will be required, beyond using the available balance of the Kepler equity financing and the EIB loan.

### Supplementary information

- **Applied research and development costs**

Research and development costs are accounted for as expenses in the year in which they are incurred.

- **Intangible fixed assets**

Patents, licenses and other intangible fixed assets have been valued at their cost of acquisition, excluding the expenses incurred in acquiring them.

The methods and periods of amortization used are as follows:

<table>
<thead>
<tr>
<th>Category</th>
<th>Mode</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licenses and software</td>
<td>Straight line</td>
<td>1 to 3 years</td>
</tr>
<tr>
<td>Patents</td>
<td>Straight line</td>
<td>15 years</td>
</tr>
</tbody>
</table>

- **Property, plant and equipment**

The gross value of property, plant and equipment corresponds to their initial book value, inclusive of any expenditure required to render the items usable but excluding costs incurred in their acquisition.

The methods and periods of depreciation used are as follows:

<table>
<thead>
<tr>
<th>Category</th>
<th>Mode</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixtures and fittings</td>
<td>Straight line</td>
<td>9 to 10 years</td>
</tr>
<tr>
<td>Technical plant</td>
<td>Straight line</td>
<td>3 to 7 years</td>
</tr>
<tr>
<td>Equipment and tooling</td>
<td>Straight line</td>
<td>2 to 6 years</td>
</tr>
<tr>
<td>Furniture</td>
<td>Straight line</td>
<td>8 years</td>
</tr>
<tr>
<td>IT equipment</td>
<td>Straight line</td>
<td>3 years</td>
</tr>
</tbody>
</table>

- **Financial assets**

### OTHER SECURITIES CLASSIFIED AS FIXED ASSETS

In 2010, the Company entered into a liquidity contract, the purpose of which is to improve the liquidity of transactions and regularize the CARMAT share price, without impeding the normal operation of the market and without misleading third parties. To this end the Company made an amount of €300,000 available.

On May 19, 2016, the Company transferred the liquidity contract to Gilbert Dupont for a period of 12 months, renewable by tacit agreement.

Treasury shares acquired through the implementation of this liquidity agreement are recorded under financial assets at their purchase price. If necessary, a provision is made for impairments based on the average official stock market price for the final month prior to the end of the
FINANCIAL INFORMATIONS

reporting period.

OTHER FINANCIAL ASSETS

These comprise:
- guarantee deposits paid, which are shown at face value; and
- the unused balance of sums made available under the liquidity agreement for the acquisition of own shares.

- Receivables and liabilities

Receivables and payables are shown at face value. If necessary, impairments are recorded against receivables to take account of difficulties with recovery that are likely to occur. Any provisions for impairments are determined by comparison between the acquisition value and the likely realization value.

Receivables and payables in foreign currencies are converted into euros on the basis of the exchange rate at the date of the invoice.

- Stocks

The equipment in stock is not valued at the end of the financial year as these are intended to be integrated into the prostheses used for the pivotal study, their net realizable value is therefore nil.

- Cash in euros

Cash on hand or at bank is recorded at face value.

- Cash in foreign currencies

Cash in foreign currencies is converted to euros at the exchange rate ruling on the balance sheet date. Gains and losses on conversion are recognized immediately in the profit or loss for the period as exchange gains and losses.

- Cash instruments

These comprise time deposit accounts, shown under assets at their acquisition cost, plus accrued interest at the closing date of the reporting period.

- Cash and cash equivalents

For the purposes of the cash flow statement, cash and cash equivalents are defined as being the sum of the « Cash instruments » and « Cash on hand » items under the assets, less the current bank overdraft liability item, to the extent that cash instruments are available in the very short term and do not present a risk of a loss in value in the event of a change in interest rate. An analysis of cash according to this definition is provided at the foot of the cash flow statement.

- Repayable advances made by public bodies

Advances received from public bodies to finance the research activities of the Company and which are subject to repayment are shown under liabilities under « Other equity – Conditional advances ». The corresponding interest is shown in balance sheet liabilities under Sundry loans and financial debts.

- Operating subsidies

Subsidies are recorded as soon as the corresponding receivable becomes certain, taking account of the conditions set at the time the subsidy was granted. Subsidies are recorded under income taking account, if necessary, of the corresponding rate of expenditure in order to adhere to the principle of matching of expenses with revenue.

- Retirement indemnities

Future payments for benefits to members of staff are valued according to an actuarial method based on assumptions concerning changes in salaries, retirement age and mortality; the resulting valuations are then discounted to their present value. These commitments are the subject of provisions in the balance sheet liabilities.

- Sub-contracting expenses

The progress of third-party sub-contract agreements for certain research services is assessed at the end of each reporting period in order to allow the cost of services already rendered to be recorded under accrued charges.

- Share issue costs

In accordance with the preferential method, share issue costs are recorded in the balance sheet as deductions from the issue premium.
### 3.2.2.4 SUPPLEMENTARY INFORMATION ON THE BALANCE SHEET

- Schedule of fixed assets

### Schedule of fixed assets

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>Gross value at start of period</th>
<th>Additions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Line to line transfers</td>
<td>Acquisitions</td>
<td></td>
</tr>
<tr>
<td>Licenses, patents and similar rights *</td>
<td>1,861,904</td>
<td>107,930</td>
<td>8,850</td>
</tr>
<tr>
<td>Assets under construction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>1,861,904</td>
<td>107,930</td>
<td>8,850</td>
</tr>
<tr>
<td>Technical plant, equipment and industrial tooling **</td>
<td>6,328,507</td>
<td>925,351</td>
<td>814,378</td>
</tr>
<tr>
<td>General plant, sundry fixtures and fittings</td>
<td>869,619</td>
<td>1,083,895</td>
<td>477,347</td>
</tr>
<tr>
<td>Office and IT equipment, furniture</td>
<td>346,667</td>
<td>29,508</td>
<td></td>
</tr>
<tr>
<td>Assets under construction ***</td>
<td>2,760,389</td>
<td>992,803</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>10,305,182</td>
<td>2,038,754</td>
<td>2,284,528</td>
</tr>
<tr>
<td>Other financial fixed assets ****</td>
<td>472,541</td>
<td>2,971,649</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>472,541</td>
<td>2,971,649</td>
<td></td>
</tr>
<tr>
<td>GRAND TOTAL</td>
<td>12,639,628</td>
<td>2,146,684</td>
<td>5,265,027</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(in euros)</th>
<th>Reductions</th>
<th>Gross value at end of period</th>
<th>Revaluation of original value at end of period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Line to line transfers</td>
<td>Disposals</td>
<td></td>
</tr>
<tr>
<td>Licenses, patents and similar rights *</td>
<td></td>
<td>1,978,684</td>
<td></td>
</tr>
<tr>
<td>Assets under construction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>1,978,684</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical plant, equipment and industrial tooling **</td>
<td>8,068,236</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General plant, sundry fixtures and fittings</td>
<td>2,430,861</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office and IT equipment, furniture</td>
<td>379,175</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assets under construction</td>
<td>2,146,684</td>
<td>1,606,508</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,146,684</td>
<td>12,481,781</td>
<td></td>
</tr>
<tr>
<td>Other financial fixed assets ***</td>
<td>2,958,314</td>
<td>485,876</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,958,314</td>
<td>485,876</td>
<td></td>
</tr>
<tr>
<td>GRAND TOTAL</td>
<td>2,146,684</td>
<td>2,958,314</td>
<td>14,946,342</td>
</tr>
</tbody>
</table>

* This item includes a sum of €411,284, accounted for as the share of the contribution in kind made on September 30, 2008, with a total value of €960,000, relating to the contribution of patents.

** This item includes the commissioning of the clean room at a total cost of €943,582. The item also includes a sum of €548,716 representing the proportion of the contribution in kind of €960,000 made on September 30, 2008 that related to the contribution of equipment and tooling.

*** This item includes the development of the new Bois d’Arcy production site, for an amount of €2,923,007.

**** This item includes the 2,463 own shares held in connection with the liquidity contract, valued at €49,007, and (i) the liquidities not invested in own shares as at the end of the period under the liquidity contract of €92,352 and (ii) guarantee deposits of €344,518, mainly comprising deposits under premises lease contracts.
**FINANCIAL INFORMATIONS**

- **Schedule of depreciation and amortization**

<table>
<thead>
<tr>
<th>Statements and movements for the period (in euros)</th>
<th>Value at start of period</th>
<th>Allowances for the period</th>
<th>Reductions Write-backs</th>
<th>Value at end of period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licenses, patents and similar rights</td>
<td>1,789,832</td>
<td>99,075</td>
<td></td>
<td>1,888,907</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>1,789,832</strong></td>
<td><strong>99,075</strong></td>
<td><strong>-</strong></td>
<td><strong>1,888,907</strong></td>
</tr>
<tr>
<td>Technical plant, equipment and industrial tooling</td>
<td>5,117,234</td>
<td>624,196</td>
<td></td>
<td>5,741,430</td>
</tr>
<tr>
<td>General plant, sundry fixtures and fittings</td>
<td>681,273</td>
<td>174,014</td>
<td></td>
<td>855,287</td>
</tr>
<tr>
<td>Office and IT equipment, furniture</td>
<td>299,596</td>
<td>22,544</td>
<td></td>
<td>322,140</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>6,098,935</strong></td>
<td><strong>820,754</strong></td>
<td><strong>-</strong></td>
<td><strong>6,918,857</strong></td>
</tr>
</tbody>
</table>

**GRAND TOTAL**

7,887,935  919,829  8,807,764

- **Schedule of provisions**

<table>
<thead>
<tr>
<th>Provisions (in euros)</th>
<th>Value at start of period</th>
<th>Increases Allowances</th>
<th>Reductions Amounts used</th>
<th>Reductions Amounts not used</th>
<th>Value at end of period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sundry risks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pensions and similar commitments *</td>
<td>274,654</td>
<td>28,314</td>
<td>302,968</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social charges on free preferential shares **</td>
<td>688,472</td>
<td>708,481</td>
<td>688,472</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>274,654</td>
<td>716,786</td>
<td>708,481</td>
<td>991,440</td>
<td></td>
</tr>
<tr>
<td>Impairment of other equity investments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**GRAND TOTAL**

983,135  716,786  708,481  991,440

Including operational allowances and write-backs  716,786  708,481
Including financial allowances and write-backs  
* See note 3.2.2.6  
** See following note Provision for expenses

- **Schedule of maturities of receivables and liabilities**

<table>
<thead>
<tr>
<th>Schedule of receivables (in euros)</th>
<th>Gross amount</th>
<th>Up to 1 year</th>
<th>More than 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social security and other social bodies</td>
<td>6,896</td>
<td>6,896</td>
<td></td>
</tr>
<tr>
<td>Income taxes *</td>
<td>2,034,203</td>
<td>2,034,203</td>
<td></td>
</tr>
<tr>
<td>Value added tax</td>
<td>2,485,154</td>
<td>2,485,154</td>
<td></td>
</tr>
<tr>
<td>Sundry debtors</td>
<td>53,618</td>
<td>53,618</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL**

4,579,871  4,579,871

* The receivable corresponds to:  
  - the CIR for the year 2018 for an amount of €1,983,916;  
  - and the CICE for the year 2018 for an amount of €50,287.

<table>
<thead>
<tr>
<th>Schedule of liabilities (in euros)</th>
<th>Gross amount</th>
<th>Up to 1 year</th>
<th>1 to 5 years</th>
<th>More than 5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sundy loans and financial debts</td>
<td>4,651,634</td>
<td></td>
<td></td>
<td>4,651,634</td>
</tr>
<tr>
<td>Trade accounts payable and related payables</td>
<td>7,615,547</td>
<td>7,615,547</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff-related liabilities</td>
<td>1,447,603</td>
<td>1,447,603</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social security and other social bodies</td>
<td>1,448,959</td>
<td>1,448,959</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Value added tax</td>
<td>52,940</td>
<td>52,940</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other taxes, duties and similar</td>
<td>36,405</td>
<td>36,405</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other debts</td>
<td>46,544</td>
<td>46,544</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL**

15,299,631  10,647,998  4,651,634
• Capital

Composition of the share capital

<table>
<thead>
<tr>
<th>Categories of shares</th>
<th>Nominal value in euros</th>
<th>Number of shares</th>
<th>Opening</th>
<th>Created</th>
<th>Redeemed</th>
<th>Closing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares</td>
<td>0.04</td>
<td></td>
<td>9,016,544</td>
<td>259,375</td>
<td></td>
<td>9,275,919</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
<td>9,016,544</td>
<td>259,375</td>
<td></td>
<td>9,275,919</td>
</tr>
</tbody>
</table>

The capital increase, through the exercise of Kepler BSA, during the financial year 2018 resulted in the creation of 242,000 ordinary shares with a par value of €0.04.

The capital increase through the exercise of BCE during the financial year 2018 resulted in the creation of 1,125 ordinary shares with a par value of €0.04.

Changes in equity

<table>
<thead>
<tr>
<th>EQUITY AT THE START OF THE PERIOD</th>
<th>44,151,297</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in capital through exercising of BCE warrants</td>
<td>9,000</td>
</tr>
<tr>
<td>Increase in capital through exercising of BSA warrants</td>
<td>161,400</td>
</tr>
<tr>
<td>Increase in capital through exercising of Kepler BSA warrants</td>
<td>4,888,867</td>
</tr>
<tr>
<td>Result for the period</td>
<td>-41,729,066</td>
</tr>
<tr>
<td>EQUITY AT THE END OF THE PERIOD</td>
<td>7,481,498</td>
</tr>
</tbody>
</table>

Stock-options

On the authorization of the combined general meeting of April 27, 2018, the board of directors decided, on December 3, 2018, to grant 46,000 options to subscribe for common shares, distributed as follows: 23,000 Options A and 23,000 Options B. These options entitle holders to subscribe to 46,000 new shares, representing the achievement of attendance and / or performance criteria, representing 0.50% of the existing capital as of December 31, 2018, at unit price of €20.35, issue premium included.

Preferential shares

2017 plan:

On the authorization of the combined general meeting of April 27, 2017, the board of directors’ meeting decided, on May 15, 2017, to allocate provisionally 5,250 preferential shares, distributed as follows: 270 AGAP 2017-01, 1,800 AGAP 2017-02, 3,180 AGAP 2017-03, and on September 25, 2017, to allocate provisionally 560 preferential shares, distributed as follows: 50 AGAP 2017-01, 200 AGAP 2017-02, 310 AGAP 2017-03.

These preferential shares may be converted based on the achievement of the performance criteria into a maximum of 421,000 ordinary shares: 32,000 ordinary shares under AGAP 2017-01, 40,000 ordinary shares under AGAP 2017-02, and 349,000 ordinary shares under AGAP 2017-03.

2018 plan:

On the authorization of the combined general meeting of April 5, 2018, the board of directors’ meeting decided, on April 16, 2018, to allocate provisionally 12,080 preferential shares, distributed as follows: 580 AGAP 2018-01 and 11,500 AGAP 2018-02, then on September 27, 2018, to allocate provisionally 370 AGAP 2018-03.

These preferential shares may be converted based on the achievement of the performance criteria into a maximum of 264,500 * ordinary shares: 58,000 ordinary shares under AGAP 2018-01, 169,500 * ordinary shares under AGAP 2018-02, and 37,000 ordinary shares under AGAP 2018-03.

* These figures take into account, on the one hand, the departure of an AGAP 2018-02 beneficiary and the non-achievement of a performance criterion attached to AGAP 2018-02.
FINANCIAL INFORMATIONS

Stock warrants

BSA 2009-1

At the general meeting and the meeting of the board of directors of July 8, 2009 and following the board of directors’ meeting of September 8, 2011, 3,096 BSA 2009-1 warrants were issued; of these 556 were canceled following the resignation of one of the directors and 1,636 have been exercised. As at December 31, 2018, there remained 904 BSA 2009-1 warrants conferring rights to subscribe for 22,600 new shares, representing 0.24% of the existing capital as at December 31, 2018, at unit price of €8.

BSA KEPLER CHEUVREUX

In accordance with the board of directors’ decision of December 9, 2014, as authorized by the combined general meeting of April 2, 2014, then in accordance with the board of directors’ decision of December 12, 2016, as authorized by the combined general meeting of June 28, 2016, a total number of 900,000 BSA warrants were issued, 742,600 of which had been exercised as at July 20, 2018, expiry date of the contract. The 157,400 BSA warrants not exercised on the same date became lapsed.

By decision of the board of directors on September 27, 2018, as authorized by the combined general meeting of April 5, 2018, 400,000 BSA warrants were issued, of which 34,000 BSA warrants were exercised on December 31, 2018.

SUMMARY TABLE OF BSA WARRANTS

<table>
<thead>
<tr>
<th>Issued</th>
<th>Subscribed</th>
<th>Lapsed</th>
<th>Reserve</th>
<th>Exercised</th>
<th>Balance</th>
<th>Lapsing on</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSA 2009-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GM of July 8, 2009</td>
<td>3,096</td>
<td>3,096</td>
<td>556</td>
<td>0</td>
<td>1,636</td>
<td>904</td>
</tr>
<tr>
<td>BSA Kepler Chevreux (old tranches)</td>
<td>900,000</td>
<td>900,000</td>
<td>157,400</td>
<td>0</td>
<td>742,600</td>
<td>0</td>
</tr>
<tr>
<td>BSA Kepler Cheuvreux (new tranches)</td>
<td>400,000</td>
<td>400,000</td>
<td>0</td>
<td>0</td>
<td>34,000</td>
<td>366,000</td>
</tr>
<tr>
<td>BSA 2017</td>
<td>12,000</td>
<td>12,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12,000</td>
</tr>
<tr>
<td>BSA 2018</td>
<td>10,000</td>
<td>10,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10,000</td>
</tr>
</tbody>
</table>

BSA 2017

By decision of the board of directors dated May 15, 2017, 12,000 warrants were issued pursuant to a delegation of authority granted by the combined general meeting of April 27, 2017, none of which had been exercised as at December 31, 2018. 12,000 warrants not exercised on the same date entitle them to subscribe for 12,000 new shares, representing 0.13% of the existing capital as at December 31, 2018, at unit price of €30.10.

BSA 2018

By decision of the board of directors dated June 11, 2018, 10,000 warrants were issued pursuant to a delegation of authority granted by the combined general meeting of April 5, 2018, none of which had been exercised as at December 31, 2018. 10,000 warrants not exercised on the same date entitle them to subscribe for 10,000 new shares, representing 0.11% of the existing capital as at December 31, 2018, at unit price of €20.93.

Start-up company stock warrants (BCE)

BCE 2009-1

At the general meeting and the meeting of the board of directors of July 8, 2009 and following the board of directors’ meeting of September 8, 2011, 3,108 fully assigned and subscribed BCE-2009-1 warrants were issued, exercised.

BCE 2009-2

At the general meeting and the meeting of the board of directors of July 8, 2009 and following the board of directors’ meeting of September 8, 2011, 7,566 fully assigned and subscribed BCE-2009-2 warrants were issued, 3,230 of which have been exercised and 1,778 of which have lapsed and been canceled. The 2,558 BCE-2009-2 warrants subscribed and not exercised as at December 31, 2018 confer the right to subscribe to 63,950 new shares, representing 0.69% of the existing capital as at December 31, 2018, at unit price of €8.
In accordance with the board of directors’ decision of June 27, 2012, as authorized by the combined general meeting of April 26, 2012, 56,500 fully assigned and subscribed BCE-2012-1 warrants were issued, of which 22,500 have lapsed and been canceled. The 34,000 BCE-2012-1 warrants subscribed and not exercised as at December 31, 2018 confer subscription rights to 34,000 new shares, representing 0.37% of the existing capital as at December 31, 2018, at unit price of €108.483.

SUMMARY TABLE OF BCE WARRANTS

<table>
<thead>
<tr>
<th>BCE 2009-1</th>
<th>Issued</th>
<th>Subscribed</th>
<th>Lapsed</th>
<th>Exercised</th>
<th>Balance</th>
<th>Lapsing on</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM of July 8, 2009</td>
<td>3,108</td>
<td>3,108</td>
<td>0</td>
<td>3,108</td>
<td>0</td>
<td>Sept. 9, 2019</td>
</tr>
<tr>
<td>BCE 2009-2</td>
<td>7,566</td>
<td>7,566</td>
<td>1,778</td>
<td>3,230</td>
<td>2,558</td>
<td>July 8, 2019</td>
</tr>
<tr>
<td>GM of July 8, 2009</td>
<td>7,566</td>
<td>7,566</td>
<td>1,778</td>
<td>3,230</td>
<td>2,558</td>
<td>July 8, 2019</td>
</tr>
<tr>
<td>BCE 2012-1</td>
<td>56,500</td>
<td>56,500</td>
<td>22,500</td>
<td>0</td>
<td>34,000</td>
<td>June 27, 2022</td>
</tr>
<tr>
<td>GM of April 26, 2012</td>
<td>56,500</td>
<td>56,500</td>
<td>22,500</td>
<td>0</td>
<td>34,000</td>
<td>June 27, 2022</td>
</tr>
<tr>
<td>BCE 2012-2</td>
<td>6,700</td>
<td>6,700</td>
<td>0</td>
<td>0</td>
<td>6,700</td>
<td>Nov. 8, 2022</td>
</tr>
<tr>
<td>GM of April 26, 2012</td>
<td>6,700</td>
<td>6,700</td>
<td>0</td>
<td>0</td>
<td>6,700</td>
<td>Nov. 8, 2022</td>
</tr>
</tbody>
</table>

- Other balance sheet details

Conditional advances

The conditional advances item comprises repayable advances received from Bpifrance, the total amount of which was €13,056,577 as at the end of the financial year. Note 3.2.2.6 below specifies the repayment conditions of these advances.

They are interest-bearing at the contracted rate of 5.59%. The interest accrued, calculated using the capitalization method, stood at €4,651,634 at the year end and appears in liabilities under Sundry loans and financial debts.

Accrued income

Value of accrued income included in the following balance sheet items | Value
--- | ---
Other debtors | 6,896
Total | 6,896

Accrued charges

Value of accrued charges included in the following balance sheet items | Value
--- | ---
Sundry loans and financial debts | 4,651,634
Trade accounts payable and related payables | 4,333,846
Tax and social liabilities | 2,278,255
Total | 11,263,735

Deferred income and charges

Deferred charges

| Deferred charges | Value |
--- | ---|
Operating expenses | 433,318 |
Total | 433,318 |

Deferred charges comprises the following:

- the share of rent for the first quarter of 2019 billed in December 2018, totaling €180,206;
- the share of subscriptions, software license royalties and insurance premiums for the period after December 31, 2018, totaling €253,112.

Deferred income

| Deferred income | Value |
--- | ---|
Operating income | None |
Total | None |

Information on related enterprises

The following balance sheet items include sums in connection with related enterprises:

| Trade accounts payable and related payables | 377,843 |

Provision for expenses

Two preferential share allocation plans, as at April 16, 2018 and September 27, 2018, allowed for the provisional
allocation of 12,450 preferential shares, which can be converted based on the achievement of the performance criteria to a maximum of 325,000 ordinary shares. The definitive vesting dates for these preferential shares are fixed at April 16, 2019 for 12,080 preferential shares and on September 27, 2019 for 370 preferential shares. At the end of the year, the Company booked a provision for expenses corresponding to the amount of the employer contributions of 20% to be due in 2019, on a porata basis of the vesting period and based on the estimate of the value of the ordinary shares that could be converted at the end of the vesting period.

The calculation assumptions made were as follows:
- Determination of a percentage of achievement of each of the performance criteria;
- Value of a ordinary share of €23.50;
- Employer contribution rate of 20%.

### 3.2.2.5 Supplementary Information on the Income Statement

- **Operating subsidies**

  The Company received the sum of €14,000 as an operating subsidy from the Association nationale de la recherche et de la technologie (national research and technology association) for employment of 1 PhD student.

  The Company did not receive any Bpifrance grants.

- **Applied research and development costs**

  Research and development costs are accounted for under expenses. They amounted to €27,193,406 in 2018, compared to €20,335,931 in the previous year. An accounting method change was implemented and has resulted in revision of the amount calculated for the 2017 financial year, previously valued at €17,051,032.

- **Research tax credit**

  The income statement for the year shows a research tax credit amounting to €1,983,916, corresponding to the amount calculated for the year 2018.

- **Auditors’ fees**

  The total amount of auditors’ fees paid over the year is €70,600 excluding taxes and disbursements and breaks down as follows:

  - fees for the statutory audit of the financial statements and the services provided for by law: €70,600 (including €41,850 for PWC and €28,750 for LCA Audit);

  - fees for consultancy and services other than the certification of accounts: none.

### 3.2.2.6 Financial Commitments and Other Information

- **Extraordinary income and expenses**

<table>
<thead>
<tr>
<th>Type</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraordinary income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Property disposal</td>
<td>60,198</td>
<td>59,740</td>
</tr>
<tr>
<td>- Disposal of own shares</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>60,198</td>
<td>59,740</td>
</tr>
<tr>
<td>Extraordinary expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Property disposal</td>
<td>58,564</td>
<td>105,513</td>
</tr>
<tr>
<td>- Disposal of own shares</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Fines and penalties</td>
<td>3,424</td>
<td>9,869</td>
</tr>
<tr>
<td>Total</td>
<td>61,987</td>
<td>115,382</td>
</tr>
</tbody>
</table>

  The extraordinary income results mainly from the sale of own shares under the liquidity contract.

- **Information on associates**

  The following income statement items include sums in connection with associates:

  | Other purchases and external expenditure | 384,506 |

### 3.2.2.6 Financial Commitments and Other Information

- **Financial commitments**

  Commitments made

  Repayable advances totaling €13,056,577 have been received at the end of the fiscal year. This amount is repayable subject to achieving cumulative revenue of at least €38,000,000. The Bpifrance agreement provides for supplementary payments if certain conditions are met, so that the total amount repayable could exceed the amount of the advance initially granted, up to a ceiling of €50,000,000.

  On June 24, 2008 the Company signed a royalties agreement with Professor Alain Carpentier and Matra Défense, who held shareholdings of 5.91% and 14.38% respectively as at December 31, 2017. Under this Agreement, the Company undertakes to pay Professor Alain Carpentier and Matra Défense 2% of the net proceeds from sales of the CARMAT Artificial Heart produced and distributed by CARMAT SA, with this sum being shared between the two beneficiaries in proportion to their respective shares in the capital of the Company on the date it was established. These royalties will be payable every six months within 30 days of the end of each six-month period, commencing after the first marketing of the CARMAT Artificial Heart and ending upon expiry of the patents shown in Annex 1 to the agreement.
The Company is also authorized to repurchase at any time the right to benefit from these royalties for a sum of €30,000,000 less any royalties already paid under the agreement, with this total sum being shared between the two beneficiaries in proportion to their respective shares in the capital of the Company on the date it was established. This sum of €30,000,000 is index-linked to the Indice du Prix à la Production de l’Industrie des Services aux Entreprises - Matériel médicochirurgical et d’orthopédie-exportation zone euro [Index of Prices for the Industrial Production of Services to Businesses - Medical-surgical and orthopedic equipment - for export within the Eurozone].

The rights allocated to Professor Alain Carpentier and to Matra Défense in this way are non-transferable.

As at December 31, 2018, since the marketing of the CARMAT Artificial Heart had not started, no royalty had been paid by the Company under the agreement.

In addition, the Company has signed a royalty agreement with the EIB providing for the payment of additional remuneration to the EIB depending on the commercial performance of the Company. This agreement runs for 13 years from the year in which the cumulative sales of CARMAT will reach €500,000. At any time, the Company may decide to terminate the royalties contract by paying a lump sum (net of royalties already paid), depending on the amount borrowed and the year of the decision.

In the event of the occurrence of certain events (in particular in the event of the declaration of the anticipated repayment of the credit by EIB or if a new shareholder were to hold 33% of the voting rights of CARMAT), the EIB could, if it considered it necessary, ask CARMAT for the advance payment of royalties up to a certain percentage of the amount of the credit actually drawn (this progressive percentage ranging from 100% of the amount borrowed if the event occurs during the first four years of the financial contract, to 160% if the event occurs after the eleventh year).

Commitments received

The Bpifrance agreement provides for payment of a total sum of €17,442,639 by way of subsidies, all of which were received at the end of the financial year.

The agreement also provides for payment of a total sum of €14,507,324 by way of repayable advances, of which €1,450,732 remains to be paid between now and the end of the program.

Pension and retirement commitments

The Company has not signed a specific agreement on retirement commitments. These are therefore limited to the agreed retirement lump-sum payment.

In accordance with the preferential method, the provision for retirement commitments has been booked as at December 31, 2018.

The calculation assumptions made were as follows:
- time-apportioned rights method in accordance with Regulation 2003 R-01 of the CNC;
- retirement on the initiative of the member of staff, at 62 years (non-management) or 65 years (management);
- salary increases of 2% per annum;
- low staff turnover;
- discount rate of 1.57% per annum (as against the rate of 1.30% used as at December 31, 2017 and 1.45% as at June 30, 2018).

The overall amount of the provision was €302,968 at the end of the period, an increase of €28,314 on the previous period.

Other information

Information on the management

ADVANCES AND LOANS TO MANAGEMENT

No loans or advances were made to the management of the Company during the period, in accordance with the provisions of Article R.123-197 of the French Commercial Code.

MANAGEMENT REMUNERATION

Total directors’ fees recognized in respect of 2018 amounted to €79,241 (amounts entered under « Other expenses » in the income statement).

The total remuneration allocated to members of the management bodies was €637,477 for the year and breaks down as follows:

<table>
<thead>
<tr>
<th>Type</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross salaries</td>
<td>471,295</td>
<td>460,314</td>
</tr>
<tr>
<td>Benefits in kind</td>
<td>5,270</td>
<td>9,062</td>
</tr>
<tr>
<td>Bonuses</td>
<td>160,912</td>
<td>156,000</td>
</tr>
<tr>
<td>Total remuneration</td>
<td>637,477</td>
<td>625,375</td>
</tr>
</tbody>
</table>

Increases and reductions in future tax liabilities

Type of temporary differences | Value
-----------------------------|--------
Allowable loss carry-forwards | 221,385,242

This amount comprises:
- the tax loss carried forward made during previous periods and available as at January 1, 2018, in the sum of €177,648,794;
- the tax loss made in the 2018 fiscal year in the sum of €177,648,794.
3.3 AUDITORS’ REPORT ON THE 2018 FINANCIAL STATEMENTS

CARMAT SA
36, Avenue de l’Europe
Immeuble l’Etandard energy III
78140 Vélizy-Villacoublay

OPINION

In execution of the mission entrusted to us by your general meeting, we have audited the financial statements of CARMAT for the year ended December 31, 2018, as attached to this report.

We certify that the annual accounts are, in the light of French accounting rules and principles, fair and accurate and give a true and fair view of the results of the operations of the past financial year and the financial position and assets of the company at the end of the year.

FOUNDATION OF THE OPINION

Auditing framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the evidence we have collected is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under these standards are set out in the «Auditors’ Responsibilities for Auditing the Annual Accounts» section of this report.

Independence

We carried out our audit mission in accordance with the independence rules applicable to us, from January 1, 2018 to the date of our report, and in particular we did not provide services prohibited by the code of ethics of the profession of auditor.

JUSTIFICATION OF OUR ASSESSMENTS

Pursuant to the provisions of Articles L. 823-9 and R.823-7 of the French Commercial Code relating to the justification of our assessments, we inform you that the most important assessments that we have made, in our professional judgment, have the appropriateness of the accounting principles applied and the reasonableness of the significant estimates used and the overall presentation of the accounts.

The assessments thus made fall within the context of the audit of the annual financial statements taken as a whole and the formation of our opinion expressed above. We do not express an opinion on items in these separate annual accounts.

SPECIFIC VERIFICATIONS

In accordance with the professional standards applicable in France, we have also performed the specific verifications required by legal and regulatory texts.

Information provided in the management report and other documents on the financial position and the annual accounts sent to shareholders

We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the management report of the Board of Directors and in the other documents with respect to the financial position and the financial statements addressed to the shareholders.

We certify the fairness and consistency with the financial statements of the information relating to the payment periods mentioned in Article D.441-4 of the French Commercial Code.

Corporate governance information

We certify the existence, in the section of the management report of the Board of Directors devoted to corporate governance, of the information required by Article L.225-37-4 of the French Commercial Code.
**FINANCIAL INFORMATIONS**

**Other information**

In application of the law, we made sure that the various information relating to the identity of the owners of the capital or the voting rights were communicated to you in the report of management.

**RESPONSIBILITIES OF THE MANAGEMENT AND THE PERSONS CONSTITUTING CORPORATE GOVERNANCE RELATING TO THE ANNUAL ACCOUNTS**

It is the responsibility of the management to prepare annual accounts presenting a true and fair view in accordance with French accounting rules and principles and to set up the internal control that it deems necessary for the preparation of annual accounts that do not contain any significant anomalies, that they come from fraud or result from errors.

When preparing the annual accounts, it is the responsibility of management to evaluate the ability of the Company to continue operating, to present in these accounts, as the case may be, the necessary information relating to the continuity of operations and operations. Apply the going concern accounting policy unless it is intended to wind up the company or cease its business.

The annual accounts have been adopted by the Board of Directors.

**RESPONSIBILITIES OF THE AUDITORS RELATING TO THE AUDIT OF THE ANNUAL ACCOUNTS**

It is our responsibility to prepare a report on the annual accounts. Our objective is to obtain reasonable assurance that the financial statements taken as a whole do not contain any material misstatements. Reasonable assurance corresponds to a high level of assurance, but does not guarantee that an audit performed in accordance with the standards of professional practice can systematically detect any significant anomaly. Anomalies may arise from fraud or error and are considered significant where it can reasonably be expected that they, taken individually or cumulatively, may influence the economic decisions that account users take in their business. Based on these.

As specified by Article L.823-10-1 of the French Commercial Code, our mission of certification of accounts is not to guarantee the viability or the quality of the management of your company.

As part of an audit conducted in accordance with the professional standards applicable in France, the statutory auditor exercises his professional judgment throughout this audit.

In addition:

- it identifies and assesses the risks that the annual accounts contain material misstatements, whether due to fraud or error, defines and implements audit procedures to address such risks, and collects considers it sufficient and appropriate to base its opinion. The risk of not detecting a significant anomaly from fraud is higher than that of a significant misstatement resulting from an error, as the fraud may involve collusion, falsification, voluntary omissions, misrepresentation or circumventing internal control;
- it becomes aware of the internal control relevant to the audit in order to define appropriate audit procedures in the circumstances, and not to express an opinion on the effectiveness of the internal control;
- it assesses the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as the information concerning them provided in the annual accounts;
- it assesses the appropriateness of management’s application of the going concern accounting policy and, depending on the elements collected, the existence or otherwise of significant uncertainty related to events or circumstances likely to cause the company’s ability to continue as a going concern. This assessment is based on the information gathered up to the date of its report, but it is recalled that subsequent circumstances or events could jeopardize the continuity of operations. If it concludes that there is significant uncertainty, it draws the attention of the readers of its report to the information provided in the annual accounts about this uncertainty or, if this information is not provided or is not relevant, it formulates a qualified certification or a refusal to certify;
- it assesses the overall presentation of the annual accounts and assesses whether the annual accounts reflect the underlying transactions and events so as to give a true and fair view.

Signed in Neuilly-Sur-Seine and Paris, Monday, March 11, 2019,

The statutory auditors

PRICEWATERHOUSCOOPERS LISON CHOURAKI
AUDIT

THIERRY CHARRON LISON CHOURAKI

94 2018 Registration document
4

CORPORATE GOVERNANCE
**4.1 COMPOSITION OF THE BOARD OF DIRECTORS**

The shareholders’ meeting of April 5, 2018 appointed Mr. Pierre Bastid as director for a six-year term expiring at the ordinary general meeting convened to approve the financial statements for the year ended December 31, 2023.

In addition, CARMAT announced on December 3, 2018 the cooptation of Mr. Jean-Pierre Garnier to the Board of Directors of the Company to replace Mr. Jean-Claude Cadudal, Chairman of the Board of Directors resigned, for the remainder of his mandate, and his appointment as new Chairman of the Board.

As a reminder, the general meeting of April 27, 2017 decided the appointment of Mr. Stéphane Piat, Chief Executive Officer of CARMAT since August 29, 2016, as a director. The Board of Directors now consists of 10 members, including 5 independent directors.

The table below details the information concerning all the members of the Board of Directors (it being specified that the information on the other mandates of the directors are those of which the Company is aware and that the companies marked with a * are listed companies):

<table>
<thead>
<tr>
<th>Full name or registered name of the member and business address</th>
<th>Term of office</th>
<th>Functions fulfilled within the Company</th>
<th>Other positions currently held in other companies</th>
<th>Previous other positions and functions in other companies over the last five years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Jean-Pierre Garnier</td>
<td>First appointed: December 3, 2018</td>
<td>Chairman of the board of directors</td>
<td>- Chairman of Idorsia</td>
<td>- Chairman of Actelion (till its acquisition by Johnson and Johnson in 2017)</td>
</tr>
<tr>
<td>CARMAT 36, avenue de l’Europe 78 941 Velizy Villacoublay</td>
<td>Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td></td>
<td>- Director at Radius Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Director at United Technology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Director at Fondation Paul Newman</td>
<td></td>
</tr>
<tr>
<td>Mr. Stéphane Piat CARMAT</td>
<td>First appointed: April 27, 2017</td>
<td>Chief Executive Officer Member of the Board of Directors</td>
<td>Board member of Triflo Cardiovascular Inc.</td>
<td>Division vice-president, Global Market Development, at Structural Heart Division - Abbott Vascular - San Francisco</td>
</tr>
<tr>
<td>CARMAT 36, avenue de l’Europe 78 941 Velizy Villacoublay</td>
<td>Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Alain Carpentier</td>
<td>First appointed: May 7, 2010</td>
<td>Director</td>
<td>- Chairman of the Scientific Council of the Fondation Lefoulon-Delalande (Institut de France)</td>
<td>- Former chairman of the Academy of Sciences</td>
</tr>
<tr>
<td>Hôpital Européen Georges Pompidou 20, rue Leblanc 75 908 Paris Cedex 15</td>
<td>Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matra Défense</td>
<td>First appointed: March 20, 2015</td>
<td>Director</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Represented by Ms Anne-Pascale Guédon</td>
<td>Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full name or registered name of the member and business address</td>
<td>Term of office</td>
<td>Functions fulfilled within the Company</td>
<td>Other positions currently held in other companies</td>
<td>Previous other positions and functions in other companies over the last five years</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>---------------</td>
<td>--------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mr. Henri Lachmann Association Marie Lannelongue 133, avenue de la Résistance 92350 Le Plessis Robinson</td>
<td>First appointed: December 23, 2010 Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td>Independent director</td>
<td>- Member of the supervisory board of Norbert Dentressangle SA* - Chairman of the board of directors of the Centre chirurgical Marie Lannelongue (Marie Lannelongue Surgical Center) (an association under the law of 1901) - Chairman of the Institut Télémaque (an association under the law of 1901) - Director of the Fondation Entreprendre - Chairman of the campaign committee of the Strasbourg University Foundation</td>
<td>- Chairman of the supervisory board of Schneider Electric SA* - Director of various companies in the Schneider Electric Group * - Honorary vice-Chairman of the supervisory board at Vivendi SA* - Vice-chairman and treasurer of the Institut Montaigne (an association under the law of 1901)</td>
</tr>
<tr>
<td>Truffle Capital Represented by Dr Philippe Pouletty Truffle Capital 5, rue de la Baume 75008 Paris</td>
<td>First appointed: May 7, 2010 Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td>Director</td>
<td>- Chairman of the board of directors of Abivax SA* - Manager at Nakostech SARL - Chief executive and director of Truffle Capital - Honorary chairman and director of France Biotech (an association under the law of 1901) As representative of Truffle Capital: - Director at Biokinesis SAS - Director at Pharnext SA* - Director at Deinove SA* - Director at Carbios SA* - Director at Affluent Medical SA - Chairman of the board of directors of Nanosive SASU - Director at Holistick Medical SASU - Chairman of the board of directors of Diaccurate SASU</td>
<td>- Director at Vexim SA* until 2017 - Director of Neovacs SA* until 2014 - Chairman and director of Splicos SAS until 2013 - Director of Wittycell SAS until 2013 - Director at Plasmaprime SAS until 2015 - Director at Immune Targeting Systems Ltd (UK) until 2015 - Director at Alttimmune, Inc. (United States) until December 2016</td>
</tr>
<tr>
<td>Mr. Pierre Bastid Hougou 480, avenue Louise 1050 Brussels Belgium</td>
<td>First appointed: April 5, 2018 Term of office: Until GM to approve the accounts for year ending December 31, 2023</td>
<td>Independent director</td>
<td>- Chairman of Babalia - Director at Hougou SA - Director at Collectis - Director at Pharnext</td>
<td>None</td>
</tr>
<tr>
<td>Santé Holdings SRL Represented by Mr. Antonino Ligresti NCTM Via Agnello 12 20121 Milano Italy</td>
<td>First appointed: April 12, 2016 Term of office: Until GM to approve the accounts for year ending December 31, 2021</td>
<td>Director</td>
<td>- Sole shareholder of Immobiliare Cosio SRL, Iniziative Immobiliari Due SRL and Iniziative Immobiliari Tre SRL</td>
<td>None</td>
</tr>
</tbody>
</table>
As far as the Company is aware:

- there is no family link between the Company’s directors;
- no director has been convicted of fraud in the last five years;
- no director has been associated with any bankruptcy, sequestration of assets or liquidation in the last five years;
- no director has been found guilty of any offense or any official public sanction pronounced by the statutory or regulatory authorities (including designated professional bodies) in the last five years; and
- no director has been prevented by a court from acting as a member of an administrative, management or supervisory board of an issuer or from taking part in the management or conduct of the affairs of an issuer over the past five years.

It should be noted that no strategic and/or historical investors acts together with others in relation to CARMAT.

### backgrounds of the members of the board of directors

#### Anne-Pascale Guédon

Anne-Pascale Guédon has more than 25 years’ experience in investment and M&A. She held a number of executive positions at leading French companies such as Bouygues, Loxam and Crédit Agricole and international firms including GE Capital and Man Group before joining Airbus. Since 2008, she has been Vice President Financial Engineering at Airbus Group, where she is responsible for managing funds to invest worldwide through joint ventures and acquisitions.

Ms Guédon graduated from HEC business school and the French society of financial analysts (SFAF). She is also an auditor of the 64th national session of the National Institute for Defence Studies (IHEDN) and is a colonel in the French Air Force reserves.

#### Dr Jean-Pierre Garnier

Scientist and business leader, Jean-Pierre Garnier graduated from Louis Pasteur University (PhD in Pharmacology) and Stanford University (Master in Business Administration). He started his career in 1975 at the pharmaceutical company Schering-Plough where he held a number of management positions in Europe before becoming President of their American division. In 1990, he joined Smithkline Beecham Laboratories as President of the Pharmaceuticals Division and became President and CEO in 1999.

In 2000, Jean-Pierre Garnier achieved the merge of two of the largest pharmaceutical groups (Smithkline Beecham and Glaxo Wellcome), to create GlaxoSmithKline (GSK), which he chaired until 2006. He was also Chairman of Actelion from 2011 to 2017.

The Best Practice Institute has nominated Jean-Pierre Garnier as one of the world’s top 20 CEOs. He is an Officier de la Légion d’Honneur (Officer of the Legion of Honour) and Knight Commander of the Order of the British Empire.
**CORPORATE GOVERNANCE**

**PROFESSOR ALAIN CARPENTIER**

Professor Emeritus at Descartes University in Paris and adjunct professor at Mount Sinai Medical School in New York, Alain Carpentier has made decisive contributions to the field of surgery for heart valves and heart failure. He is considered by many in the international community to be the founding father of modern valve surgery, after breaking with the traditional use of mechanical prostheses to develop biological and physiological solutions to problems related to heart valve replacement.

He was awarded the Grand Prize by the French Foundation for Medical Research and in 2007 received the prestigious Albert Lasker Medical Research Award for the invention of bioprostheses and the development of plastic/reconstructive surgery for heart valves.

Professor Carpentier also holds a range of responsibilities as Chair of the Scientific Committee at Foundation Lefoulon-Delalande Institut de France, Member of the Board at Fondation Singer Polignac, and Director of the Alain Carpentier Foundation Scientific Research Association (ARSFAC).

**DR PHILIPPE POULETTY**

Dr Philippe Pouletty is a pioneer in biotechnology and medical devices. He founded SangStat in 1988, a company specialising in organ transplant therapy, listed on the NASDAQ, then Conjuchem in 1993, a biotech firm specialised in developing next-gen medicines from therapeutic peptides, listed on the Toronto Stock Exchange.

He is the co-founder and CEO of Truffle Capital, founder and Chairman of Deinove, a biotech company that develops compounds for industry from rare microorganisms, and Abivax, an innovative biotech firm that targets the immune system to eliminate viral and inflammatory diseases. Dr Pouletty is also founder of Carbios, a green chemical company developing innovative enzyme processes to reshape the lifecycle of plastics, co-founder and board member of Pharmnext, a leading biopharma company in combinatorial medicine, and Vexim, an innovative medical devices company, Chairman of Diaccurate, a biotech company specialising in immunomodulation, and board member at Myopowers, Biokinesis, Kephalios and all other companies in the Truffle Capital portfolio.

Dr Pouletty graduated as a doctor of medicine from the University of Paris VI and holds master’s degrees in immunology and virology from Institut Pasteur. He is also a post-doctoral research fellow at Stanford University, the 1999 laureate of the American Liver Foundation and Chevalier de la Légion d’Honneur. Dr Pouletty is the former Chairman and Honorary Chairman of France Biotech, the French biotech industry association, former Vice Chairman of Europabio and the author of 29 patents.

**HENRI LACHMANN**

Henri Lachmann began his career in 1963 as an auditor at Arthur Andersen. Seven years later, he joined French metal company Strafor-Facom and became the company’s CEO in 1981. He has been a member of the board at Schneider Electric since 1996 and became the company’s CEO in 1999. He also held the position of Chairman of the Supervisory Board from 2006.

Mr Lachmann graduated from HEC business school and is a qualified chartered accountant. He sits on the board at a number of companies, including responsibilities as Vice Chairman of the Supervisory Board at Vivendi, member of the Supervisory Board at Norbert Dentressangle, member of the board of AXA Mutuelles, Chairman of the Board at Centre Chirurgical Marie Lannelongue, Chairman of the Foundation for Continental Law, Chairman of Institut Télémaque, non-voting Director at Fimalac, member of the board at Fondation Entreprendre, Chairman of the Advisory Board of Campus d’Excellence at the Commissariat Général à l’Investissement (Grand Emprunt), Vice Chairman and Treasurer for Institut Montaigne, and member of the Steering Committee for Institut de l’Entreprise.

**PIERRE BASTID**

Former manager at Schneider Electric then Valeo, Pierre Bastid becomes in 1998 Vice President of Thomson Television Components France (Thomson Multimedia Group). In 2004, via the Magenta Participations structure, it successfully participated in the acquisition of Alstom Power Conversion, a group that later became Converteam Group, sold to General Electric in 2011.

Since that date, Pierre Bastid manages his assets resulting from the sale of his shares of Converteam.

**DR ANTONINO LIGRESTI**

Dr Antonino Ligresti began his career in the Medical Clinic at Milan University and at the city’s Fatebenefratelli Hospital. In 1979, following the gradual acquisition of several high-profile establishments in Lombardy, he created Italy’s first private hospital group, acknowledged for the quality of its services and patient-centric care, as well as its ties with teaching and academic research. Dr Ligresti joined the Générale de Santé board of directors in 2003 and became its chairman a year later. He was also instrumental in creating the European Oncology Institute.

Dr Ligresti is a qualified physician and surgeon, specialising in cardiology and internal medicine.

**JEAN-LUC LEMERCIER**

Jean-Luc Lemercier draws on more than 30 years’ experience and acknowledged leadership in medical devices. During his career, he has held a number of key positions in
the field of cardiology, notably at Johnson & Johnson Cordis from 1996 to 2008, where he created and headed the Structural Heart Disease division. Since 2017, he has been Corporate Vice President EMEA, Canada & Latin America at Edwards Lifescience.

Mr Lemercier graduated in pharmacy from Claude Bernard Lyon 1 University.

**DR MICHAEL MACK**

Michael Mack is an internationally renowned cardiac surgeon with extensive experience in the introduction of medical devices and innovative procedures for cardiovascular disease. He has authored more than 650 scientific publications and has received the Presidential Citation from the American College of Cardiology (ACC) and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award.

Dr Mack is a graduate of Boston College, St Louis University and the University of Texas Southwestern Medical School. He is also the Director of the Cardiovascular department for pharmaceutical firm Baylor Scott & White Health, a Director on the American Board of Thoracic Surgery and a member of the FDA Medical Device Epidemiology Network Initiative (MDEpiNet) Advisory Committee.

**STÉPHANE PIAT**

Stéphane Piat is an acknowledged specialist in the medical device business, particularly in the field of cardiology. He joined Carmat as Chief Executive Officer in September 2016.

Mr Piat started his career at Becton Dickinson European Headquarters as a Market Researcher in 1995. He was appointed European Platform Leader for Locoregional Anaesthesia five years later. In 2002, he joined Cordis, a Johnson & Johnson company, where he spent five years in several management positions ranging from Business Director France to European Marketing Director for Cardiology. In 2007, he moved to Abbott Vascular as General Manager for mid-size countries, EMEA, and two years later oversaw the integration of Evalve as the company’s General Manager EMEA, heading clinical and commercial development of a new interventional cardiology product, Mitraclip. In 2014, he led Global Market Development of the Abbott Vascular Structural Heart Division in San Francisco as Division Vice President.

Mr Piat holds a master’s degree in Management Science from IAE Dijon School of Management, and a post-graduate degree in Quantitative Marketing from ESA business school in Grenoble.

**ÉRIC RICHEZ**

Eric Richez joined CARMAT in September 2014 after a career in the European medical device industry.

He has over 13 years’ experience in sales & marketing with Thoratec, a global leader in ventricular assistance devices, where he served as Sales & Marketing Director from 2002 to 2011 and Sales Director EMEA from 2011 to 2013. He then joined CircuLite, a company developing a circulatory support system to treat chronic heart failure, as Sales Director for Southern Europe.

Mr Richez holds a degree in Mathematics and training in Business & Management and Sales Force Management.

**PASCALE D’ARBONNEAU**

A graduate of the ESCP Europe business school and holder of a DEA in Management Control and a Postgraduate Diploma in Finance and Accounting, Pascale d’Arbonneau is also a lecturer at Paris Diderot University. Before joining CARMAT at the end of 2018, Pascale d’Arbonneau was Executive Director of the Econocom International B.V. (EIBV) family office.

She began her career in 1989 as an auditor at Coopers
CORPORATE GOVERNANCE

& Lybrand (now PWC) before entering the pharmaceutical industry as Head of Finance & IT France at Johnson & Johnson – MSD (1995-1999). She spent most of her career (1999-2016) at GlaxoSmithKline (GSK). She joined as Director, Head of Controlling & Finance Partnering, and then held a number of senior positions within the Group (Vice President & Finance Controller, Pharma Europe from 2006 to 2010, Vice President & Area Finance Director, Western Europe from 2010 to 2014) before becoming Vice President Compliance and Control Integration for all business units worldwide.

MARC GRIMME

Since 1996, Marc Grimmé has been the technical lead on the programme to develop the Carmat bioprosthetic heart.

He began his career in 1991 at MBDA France, where he worked on a range of issues linked to the development of mission-critical electronics, from upstream studies and the design phase to production commissioning.

Marc Grimmé is a graduate of the Institute Supérieur d’Electronique et du Numérique (ISEN).

THIERRY DUPOUX

Thierry Dupoux joined CARMAT in July 2018 as Director of Quality.

Thierry Dupoux is a seasoned medical device professional with a strong and large expertise in Quality Assurance / Regulatory Affairs and R&D. Engineering Graduate from Ecole Centrale de Lyon (France), he has worked most of his career for Life Sciences companies such as General Electric where he became Supply Chain Quality & Compliance Manager for the plant of Buc (France) in his last position. In 2006, he joined Sorin Group, now named LivaNova, a world leader in Cardiac Surgery and Neuromodulation. Over the past 12 years at LivaNova, he held several senior positions in Quality Assurance, Regulatory Affairs and R&D. Prior to joining CARMAT, he was Vice President of Quality Assurance at LivaNova where he led the integration of the Quality Systems following the merger between Sorin Group and Cyberonics.

WENZEL HURTAK

Wenzel Hurtak is a seasoned medical device professional with a strong and broad expertise in R&D and manufacturing, engineering Graduate in Physics and Materials Science from the University of Groningen (The Netherlands), he has spent most of his career in Life Sciences companies such as Cordis / Johnson & Johnson where he held several management positions in manufacturing and process engineering as well as Advanced R&D. In 2004, he joined Integra LifeSciences Corporation, a world leader in Neurosurgery and Orthopaedics, where he became Vice President of European Operations. In that role, he was responsible for 5 manufacturing facilities across Europe and contributed to the development of over 10 products.

Prior to joining CARMAT, Wenzel Hurtak was Business Director for new products at Contract Medical International GmbH, a leader in product development for minimally invasive devices in cardiology and various other applications.

FRANCESCO ARECCHI

A marketing professional with strong experience in global leading companies within the healthcare industry, Francesco Arecchi joins Carmat in September 2017. Francesco Arecchi spent most of his career in Life Sciences companies such as Johnson & Johnson and Abbott, where he holds a number of positions from sales to marketing in Cardiology breakthrough technology products such as Cypher and MitraClip.

Prior to joining Carmat, he stood as Product Manager EMEA Structural Heart at Abbott. Francesco Arecchi is a biomedical engineer and graduated from Politecnico di Milano (Italy) with an MBA from Rotterdam School of Management (Netherlands).

RAOUIA BOUYANZER


4.2 CONFLICTS OF INTEREST IN THE GOVERNING, MANAGEMENT AND SUPERVISORY BODIES AND THE EXECUTIVE BOARD

4.2.1 POTENTIAL CONFLICTS OF INTEREST
At the date of this registration document and as far as the Company is aware, there are no current or potential conflicts of interest between the private interests of the members of the board of directors of the Company and the interests of the Company.

Similarly, as at the same date, the Company has no knowledge of any current or potential conflicts of interest between the private interests of the members of the audit committee, the compensation committee or the scientific committee and the interests of the Company.

As far as the Company is aware, there are no current or potential conflicts of interest between the duties of the members of the board of directors towards the Company and their private interests and/or other duties.

As at the date of this registration document, there were no service contracts linking the members of the board of directors and the general management of the Company.

4.2.2 COMMITMENTS OF THE DIRECTORS AND EXECUTIVE MEMBERS TO PRESERVE SHAREHOLDINGS
Historically, there was no commitment of the directors and executive members to preserve shareholdings.

As part of the investment protocol signed on February 26, 2016, in connection with the Company’s €50 million private placement, investors (ALIAD (Air Liquide), Cornovum, Babalia and Santé Holdings SRL) and shareholders (Matra Défense (Airbus Group), the funds managed by Truffle Capital, Professor Alain Carpentier and the Scientific Research Association of the Alain Carpentier Foundation) had undertaken not to sell their shares of the Company (shares held on that date as well as those subscribed in the context of the private placement), directly or indirectly, except with the prior consent of the investors and historical shareholders, until the earliest of the following two dates: (i) 2 years from the settlement-delivery of the reserved capital increase (ie April 28, 2018) and (ii) the date of the CE marking of the CARMAT heart.

4.3 SPECIALIZED COMMITTEES
As at the date of this registration document, the Company had set up the following committees:

4.3.1 AUDIT COMMITTEE
By decision of the board of directors of July 8, 2009 the Company set up an audit committee for an unlimited duration. Till December 3, 2018, the date on which Jean-Claude Cadudal left office, the audit committee comprised three members:

- Jean-Claude Cadudal, chairman of the board of directors and chairman of the audit committee;
- Henri Lachmann, independent director and member of the audit committee;
- Matra Defense, represented by Ms Anne-Pascale Guédon, director and member of the audit committee.

Under the exclusive and collective responsibility of the members of the Board of Directors of the Company and in order to ensure the quality of internal control and the reliability of the information provided to shareholders and financial markets, the Committee assume the matters relating to the preparation and control of accounting and financial information and, to this end, shall in particular:
• follow-up on the process of developing information and financial communication;

• monitor the effectiveness of the internal control and risk management systems and in particular:
  - evaluate the internal control procedures and any measures taken to remedy any significant internal control dysfunctions;
  - review the annual work programs of the auditors;
  - evaluate the adequacy of the risk monitoring procedure;

• monitor the statutory audit of the annual and consolidated financial statements by the auditors and in particular:
  - reviewing the assumptions used for the preparation of the annual financial statements of the Company and the half-yearly and, where applicable, quarterly accounts before their examination by the Board of Directors, financial position, cash position and commitments of the Company;
  - evaluate, in consultation with the auditors, the appropriateness of the choice of accounting principles and methods;
  - consult the members of the board responsible for the financial aspects as well as the administrative and financial director if he is not a member of the board between the end of any financial year and the date on which the Committee decides on the draft annual accounts, the adequacy of the accounting principles and methods used, the effectiveness of the accounting control procedures and any other appropriate matters;
  - issuing a recommendation on the auditors proposed for appointment by the shareholders’ meeting and to review the terms of their remuneration;

• monitor the independence of the auditors and in particular:
  - propose the establishment of rules for recourse to auditors for work other than auditing in order to guarantee the independence of the audit services provided by auditors in accordance with the laws, regulations and recommendations applicable to the Company, and verify its proper application;
  - authorize the use of auditors for work other than auditing;
  - examine the conditions of use of derivatives;
  - execute periodic review of the status of significant litigation;

• review the Company’s procedures for the receipt, retention and treatment of claims relating to internal accounting and accounting controls, audit matters and documents transmitted by employees on a anonymous and confidential basis and which would call into question accounting or auditing practices; and

• generally, provide advice and make any appropriate recommendations in the above areas.

During the financial year 2018, the Audit Committee met three times, in particular to review the financial statements prepared for the financial year 2017, for the analysis of the needs and various financing options for CARMAT as well as to review the semi annual financial statements for HY 2018.

As at the date of this registration document, the audit committee comprises two members:

• Henri Lachmann, independent director and chairman of the audit committee;
• Matra Defense, represented by Ms Anne-Pascale Guédon, director and member of the audit committee.

4.3.2 APPOINTMENTS AND COMPENSATION COMMITTEE

The Company has established an appointments and compensation committee which as at the date of this registration document is comprised of three members, appointed by the board of directors at its meeting for an unlimited term:

• Truffle Capital, represented by Dr Philippe Pouletty, director and chairman of the appointment and compensation committee;
• Matra Defense, represented by Ms Anne-Pascale Guédon, director and member of the appointment and compensation committee;
• Mr Jean-luc Lemercier, independent director.

The main objectives of the appointments and compensation committee are:

• to recommend to the Board of Directors the persons who should be appointed to the general management, the board of directors and the main functions of the Company, as the case may be;
• review the remuneration policies for managers and high-potential staff within CARMAT, propose the
remuneration of the officers and, where applicable, the members of the board of directors and prepare any report that the Company must present on these subjects. It reports to the board of directors on its activities at regular intervals.

4.3.3 Boards of Observers

Article 17-VI of the Articles of Association gives the ordinary general meeting the power to appoint, at its discretion, up to three persons or legal entities, who may or may not be shareholders, for a term of office of one year expiring at the general meeting of shareholders called to decide on the accounts for the year just ended and held during the year in which their terms of office expire. This term of office may be renewed an unlimited number of times. The duty of the observers is to ensure the strict application of the Articles of Association and to present their observations at the meetings of the board of directors. The observers perform a general and permanent duty within the company of advice and monitoring. In connection with their role they may make observations to the board of directors.

Observers must be invited to each meeting of the board of directors in the same way as directors. Observers have only consultative powers on an individual or joint basis and have no voting rights on the board.

As at the date of this registration document, no observer has been appointed.

4.4 Statement on Corporate Governance

4.4.1 Corporate Governance

The Company is referring to the recommendations of the code of corporate governance for quoted companies issued by the AFEP-MEDEF in December 2008, to the extent that these principles are compatible with the organisation, the size, the resources and the ownership structure of the Company.

To this end, the Company regularly proceeds with a review of its corporate governance in respect of the recommendations of the code of corporate governance for quoted companies issued by the AFEP-MEDEF and updated in June 2018. The principal recommendations not applied are as follows:

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>Reasons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of the board of directors</td>
<td>There is no formal system to measure the individual contribution of each director. Reason: All board members gave positive feedback on the board’s operation as a collective body, which is only possible if individual contributions are satisfactory.</td>
</tr>
<tr>
<td>Term of office of directors</td>
<td>The Company’s Articles of Association provide for terms of office of the directors of six years, whereas the AFEP-MEDEF recommends a limit of four years. Reason: When the Company was established, it was deemed that a longer term would ensure the stability of the Company’s governance.</td>
</tr>
<tr>
<td>Composition of the appointments and compensation committee</td>
<td>The appointments and compensation committee does not include 2/3 of independent directors. Reason: In 2018, an independent director was added to the appointments and compensation committee; the Company plans to continue to increase the proportion of independent directors on this committee.</td>
</tr>
</tbody>
</table>
Apart from setting up the board of auditors, the appointments and compensation committee and the scientific committees mentioned in Paragraph 4.3 « Specialized committees », and in order to meet the standards of corporate governance that the Company has set itself, the elements described below have now been put in place.

### 4.4.2 BYLAWS

In 2011, the board of directors adopted bylaws, the purpose of which is to define the ways in which it is organized and operates over and above the legal and statutory provisions in force. These rules were reviewed during 2016 year.

In addition to respecting the legal, regulatory and statutory provisions applicable to the Board, the Board of Directors:

- determine the orientations of the Company’s activity and ensure their implementation. Subject to the capabilities expressly granted by shareholders’ meetings and within the scope of the Company’s purpose, it shall consider any matter affecting the proper functioning of the Company and shall, by its deliberations, resolve matters affecting it,
- appoint the chairman of the Board, the chief executive officer and the deputy chief executive officers, determine their duties and determine their remuneration,
- authorize the agreements and commitments referred to in Articles L.225-38 and followings of the Commercial Code,
- authorize the decisions and commitments listed in the Annex to the Rules of Procedure. It ensures the quality of information provided to shareholders and the markets.

### 4.4.3 SEPARATION OF THE MANDATES OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND THE CHIEF EXECUTIVE

When the Company converted to a société anonyme, the board of directors opted for a dissociation of the mandates of the chairman of the board of directors and of the chief executive.

The board of directors must approve in advance the following decisions and commitments, it being specified that the thresholds mentioned below in these decisions will be assessed (i) individually for each operation and (ii) annually:

A. Corporate life of the Company:

(a) any amendment to the articles or other documents constituting the Company or its subsidiaries;

(b) liquidation, amicable dissolution or other similar proceedings relating to the Company and / or the companies or entities controlled by the Company (the «Subsidiaries») and withdrawal from the Company;
B. Strategic decisions:

(a) defining the strategic, economic, social, financial and scientific orientations of the Company;

(b) operations outside the strategy announced by the Company;

(c) significant development of related or derivative activities, directly within the Company, or through subsidiaries controlled or not;

(d) the change in the normal business of the Company and its development strategy;

(e) any significant agreement to use patents or production licenses granted to third parties outside the ordinary course of business;

(f) any transfer, acquisition, contribution or exchange of assets of a unit amount exceeding three hundred thousand euros (€ 300,000);

(g) any investment in excess of three hundred thousand euros (€ 300,000);

(h) mergers, spin-offs, contributions, partnerships, joint ventures or similar significant transactions;

(i) transfer and relocation of the Company’s registered office outside France, cross-border merger or conversion of the Company into a European company;

(j) additional indebtedness, modification, refinancing of a loan amounting to more than three hundred thousand euros (€ 300,000);

(k) significant change in the accounting rules and principles applied by the Company;

(l) the hiring, firing and alteration of employment contracts (including the remuneration) of any employee who has an executive function (i.e. medical director, director of operations, sales manager and administrative director and financial director);

(m) selection of advisers and intermediaries in strategic decision-making and remuneration;

C. Regulated agreements and related party agreements (approval and annual review of contracts in progress);

D. Titles:

(a) issue of any securities giving access, immediately or in the future, to 5% or more of the share capital of the Company;

(b) transfer of securities of subsidiaries to third parties or subscription or acquisition of securities issued by an entity other than a subsidiary;

E. Any proposal to the general meeting of shareholders relating to the policy of dividend distribution, redemption of shares or other payments or distribution to shareholders;

F. Adoption and modification of the annual budget, approval and modification of the business plan;

G. Any commitment exceeding three hundred thousand euros (€ 300,000);

H. Remuneration and profit-sharing of officers in respect of their mandate or employment contract (including any stock option plans, bonus shares or other similar arrangements) on the proposal of the appointments and compensation committee;

I. Appointment and dismissal of the officers, the administrative and financial director, the scientific director and the medical director;

J. Decision of commitment or transaction relating to a dispute of more than two hundred and fifty thousand euros (250,000 €);

K. Site closure; adoption of a plan to safeguard employment;

L. Appointment of statutory auditors and substitutes;

M. Subscription of any loan or advance to acquire securities of any subsidiary company except in the event that such subsidiary is wholly or partly owned by the Company; and

N. Granting of guarantees, endorsements or guarantees for the benefit of third parties (including for the benefit of a subsidiary) or granting of security rights to guarantee debts of the Company,

being specified that:

- one of the aforementioned decisions that would have been foreseen within the annual budget in a precise manner will not have to be approved again when it is implemented; and

- decisions A to E shall be adopted by a majority of (i) half of the directors on first notice and (ii) one - half of the directors present or represented on second call.

For a detailed description of the provisions governing the functioning of the board of directors and the general management, please refer to Paragraph 5.4.2 « Provisions
4.4.4 INDEPENDENT DIRECTORS

The Company has five independent directors: Henri Lachmann, Jean-Luc Lemercier, Michael Mack and Pierre Bastid, and the company Santé Holding SRL; the Company believes that since their appointment they have met the criteria of the AFEP-MEDEF code of December 2008 (as amended in June 2018), that is:

- not be or have been in the past five years:
  - employee or director of the Company (the chairman of the Board may be considered as independent if the Company justifies it) or of a group company,
  - director of another company in which the Company directly or indirectly holds a mandate or in which an employee or a director of the Company (present or having been less than five years) holds a mandate;
- not be (directly or indirectly) a significant customer, supplier or banker of the Company or its group or for which the Company or its group represents a significant part of the business;
- have no close family ties with a corporate officer;
- have not been an auditor of the Company during the last five years;
- have not been a member of the Board of the Company for more than twelve years;
- not to be a reference shareholder of the Company or of its parent company exercising control or controlling interest in the Company. Beyond a 10% holding, the Board must consider the independence with regard to the composition of the capital and the existence of potential conflicts of interest.

4.4.5 INTERNAL CONTROL

At the date of this registration document, the Company had internal control procedures, in particular in the administrative, accounting, and financial areas, with a view to implementing its strategic policies.

Following the new Regulation No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the so-called MAR Regulation), CARMAT must now, like companies listed on a regulated market, establish and maintain the list of persons who have access to privileged information concerning them.

CARMAT has therefore put in place a code of ethics in order to sensitize all the company’s managers and employees, third parties having access to privileged information as well as the persons with whom they are in and to prevent any improper use or disclosure of inside information.

The Board of Directors of 12 December 2016 adopted this code of ethics, which was previously revised by the Audit Committee.
4.5 COMPENSATION AND BENEFITS OF DIRECTORS AND MANAGEMENT

4.5.1 COMPENSATION AND BENEFITS IN KIND GRANTED TO MANAGERS AND DIRECTORS

Summary table of compensation and options, warrants and bonus shares awarded to each executive officer (in euros):

<table>
<thead>
<tr>
<th>Name</th>
<th>FY 2017</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean Claude Cadudal - Chairman of the Board of Directors (till December 3, 2018)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual compensation</td>
<td>63,001</td>
<td>62,551</td>
</tr>
<tr>
<td>Value of options and warrants awarded during the FY</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of bonus shares awarded for the FY</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TOTAL</td>
<td>63,001</td>
<td>62,551</td>
</tr>
<tr>
<td>Jean-Pierre Garnier - Chairman of the Board of Directors (since December 3, 2018)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual compensation *</td>
<td>-</td>
<td>8,333</td>
</tr>
<tr>
<td>Value of options and warrants awarded during the FY</td>
<td>-</td>
<td>114,900 *</td>
</tr>
<tr>
<td>Value of bonus shares awarded for the FY</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TOTAL</td>
<td>-</td>
<td>123,233</td>
</tr>
</tbody>
</table>

*: 46,000 stock options granted in December 2018, subject to conditions, with an exercise price of €20.35. Taking into account the price of the CARMAT share at December 31, 2018, ie €23.50, the potential capital gain relating to these stock options was €144,900 at December 31, 2018.

<table>
<thead>
<tr>
<th>Name</th>
<th>FY 2017</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stéphane Piat - Chief executive officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual compensation *</td>
<td>577,201</td>
<td>594,028</td>
</tr>
<tr>
<td>Value of options and warrants awarded during the FY</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of bonus shares awarded for the FY **</td>
<td>2,316,313</td>
<td>3,598,438</td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,893,514</td>
<td>4,192,466</td>
</tr>
</tbody>
</table>

*: including benefits in kind. Stéphane Piat benefited in 2018 from a 3% increase in his fixed compensation. It also benefits from variable compensation, subject to the achievement of objectives, up to 45% of its fixed compensation.

**: free shares granted during the financial year are subject to performance conditions. Their values as at December 31, 2017 and as at December 31, 2018 correspond to the estimate done by the company, given the probability of the criteria being met. The valuation assumptions are specified in the note Provision for expenses in the annex to the annual accounts.

To the best of the Company’s knowledge, no hedging instrument is put in place.
Summary table of the compensation of each executive officer (in euros):

<table>
<thead>
<tr>
<th>Jean Claude Cadudal - Chairman of the Board of Directors (till December 3, 2018)</th>
<th>FY 2017</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amounts due *</td>
<td>Amounts paid **</td>
</tr>
<tr>
<td>Fixed remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Variable remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Special remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Directors’ fees</td>
<td>63,001 ***</td>
<td>63,001 ***</td>
</tr>
<tr>
<td>Benefits in kind</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TOTAL</td>
<td>63,001</td>
<td>63,001</td>
</tr>
</tbody>
</table>

*: For the financial year. **: During the financial year, including the previous year.
***: At the meeting of December 19, 2013, the board decided that, to comply with the applicable regulations, the remuneration of its chairman would be treated for tax and social security purposes as wages. This amount was raised to €63,001 in 2017 and to €62,551 in 2018.

<table>
<thead>
<tr>
<th>Jean-Pierre Garnier - Chairman of the Board of Director (since December 3, 2018)</th>
<th>FY 2017</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amounts due *</td>
<td>Amounts paid **</td>
</tr>
<tr>
<td>Fixed remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Variable remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Special remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Directors’ fees</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benefits in kind</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TOTAL</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*: For the financial year. **: During the financial year, including the previous year.
***: under a contract of employment as US Business Development Manager

<table>
<thead>
<tr>
<th>Stéphane Piat - Chief executive officer</th>
<th>FY 2017</th>
<th>FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amounts due *</td>
<td>Amounts paid **</td>
</tr>
<tr>
<td>Fixed remuneration ***</td>
<td>397,313</td>
<td>397,313</td>
</tr>
<tr>
<td>Variable remuneration ***</td>
<td>179,888</td>
<td>156,000</td>
</tr>
<tr>
<td>Special remuneration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Directors’ fees</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benefits in kind</td>
<td>9,062</td>
<td>9,062</td>
</tr>
<tr>
<td>TOTAL</td>
<td>586,263</td>
<td>562,375</td>
</tr>
</tbody>
</table>

*: For the financial year. **: During the financial year, including the previous year.
***: Stéphane Piat benefited in 2018 from a 3% increase in his fixed remuneration. He benefits from a variable remuneration subject to the achievement of objectives. This variable remuneration can reach 45% of his fixed remuneration.
Directors’ fees and other compensation allocated to non-executive officers during the years ended December 31, 2017 and 2018

<table>
<thead>
<tr>
<th>Name</th>
<th>Director’s fees FY 2017</th>
<th>Director’s fees FY 2018</th>
<th>Other compensation FY 2017</th>
<th>Other compensation FY 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Alain Carpentier - Director</td>
<td>5,000</td>
<td>6,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Philippe Pouletty, representing Truffle Capital - Director</td>
<td>5,000</td>
<td>7,500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anne Pascale Guedon, representing Airbus Group - Director</td>
<td>5,000</td>
<td>7,500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stéphane Piat - Director</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jean Claude Cadudal - Chairman of the board</td>
<td>63,001</td>
<td>62,551</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jean Pierre Garnier - Chairman of the board</td>
<td></td>
<td></td>
<td>-</td>
<td>8,333</td>
</tr>
<tr>
<td>Henri Lachmann - Director</td>
<td></td>
<td>7,500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pierre Bastid - Director</td>
<td></td>
<td>-</td>
<td>6,000</td>
<td>-</td>
</tr>
<tr>
<td>Antonino Ligresti, representing Santé Holding SRL - Director</td>
<td>5,000</td>
<td>7,500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jean Luc Lemercier - Director</td>
<td></td>
<td>10,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Michael Mack - Director</td>
<td>24,960</td>
<td>28,390</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Share subscription or share purchase options awarded to each executive officer during the years ended December 31, 2017 and 2018

On December 3, 2018, the Company granted Mr. Jean-Pierre Garnier the stock option program as summarized below:

<table>
<thead>
<tr>
<th>Type of security</th>
<th>Stock options - 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of options issued and allocated</td>
<td>46,000</td>
</tr>
<tr>
<td>Number of options lapsed</td>
<td>-</td>
</tr>
<tr>
<td>Number of options exercised</td>
<td>-</td>
</tr>
<tr>
<td>Balance of options to be exercised</td>
<td>46,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 5, 2018</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>December 3, 2018</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>€20.35</td>
</tr>
<tr>
<td>Options exercise deadline</td>
<td>Ten years from the date of allocation of the options</td>
</tr>
<tr>
<td>Ratio</td>
<td>One option - 2018 for 1 new CARMAT share</td>
</tr>
</tbody>
</table>

- 50% of the options may be exercised in increments of 1/36 each month elapsed from 1 January 2019, and in any event no later than 10 years after their date of allocation to the beneficiary;

- 50% of the options are exercisable when the Company succeeds in successfully raising additional financing (excluding Equity Line financing and EIB type loans) for an amount of at least €100 million between the date of grant and December 31, 2020, and in any event no later than 10 years after their date of allocation to the beneficiary.

Number of new shares that may be subscribed: 46,000

Share subscription or share purchase options exercised by each executive officer during the years ended December 31, 2017 and 2018

None.

Free shares awarded to each executive officer during the years ended December 31, 2017 and 2018

As detailed in Section 5.2.1 of this registration document, the general meeting of April 27, 2017 decided to introduce within Article 12.2 of the Articles of Association of the Company three new preferential share classes respectively named « AGAP 2017-01 », « AGAP 2017-02 » and « AGAP 2017-03 » (hereinafter together referred to as the « Preferential Shares - 2017 »), the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on May 15, 2017:

- 270 AGAP 2017-01, including 180 AGAP 2017-01 to Stéphane Piat (Managing Director and Director),
- 1,800 AGAP 2017-02, including 1,000 AGAP 2017-02 to Stéphane Piat (Managing Director and Director), and
- 3,180 AGAP 2017-03, including 1,720 AGAP 2017-03 to Stéphane Piat (Managing Director and Director).

If all the performance criteria are met, the beneficiaries of the aforementioned allocation of 5,250 Preferential Shares - 2017 could convert them into a maximum of 381,000 ordinary shares, including 2,900 Preferential Shares - 2017 convertible into a maximum of 210,000 ordinary shares held by Stéphane Piat, CEO. For information, the value of these shares, based on the closing price of the ordinary share on May 15, 2017 (ie €29.96), would be €11,414,760 and €6,291,600 respectively.

In the same way, the general meeting of April 5, 2018 decided to introduce within Article 12.2 of the Articles of Association of the Company three new preferential share classes respectively named « AGAP 2018-01 », « AGAP 2018-02 » and « AGAP 2018-03 » (hereinafter together referred to as the « Preferential Shares - 2018 »), the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on April 5, 2018:

- 580 AGAP 2018-01, including 500 AGAP 2018-01 to Stéphane Piat (Managing Director and Director), and
- 11,500 AGAP 2018-02, including 7,500 AGAP 2018-02 to Stéphane Piat (Managing Director and Director).

If all the performance criteria are met, the beneficiaries of the aforementioned allocation of 12,080 Preferential Shares - 2018 could convert them into a maximum of 288,000 ordinary shares, including 8,000 Preferential...
Shares - 2018 convertible into a maximum of 200,000 ordinary shares held by Stéphane Piat, CEO. For information, the value of these shares, based on the closing price of the ordinary share on April 16, 2018 (ie €21.35), would be €6,148,800 and €4,270,000 respectively.

Free shares awarded to each executive officer which became freely disposable during the years ended December 31, 2017 and 2018

After taking into account the required one-year period, the Preference Shares - 2017 granted on May 15 and September 25, 2017 became effective during the year 2018. In particular, as of the date of this registration document, Stéphane Piat has definitively the following:

- 180 AGAP 2017-01 acquired definitively on May 15, 2018,
- 1,000 AGAP 2017-02 acquired definitively on May 15, 2018, and
- 1,720 AGAP 2017-03 acquired definitively on May 15, 2018.

See section 5.4.3 « Rights, privileges and restrictions attaching to shares (Articles 9 to 14 of the Articles of Association) » of the registration document, relative to the conversion rights of preferential shares into ordinary shares.

Historic table of share subscription or share purchase options awarded to executive officers

The Company has never awarded options. However, it has awarded share subscription warrants and start-up company stock warrants (see Paragraph 5.2.5). Thus, on May 15, 2017, the board of directors issued 12,000 BSA-2017 for the benefit of two independent directors, 6,000 BSA-2017 for Jean Luc Lemercier and 6,000 BSA-2017 for Michael Mack (see paragraph 5.2.5).

History of options to subscribe or purchase shares granted to the top ten employees who are not officers, and options exercised by them

The Company has never awarded options. However, it has awarded share warrants and start-up company stock warrants (see Paragraph 5.2.5).

History of bonus shares awarded

The general meeting of April 27, 2017 decided to introduce within Article 12.2 of the Articles of Association of the Company three new preferential share classes respectively named « AGAP 2017-01 », « AGAP 2017-02 » and « AGAP 2017-03 », the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on May 15, 2017:

- 270 AGAP 2017-01, including 70 AGAP 2017-01 to Marc Grimmé (R&D Director) and 180 AGAP 2017-01 to Stéphane Piat (Managing Director and Director),
- 1,800 AGAP 2017-02, including 200 AGAP 2017-02 to Marc Grimmé (R&D Director), 400 AGAP 2017-02 to Dr. Piet Jansen (Medical Director), 1,000 AGAP 2017-02 to Stéphane Piat (Managing Director and Director) and 200 AGAP 2017-02 to Eric Richez (Director of Development), and
- 3,180 AGAP 2017-03, including 180 AGAP 2017-03 to Benoît de la Motte (former Administrative and Financial Director), 280 AGAP 2017-03 to Marc Grimmé (R&D Director), 310 AGAP 2017-03 to Dr. Piet Jansen (Medical Director), 90 AGAP 2017-03 to Joëlle Monnier (former Quality Director), 1,720 AGAP 2017-03 to Stéphane Piat (Managing Director and Director), 140 AGAP 2017-03 to Eric Richez (Director of Development) and 60 AGAP 2017-03 to Raouia Bouyanzer (Human Resources Manager).

The board of directors of the Company, once again making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on September 25, 2017:

- 50 AGAP 2017-01 and 200 AGAP 2017-02 to Wenzel Hurtak (Manufacturing Director), and
- 310 AGAP 2017-03, including 190 AGAP 2017-03 to Wenzel Hurtak (Manufacturing Director) and 120 AGAP 2017-03 to Francesco Arecchi (Marketing Manager).

Preferential Shares - 2017 are subject to vesting and holding periods and performance criteria to enable their conversion into ordinary shares, as described in section 5.2.6 of the registration document.

In the same way, the general meeting of April 5, 2018 decided to introduce within Article 12.2 of the Articles of Association of the Company three new preferential share classes respectively named « AGAP 2018-01 », « AGAP 2018-02 » and « AGAP 2018-03 », the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on April 5, 2018:

- 580 AGAP 2018-01, including 80 AGAP 2018-01 to Marc Grimmé (R&D Director) and 500 AGAP 2018-01 to Stéphane Piat (Managing Director and Director), and
- 11,500 AGAP 2018-02, including 950 AGAP 2018-02 to Marc Grimmé (R&D Director), 950 AGAP 2018-02 to Dr. Piet Jansen (Medical Director), 7,500 AGAP 2018-02 to Stéphane Piat (Managing Director and Director), 350 AGAP 2018-02 to Eric Richez (Director of Development), 200 AGAP 2018-02 to Benoît de la Motte (former Administrative and Financial Director), 550 AGAP 2018-02 to...
to Wenzel Hurtak (Manufacturing Director), 175 AGAP 2018-02 to Francesco Arecchi (Marketing Manager), 100 AGAP 2018-02 to Joëlle Monnier (former Quality Director) and 100 AGAP 2018-02 to Jean-Marc Parquet and Elizabeth Vacher.

The board of directors of the Company, once again making use of the delegations of authority approved at the general meeting of April 5, 2018, awarded free of charge on September 27, 2018:

- 370 AGAP 2018-03 to Thierry Dupoux (Director of Quality).

Preferential Shares - 2018 are subject to vesting and holding periods and performance criteria to enable their conversion into ordinary shares, as described in section 5.2.6 of the registration document.

Clarification regarding the terms of compensation and other benefits granted to executive officers:

The chief executive and the directors do not enjoy any particular retirement benefits, severance payments due when they leave office, or non-competition payments.

## Executive Officers

<table>
<thead>
<tr>
<th>Executive officers</th>
<th>Employment contract</th>
<th>Supplementary pension scheme</th>
<th>Allowances or benefits due or likely to be due upon severance or change in role</th>
<th>Allowances connected to a non-competition clause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Claude Cadudal, chairman of the Board</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Start date of office</td>
<td>May 7, 2010 (first term since conversion to a société anonyme)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End date of office</td>
<td>December 3, 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jean-Pierre Garnier, chairman of the Board</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Start date of office</td>
<td>December 3, 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End date of office</td>
<td>At the end of the annual general meeting approving the financial statements for the year ended December 31, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stéphane Piat, chief executive officer</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Start date of office</td>
<td>August 29, 2016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End date of office</td>
<td>Indefinite period</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 4.5.2 SUMS SET ASIDE OR DETERMINED BY THE COMPANY FOR THE PAYMENT OF PENSIONS, RETIREMENT OR OTHER BENEFITS FOR THE MANAGEMENT AND DIRECTORS

The Company has not signed a specific agreement on retirement commitments. These are therefore limited to the agreed retirement lump-sum payment.

In accordance with the preferential method, the provision for retirement commitments has been accounted for as at December 31, 2018.

Refer to the annex 3.2.2.6 within the financial statements.

The overall provision for managers stands at €14,017 at the end of the period.

### 4.5.3 SHARE SUBSCRIPTION WARRANTS (BSA) OR START-UP COMPANY STOCK WARRANTS (BCE) ASSIGNED TO MANAGEMENT AND DIRECTORS

The following table shows all non-lapsed share subscription warrants (BSA) or start-up company stock warrants (BCE) issued by the Company to its corporate officers and managers and not exercised by the beneficiaries as at the date of this registration document: (next page)

On December 18, 2018, Jean Claude Cadudal exercised 650 BSA-2009-1 he owned, involving the issue of 16,250 new shares.

The exercise of each BSA-2009-1 entitles the holder to 25 new shares in CARMAT. The exercise of each BSA-2017-Board members entitles the holder to one new share in CARMAT.
For a detailed description of BSA-2009-1 and BSA-2017-Board members, please refer to Paragraph 5.2.5 « Other securities giving access to capital ».

4.5.4 STATEMENT ON SERVICE CONTRACTS

There is no service contract binding the members of the Board of Directors or management of the Company and providing for the granting of benefits under such a contract.

4.6 STAFF AND ORGANIZATION

4.6.1 HUMAN RESOURCES

OPERATIONAL STRUCTURE

As at December 31, 2018, the operational structure of the Company was as follows:

<table>
<thead>
<tr>
<th>Holder</th>
<th>BSA-2009-1</th>
<th>BSA-2017-Board members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean Claude Cadudal</td>
<td>904</td>
<td>-</td>
</tr>
<tr>
<td>Chairman of the Board of Directors till December 3, 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jean Luc Lemercier</td>
<td>-</td>
<td>6,000</td>
</tr>
<tr>
<td>Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Mack</td>
<td>-</td>
<td>6,000</td>
</tr>
<tr>
<td>Director</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For certain stages of the development of the bioprosthetic artificial heart project, the Company uses a number of outside providers of specific services. At at December 31, 2018, 79 outside service providers work for CARMAT and are divided up as follows:

- 1 Management Business Development,
- 1 Purchasing Department,
- 6 Medical Direction,
- 14 Quality Department,
- 5 IT Department,
- 2 Marketing Department,
- 17 Production Department,
- 33 Research and Development Department.

NUMBER AND BREAKDOWN OF STAFF

At at December 31, 2018, the Company’s workforce numbered 90 people, including 3 temporary workers.

At at December 31, 2018, all members of staff were employed under permanent employment contracts, except 9 staff under temporary employment contracts and 3 trainees.

HUMAN RESOURCES POLICY

Staff management is of considerable importance to the company. In fact, the Company must have qualified employees available with strong skill sets since the business of CARMAT relies to a significant extent on the quality and effectiveness of its members of staff. The company believes that it has good staff relations.

The workforce at December 31, 2018 was made up of 31 women and 59 men and included 2 doctors, 53 engineers and 8 senior graduate technicians. The average age of the salaried workforce was 40. Around 23% of the staff are aged under 30. During the 2018 fiscal year, the Company financed approximately 640 hours of training.

The company applies the National Collective Agreements of the “Metallurgical Industries: workers, employees, technicians, and supervisors of the Paris Region”. There are no company agreements other than the rules of procedure.

Standard contracts of employment contain no clauses relating to breach of the contract of employment or to undertakings relating to non-competition and non-solicitation (staff and/or customers).

All members of staff of the Company benefit, in addition to their basic salary, from a potential annual bonus subject to achieving quantitative and qualitative targets set in advance by the board of directors of the Company and individual targets agreed in advance with the line manager. The amount of this bonus is limited to a percentage of the gross annual salary (between 5% and 45% of the gross annual salary according to the staff or managers concerned).

The working week at the company is 35 hours for non-managers with a fixed number of days per year for managers of 218. There is no agreement on work time within the Company, but an internal memorandum concerning work time and working hour arrangements was issued on July 1, 2016 (over and above the provisions of the collective agreement applicable within the company). This memorandum in particular specifies the length of the working day (7.30 am - 8.30 pm) and sets core hours (9.15 am - 11.45 am and 1.45 pm - 4.45 pm).

The Company’s workforce increased by 20 employees with 90 employees as of December 31, 2018 (including 2 temporary staff on support functions), compared with 70 at December 31, 2017. 12 hirings have been carried out since December 31, 2017 within of the industrial management, 5 R&D engineers, a product manager, a Senior Director of Quality Assurance (Thierry Dupoux) and a Quality Risk Manager, a Financial Director (Pascale D’Arbonneau), an engineer in the medical department and two clinical specialists for strengthen the development direction of the Company.
4.6.2 INTERESTS AND SHARE OPTIONS HELD BY MEMBERS OF THE MANAGEMENT AND SUPERVISORY BODIES AND BY EMPLOYEES

All the share subscription warrants (BSA) and founders’ stock warrants (BCE) not yet exercised or expired issued by the Company for the benefit of its corporate officers and employees are presented in the tables in section 5.2.5 « Other securities giving access to the capital » of the registration document. It is specified that the top ten non-corporate officers hold BCEs that entitle them to subscribe for a total 73,925 shares of the Company (of which 23,500 for BCE-2012-1 and 50,425 for BCE-2009-2).

In addition, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017 and April 5, 2018, awarded free of charge on May 15, 2017, on September 25, 2017, on April 16, 2018 and on September 27, 2018, preferential shares for the benefit of several corporate officers and employees as detailed in section 4.5.1 « Compensation and benefits in kind of officers and directors » of the registration document.

Lastly, on December 3, 2018, the board of directors decided to grant Mr. Jean-Pierre Garnier a stock option plan for 46,000 stock options.

4.6.3 EMPLOYEE OWNERSHIP AND PROFIT SHARING SCHEMES

As at the date of this registration document, the Company had not set up any employee ownership or profit sharing schemes.
INFORMATION ON THE COMPANY AND ITS CAPITAL
5.1 LEGAL STRUCTURE

5.1.1 REGISTERED NAME
The Company’s registered name is: “CARMAT”.

5.1.2 PLACE AND NUMBER OF THE COMPANY’S REGISTRATION
The Company is registered in the Versailles Trade and Companies Register under number 504 937 905.

5.1.3 DATE OF INCORPORATION AND TERM
The Company was incorporated on June 25, 2008 and registered on June 30, 2008 for a term of 99 years, subject to any extension or early dissolution.

5.1.4 REGISTERED ADDRESS, LEGAL FORM AND APPLICABLE LAW
The Company’s registered office is located at 36, avenue de l’Europe – Immeuble l’Etendard-Energy III – 78140 Vélizy-Villacoublay. The Company is a corporation (société anonyme) under French law with a single board of directors, and is governed especially by the provisions of Book II of the French Commercial Code.

5.1.5 ORGANIZATION OF THE GROUP
The Company is not part of a group.

5.1.6 SUBSIDIARIES AND SHAREHOLDINGS
The Company has no subsidiaries or shareholdings.

5.2 SHARE CAPITAL

5.2.1 VALUE OF THE SHARE CAPITAL
As at December 31, 2018, the fully paid-up share capital amounted to €371,036.76, divided into 9,275,919 shares with a par value of €0.04 each (hereinafter referred to as the « Ordinary Shares »).

The general meeting of 27 April 2017 decided to introduce within article 12.2 of the Company’s Articles of Association three categories of preferential shares convertible into ordinary shares governed by articles L. 228-11 et seq.

Code of Commerce respectively named « AGAP 2017-01 », « AGAP 2017-02 » and « AGAP 2017-03 » (hereinafter together referred to as the « Preferential Shares - 2017 »).

On May 15, 2017, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge:

- 270 AGAP 2017-01,
- 1,800 AGAP 2017-02, and
- 3,180 AGAP 2017-03.
On September 25, 2017, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free:

- 50 AGAP 2017-01,
- 200 AGAP 2017-02, and
- 310 AGAP 2017-03.

Preferential Shares - 2017 are subject to vesting and holding periods and performance criteria to enable their conversion into Ordinary Shares, as described in section 5.2.6 of the registration document.

In the same way, the general meeting of 5 April 2018 decided to introduce within article 12.2 of the Company’s Articles of Association three new categories of preferential shares convertible into ordinary shares respectively named « AGAP 2018-01 », « AGAP 2018-02 » and « AGAP 2018-03 » (hereinafter together referred to as the « Preferential Shares - 2018 »).

On April 16, 2018, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 5, 2018, awarded free:

- 580 AGAP 2018-01, and
- 11,500 AGAP 2018-02.

On September 27, 2018, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 5, 2018, awarded free:

- 370 AGAP 2018-03.

Preferential Shares - 2018 are too subject to vesting and holding periods and performance criteria to enable their conversion into Ordinary Shares, as described in section 5.2.6 of the registration document.

As at the date of this registration document, taking into account the required one-year vesting period, have been definitively issued:

- 320 AGAP 2017-01,
- 2,000 AGAP 2017-02, and
- 3,490 AGAP 2017-03.

5.2.2 SECURITIES NOT REPRESENTING CAPITAL

As at the date of this registration document, there were no securities not representing capital.

5.2.3 PLEDGES, GUARANTEES AND COLLATERAL

As at the date of this registration document, and to the best of the Company’s knowledge, there exist no pledges, guarantees or collateral taken on the Company’s equity.

5.2.4 ACQUISITION BY THE COMPANY OF ITS OWN SHARES

As at December 31, 2018, the Company held 2,463 treasury shares, representing 0.03% of its share capital.

The combined general meeting of April 5, 2018, authorized the implementation by the board of directors of an 18-month program to buy back company shares, starting from the meeting, pursuant to the provisions of Article L.225-209 of the French Commercial Code and in compliance with the General Regulation of the French Financial Markets Authority (AMF). The main terms of this authorization are the following:

Number of shares that can be purchased: 10% of the share capital on the date of the buyback. When shares are acquired in order to promote the trading and liquidity of shares, the number of shares taken into account to determine the 10% limit referred to above corresponds to the number of shares purchased, less the number of shares sold during the period of authorization.

Objectives of the share buyback program:

- to ensure the liquidity of the shares of the Company as part of a liquidity contract to be signed with an investment services provider, in accordance with a code of ethics recognized by the French Financial Markets Authority;
- to honor the obligations linked to stock option purchase programs, bonus share allocations, employee savings or other allocations of shares to employees and managers of the Company or affiliated companies;
- to deliver shares when the rights attached to securities giving access to capital are exercised;
- to purchase shares for keeping and later delivery or exchange or payment as part of possible acquisitions;
- to cancel all or a portion of the shares bought back
accordingly; or

- more generally, to operate for any objective that would be authorized by law or any market practice that would be authorized by market authorities, with the understanding that in such an event, the Company would inform its shareholders in a press release.

Maximum purchase price: €240, excluding any fees and commissions and adjustments in order to account for capital transactions.

It is specified that the number of shares acquired by the Company to keep and later deliver as payment or in exchange as part of a merger, demerger or contribution transaction cannot exceed 5% of its capital.

Maximum amount of funds that can be used to buy back shares: €5,000,000

The shares bought back can be canceled up to a limit of 10% of the share capital every 24 month period.

5.2.5 OTHER SECURITIES GIVING ACCESS TO CAPITAL

As at December 31, 2018, the exercise or the conversion of all securities giving access to capital would allow the subscription of 1,246,750 new ordinary shares representing 13.44% of the current issued share capital and 11.85% of share capital after issue of these new ordinary shares.

The exercise of the rights of shareholders would result in the size of the holding of a shareholder holding 1% of the current share capital would reduce to 0.88% if the rights to all these securities were exercised.

Refer to the table below:

<table>
<thead>
<tr>
<th>Type of security</th>
<th>Number of new ordinary shares that may be created (as at December 31, 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incentive instruments for the management and board members</td>
<td></td>
</tr>
<tr>
<td>- BCE-2009-2</td>
<td>63,950</td>
</tr>
<tr>
<td>- BCE-2012-1</td>
<td>34,000</td>
</tr>
<tr>
<td>- BCE-2012-2</td>
<td>6,700</td>
</tr>
<tr>
<td>- BSA-2009-1</td>
<td>22,600</td>
</tr>
<tr>
<td>- BSA-2017-Board members</td>
<td>12,000</td>
</tr>
<tr>
<td>- BSA-2018-Consultant</td>
<td>10,000</td>
</tr>
<tr>
<td>- Stock options</td>
<td>46,000</td>
</tr>
<tr>
<td>- Preferential shares - 2017</td>
<td>421,000</td>
</tr>
<tr>
<td>- Preferential shares - 2018</td>
<td>264,500</td>
</tr>
<tr>
<td>Total incentive instruments</td>
<td>880,750</td>
</tr>
<tr>
<td>Financing tool</td>
<td></td>
</tr>
<tr>
<td>- BSA Kepler Cheuvreux Tranche 1 &amp; 2</td>
<td>366,000</td>
</tr>
<tr>
<td>Total financing instruments</td>
<td>366,000</td>
</tr>
</tbody>
</table>
The tables below detail all the securities giving access to the issued capital of the Company, granted and in effect as at December 31, 2018, allowing the subscription of 1,246,750 new Ordinary Shares.

**START-UP COMPANY STOCK WARRANTS (BCE)**

<table>
<thead>
<tr>
<th>Type of security</th>
<th>BCE-2009-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BCE warrants issued and allocated</td>
<td>7,566 *</td>
</tr>
<tr>
<td>Number of BCE warrants lapsed</td>
<td>1,778 *</td>
</tr>
<tr>
<td>Number of BCE warrants exercised</td>
<td>3,230 *</td>
</tr>
<tr>
<td>Balance of BCE warrants to be exercised</td>
<td>2,558 *</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>July 8, 2009</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>July 8, 2009</td>
</tr>
<tr>
<td>Exercise price per new share subscribed</td>
<td>€8</td>
</tr>
<tr>
<td>BCE warrant exercise deadline</td>
<td>Ten years from the date of the allocation of the BCE warrants</td>
</tr>
<tr>
<td>Ratio</td>
<td>1 BCE-2009-2 warrant for 25 new CARMAT shares</td>
</tr>
</tbody>
</table>

- 20% of the BCE-2009-2 warrants may be exercised on the date of the first anniversary of the beneficiary joining the Company, subject to his/her actual and continued presence within the Company at that date;
- 40% of the BCE-2009-2 warrants may be exercised per completed monthly period in tranches of 1/48th from the date of the first anniversary of the beneficiary joining the Company;
- 10% of the BCE-2009-2 warrants may be exercised from the completion and successful outcome of the initial clinical trials of the CARMAT total artificial heart before the end of the second quarter of 2012 (medical report on completion of the trial covering the safety and end point aspects), subject to his/her actual and continued presence within the Company at that date;
- 10% of the BCE-2009-2 warrants may be exercised after the successful outcome of the first clinical implantation of the CARMAT total artificial heart before the end of November 2012 (report from a third party), subject to the actual and continued presence of the beneficiary within the Company at that date;
- 6.5% of the BCE-2009-2 warrants may be exercised after the successful outcome of the pivotal clinical trials of the CARMAT total artificial heart (report from the scientific advisory committee), subject to his/her actual and continued presence within the Company at that date;
- 6.5% of the BCE-2009-2 warrants may be exercised from the date on which the CE marking is obtained for the CARMAT total artificial heart, subject to actual and continued presence of the beneficiary within the Company at that date;
- 7% of the BCE-2009-2 warrants may be exercised after completion at December 31 of the first year of marketing of the CARMAT total artificial heart, confirmed by the board of directors, in accordance with the expectations in terms of revenue and gross profit margin set out in the business plan drawn up by the general management and approved by the board of directors, subject to the actual and continued presence of the beneficiary within the Company at that date.

Number of new shares that may be subscribed 63,950

* : after adjustments resulting from the increase in capital with preferential subscription rights performed in August 2011.
# INFORMATION ON THE COMPANY AND ITS CAPITAL

## Type of security BCE-2012-1

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BCE warrants issued and allocated</td>
<td>56,500</td>
</tr>
<tr>
<td>Number of BCE warrants lapsed</td>
<td>22,500</td>
</tr>
<tr>
<td>Number of BCE warrants exercised</td>
<td>0</td>
</tr>
<tr>
<td>Balance of BCE warrants to be exercised</td>
<td>34,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 26, 2012</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>June 27, 2012</td>
</tr>
<tr>
<td>Exercise price per new share subscribed</td>
<td>€108,483</td>
</tr>
<tr>
<td>BCE warrant exercise deadline</td>
<td>Ten years from the date of allocation of the BCE warrants</td>
</tr>
<tr>
<td>Ratio</td>
<td>One BCE-2012-1 warrant for 1 new CARMAT share</td>
</tr>
</tbody>
</table>

**General conditions of exercise**

- 50% of BCE-2012-1 warrants may be exercised on the basis of monthly periods in tranches of 1/48th from the date on which the BCE-2012-1 options are awarded to the beneficiary, subject to his/her actual and continued presence within the Company at that date;
- 16.25% of BCE-2012-1 warrants may be exercised after the successful outcome of the pivotal clinical trials of the CARMAT total artificial heart (report from the scientific advisory committee), subject to his/her actual and continued presence within the Company at that date;
- 16.25% of the BCE-2012-1 warrants may be exercised from the date on which the CE marking is obtained for the CARMAT total artificial heart, subject to actual and continued presence of the beneficiary within the Company at that date;
- 17.5% of the BCE-2012-1 warrants may be exercised after completion at December 31 of the first year of marketing of the CARMAT total artificial heart, confirmed by the board of directors, in accordance with the expectations in terms of revenue and gross profit margin set out in the business plan drawn up by the general management and approved by the board of directors, subject to the actual and continued presence of the beneficiary within the Company at that date.

## Type of security BCE-2012-2

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BCE warrants issued and allocated</td>
<td>6,700</td>
</tr>
<tr>
<td>Number of BCE warrants lapsed</td>
<td>0</td>
</tr>
<tr>
<td>Number of BCE warrants exercised</td>
<td>0</td>
</tr>
<tr>
<td>Balance of BCE warrants to be exercised</td>
<td>6,700</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 26, 2012</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>November 8, 2012</td>
</tr>
<tr>
<td>Exercise price per new share subscribed</td>
<td>€122,003</td>
</tr>
<tr>
<td>BCE warrant exercise deadline</td>
<td>Ten years from the date of allocation of the BCE warrants</td>
</tr>
<tr>
<td>Ratio</td>
<td>One BCE-2012-2 warrant for 1 new CARMAT share</td>
</tr>
</tbody>
</table>

**General conditions of exercise**

- 50% of BCE-2012-2 warrants may be exercised on the basis of monthly periods in tranches of 1/48th from the date on which the BCE-2012-2 options are awarded to the beneficiary, subject to his/her actual and continued presence within the Company at that date;
- 16.25% of BCE-2012-2 warrants may be exercised after the successful outcome of the pivotal clinical trials of the CARMAT total artificial heart (report from the scientific advisory committee), subject to his/her actual and continued presence within the Company at that date;
- 16.25% of the BCE-2012-2 warrants may be exercised from the date on which the CE marking is obtained for the CARMAT total artificial heart, subject to actual and continued presence of the beneficiary within the Company at that date;
- 17.5% of the BCE-2012-2 warrants may be exercised after completion at December 31 of the first year of marketing of the CARMAT total artificial heart, confirmed by the board of directors, in accordance with the expectations in terms of revenue and gross profit margin set out in the business plan drawn up by the general management and approved by the board of directors, subject to the actual and continued presence of the beneficiary within the Company at that date.

## Number of new shares that may be subscribed

<table>
<thead>
<tr>
<th>Type of security</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCE-2012-1</td>
<td>34,000</td>
</tr>
<tr>
<td>BCE-2012-2</td>
<td>6,700</td>
</tr>
</tbody>
</table>
SHARE SUBSCRIPTION WARRANTS (BSA)

<table>
<thead>
<tr>
<th>Type of security</th>
<th>BSA-2009-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BSA warrants issued and allocated</td>
<td>3,096 *</td>
</tr>
<tr>
<td>Number of BSA warrants lapsed</td>
<td>556 *</td>
</tr>
<tr>
<td>Number of BSA warrants exercised</td>
<td>1,636 *</td>
</tr>
<tr>
<td>Balance of BSA warrants to be exercised</td>
<td>904 *</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>July 8, 2009</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>July 8, 2009</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>€8</td>
</tr>
<tr>
<td>BSA warrant exercise deadline</td>
<td>Ten years from the date of allocation of the BSA warrants</td>
</tr>
<tr>
<td>Ratio</td>
<td>One BSA-2009-1 warrant for 25 new CARMAT shares</td>
</tr>
</tbody>
</table>

- 25% of the BSA-2009-1 warrants may be exercised on the date of the first anniversary of the beneficiary joining the Company, subject to his/her actual and continued presence within the Company at that date;
- 75% of BSA-2009-1 warrants may be exercised on the basis of monthly periods in tranches of 1/36th from the date of the first anniversary of the beneficiary joining the Company, subject to his/her actual and continued presence within the Company at that date.

General conditions of exercise

Early exercise at the end of a period expiring 18 months after the establishment of the Company if the beneficiary has occupied the position of chairman of the Company for a period expiring 18 months after the establishment of the Company.

As a result of the success of the initial listing of the Company on the Euronext Paris Alternext market, according to the assessment of the meeting of the Company’s board of directors of September 8, 2010, 20% of the BSA-2009-1 warrants that were not exercisable as at the date of the initial listing may be exercised early.

The board of directors of December 3, 2018, acting on the departure of Mr. Jean Claude Cadudal, modified the conditions of exercise of the BSA-2009-1, BSA which remain exercisable until July 8, 2019, even after the departure of his holder.

<table>
<thead>
<tr>
<th>Type of security</th>
<th>BSA Kepler Cheuvreux - Tranches 1 &amp; 2 (all exercisable by Kepler Cheuvreux)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BSA warrants issued and allocated</td>
<td>400,000</td>
</tr>
<tr>
<td>Number of BSA warrants lapsed</td>
<td>0</td>
</tr>
<tr>
<td>Number of BSA warrants exercised</td>
<td>34,000</td>
</tr>
<tr>
<td>Balance of BSA warrants to be exercised</td>
<td>366,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 5, 2018</td>
</tr>
<tr>
<td>Date of CEO’s decision</td>
<td>September 27, 2018</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>94% of the average volume-weighted trading price</td>
</tr>
<tr>
<td>BSA warrant exercise deadline</td>
<td>September 26, 2020, at the latest date</td>
</tr>
<tr>
<td>Ratio</td>
<td>One Kepler BSA warrant for one new CARMAT share</td>
</tr>
<tr>
<td>Number of new shares that may be subscribed</td>
<td>366,000</td>
</tr>
</tbody>
</table>

The Company has put in place a new flexible equity financing arrangement with Kepler Cheuvreux, as the previous one ended in July 2018. Signed in September 2018, this new framework agreement comprises up to two consecutive 12-month tranches, namely a first €12 million tranche beginning on the date of signing of the agreement followed by one tranche making the global amount (Tranche 1 + Tranche 2) of a total of €25 million.

Under this mechanism, Kepler Cheuvreux has made a firm and definitive commitment to purchase new shares under Tranches 1 & 2 for €25 million at times and intervals of its own choosing over the next 24 months, subject to compliance with the terms agreed upon by the two parties. The Company may terminate the agreement at any time. Kepler Cheuvreux does not intend to retain the shares subscribed under these arrangements, and will subsequently sell them to investors or on the open market.
### INFORMATION ON THE COMPANY AND ITS CAPITAL

#### Type of security

<table>
<thead>
<tr>
<th><strong>BSA-2017-Board members</strong></th>
<th><strong>Type of security</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BSA warrants issued and allocated for free</td>
<td>12,000</td>
</tr>
<tr>
<td>Number of BSA warrants lapsed</td>
<td>0</td>
</tr>
<tr>
<td>Number of BSA warrants exercised</td>
<td>0</td>
</tr>
<tr>
<td>Balance of BSA warrants to be exercised</td>
<td>12,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 27, 2017</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>May 15, 2017</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>€30.10</td>
</tr>
<tr>
<td>BSA warrant exercise deadline</td>
<td>May 15, 2027</td>
</tr>
<tr>
<td>Ratio</td>
<td>One BSA-2017-Board members warrant for one new CARMAT share</td>
</tr>
<tr>
<td>General conditions of exercise</td>
<td>- up to 1,500 warrants will be exercisable from January 2, 2018;</td>
</tr>
<tr>
<td></td>
<td>- up to 94 additional warrants will be exercisable from each month starting on January 2, 2018, ie from February 2, 2018 for the first tranche, it being specified that the last tranche will be limited to 82 warrants.</td>
</tr>
<tr>
<td>Number of new shares that may be subscribed</td>
<td>12,000</td>
</tr>
</tbody>
</table>

#### Type of security

<table>
<thead>
<tr>
<th><strong>BSA-2018-Consultant</strong></th>
<th><strong>Type of security</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BSA warrants issued (€3.14 issue price)</td>
<td>10,000</td>
</tr>
<tr>
<td>Number of BSA warrants lapsed</td>
<td>0</td>
</tr>
<tr>
<td>Number of BSA warrants exercised</td>
<td>0</td>
</tr>
<tr>
<td>Balance of BSA warrants to be exercised</td>
<td>10,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 5, 2018</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>June 11, 2018</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>€20.93</td>
</tr>
<tr>
<td>BSA warrant exercise deadline</td>
<td>June 11, 2028</td>
</tr>
<tr>
<td>Ratio</td>
<td>One BSA-2018-Consultant warrant for one new CARMAT share</td>
</tr>
<tr>
<td>General conditions of exercise</td>
<td>- up to 2,500 warrants will be exercisable after each 12 months period starting as at June 11, 2018, taking into account that the consulting agreement with the Company would have to be maintained during that 12 months period;</td>
</tr>
<tr>
<td></td>
<td>- June 11, 2028, at the latest date</td>
</tr>
</tbody>
</table>

#### Stock options

<table>
<thead>
<tr>
<th><strong>Stock options - 2018</strong></th>
<th><strong>Type of security</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of options issued and allocated</td>
<td>46,000</td>
</tr>
<tr>
<td>Number of options lapsed</td>
<td>-</td>
</tr>
<tr>
<td>Number of options exercised</td>
<td>-</td>
</tr>
<tr>
<td>Balance of options to be exercised</td>
<td>46,000</td>
</tr>
<tr>
<td>Date of the general meeting</td>
<td>April 5, 2018</td>
</tr>
<tr>
<td>Date of the meeting of the board of directors</td>
<td>December 3, 2018</td>
</tr>
<tr>
<td>Exercise price per new share</td>
<td>€20.35</td>
</tr>
<tr>
<td>Options exercise deadline</td>
<td>Ten years from the date of allocation of the options</td>
</tr>
<tr>
<td>Ratio</td>
<td>One option - 2018 for 1 new CARMAT share</td>
</tr>
<tr>
<td>General conditions of exercise</td>
<td>- 50% of the options may be exercised in increments of 1/36 each month elapsed from 1 January 2019, and in any event no later than 10 years after their date of allocation to the beneficiary;</td>
</tr>
<tr>
<td></td>
<td>- 50% of the options are exercisable when the Company succeeds in successfully raising additional financing (excluding Equity Line financing and EIB type loans) for an amount of at least €100 million between the date of grant and December 31, 2020, and in any event no later than 10 years after their date of allocation to the beneficiary.</td>
</tr>
<tr>
<td>Number of new shares that may be subscribed</td>
<td>46,000</td>
</tr>
</tbody>
</table>
## INFORMATION ON THE COMPANY AND ITS CAPITAL

### PREFERENTIAL SHARES (FREE PREFERENTIAL SHARES SUBJECT TO PERFORMANCE CRITERIA OVER A 3 YEARS PERIOD)

(see section 5.4.3 « Rights, privileges and restrictions attaching to shares (Articles 9 to 14 of the Articles of Association) » of the registration document, specifying the characteristics of Preferential Shares and conversion ratios into Ordinary Shares).

<table>
<thead>
<tr>
<th>AGAP 2017 Preferential shares classes</th>
<th>Performance criteria</th>
<th>Number of preferential shares issued (as at December 31, 2018)</th>
<th>Maximum conversion ratio applicable for each performance criteria</th>
<th>Number of common shares issuable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class 1</td>
<td>Definition of the Company's industrial development plan</td>
<td>320</td>
<td>100</td>
<td>32,000</td>
</tr>
<tr>
<td>Class 2</td>
<td>Successful implantation of the bioprosthesis evaluated on 10 patients in total in the world</td>
<td>2,000</td>
<td>20</td>
<td>40,000</td>
</tr>
<tr>
<td>Class 3</td>
<td>Filing of the clinical module of the CE marking of the bioprosthesis</td>
<td>15</td>
<td>52,350</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CE marking of the bioprosthesis</td>
<td>20</td>
<td>69,800</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obtaining additional financing for the Company for an aggregate amount, between the grant date and the convertibility date, of €100 million</td>
<td>25</td>
<td>87,250</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implementation of a production process meeting certain criteria</td>
<td>15</td>
<td>52,350</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effective commercialization of bioprostheses at 15 European implantation centers</td>
<td>10</td>
<td>34,900</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Successful implantation of the bioprosthesis evaluated on 10 patients in the United States</td>
<td>10</td>
<td>34,900</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Successful implantation of the bioprosthesis evaluated on 100 patients in total in the world</td>
<td>10</td>
<td>34,900</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Positive development of the ordinary share price according to specific criteria</td>
<td>10</td>
<td>34,900</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum number of ordinary shares that may be created, regardless of the number of performance achieved for Class 3</td>
<td>100</td>
<td>349,000</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>5,810</td>
<td></td>
<td>421,000</td>
</tr>
</tbody>
</table>
## INFORMATION ON THE COMPANY AND ITS CAPITAL

<table>
<thead>
<tr>
<th>AGAP 2018</th>
<th>Performance criteria</th>
<th>Number of preferential shares issued (as at December 31, 2018)</th>
<th>Maximum conversion ratio applicable for each performance criteria</th>
<th>Number of common shares issuable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class 1</strong></td>
<td>Successful execution of « prosthesis» test benches for CE marking</td>
<td>580</td>
<td>100</td>
<td>58,000</td>
</tr>
<tr>
<td><strong>Class 2</strong></td>
<td>Recruitment of 10 patients in the pivotal study for CE marking</td>
<td>10</td>
<td>11,300</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recruitment of the 20th patient in the pivotal study to obtain the CE marking or finalization of the pivotal study for submission of the dossier to DEKRA</td>
<td>11,300 *</td>
<td>5</td>
<td>56,500</td>
</tr>
<tr>
<td></td>
<td>Obtaining authorization to conduct an Early Feasibility Study in the United States by December 31, 2018</td>
<td>5</td>
<td>0 *</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum number of ordinary shares that may be created, regardless of the number of performance achieved for Class 2</td>
<td>20</td>
<td>169,500</td>
<td></td>
</tr>
<tr>
<td><strong>Class 3</strong></td>
<td>Filing of the clinical module of the CE marking of the bioprosthesis</td>
<td>15</td>
<td>5,550</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CE marking of the bioprosthesis</td>
<td>20</td>
<td>7,400</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obtaining additional financing for the Company for an aggregate amount, between the grant date and the convertibility date, of €38.5 million</td>
<td>25</td>
<td>9,250</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implementation of a production process meeting certain criteria</td>
<td>370</td>
<td>15</td>
<td>5,550</td>
</tr>
<tr>
<td></td>
<td>Effective commercialization of bioprostheses at 15 European implantation centers</td>
<td>10</td>
<td>3,700</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Successful implantation of the bioprosthesis evaluated on 10 patients in the United States</td>
<td>10</td>
<td>3,700</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Successful implantation of the bioprosthesis evaluated on 100 patients in total in the world</td>
<td>10</td>
<td>3,700</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Positive development of the ordinary share price according to specific criteria</td>
<td>10</td>
<td>3,700</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum number of ordinary shares that may be created, regardless of the number of performance achieved for Class 3</td>
<td>100</td>
<td>37,000</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>12,450</td>
<td>264,500</td>
<td></td>
</tr>
</tbody>
</table>

*: 11,500 AGAP-2018-02 had been awarded by the Board of Directors, now reduced to 11,300 because of the departure of a beneficiary.

**: The corresponding performance criterion has not been respected.
5.2.6 SHARE CAPITAL AUTHORIZED BUT NOT ISSUED

Shareholders’ meeting of April 5, 2018

On the date of filing of this registration document, the board of directors made use of the delegations of authority approved at the general meeting of shareholders of the Company of April 5, 2018 detailed below, as follows:

- the board of directors, making use of the delegations of authority approved at the general meeting of April 5, 2018, proceeded on April 16, 2018 to the free allocation of:
  • 580 AGAP 2018-01, and
  • 11,500 AGAP 2018-02.

- the board of directors, making use of the delegations of authority approved at the general meeting of April 5, 2018, proceeded on April 16, 2018 to issue of 10,000 BSA for the benefit of a consultant of the Company.

- the board of directors, making use of the delegations of authority approved at the general meeting of April 5, 2018, proceeded on September 27, 2018 to issue of 400,000 BSA Kepler Cheuvreux, linked to a new flexible equity financing arrangement with this financial institution.

This same board of directors decided the free allocation of 370 AGAP 2018-03 under the 27th resolution voted at the general meeting of April 5, 2018.

- on December 3, 2018, the board of directors decided to grant Mr. Jean-Pierre Garnier a stock option plan for 46,000 stock options.

- lastly, on February 11, 2019, the board of directors decided the free allocation of 370 AGAP 2018-03 under the 27th resolution voted at the general meeting of April 5, 2018.

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Subject matter of the resolution</th>
<th>Maximum nominal amount in euros</th>
<th>Maximum nominal amount in euros</th>
<th>Period of authorization and expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>11th resolution</td>
<td>Delegation of authority allowing the board of directors to increase capital immediately or in the future by issuing ordinary shares or any other securities giving access to the capital or giving right to the allocation of debt securities, with retention of preferential subscription rights</td>
<td>Nominal value of increases in capital: €160,000 (1)</td>
<td>N / A</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Face value of bonds and other debt instruments giving access to capital: €120,000,000 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12th resolution</td>
<td>Delegation of authority allowing the board of directors to decide on the issue of shares and/or transferable securities giving immediate or future access to capital or giving right to the allocation of debt securities, with removal of the preferential subscription right by way of a public offer (Article L.225-136)</td>
<td>Nominal value of increases in capital: €160,000 (1)</td>
<td>At least equal to the average volume-weighted price of the last five stock market sessions prior to the defining of the issue price less any discount (maximum 30%)</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nominal amount of bonds and other debt instruments giving access to capital: €120,000,000 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13th resolution</td>
<td>Delegation of authority allowing the board of directors to decide on the issue of shares and/or transferable securities giving immediate or future access to capital or giving right to the allocation of debt securities, with removal of the preferential subscription rights, by offering to qualified investors or to a limited circle of investors in the meaning of Paragraph II of Article L.411-2 of the French Monetary and Financial Code (Article L.225-136 3)</td>
<td>Nominal value of increases in capital: €160,000 (1)</td>
<td>At least equal to the average volume-weighted price of the last five stock market sessions prior to the defining of the issue price less any discount (maximum 30%)</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nominal amount of bonds and other debt instruments giving access to capital: €120,000,000 (1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) These amounts are not cumulative. The overall maximum nominal amount of capital increases that can be carried out under the delegations granted under resolutions 11 to 18 is set at €160,000. The maximum nominal amount of debt securities which can be issued under the above delegations is set at €120,000,000.
### INFORMATION ON THE COMPANY AND ITS CAPITAL

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Subject matter of the resolution</th>
<th>Maximum nominal amount in euros</th>
<th>Maximum nominal amount in euros</th>
<th>Period of authorization and expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>14th resolution</td>
<td>Subject to the listing of the Company’s shares on a regulated market, the authorization allowing the board of directors, in the event of the issue of shares or of any security giving access to capital with removal of the preferential subscription right, to set the issue price at a maximum of 10% of the share capital and within the limits determined by general meeting</td>
<td>Limited to 10% of the Company’s capital (as existing on the date of the transaction) per 12 month period</td>
<td>At least equal to the average volume-weighted price of the last five stock market sessions prior to the defining of the issue price, less any discount (maximum 30%)</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td>15th resolution</td>
<td>Delegation of authority allowing the board of directors to increase the amount of each of the issues with or without preferential subscription right which would be decided under resolutions 11 to 13.</td>
<td>Limited to 15% of the initial issue</td>
<td>Price identical to that of the initial issue</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td>16th resolution</td>
<td>Delegation of authority allowing the board of directors to increase capital immediately or in the future by issuing ordinary shares or any other securities giving access to the capital, with removal of the preferential subscription right to categories of beneficiaries (Biotech/Medtech investors)</td>
<td>Nominal value of increases in capital: €160,000,000 (1)</td>
<td>At least equal to the average volume-weighted price of the last five stock market sessions prior to the defining of the issue price less any discount (maximum 30%)</td>
<td>October 5, 2019 (18 months)</td>
</tr>
<tr>
<td>17th resolution</td>
<td>Delegation of authority allowing the board of directors to increase capital immediately or in the future by issuing ordinary shares or any other securities giving access to the capital, with removal of the preferential subscription right to categories of beneficiaries (Strategic partners)</td>
<td>Nominal value of increases in capital: €160,000,000 (1)</td>
<td>At least equal to the average volume-weighted price of the last five stock market sessions prior to the defining of the issue price less any discount (maximum 30%)</td>
<td>October 5, 2019 (18 months)</td>
</tr>
<tr>
<td>18th resolution</td>
<td>Delegation of authority allowing the board of directors to decide on the issue of shares and/or securities giving immediate or future access to the capital or providing a right to a debt instrument, with removal of the preferential subscription right of shareholders for the benefit of a category of beneficiaries (equity line financing plan)</td>
<td>Nominal value of increases in capital: €160,000,000 (1)</td>
<td>At least equal to the average volume-weighted price of the last three stock market sessions prior to the defining of the issue price less any discount (maximum 30%)</td>
<td>October 5, 2019 (18 months)</td>
</tr>
<tr>
<td>20th resolution</td>
<td>Authorization granted to the board of directors to award options for the subscription or purchasing of shares</td>
<td>Nominal value of increases in capital: €160,000,000 (2)</td>
<td>N/A</td>
<td>June 5, 2020 (26 months)</td>
</tr>
<tr>
<td>22nd resolution</td>
<td>Authorization granted to the board of directors to award options for the subscription or purchasing of shares</td>
<td>€2,412 (corresponding to 60,300 shares) (3)</td>
<td>(4)</td>
<td>June 5, 2021 (38 months)</td>
</tr>
</tbody>
</table>

(1) These amounts are not cumulative. The overall maximum nominal amount of capital increases that can be carried out under the delegations granted under resolutions 11 to 18 is set at €160,000. The maximum nominal amount of debt securities which can be issued under the above delegations is set at €120,000,000.

(2) Separate limit to the limit for resolutions 11 to 18 above.

(3) These amounts are not cumulative. The overall maximum nominal amount of capital increases that can be carried out under the delegations granted under resolutions 21 and 22 is set at €2,412.

(4) The purchase or subscription price per share will be set by the board on the day the option is granted, based on the following:
- for as long as the shares are admitted for trading on the Euronext Growth market, the purchase or subscription price shall be determined in accordance with the provisions of Article L. 225-177 of the French Commercial Code and must be at least equal to the sales price of one share at the close of the Euronext Growth market on the day prior to the decision of the board of directors to allocate the options;
- in the event that the Company’s shares are admitted for trading on a regulated market, the board may determine the purchase or subscription price per share with reference to the sales price of one share at the close of that regulated market on the day prior to the decision of the board to allocate the options. However, the purchase or subscription price per share may under no circumstances be less than ninety-five percent (95%) of the average sales price of one share at the close of the said market during the twenty trading days prior to the decision of the board of directors to allocate the options rounded down to the nearest euro, nor, for the bonds, to 80% of the average sales price of the bonus shares of the Company, rounded down to the nearest euro.
**Ordinary shares warrants issue:**

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Subject matter of the resolution</th>
<th>Maximum nominal amount in euros</th>
<th>Method of determining the issue price</th>
<th>Method of determining the exercise price</th>
<th>Period of authorization and expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>21st resolution</td>
<td>Delegation of authority allowing the board of directors to issue warrants dedicated to board members (not having the quality of employees or managers), persons bound by a contract of services or members of Committees set up by the board of directors</td>
<td>€2,412 (corresponding to 60,300 shares) (1)</td>
<td>To be fixed by the board of directors</td>
<td>At least equal to the average of the prices weighted by the volumes of the last 20 trading sessions preceding the fixing of the issue price of the warrants</td>
<td>October 5, 2019 (18 months)</td>
</tr>
</tbody>
</table>

(1) These amounts are not cumulative. The overall maximum nominal amount of capital increases that can be carried out under the delegations granted under resolutions 21 and 22 is set at €2,412.

**Free allocation of preferential shares:**

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Subject matter of the resolution</th>
<th>Maximum nominal amount in euros</th>
<th>Acquisition period for the preferred shares</th>
<th>Lockup period applicable to the preferred shares</th>
<th>Exercise period of the conversion option into ordinary shares</th>
<th>Period of authorization and expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>25th resolution</td>
<td>Delegation of authority allowing the board of directors to allocate free preferential shares convertible into ordinary shares «AGAP 2018-01» dedicated to employees and / or corporate officers</td>
<td>€2,220 (corresponding to 58,000 ordinary shares)</td>
<td>1 year</td>
<td>2 years minimum</td>
<td>5 years and 3 months from the end of the lock-up period</td>
<td>June 5, 2021 (38 months)</td>
</tr>
<tr>
<td>26th resolution</td>
<td>Delegation of authority allowing the board of directors to allocate free preferential shares convertible into ordinary shares «AGAP 2018-02» dedicated to employees and / or corporate officers</td>
<td>€9,200 (corresponding to 230,000 ordinary shares)</td>
<td>1 year</td>
<td>2 years minimum</td>
<td>5 years and 3 months from the end of the lock-up period</td>
<td>June 5, 2021 (38 months)</td>
</tr>
<tr>
<td>27th resolution</td>
<td>Delegation of authority allowing the board of directors to allocate free preferential shares convertible into ordinary shares «AGAP 2018-03» dedicated to employees and / or corporate officers</td>
<td>€7,600 (corresponding to 190,000 ordinary shares)</td>
<td>1 year</td>
<td>2 years minimum</td>
<td>5 years and 3 months from the end of the lock-up period</td>
<td>June 5, 2021 (38 months)</td>
</tr>
</tbody>
</table>
Performance criteria to be met in order to make the preferential shares AGAP 2018-01, AGAP 2018-02 and AGAP 2018-03 convertible into ordinary shares:

• For AGAP 2018-01:
  - the successful completion of «prosthesis» test benches for CE marking, which will give the right to convert each AGAP 2018-01 preferential share into 100 ordinary shares.

• For AGAP 2018-02:
  - the recruitment of 10 patients in the pivotal study to obtain the CE mark, which will give the right to convert each AGAP 2018-02 preferential share into 10 ordinary shares;
  - the recruitment of the 20th patient in the pivotal study to obtain the CE marking or the completion of the PIVOT study for submission of the dossier to DEKRA, which will give the right to convert each AGAP 2018-02 preferential share into 5 ordinary actions;
  - obtaining authorization to perform the Early Feasibility Study in the US by December 31, 2018, which will give the right to convert each AGAP 2018-02 preferential share into 5 common shares.

• For AGAP 2018-03:
  - the filing of the clinical module of the CE marking of the bioprosthesis, which will give the right to convert each AGAP 2018-03 preferential share into 15 ordinary shares;
  - the CE marking of the bioprosthesis, which will give the right to convert each AGAP 2018-03 preferential share into 20 ordinary shares;
  - obtaining additional financing for the Company for a cumulative amount of € 38.5 million between the grant date and the convertibility date, giving the right to convert each AGAP 2018-03 preferential share into 25 ordinary shares;
  - the implementation of a production process meeting certain criteria, which will give the right to convert each AGAP 2018-03 preferential share into 15 ordinary shares;
  - the effective commercialization of the bioprosthesis at 15 European centers, which will give the right to convert each AGAP 2018-03 preferential share into 10 ordinary shares;
  - the successful implementation of the bioprosthesis evaluated on 10 patients in the United States, which will give the right to convert each AGAP 2018-03 preferential share into 5 ordinary shares;
  - the successful implementation of the bioprosthesis evaluated in 100 patients worldwide, which will give the right to convert each AGAP 2018-03 preferential share into a maximum of 10 ordinary shares;
  - a favorable change in the price of the ordinary share according to specific criteria will give the right to convert each AGAP 2018-03 preferential share into a maximum of 10 ordinary shares.

At the date of filing of this registration document, the Company made use of the delegations of authority voted at the general meeting of April 5, 2018 and proceeded to:

(i) April 16, 2018, at the free allocation of:
  - 580 AGAP 2018-01; and
  - 11,500 AGAP 2018-02.

(ii) on September 27, 2018, at the free allocation of:
  - 370 AGAP 2018-03.

(iii) on February 11, 2019, at the free allocation of:
  - 370 AGAP 2018-03.

None.
The Company was registered in the Versailles Trade and Companies Register on June 30, 2008 with an initial share capital of €40,000. The table below shows a summary of the changes in share capital during the last 3 years.

<table>
<thead>
<tr>
<th>Date of realization of the operation</th>
<th>Type of operation</th>
<th>Increase in capital (in euros)</th>
<th>Issue premium or contribution (in euros)</th>
<th>Number of shares created</th>
<th>Nominal value of shares (in euros)</th>
<th>Cumulative number of shares</th>
<th>Share capital following the operation (in euros)</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 10, 2016</td>
<td>Increase in capital by cash contribution through the exercise of Kepler BSA warrants</td>
<td>600.00</td>
<td>468,000.00</td>
<td>15,000</td>
<td>0.04</td>
<td>4,592,935</td>
<td>183,717.40</td>
</tr>
<tr>
<td>April 12, 2016</td>
<td>Increase in capital by cash contribution through private placement</td>
<td>53,966.36</td>
<td>49,945,866.18</td>
<td>1,349,159</td>
<td>0.04</td>
<td>5,942,094</td>
<td>237,683.76</td>
</tr>
<tr>
<td>August 29, 2016</td>
<td>Increase in capital by cash contribution through the exercise of BCE warrants</td>
<td>80.00</td>
<td>15,920.00</td>
<td>2,000</td>
<td>0.04</td>
<td>5,944,094</td>
<td>237,763.76</td>
</tr>
<tr>
<td>December 12, 2016</td>
<td>Increase in capital by cash contribution through the exercise of BCE warrants</td>
<td>3,274.00</td>
<td>651,526.00</td>
<td>81,850</td>
<td>0.04</td>
<td>6,025,944</td>
<td>241,037.76</td>
</tr>
<tr>
<td>February 10, 2017</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrants</td>
<td>380.00</td>
<td>245,975.00</td>
<td>9,500</td>
<td>0.04</td>
<td>6,035,444</td>
<td>241,417.76</td>
</tr>
<tr>
<td>May 15, 2017</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrants</td>
<td>1,520.00</td>
<td>971,430.00</td>
<td>38,000</td>
<td>0.04</td>
<td>6,073,444</td>
<td>242,937.76</td>
</tr>
<tr>
<td>June 12, 2017</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrant</td>
<td>2,644.00</td>
<td>1,760,686.00</td>
<td>66,100</td>
<td>0.04</td>
<td>6,139,544</td>
<td>245,581.76</td>
</tr>
<tr>
<td>September 25, 2017</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrant</td>
<td>3,080.00</td>
<td>1,871,760.00</td>
<td>77,000</td>
<td>0.04</td>
<td>6,216,544</td>
<td>248,661.76</td>
</tr>
<tr>
<td>December 1, 2017</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrant</td>
<td>6,200.00</td>
<td>3,402,140.00</td>
<td>155,000</td>
<td>0.04</td>
<td>6,371,544</td>
<td>254,861.76</td>
</tr>
<tr>
<td>December 12, 2017</td>
<td>Increase in capital by cash contribution</td>
<td>105,800.00</td>
<td>52,794,200.00</td>
<td>2,645,000</td>
<td>0.04</td>
<td>9,016,544</td>
<td>360,661.76</td>
</tr>
<tr>
<td>February 12, 2018</td>
<td>Increase in capital by cash contribution through the exercise of Kepler BSA warrants</td>
<td>1,840.00</td>
<td>957,800.00</td>
<td>46,000</td>
<td>0.04</td>
<td>9,062,544</td>
<td>362,501.76</td>
</tr>
<tr>
<td>April 16, 2018</td>
<td>Increase in capital by cash contribution through the exercise of Kepler BSA warrants</td>
<td>3,640.00</td>
<td>1,837,500.00</td>
<td>91,000</td>
<td>0.04</td>
<td>9,153,544</td>
<td>366,141.76</td>
</tr>
<tr>
<td>December 3, 2018</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrant</td>
<td>3,445.00</td>
<td>1,785,240.00</td>
<td>86,125</td>
<td>0.04</td>
<td>9,239,669</td>
<td>369,586.76</td>
</tr>
<tr>
<td>February 11, 2019 *</td>
<td>Increase in capital by cash contribution through the exercise of both Kepler BSA warrants and BCE warrant</td>
<td>1,450.00</td>
<td>558,550.00</td>
<td>36,250</td>
<td>0.04</td>
<td>9,275,919</td>
<td>371,036.76</td>
</tr>
</tbody>
</table>

Note that Kepler Cheuvreux does not intend to retain the shares subscribed under the share issue agreements made in January 2015 and in September 2018, and will subsequently sell them to investors or on the open market.

*: New shares issued before December 31, 2018 and legally recognized by the board of directors on February 11, 2019.
5.3 **MAJOR SHAREHOLDERS**

5.3.1 **DISTRIBUTION OF CAPITAL AND VOTING RIGHTS**

**CURRENT DISTRIBUTION OF CAPITAL AND VOTING RIGHTS**

The table below shows the distribution of the capital and voting rights (please refer to Paragraph 5.3.2 « Voting rights » of this registration document, which indicates the conditions under which double voting rights may be obtained) of the Company at December 31, 2018, to the best of the Company’s knowledge:

<table>
<thead>
<tr>
<th>Shareholders (December 31, 2018)</th>
<th>Number of shares</th>
<th>Number of voting rights</th>
<th>% of capital</th>
<th>% of voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matra Défense (Airbus Group)</td>
<td>1,333,798</td>
<td>2,315,198</td>
<td>14.4%</td>
<td>20.9%</td>
</tr>
<tr>
<td>Professor Alain Carpentier</td>
<td>548,583</td>
<td>1,097,166</td>
<td>5.9%</td>
<td>9.9%</td>
</tr>
<tr>
<td>Research Association of the Alain Carpentier Foundation</td>
<td>115,000</td>
<td>230,000</td>
<td>1.2%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Funds managed by Truffle Capital</td>
<td>356,024</td>
<td>470,103</td>
<td>2.4%</td>
<td>3.8%</td>
</tr>
<tr>
<td>Air Liquide</td>
<td>76,982</td>
<td>76,982</td>
<td>0.5%</td>
<td>0.7%</td>
</tr>
<tr>
<td>Cornovum</td>
<td>458,715</td>
<td>458,715</td>
<td>4.4%</td>
<td>5.0%</td>
</tr>
<tr>
<td>Lohas</td>
<td>1,291,959</td>
<td>1,291,959</td>
<td>13.3%</td>
<td>13.3%</td>
</tr>
<tr>
<td>Santé Holdings SRL</td>
<td>688,881</td>
<td>688,881</td>
<td>7.2%</td>
<td>6.2%</td>
</tr>
<tr>
<td>Therabel Pharma</td>
<td>125,000</td>
<td>125,000</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Treasury stock</td>
<td>2,463</td>
<td>-</td>
<td>0.0%</td>
<td>-</td>
</tr>
<tr>
<td>Secondary offering</td>
<td>4,278,514</td>
<td>4,337,105</td>
<td>46.1%</td>
<td>39.1%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>9,275,919</strong></td>
<td><strong>11,091,109</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

To the best of the Company’s knowledge, there is no other shareholder owning more than 5% of the capital or the voting rights.

**Truffle Capital**

**Founded in 2001 in Paris, Truffle Capital is an acknowledged European player in the area of investment capital, investing in and developing innovative SMEs and building technological leaders in the areas of Life Sciences, Information Technology and Energy.**

Truffle Capital often acts as leader, as the single or majority investor, and finances in particular technology spin-offs from large industrial groups, technological research institutes and universities, but also new start-ups. Truffle Capital is a co-founder and shareholder of CARMAT.

**Airbus Group**

Airbus Group (formerly EADS), born out of a merger in July 2000 between DaimlerChrysler Aerospace AG, Aérospatiale-Matra and Construcciones Aeronáuticas SA, is a world leader in the aeronautic, space and defense and associated services sectors. Airbus Group holds shares in CARMAT through its wholly-owned subsidiary, Matra Défense.

**Professor Carpentier**

Professor emeritus at the Pierre and Marie Curie University (University of Paris VI) and Professor at the Mount Sinai School of Medicine in New York, he is the founder and director of the Biosurgical Research Laboratory at the Scientific Research Association of the Alain Carpentier Foundation.

Winner of the 1998 Foundation for Medical Research Grand Prize, and vice-chairman of the Academy of Sciences, he also received the prestigious Albert Lasker Award for Clinical Medical Research in 2007 in recognition of his two main contributions to the field - invention of valve bioprostheses (Carpentier-Edwards valves) and the development of techniques for plastic and reconstructive surgery of heart valves, which benefit several hundred thousand patients worldwide each year.
**Scientific Research Association of the Alain Carpentier Foundation (ARSFAC)**

Set up in December 2007 by Professor Alain Carpentier, the purpose of the Scientific Research Association of the Alain Carpentier Foundation is to finance medical research projects, in particular in the surgical, cardiovascular and neurological areas.

**Lohas**

This entity is a family office of Mr. Pierre Bastid, having acquired the Existing Shares originally subscribed by ZAKA (another family office of Mr. Pierre Bastid) as part of the Company’s private placement executed in 2016, from Babalia (another family office of Mr. Pierre Bastid) in July 2018.

**Santé Holdings SRL**

This entity is the family office of Dr. Antonino Ligresti.

**CorNovum**

This entity is an investment vehicle, a structure held at parity, at the initiative of the French State and BPI France.

**CHANGE IN THE DISTRIBUTION OF CAPITAL AND VOTING RIGHTS**

The table below shows the distribution of capital and voting rights in the Company as at December 31, 2017, December 31, 2016 and as at December 31, 2015, insofar as known to the Company.

It should be noted that on February 26, 2016 the Company announced a significant fund-raising initiative, for €50 million, via a reserved capital increase operation after the effective extraordinary general meeting held on April 12, 2016, capital increase subscribed by a pool of strategic investors, composed of Air Liquide via its investment holding company ALIAD, of the joint investment vehicle of Bpifrance and the State (Programme des Investissements d’Avenir (future investments program - CorNovum), the family offices of Mr. Pierre Bastid (ZAKA) and of Dr. Ligresti (Santé Holdings SRL) and by the reference shareholders, Matra Défense (Airbus Group) and Truffle Capital (via one previous fund and several new funds).

In addition, last December, the Company launched a capital increase operation through a public offering, a transaction that benefited from the support of the historic shareholders, in particular the family offices of Mr. Pierre Bastid (Babalia) and Dr. Ligresti (Santé Holdings SRL).

These two operations explain the observable changes in the composition of the shareholders between the end of December 2015 and the end of December 2017.

<table>
<thead>
<tr>
<th>Shareholders</th>
<th>As at December 31, 2017</th>
<th>% of capital</th>
<th>% of voting rights</th>
<th>As at December 31, 2016</th>
<th>% of capital</th>
<th>% of voting rights</th>
<th>As at December 31, 2015</th>
<th>% of capital</th>
<th>% of voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matra Défense (Airbus Group)</td>
<td>14.8</td>
<td>20.7</td>
<td>22.1</td>
<td>27.5</td>
<td>22.6</td>
<td>28.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Alain Carpentier</td>
<td>6.1</td>
<td>9.8</td>
<td>9.1</td>
<td>13.0</td>
<td>12.0</td>
<td>15.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARSFAC</td>
<td>1.3</td>
<td>2.1</td>
<td>1.9</td>
<td>2.7</td>
<td>2.5</td>
<td>3.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funds managed by Truffle Capital</td>
<td>8.5</td>
<td>11.5</td>
<td>15.4</td>
<td>19.6</td>
<td>19.2</td>
<td>24.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Air Liquide</td>
<td>0.9</td>
<td>0.7</td>
<td>0.5</td>
<td>0.3</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CorNovum</td>
<td>5.1</td>
<td>4.1</td>
<td>7.6</td>
<td>5.4</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lohas</td>
<td>14.3</td>
<td>11.5</td>
<td>4.8</td>
<td>3.5</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santé Holdings SRL</td>
<td>7.6</td>
<td>6.1</td>
<td>3.1</td>
<td>2.2</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treasury stock</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary offering</td>
<td>41.4</td>
<td>33.6</td>
<td>35.4</td>
<td>25.7</td>
<td>43.6</td>
<td>28.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**5.3.2 VOTING RIGHTS**

The voting right attaching to shares is proportional to the percentage of capital that they represent and each share gives an entitlement to at least one vote.

However, in accordance with Article 14 of the Articles of Association and in accordance with the provisions of the French Commercial Code, all fully paid up shares which can be shown to have been registered to the same shareholder for at least two years will benefit, with effect from the first listing of the shares of the Company on the Euronext Growth market, from double voting rights compared with those given to other shares having regard to the percentage of share capital that they represent.
### 5.3.3 Statement Concerning Control of the Company

As at the date of this registration document, to the best of the Company's knowledge, no single shareholder was in control of the Company, directly or indirectly or with others, within the meaning of Article L.233-3 et seq. of the French Commercial Code.

### 5.3.4 Agreements That May Bring About a Change in the Control

As at the date of this registration document, and to the best of the Company’s knowledge, there are no agreements that may bring about a change in control of the Company.

### 5.4 Memorandum and Articles of Association

#### 5.4.1 Corporate Purpose (Article 2 of the Memorandum and Articles of Association)

The purpose of the Company is, either directly or indirectly, both in France and abroad:

- research and development in the field of medical devices and equipment, specifically in the cardiovascular field, and in all scientific fields directly or indirectly related thereto;
- production and marketing of (i) medical devices and equipment in the cardiovascular field and (ii) all associated technologies;
- acquisition or creation of technology products and licenses connected with the cardiovascular field;
- investment in French or foreign enterprises having activities that are similar to, or which complement those mentioned above;
- and, more generally, all operations of any kind - economic, legal, financial, civil or commercial, industrial, moveables or real estate – that may be directly or indirectly connected with the above-mentioned object or likely to contribute to the development thereof.

#### 5.4.2 Provisions of the Memorandum and Articles of Association, a Charter or Bylaws of the Company Concerning the Members of the Board of Directors and the General Management (Articles 15 - 21 of the Memorandum and Articles of Association)

**Article 15 - Board of Directors**

The Company is administered by a board of directors consisting of a minimum of five (5) and a maximum of eighteen (18) members subject to the derogation provided for by law in the case of a merger.

**Article 16 - Appointment and Removal of Directors**

I. Appointment/removal of directors

Over the life of the Company, the directors are appointed by the ordinary general meeting. However, in the event of a merger or demerger, appointments may be made by an extraordinary general meeting. Their term of office is six (6) years. It concludes at the end of the ordinary general meeting of shareholders that approves the financial statements for the period just closed, and which is held in the year in which the term of office of the said director expires.

Any outgoing director may be re-elected subject to fulfilling the conditions of this Article.

Directors may be removed from office and replaced at any time by the ordinary general meeting.
Natural persons aged more than eighty-five (85) years may not be directors; where a director passes this age during a term of office they are deemed to have officially resigned at the next general meeting. Any appointment made in breach of the above provisions is null and void, with the exception of those which may be made on an interim basis.

Any director who is a natural person must, at the time of their appointment and throughout their term of office, meet the legal requirements in terms of the total number of directorships that a single person may hold in sociétés anonymes (corporations) based in Metropolitan France, save as otherwise provided for by law.

A Company staff member may only be appointed as a director if their contract of employment relates to an actual position within the Company. The number of directors having a contract of employment with the Company may not exceed one third of the directors in post.

II. Director in the form of a legal entity

Directors may be natural persons or legal entities. In the latter case, at the time of appointment, the legal entity is required to designate a permanent representative who will be subject to the same conditions and obligations and with the same civil and criminal liabilities as if they were a director in their own right, without prejudice to the joint and several liability of the legal entity that they represent. The permanent representative of a director in the form of a legal entity is subject to the age conditions that relate to directors who are natural persons.

The term of office of the permanent representative designated by the legal entity appointed as director is the same as the term of office of the latter.

If the legal entity revokes the mandate of its permanent representative, it is required to notify the Company, without delay, by registered letter, of this revocation and of the identity of its new representative. The same applies in the case of death or resignation of the permanent representative.

The designation of the permanent representative and the termination of their mandate are subject to the same publication formalities as if they were a director in their own right.

III. Vacancies, death, resignation

In the event of a vacancy due to death or resignation of one or more directors, the board of directors may proceed with interim appointments between two general meetings.

When the number of directors falls below the legal minimum, the remaining directors must immediately call an ordinary general meeting in order to bring the board up to strength.

Interim appointments made by the board are subject to ratification by the next ordinary general meeting. In the absence of ratification, resolutions passed and acts performed previously by the board will remain valid.

ARTICLE 17 - ORGANIZATION AND DELIBERATIONS OF THE BOARD

I. Chairman

The board of directors elects a chairman from among its members, who must be a natural person, failing which the appointment will be null and void. The board of directors determines the remuneration of the chairman.

The chairman of the board of directors organizes and directs the work of the latter, and reports thereon to the general meeting. He ensures that the Company bodies are operating properly, and in particular that the directors are capable of performing their duties.

In order to perform his duties, the chairman of the board of directors must be less than eighty-five (85) years of age. If the chairman of the board of directors passes this age during his term of office, he will be deemed to have officially resigned and the appointment of a new chairman will take place subject to the conditions provided for in this Article.

The chairman is appointed for a term that may not exceed that of his term of office as a director. The Chairman is eligible for re-election.

The board of directors may revoke the appointment at any time.

In the event of the chairman being temporarily unavailable, or of his death, the board of directors may delegate the duties of chairman to a director.

In the event of a temporary impediment, this delegation is made for a limited period; it is renewable. In the event of death it remains valid until the election of a new chairman.

II. Board meetings

The board of directors meets as often as the interests of the Company dictate, at the invitation of the chairman and at least every two (2) months.

When it has not met for more than two (2) months, a minimum of one third of the members of the board of directors may ask the chairman to call a meeting with a specific agenda.

The chief executive may also ask the chairman to call a meeting of the board of directors with a specific agenda.
The chairman is bound to act on requests made to him by virtue of the above two paragraphs.

Notices may be given by any means and even verbally.

The board meets at the head office or at any other location (in France or abroad) indicated in the notice, under the chairmanship of the chairman or, if he is unavailable, the member designated by the board to chair it.

The chairman of the board of directors chairs the meetings. In the event of the chairman being unavailable, the board appoints a chairman for each meeting from among the members present.

At each meeting, the board may appoint a secretary, who does not necessarily have to be a member.

A register is kept which is signed by the directors attending the board meeting.

The directors and any person called upon to attend the meetings of the board of directors are bound by secrecy in respect of information of a confidential nature indicated as such by the chairman.

III. Quorum, majority

Deliberations of the board will only be valid if at least half of the directors are present or deemed present under the arrangements laid down in the Bylaws where videoconferencing and other means of telecommunication are used.

Unless otherwise stipulated by these Articles of Association and subject to the arrangements laid down in the Bylaws, where videoconferencing or other means of telecommunication are used, decisions are taken by a majority of votes of the members present or represented or deemed present.

Directors are deemed present for the purposes of calculating a quorum or majority where they take part via video-conference or telecommunication under the conditions defined by the Bylaws of the board of directors. However, physical presence or representation will be necessary for all deliberations of the board relating to adoption of the annual financial statements and the consolidated financial statements, and also for drawing up the management report and the consolidated management report, as well as for decisions concerning the removal of the chairman of the board of directors, the chief executive and the deputy chief executive.

Furthermore, half of the directors in post may oppose a meeting of the board being held via video-conference or telecommunication. Such opposition must be notified in the forms and by the deadline required by the Bylaws and/or in those that may be laid down in the legal or regulatory provisions.

IV. Representation

Any director may give another director written authority to represent him at a meeting of the board.

Each director may hold only one proxy for the same meeting given by application of the above paragraph.

These provisions are applicable to the permanent representative of a director who is a legal entity.

V. Minutes of deliberations

The deliberations of the board of directors are recorded in minutes drawn up in a special register, numbered and initialed, and kept at the head office in accordance with the regulatory provisions.

VI. Observers

Throughout the lifetime of the Company, the ordinary general meeting may proceed with the appointment of observers who may or may not be shareholders.

The number of observers may not exceed three (3).

Observers are appointed for a term of one (1) year. Their terms of office conclude at the end of the ordinary general meeting of shareholders called to approve the financial statements for the period just closed, and held in the year during which their terms of office cease.

Any outgoing observer may be re-elected subject to meeting the conditions of this Article.

Observers may be removed and replaced at any time by the ordinary general meeting without any compensation being due to them. The functions of the observers also cease upon the death or incapacity of an observer who is a natural person, or in the event of winding up or receivership in the case of an observer who is a legal entity.

Observers may be natural persons or legal entities. In the latter case, at the time of appointment, the legal entity is required to designate a permanent representative who will be subject to the same conditions and obligations and with the same civil and criminal liabilities as if they were an observer in their own right, without prejudice to the joint and several liability of the legal entity that they represent.

The duty of the observers is to ensure the strict application of the Articles of Association and to present their observations at the meetings of the board of directors.

The observers perform a general and permanent duty within the Company through advice and monitoring. In the context of their duties they may make observations to the board of directors and request access to information at...
the head office of the Company.

Observers must be invited to each meeting of the board of directors in the same way as directors.

Observers have only consultative powers on an individual or joint basis and have no voting rights on the board.

Failure to invite an observer or to send documents to an observer or observers prior to the meeting of the board of directors may in no case constitute grounds for nullity of the deliberations of the board of directors.

ARTICLE 18 - POWERS OF THE BOARD OF DIRECTORS

The board of directors sets the business policy of the Company and ensures that this is implemented.

Save for the powers expressly reserved to the meetings of shareholders and within the scope of the corporate purpose, the board of directors considers any matter relating to the proper operation of the Company and through its deliberations, deals with matters affecting it.

In its relations with third parties, the Company assumes an obligation, even for acts of the board of directors that do not fall within the scope of the corporate purpose, unless it can prove that the third party was aware that the act exceeded that scope, or, under the circumstances, must have been aware, although the simple publication of the Articles of Association will not suffice as proof.

The board of directors will proceed with the controls and verification that it deems appropriate.

Each director must receive the information necessary to perform his duties and may obtain from the general management all documents he considers useful.

The board of directors may decide to set up working groups to look into matters that the board or its chairman may refer to them.

ARTICLE 19 - GENERAL MANAGEMENT – DELEGATION OF POWERS

I. Organizational principles

In accordance with the legal provisions, the general management of the Company is undertaken, on behalf of the Company, either by the chairman of the board of directors or by another natural person appointed by the board of directors and bearing the title of chief executive.

The choice between the two methods of exercising general management is made by the board of directors, which must inform the shareholders and third parties subject to the regulatory requirements.

The decision of the board concerning the choice of the method of exercising general management is taken by a majority vote of the directors present or represented, subject to the specific provisions of Article 17-III where directors attend the meeting by video-conference or other means of telecommunication.

A change in the method for undertaking general management does not result in a change to the Articles of Association.

Where general management of the Company is undertaken by the chairman of the board of directors, the following provisions relating to the chief executive are applicable to him.

II. General management

Chief executive

Depending on the choice made by the board of directors in accordance with the provisions of the above paragraph, the general management of the Company is exercised by the chairman of the board of directors, or by a natural person, who may or may not be a director, who is appointed by the board of directors and bears the title of chief executive. Where the board of directors chooses to separate the functions of chairman and chief executive, it will proceed to appoint the chief executive, define his term of office, determine his remuneration and, as necessary, the limits to his powers.

A person over the age of eighty-five (85) years may not be appointed as chief executive. If a chief executive in post passes this age he is deemed to have officially resigned.

The chief executive may be removed from office at any time by the board of directors. Where the chief executive does not perform the role of chairman of the board of directors, his removal may be subject to payment of compensation if this takes place without good cause.

The chief executive is invested with the widest powers to act in all circumstances on behalf of the Company. He exercises these powers within the scope of the corporate purpose, save for those which the law expressly reserves to the meetings of shareholders and to the board of directors.

He represents the Company in its relations with third parties. The Company assumes an obligation, even for acts of the chief executive that do not fall within the scope of the corporate purpose, unless it can prove that the third party was aware that the act exceeded that scope, or, under the circumstances, must have been aware, although the simple publication of the Articles of Association will not suffice as proof.

In respect of the shareholders and without this restriction
being binding upon third parties, the chief executive may not take any decision on behalf of the Company in the following areas without the prior authorization of the board of directors:

- the securing of loans or advances in order to acquire shares or securities of any subsidiary company except where such subsidiary is wholly-owned;
- the furnishing of guarantees on behalf of a subsidiary or to guarantee bank accounts;
- all investments in excess of €250,000;
- all commitments in excess of €100,000 and not provided for in the annual budget;
- hiring, laying off and amending the contracts of employment of employees at management level;
- a change in the normal business of the Company and in its development strategy;
- the disposal, transfer, licensing or pledging of any industrial or intellectual property or of any substantial asset;
- approval of the budget and the strategic plan.

The chief executive may not, without a prior decision of the board of directors by a qualified majority of three quarters of the directors making up the board as at the date that the decision is taken:

- take any decision to proceed with the transfer of any substantial asset or any intellectual/industrial property belonging to the Company;
- take any decision to acquire a holding in a listed or unlisted company.

Deputy chief executives

At the proposal of the chief executive that this function be assumed by the chairman of the board of directors or by another person, the board of directors may appoint one or more actual persons, known as deputy chief executives, who may or may not be chosen from among the directors and shareholders, who are charged with assisting the chief executive. The number of deputy chief executives may not exceed five. If the deputy chief executive is a director, his term of office may not exceed that of his term of office as a director.

A person over the age of eighty-five (85) years may not be appointed as deputy chief executive. If a deputy chief executive in post passes this age he is deemed to have officially resigned.

Deputy chief executives may be removed at any time by the board of directors at the proposal of the chief executive. Removal without just cause may give rise to damages. By agreement with the chief executive, the board of directors decides on the scope and the duration of the powers granted to the deputy chief executives. The deputy chief executives have the same powers in respect of third parties as the chief executive.

Where the chief executive ceases or is prevented from performing his duties, the deputy chief executives will retain their functions and powers until the new chief executive is appointed, unless otherwise decided by the board.

The board of directors decides on the remuneration of the deputy chief executives.

III. Delegation of powers

The board of directors may entrust to its agents, who may or may not be directors, the permanent or temporary duties it decides upon, delegate powers to them and set the remuneration it considers appropriate.

ARTICLE 20 - DIRECTORS’ REMUNERATION

The general meeting may allocate to the directors, to compensate them for their work, by way of directors’ fees, a fixed annual sum defined by the meeting, without being bound by previous decisions. The amount is posted to the operating expenses.

The board of directors freely distributes among its members the total amounts allocated to the directors as directors’ fees; it may in particular allocate a higher share to those directors who are members of working groups than that allocated to the other directors.

The board of directors may award exceptional remuneration for the duties or mandates entrusted to directors.

The board of directors may authorize the reimbursement of travel and subsistence costs and expenses incurred by the directors in the interests of the Company.

ARTICLE 21 - AGREEMENTS BETWEEN THE COMPANY AND A DIRECTOR, THE CHIEF EXECUTIVE OR A DEPUTY CHIEF EXECUTIVE

I. Agreements subject to authorization.

Except for those relating to day to day operations and entered into under normal conditions, any agreement that is made, directly or through a nominee, between the Company and one of its directors, chief executives or deputy chief executives, or a shareholder holding more than 10% of the voting rights in the Company, or in the case of a shareholding company, the Company controlling it pursuant to Article L.233-3 of the French Commercial Code, must be referred for prior authorization by the board of directors.

The same applies to agreements in which one of the persons referred to in the above paragraph has an indirect interest.

Agreements entered into by the Company and an
enterprise are also subject to prior authorization if they are with an enterprise where the chief executive, one of the deputy chief executives or one of the directors of the Company, is the owner, partner with unlimited liability, manager, director, member of the supervisory committee or, generally speaking, an executive of the enterprise.

Such agreements must be authorized and approved in accordance with the statutory provisions.

II. Prohibited agreements

It is prohibited, on pain of nullity of the contract, for directors other than those who are legal entities, to contract for loans of whatever kind with the Company, to have an overdraft granted by it, on a current or other account, or to have it act as guarantor or stand surety for undertakings by them to third parties.

The same prohibition applies to the chief executive, deputy chief executives and permanent representatives of directors in the form of legal entities. It also applies to the spouses, ascendants and descendants of the persons mentioned in this article and to any nominee.

III. Current agreements

Agreements relating to current and ordinary transactions and agreements concluded between two companies, one of which holds, directly or indirectly, the whole capital of the other, if any, less the minimum number of shares required to satisfy the requirements of Article 1832 of the Civil Code or Articles L. 225-1 and L. 226-1 of the Commercial Code are not subject to the legal authorization and approval procedure. However, these agreements, unless as a result of their subject-matter or their financial implications they are not significant for any of the parties, must be notified by the interested party to the chairman of the board of directors. A list and subject-matter of such agreements are notified by the chairman to the members of the board of directors and to the auditors at the latest on the day of the meeting of the board to approve the financial statements for the year ended.

Shareholders may also be sent the list and subject-matter of these agreements.

5.4.3 RIGHTS, PRIVILEGES AND RESTRICTIONS ATTACHING TO SHARES (ARTICLES 9 - 14 OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION)

ARTICLE 9 - DEPRECIATION OF THE SHARE CAPITAL

The share capital may be depreciated in accordance with the provisions of Articles L.225-198 et seq. of the French Commercial Code.

ARTICLE 10 - SETTLEMENT OF SHARES

At the time of any increase in capital, cash shares are settled, upon subscription, for at least a quarter of their face value and, as appropriate, the full issue premium.

Settlement of the balance must take place on one or more occasions at the call of the board of directors and within five years of the date when the transaction becomes definitive in the case of an increase in capital.

Calls for funds are notified to the subscribers and shareholders at least fifteen days prior to the date set for payment by individual recorded delivery letter with acknowledgment of receipt.

A shareholder who does not make the required payments for shares on the due dates will be liable to pay the Company, automatically and without prior warning, delay interest calculated on a daily basis from the due date at the legal rate for commercial court matters plus three points. In order to obtain payment of these sums the Company is entitled to take the enforcement action and apply the sanctions provided for by Articles L.228-27 et seq. of the French Commercial Code.

ARTICLE 11 - FORM OF SHARES

The ordinary shares are in registered or bearer form at the option of the holders. They can take the bearer form only after their complete release. Preferred fully paid-up shares are nominative.

The Company is authorized to identify holders of bearer shares by simple request, to the body in charge of the clearing of securities, of the name or company name, nationality, year of birth or establishment, shareholders’ addresses or number of shares held by each of them.

ARTICLE 12 - TRANSFER OF SHARES - RIGHTS AND OBLIGATIONS ASSOCIATED WITH SHARES - EXCEEDING OF LIMITS

12.1 - Transfer of shares

The ordinary shares may be freely traded once issued in accordance with the procedures set out by law.

They remain negotiable following the winding up of the Company and until liquidation is complete. Preferred shares are transferable in accordance with paragraph 12.2.

The ordinary shares and the preferred shares give rise to a book entry and are transferred by a movement between
The provisions of this Article are generally applicable to all securities issued by the Company.

II. Rights attached to ordinary shares

Without prejudice to the rights attached to the preferred shares, each ordinary share entitles the holder to a share in the profits and in the share capital in proportion to the portion of the capital it represents. It gives the right to participate, in the conditions set by the law and the present articles of association, at general meetings and vote on resolutions.

The ownership of an ordinary share automatically entails unreserved compliance with the articles of association and decisions of the general meeting of the Company.

The rights and obligations attached to the ordinary shares follow the title regardless of the holder.

Whenever it is necessary to own more than one share to exercise any right, in case of exchange, consolidation, allocation of shares, capital increase or reduction, merger or any other owners of individual securities or less than the required number can exercise these rights only if they do their personal business of grouping and possibly purchasing or saling the necessary number of securities.

II. Rights attached to preferential shares

Preferential shares and the rights of their holders are governed by the applicable provisions of the French Commercial Code, in particular Articles L. 228-11 et seq.

The maximum number of preferential shares that can be issued is:

- 7,600 for the 2017 preferential shares, and
- 13,980 for the 2018 preferential shares.

The preferential shares are classified into six distinct categories according to the performance criteria attached to them:

- «AGAP 2018-01» for a maximum of 320,
- «AGAP 2017-02» for a maximum of 2,000,
- «AGAP 2017-03» for a maximum of 5,280,
- «AGAP 2018-02» for a maximum of 11,500, and
- «AGAP 2018-03» for a maximum of 1,900.

From the time of their definitive grant and until they become convertible, the preferential shares have the right to vote at the ordinary and extraordinary meetings of ordinary shareholders, with one voting right per preferential share. From the date on which they become convertible, the number of voting rights to which each preferential share entitles becomes equal to the number of ordinary shares to which the conversion of each preferential share gives entitlement.

Preferential shares shall have the right to vote at a special meeting of the holders of each class of preferential shares. The holders of each class of preferential shares shall meet in a special meeting for any proposed amendment to the rights attached to such class of preferential shares. In addition, in accordance with the provisions of Article L. 228-17 of the French Commercial Code, any proposed merger or demerger of the Company will be subject to the approval of any special meeting concerned, could not be exchanged for shares with specific equivalent rights.

Special meetings shall only validly deliberate if the shareholders present or represented possess at least, on the first convocation, one third of the preferential shares and, on the second convocation, one fifth of the preferential shares with the right to vote. In the event of a change or amortization of the share capital, the rights of the holders of preferential shares are adjusted in such a way as to preserve their rights pursuant to Article L. 228-99 of the French Commercial Code. Other rights attached to preferential shares are set out in the following paragraph.

From the time of their definitive allocation and until they become convertible, the preferential shares benefit from a dividend and give right to the reserves. The amount of the dividend (and, where applicable, the reserves) to which each preferential share entitles is equal to the amount due in respect of one ordinary share multiplied by the number of ordinary shares to which the conversion of each preferential share gives right. For this purpose, the preferential shares shall bear dividends from the first day of the financial year preceding the year in which they are finally allocated. From the date on which they become convertible, the amount of the dividend (and, where applicable, the reserves) to which each preferential share entitles becomes equal to the amount due in respect of one ordinary share multiplied by the number of ordinary shares to which the conversion of each preferential share is entitled.

In the event of the liquidation of the Company, preferential shares enjoy the same right to the liquidation bonus as the ordinary shares, i.e., a right proportional to the share that their nominal amount represents in the share capital.

Preferential shares are entitled to preferential subscription...
rights for any capital increase or any transaction with rights to the ordinary shares.

In the case of capital depreciation or reduction, changes in the distribution of profits, the allocation of free shares, capitalization of reserves, profits or issue premiums, distribution of reserves or any equity securities or securities giving the right to the allocation of capital securities with a subscription right reserved for shareholders before the preferential shares are convertible under the conditions set out in paragraph III. the maximum number of ordinary shares to which the preferential shares may be entitled by conversion shall be adjusted to take account of such transaction in accordance with the provisions of Article L. 228-99 paragraph 2, 3 ° and paragraph 5 of the Commercial Code.

For the purposes of this adjustment, the board of directors will calculate, at the time of fixing the final number of ordinary shares to which each preferential share entitles, the conversion ratio applicable according to the degree to which the performance criteria are met, such as this is provided for in paragraph III. below, and adjust this ratio for all transactions previously completed, in accordance with the above provisions.

Each beneficiary will be informed of the practical details of this adjustment and of its consequences on the allocation of ordinary shares on conversion of the preferential shares he / she has benefited from.

After the preferential shares have become convertible and the board of directors has calculated the conversion ratio as provided for in paragraph III. 5. below (as adjusted in accordance with this Article, if any), no adjustment shall be made to this conversion ratio, as the holders of preferential shares may thereafter convert them freely.

The preferential shares will be fully paid up when they are issued by capitalizing the Company’s reserves, premiums or profits.

**III. Conversion of preferential shares into ordinary shares**

The issue of preferential shares may only be decided in the context of a free allocation of shares to employees and corporate officers of the Company in accordance with the provisions of Articles L. 225-197-1 et seq. Of the French Commercial Code.

The preferential shares will be definitively vested (the « Final Award ») by the beneficiaries at the end of a vesting period of one (1) year from their allocation by the board of directors (the « Provisional Allocation »).

However, if the beneficiary is invalid for classification in the second or third of the categories provided for in Article L. 341-4 of the Social Security Code (or their equivalent in applicable foreign law), the preferential shares will be allocated definitively before the end of the remaining vesting period. In the event of the beneficiary’s death, in accordance with the provisions of Article L. 225-197-3 of the Commercial Code, the beneficiary’s heirs or beneficiaries may, if they wish, apply for the definitive allocation of the preferential shares within six months of the date of death. In the event of retirement, the beneficiaries will retain their right to the definitive allocation of preferential shares even though they are no longer bound by a contract of employment.

Holders of preferential shares may request conversion of their preferential shares into new or existing ordinary shares (at the Company’s option) of the Company as follows:

1. Preferential shares become convertible by their holder into new or existing ordinary shares (at the option of the Company) at the end of a two year retention period beginning on the date of the Final Assignment (the « Lock-Up Period ») under the conditions set out in paragraphs 2 to 9 below. From the date they become convertible (the « Convertibility Date »), preferential shares may be converted for five (5) years and three (3) months (the « Conversion Period »).

2. In accordance with the provisions of Article L. 225-197-11, paragraph 7 of the Commercial Code, preferential shares will be freely transferable during the Lock-Up Period if the beneficiary becomes disabled in accordance with his classification in the second or third of the categories provided for in Article L. 341-4 of the Social Security Code (or their equivalent in applicable foreign law), regardless of whether the disability occurs before or after the Final Award Date.

In the event of the beneficiary’s death, whether the beneficiary dies during the vesting period or the Lock-Up Period, his / her heirs will no longer be required to comply with this non-assignment commitment, so that the preferential shares they have applied for the definitive allocation shall become freely transferable.

3. 2017 preferential shares are classified into three distinct classes according to the performance criteria attached to them: « AGAP 2017-01 » , « AGAP 2017-02 » and « AGAP 2017-03 ». The number of ordinary shares to which the conversion of a 2017 preferential share will give entitlement will depend on whether one or more (or all) of the 2017 Performance Criteria have been met on the Convertibility Date (the « Performance »).

For the « AGAP 2017-01 » 2017 preferential shares, the 2017 Performance Criterion will be the definition of the Company’s industrial development plan, which will give the right to convert each preferential share into 100 ordinary shares.

For the « AGAP 2017-02 » 2017 preferential shares, the
2017 Performance Criterion will be the successful implementation of the bioprosthesis evaluated on a total of 10 patients worldwide, which will give the right to convert each preferential share into 20 ordinary shares.

For the « AGAP 2017-03 » 2017 preferential shares, the 2017 Performance Criteria will be as follows:

- the filing of the clinical module of the CE marking of the bioprosthesis, which will give the right to convert each preferential share into 15 ordinary shares;
- the CE marking of the bioprosthesis, which will give the right to convert each preferential share into 20 ordinary shares;
- obtaining additional financing for the Company for a cumulative amount of €100 million between the Provisional Allocation Date and the Convertibility Date which will give the right to convert each preferential share into 25 ordinary shares being that such financing may take the form of, in particular, capital increases, debt instruments, conditional advances, operating subsidies or revenues received from collaborative arrangements or licence;
- the establishment of a production process that (i) meets the applicable regulatory and quality standards, and (ii) enables the bioprosthesis to be produced in sufficient number and time to carry out the necessary clinical trials and to respond to commercial orders in the contractual deadlines, without any major interruption of production or quality problems leading to a recall of products sold, which will give the right to convert each preferential share into 15 ordinary shares;
- the effective commercialization of the bioprosthesis at 15 European centers, which will give the right to convert each preferential share into 10 ordinary shares;
- the successful implementation of the bioprosthesis evaluated on 10 patients in the United States, which will give the right to convert each preferential share into 10 ordinary shares;
- the successful implementation of the bioprosthesis evaluated on 100 patients worldwide, which will give the right to convert each preferential share into 10 ordinary shares;
- the change in the price of the common share according to the following criteria, which will give the right to convert each preferential share into a maximum of 10 ordinary shares.

(a) If the Final Price is strictly lower than the Initial Price, the number of ordinary shares in which each preferential share will be converted will be equal to 0;

(b) If the Final Price is comprised between (i) a value equal to or greater than the Initial Price and (ii) a value below the Ceiling Price, the number of ordinary shares in which each preferential share will be converted will be equal to:

\[ ((\text{Final Price} / \text{Initial Price}) - 1) \times 10 \]

(c) If the Final Price is equal to or greater than the Ceiling Price, the number of ordinary shares in which each preferential share will be converted will be equal to 10.

The « Final Price » is the highest average of the closing prices of the ordinary shares of the stock exchange sessions taken over a period of sixty consecutive days, calculated at any time during the three (3) years preceding the Convertibility Date.

The « Ceiling Price » is equal to the Initial Price multiplied by three, with a maximum of €114.

The « Initial Price » is equal to the closing price of the ordinary share on the date of the Provisional Allocation, with a minimum of €30 and a maximum of €38 per ordinary share.

It is specified that the conversion ratio thus determined for each category of 2017 preferential shares will be adjusted to take account of the shares to be issued in order to preserve the rights of holders of securities giving access to the capital of the Company and holders of 2017 preferential shares in accordance with the applicable legal and regulatory provisions and paragraph II above.

4. 2018 preferential shares are classified into three distinct classes according to the performance criteria attached to them: « AGAP 2018-01 », « AGAP 2018-02 » and « AGAP 2018-03 ». The number of ordinary shares to which the conversion of a 2018 preferential share will give entitlement will depend on whether one or more (or all) of the 2018 Performance Criteria have been met on the Convertibility Date (the « Performance »).

For the « AGAP 2018-01 » 2018 preferential shares, the 2018 Performance Criterion will be the successful completion of the «prosthesis» test benches used to obtain CE marking, which will give the right to convert each AGAP 2018-01 into 100 ordinary shares.

For the « AGAP 2018-02 » 2018 preferential shares, the 2018 Performance Criterion will be as follows:

- i. the recruitment of 10 patients in the pivotal study to obtain the CE mark, which will give the right to convert each AGAP 2018-2 into 10 ordinary shares;
- ii. the recruitment of the 20th patient in the pivotal study to obtain CE marking or the finalization of the pivotal study for submission of the dossier to DEKRA, which will give the right to convert each AGAP 2018-2 into 5 ordinary shares;
- iii. obtaining authorization to complete the Early Feasibility Study in the US by December 31, 2018, which will entitle the holder to convert each AGAP 2018-2 into 5 ordinary shares.
For the « AGAP 2018-03 » 2018 preferential shares, the 2018 Performance Criteria will be as follows:

- the filing of the clinical module of the CE marking of the bioprosthesis, which will give the right to convert each preferential share into 15 ordinary shares;
- the CE marking of the bioprosthesis, which will give the right to convert each preferential share into 20 ordinary shares;
- obtaining additional financing for the Company for a cumulative amount of € 38.5 million between the Provisional Allocation Date and the Convertibility Date which will give the right to convert each preferential share into 25 ordinary shares being that such financing may take the form of, in particular, capital increases, debt instruments, conditional advances, operating subsidies or revenues received from collaborative arrangements or licence;
- the establishment of a production process that (i) meets the applicable regulatory and quality standards, and (ii) enables the bioprosthesis to be produced in sufficient number and time to carry out the necessary clinical trials and to respond to commercial orders in the contractual deadlines, without any major interruption of production or quality problems leading to a recall of products sold, which will give the right to convert each preferential share into 15 ordinary shares;
- the effective commercialization of the bioprosthesis at 15 European centers, which will give the right to convert each preferential share into 10 ordinary shares;
- the successful implementation of the bioprosthesis evaluated on 10 patients in the United States, which will give the right to convert each preferential share into 10 ordinary shares;
- the successful implementation of the bioprosthesis evaluated on 100 patients worldwide, which will give the right to convert each preferential share into 10 ordinary shares;
- the change in the price of the common share according to the following criteria, which will give the right to convert each preferential share into a maximum of 10 ordinary shares.

(a) If the Final Price is strictly lower than the Initial Price, the number of ordinary shares in which each preferential share will be converted will be equal to 0;

(b) If the Final Price is comprised between (i) a value equal to or greater than the Initial Price and (ii) a value below the Ceiling Price, the number of ordinary shares in which each preferential share will be converted will be equal to:

\[ \left( \frac{\text{Final Price}}{\text{Initial Price}} - 1 \right) \times 10 \]

(c) If the Final Price is equal to or greater than the Ceiling Price, the number of ordinary shares in which each preferential share will be converted will be equal to 10.

The « Final Price » is the highest average of the closing prices of the ordinary shares of the stock exchange sessions taken over a period of sixty consecutive days, calculated at any time during the three (3) years preceding the Convertibility Date.

The « Ceiling Price » is equal to the Initial Price multiplied by three, with a maximum of €114.

The « Initial Price » is equal to the closing price of the ordinary share on the date of the Provisional Allocation, with a minimum of €30 and a maximum of €38 per ordinary share.

It is specified that the conversion ratio thus determined for each category of 2018 preferential shares will be adjusted to take account of the shares to be issued in order to preserve the rights of holders of securities giving access to the capital of the Company and holders of 2018 preferential shares in accordance with the applicable legal and regulatory provisions and paragraph II above.

5. The performance of each Performance Criterion shall be determined at a meeting of the board of directors held as soon as possible after completion of the Performance Criterion, which shall determine the number of ordinary shares to which each preferential share will be entitled to this date. As soon as possible after the Convertibility Date, the board of directors will meet to determine the final number of ordinary shares to which each preferential share will be entitled, with the conversion ratio of AGAP 2017-03 and of AGAP 2018-03 may under no circumstances exceed 100, regardless of the number of Performance Criteria performed.

However, in the event of a takeover bid or exchange on the ordinary shares:

- happening as of the Provisional Allocation Date,
- whose definitive results are announced no later than the day before the Convertibility Date, and
- made at a price per share between the Initial Price and a ceiling equal to three times the Initial Price,

the board of directors will determine the number of ordinary shares to which the preferential shares will be entitled on the date of announcement of the final results of the offer exclusively under the following conditions:

- For each beneficiary, a number « p » equal to the ratio (i) of the cumulative number of ordinary shares to which all the preferential shares (all categories) which have been allocated entitle the beneficiary to be entitled according to the realization of the Performance Criteria on the date of the announcement of the final results of the Offer, on (ii) the aggregate number of ordinary shares to which all preferential shares (all classes) all Performance Criteria are met.
- If « p » is less than or equal to 0.35, the « N » number of ordinary shares to which each of the preferential shares
INFORMATION ON THE COMPANY AND ITS CAPITAL

(whichever class) has been allocated will be calculated using the following formula:

\[
N = [0.35 + 0.65 \times (R-1) / 2] \times n
\]

N being capped at 100 for AGAP 2017-01, 20 for AGAP 2017-02, 100 for AGAP 2017-03, 100 for AGAP 2018-01, 20 for AGAP 2018-02 and 100 for AGAP 2018-03.

\[n\] being equal to 100 for AGAP 2017-01, 20 for AGAP 2017-02, 100 for AGAP 2017-03, 100 for AGAP 2018-01, 20 for AGAP 2018-02 and 100 for AGAP 2018-03.

with

\[R = \frac{\text{Acquisition Price}}{\text{Initial Price}}\]

The « Acquisition Price » is equal to the closing price of the common share on the last day of the offering period, with a maximum of €114 per ordinary share.

The « Initial Price » is equal to the closing price of the ordinary share on the day of the allotment of preferential shares, with a minimum of €30 and a maximum of €38 per ordinary share.

- If « \( p \) » is greater than 0.35, \( N \) will be calculated according to the following formula:

\[
N = [p + (1-p) \times (R-1) / 2] \times n
\]

knowing that, in any case, \( N \) can not be less than \( n \times 0.35 \), that is to say 35 for AGAP 2014-01, 7 for AGAP 2017-02, 35 for AGAP 2017-03, 35 for AGAP 2018-01, 7 for AGAP 2018-02 and 35 for AGAP 2018-03.

The preferential shares concerned will be definitively allocated to the beneficiaries on the Final Award Date, irrespective of whether or not a new attendance condition is provided for in the terms of the Preferential Share Plan and of the Performance Criteria above. In any case, preferential shares will become convertible only on the Convertibility Date.

6. If on the Convertibility Date none of the Performance Criteria is satisfied or if no takeover bid has been made under the conditions described above, the Company may (but without being an obligation for the Company) to redeem the preferential shares at any time at nominal value.

Similarly, preferential shares which may be converted but which have not been converted at the end of the Convertibility Period, may (without this being in no case an obligation for the Company) be bought at any time by the Company at their nominal value.

7. At the end of the Convertibility Period, the Company may, in accordance with the applicable legal and regulatory provisions, cancel preferential shares not yet converted, including those which it has bought back. The share capital will then be comparatively reduced, creditors having a right of opposition under the conditions provided for in Article L. 225-205 of the Commercial Code.

8. The new ordinary shares resulting from the conversion of the preferential shares shall be assimilated to the ordinary shares in circulation and shall bear dividend from the first day of the financial year preceding that in which the preferential shares are converted and will confer on their holders, upon delivery, all rights attached to the ordinary shares. They will be the subject of a request for admission to trading on the Alternext Paris market on the same trading line as the ordinary shares.

9. The board of directors will recognize the conversion of the preferential shares into ordinary shares for which the conversion is in accordance with the conditions set out above, take note of the number of ordinary shares resulting from the conversions of preferential shares and amendments to the articles of association, in particular as regards the allocation of shares by category. This option may be delegated to the Director General under the conditions laid down by law.

10. Shareholders will be informed of the conversions made by the reports of the board of directors and the statutory auditors provided for in Article R. 228-18 of the French Commercial Code. These additional reports will be made available to the shareholders at the registered office as from the date of the convening of each meeting.

11. Capital increases resulting from the creation of preferential shares and new ordinary shares will be carried out by special incorporation of all or part of available reserve accounts and, in particular, into the share premium account.

12.3 – Exceeding of limits

Any natural person or legal entity acting alone or together with others who comes to possess a number of shares representing a percentage of the capital or the voting rights in excess of the limits set by law, will inform the Company within the statutory period, counting from when the holding limit is reached, of the total number of shares or voting rights held.

This information is also provided within the same time frames when the holding of share capital or voting rights drops below the limits mentioned in this paragraph.

A person required to provide this information will state the number of securities held giving access to capital and the voting rights attaching to these.

If required by the rules of a securities market other than a regulated market on which the securities of the Company
are admitted for trading, this person will also inform the Financial Markets Authority within a time frame and according to the arrangements set by the General Regulations of the latter, with effect from when the limit to the holding is passed. If necessary, this information is made public under the conditions laid down by the General Regulations of the Financial Markets Authority.

Failure to make a due declaration under the above conditions will result in the shares exceeding the fraction that should have been declared by law having their voting right removed for any meeting of shareholders held within a period expiring two years after the date that the notification is dealt with.

Similarly, voting rights attaching to these shares and which are not duly declared may not be exercised or delegated by the defaulting shareholder.

The commercial court having jurisdiction for the registered office, at the request of the chairman of the Company, a shareholder or the Financial Markets Authority, holds sole jurisdiction to pronounce a total or partial suspension, for a period not to exceed five years, of the voting rights of any shareholder who has not made the required declarations.

ARTICLE 13 - INDIVISIBILITY OF SHARES - BARE OWNERSHIP - USUFRUCT

1. Shares are indivisible with respect to the Company.

Co-owners of undivided shares are represented at general meetings by one of these or by a single proxy. In the event of disagreement, the proxy is appointed by a court at the application of the most diligent co-owner.

2. The voting right belongs to the usufructuary at Ordinary General Meetings and to the bare owner at Extraordinary General Meetings. However, shareholders may agree any other distribution of the voting right at General Meetings. The agreement is notified by registered letter to the Company, which will be required to apply this agreement at any meeting that takes place following expiry of a period of one month after such letter is sent.

The voting right is exercised by the owner where securities are pledged.

ARTICLE 14 - DOUBLE VOTING RIGHT

The voting right attaching to capital or dividend shares is proportional to the percentage of the capital that they represent. Each share gives an entitlement to one vote.

However, a voting right that is double that conferred on other shares, having regard to the percentage of the capital that they represent, is attributed to all shares that are fully paid up, and which can be shown to have been registered to the same shareholder for at least two (2) years. This right is exercised subject to the provisions of No. 12.3 (5) of the Articles of Association.

This double voting right is also conferred from the time they are issued, in the event of an increase in capital through capitalization of reserves, profits or issue premiums, upon registered shares in a scrip issue to a shareholder based on previous shares providing such an entitlement.

The transfer of a share as a result of succession, liquidation of community of property between spouses or donation between living persons to a spouse or a parent entitled to inherit, does not result in loss of the right acquired and does not interrupt the periods provided for above.

5.4.4 CONDITIONS FOR CHANGING SHAREHOLDERS’ RIGHTS

The Articles of Association of the Company do not make any special provision that derogates from general company law.

5.4.5 GENERAL MEETINGS OF SHAREHOLDERS (ARTICLES 24 - 31 OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION)

ARTICLE 24 - QUORUM AND MAJORITY

General meetings deliberate under the conditions set by law.

The ordinary general meeting takes all decisions other than those reserved to the extraordinary general meeting by law and by these Articles of Association. It may not validly deliberate at the first calling unless the shareholders present or represented hold at least one fifth of shares with voting rights. At the second calling no quorum is required. It acts by a majority of the votes cast by the shareholders present or represented.

The extraordinary general meeting alone has the power to modify any of the provisions of the Articles of Association. It may not validly deliberate unless the shareholders present or represented hold at least one quarter of shares with voting rights at the first calling and one fifth of the
shares at the second calling. In the absence of the latter quorum, the second meeting may be postponed to a later date not more than two months after that when it was originally called. It acts by a two-thirds majority of the votes cast by the shareholders who are present or represented.

Where videoconferencing or other means of telecommunication permitted by law is used under the conditions set out in Article 25 below, shareholders are deemed present for the purposes of calculating a quorum or majority where they take part by such videoconferencing or other means of telecommunications.

**ARTICLE 25 - CALLING OF GENERAL MEETINGS**

General meetings are called either by the board of directors, or by the auditors, or by a proxy appointed by a court under the conditions and arrangements laid down by law.

They take place at the head office or at any other location specified in the notice of the meeting.

Where shares in the Company are not traded on a regulated market or if all its shares are not registered shares, the Company is required to publish in the Bulletin des Annonces Légales Obligatoires (BALO - French Mandatory Legal Announcements Bulletin), at least thirty-five (35) days before the meeting, a notice of such meeting containing the information required by the current regulations in force.

General meetings are called by publication in a journal authorized to carry legal notices in the department where the head office is based and also in the Bulletin des Annonces Légales et Obligatoires (BALO).

However, the publications referred to in the above paragraph may be replaced by a call made, at the cost of the Company, by normal or registered letter sent to each shareholder. Such a call may also be sent by electronic means of telecommunication employed under the regulatory conditions.

If this is decided by the board at the time the meeting is called, any shareholder may also take part and vote in meetings by video-conference or by any other means of telecommunication allowing them to be identified, under the following conditions and according to the arrangements provided for by law and decree.

Any meeting not duly called may be canceled. However, cancelation may not take place if all shareholders are present or represented.

**ARTICLE 26 - MEETING AGENDA**

The agenda is set by whoever issues the notice of the meeting.

However, one or more shareholders representing at least 5% of the capital (or an association of shareholders meeting the legal conditions) are empowered to request, under the conditions laid down by law, the inclusion in the agenda of draft resolutions. Such a request must be accompanied by the text of the draft resolutions which may be accompanied by a brief outline of the reasoning.

These draft resolutions, which must be brought to the attention of the shareholders, are included in the agenda and put to a vote of the meeting.

The meeting may not deliberate on a matter that is not included in the agenda.

However, it may under any circumstances remove one or more directors and proceed with their replacement.

The agenda may not be changed if the meeting has to be called a second time.

When the meeting is called upon to deliberate on changes to the economic or legal organization of the Company, in respect of which the works council has been consulted in accordance with Article L.2323-6 of the French Labor Code, the opinion of the council is made known to the meeting.

**ARTICLE 27 - ADMISSION TO MEETINGS**

Any shareholder may participate personally, by proxy, or by correspondence in general meetings, of whatever kind.

A legal right of participation in General Meetings exists:

- for registered shares, as a result of the entry of these in the books of registered shares kept by the Company at midnight at the start of the second working day prior to the meeting, Paris time;
- for bearer shares, as a result of the entry of these in the books of bearer shares kept by the authorized intermediary, at midnight at the start of the second working day prior to the meeting, Paris time.

The entry or registration of securities in the books of bearer shares kept by the authorized intermediary is acknowledged by a shareholding certificate issued by the latter.

However, the board of directors may reduce or remove these timings, provided that it is in the interests of shareholders.

Shareholders who have not settled their shares by making the payments due are not admitted to meetings.
ARTICLE 28 - REPRESENTATION OF SHAREHOLDERS AND POSTAL VOTING

I. Representation of shareholders

A shareholder may be represented by another shareholder or by their spouse.

Any shareholder may be empowered by other shareholders to represent them at a meeting, without any restriction other than those resulting from the legal provisions setting the maximum number of votes that the same person may hold in their own name and as a proxy.

II. Postal voting

Once the meeting has been called, a postal voting form and attachments will be sent, at the cost of the Company, to any shareholder who makes a written request for this.

The Company must comply with any request filed or received at the head office at the latest six days prior to the date of the meeting.

ARTICLE 29 - OFFICERS FOR THE MEETING

Shareholder meetings are chaired by the chairman of the board of directors or, in his absence, by a director delegated for this purpose by the board. Failing this, the meeting elects a chairman itself.

Where a meeting is called by the auditors, a court-appointed proxy or by the liquidators, the meeting is chaired by whichever of these has called it.

The two attendees at such meeting holding the largest number of shares and accepting this function will act as vote tellers.

The officers for the meeting will appoint a secretary, who need not be a shareholder.

ARTICLE 30 - MINUTES OF DELIBERATIONS

The deliberations of shareholder meetings are recorded in minutes drawn up by the meeting officers and signed by them.

These will state the date and place of the meeting, how it was called, the agenda, the composition of the group of meeting officials, the number of shares participating in the voting and the quorum achieved, the documents and reports submitted to the meeting, a summary of the proceedings, the text of the resolutions voted upon and the outcome of these votes.

The minutes are recorded in a special register kept at the head office under the conditions laid down in the regulations.

If, in the absence of a quorum, a meeting is unable to deliberate properly, minutes to that effect are drawn up by the officers of said meeting.

ARTICLE 31 – SHAREHOLDERS’ RIGHT OF INFORMATION AND CONTROL

Before each meeting, the board of directors must make available to shareholders the documents necessary to allow them to speak in full knowledge of the facts and to come to an informed judgment on the functioning of the Company.

Upon receipt of the communication referred to above, any shareholder will be entitled to submit written questions, to which the board of directors will be required to respond during the meeting.

At any time, any shareholder has an entitlement to receive the documents that the board of directors is required, as the case may be, to keep available at the head office, or to send them, in accordance with the legislative and regulatory provisions in force.

5.4.6 PROVISIONS OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION, A CHARTER OR BYLAWS OF THE COMPANY THAT MAY HAVE THE EFFECT OF DELAYING, DEFERING OR PREVENTING A CHANGE IN ITS CONTROL

The Articles of Association of the Company do not make any special provision that derogates from general company law.
5.4.7 CHANGES TO THE SHARE CAPITAL (ARTICLE 8 OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION)

1 - The capital stock may be increased by any process and under any arrangements provided for by law.

Only an extraordinary general meeting is competent to decide on an increase in capital based on a report from the board of directors.

Shareholders have a preferential right, in proportion to the number of shares they hold, to subscribe to cash shares issued in order to increase the capital, and may waive this on an individual basis. The extraordinary meeting may decide to withdraw this preferential right of subscription in accordance with the statutory provisions.

2 - A reduction in capital is authorized or decided upon by the Extraordinary General Meeting and may in no case adversely affect the equality of shareholders.

A reduction in capital to below the legal minimum may only be decided subject to the condition precedent of an increase in capital intended to bring this up to at least the legal minimum, unless the Company converts into another form of company that does not require capital in excess of the share capital after it has been reduced. Failing this, any interested party may seek a legal order to wind up the Company. This may not be issued if, on the day on which the court rules on the merits of the case, the situation has been regularized.

5.5 PARTICULARS OF THE LEGAL AFFAIRS OF THE COMPANY IN THE FINANCIAL PERIOD

5.5.1 PARTICULARS OF COMPANY REPRESENTATIVES AND AUDITORS

BONUS SHARES AND STOCK OPTIONS

As detailed in sections 4.5.1 and 5.2.1 of the registration document, the board of directors of the Company, making use of the delegations of authority approved at the general meeting of April 27, 2017, awarded free of charge on April 5, 2018:

- 580 AGAP 2018-01, including 80 AGAP 2018-01 to Marc Grimmé (R&D Director) and 500 AGAP 2018-01 to Stéphane Piat (Managing Director and Director), and

- 11,500 AGAP 2018-02, including 950 AGAP 2018-02 to Marc Grimmé (R&D Director), 950 AGAP 2018-02 to Dr. Piet Jansen (Medical Director), 7,500 AGAP 2018-02 to Stéphane Piat (Managing Director and Director), 350 AGAP 2018-02 to Eric Richez (Director of Development), 200 AGAP 2018-02 to Benoît de la Motte (former Administrative and Financial Director), 175 AGAP 2018-02 to Francesco Arecchi (Marketing Manager), 100 AGAP 2018-02 to Joëlle Monnier (former Quality Director) and 100 AGAP 2018-02 to Jean-Marc Parquet and Elizabeth Vacher.

On December 3, 2018, the Company granted Mr. Jean-Pierre Garnier a stock option program representing 46,000 stock options.

2018 preferential shares are subject to vesting and retention periods and performance criteria to enable their conversion to ordinary shares, as described in section 5.2.6 of the registration document.

September 27, 2018:

- 370 AGAP 2018-03 to Thierry Dupoux (Director of Quality Assurance).

SHARE TRANSACTIONS BY THE EXECUTIVES

We indicate below the transactions made by the directors and their relatives on the shares of the Company during the 2018 financial year, as declared by these officers and their relatives pursuant to the provisions of Articles 223-22 A and 223-26 of the AMF General Regulation.

Refer to the following page
5.5.2 INFORMATION ON THE COMPANY’S SECURITIES

EMPLOYEE SHAREHOLDING

In accordance with the provisions of Article L.225-102 of the French Commercial Code, we hereby indicate that the Company has not set up any company savings plan for the benefit of employees.

As at December 31, 2018, as far as the Company is aware, the employees held 7,025 CARMAT shares, i.e. 0.08% of the Company’s share capital.

DEALINGS BY THE COMPANY IN ITS OWN SHARES

We are also obliged to report to you on purchases and sales by the Company of its own shares for the purposes of regulating the price, in accordance with the provisions of Article L.225-209-1 of the French Commercial Code.

During the period ended December 31, 2018, the Company made the following dealings in its own shares under the liquidity agreement entered into for a period of one year with an independent financial services provider, as authorized by the general meetings of April 27, 2017 (Resolution 12) and of April 5, 2018 (Resolution 9):

- purchase of 128,774 shares at an average price of €23.01;
- sale of 128,517 shares at an average price of €23.02.

As at December 31, 2018, the Company held 2,463 treasury shares, i.e. 0.03% of the share capital, acquired at a total purchase price of €49,007.

These disposals of treasury shares performed under the liquidity agreement resulted in a capital gain of €1,634.

SECURITIES GIVING ACCESS TO CAPITAL

In total, these securities confer subscription rights to 1,246,750 new shares (13.44% of the existing capital as at December 31, 2018), which includes 86,550 shares at a unit price of €8, 34,000 shares at a unit price of €108.48, 6,700 shares at a unit price of €122, 12,000 shares at a unit price of €30.10, 10,000 shares at a unit price of €20.93 and 46,000 shares at a unit price of €20.35.

For details on the securities giving access to the Company’s capital and in force, see Paragraph 5.2.5 « Other securities giving access to capital ».

PARTICIPATING AND CONTROLLING INTERESTS

In accordance with the provisions of Articles L.233-6 and L.247-1 of the French Commercial Code, we can report that the Company has not acquired any participating or controlling interests during the reporting period.
5.6 REGULATED AGREEMENTS

5.6.1 REGULATED AGREEMENTS DESCRIPTION

ROYALTIES AGREEMENT

Under a royalties agreement signed on June 24, 2008 and amended by an addendum of February 5, 2010 between CARMAT, Professor Alain Carpentier and Matra Défense (a subsidiary of the Airbus Group) as a result of contributions made when the Company was established, it was agreed that CARMAT will pay Professor Alain Carpentier and Matra Défense a total sum equal to 2% of the direct net sales generated by the Total Artificial Heart in the countries covered by at least one of the patents initially contributed by them to the Company. These payments will be made on a half-yearly basis within thirty days of the end of each sixth-month period, according to a distribution between Professor Alain Carpentier and Matra Défense established in proportion to their holdings in the capital of the Company on the date it was established.

However, CARMAT may repurchase this right to royalties by paying Professor Alain Carpentier and Matra Défense, in proportion to their holdings in the capital of the Company on the date it was established, a total sum of €30 million less the amount of royalties already paid at the time this right to royalties is repurchased. This sum of €30 million is indexed-linked to the –Indice du Prix à la Production de l’Industrie et des Services aux Entreprises – Matériel médicochirurgical et d’orthopédie-exportation zone Euro – Code PVIC 3310921007M (Production prices index for industry and services to companies – Medico-surgical and orthopedic material for export in the Eurozone PVIC Code 3310921007M) with a base level of 100.3 in April 2008 as calculated and published by the French National Institute for Statistics and Economic Studies (INSEE).

5.6.2 SPECIAL REPORT OF THE STATUTORY AUDITORS ON THE REGULATED AGREEMENTS

CARMAT SA
36, Avenue de l’Europe
78941 Vélizy-Villacoublay cedex

To shareholders,

As auditors of your company, we present to you our report on regulated agreements.

It is our responsibility to communicate to you, on the basis of the information given to us, the characteristics and the essential terms and the reasons justifying the interest for the company of the agreements of which we have been informed or which we would have discovered at the time. Opportunity of our mission, without having to pronounce on their usefulness and their merits nor to seek the existence of other conventions. It is your responsibility, under the terms of Article R. 225-31 of the French Commercial Code, to assess the interest involved in concluding these agreements with a view to their approval.

RELATIONS BETWEEN CARMAT AND THE SCIENTIFIC RESEARCH ASSOCIATION OF THE ALAIN CARPENTIER FOUNDATION

Owing to the specific competencies sought and historical relations, the Company maintains commercial relations with the Scientific Research Association of the Alain Carpentier Foundation (ARSFAC) in the normal conduct of its business and ordinary financial conditions for the type of services performed.

It thus signed a collaboration agreement for medical research with ARSFAC on April 30, 2013 which was since renewed. Under the terms of this agreement, the Company committed to repay to ARSFAC all the costs mentioned in the appendices to said agreement. For 2018 fiscal year 2018, expenses of €66,364.42 excluding tax were recorded under this agreement.

RELATIONS BETWEEN CARMAT AND THE MARIE LANELONGUE SURGICAL CENTER (CCML)

Owing to the specific competencies sought, the Company maintains commercial relations with the Marie Lannelongue Surgical Center (CCML) in the normal conduct of its business and under ordinary financial conditions for the type of services performed.

It thus signed a collaboration agreement for medical research with CCML on June 12, 2014. Under the terms of this agreement, the Company undertook in particular to reimburse CCML for all the costs mentioned in the appendices to said agreement. For 2018, no expenses were recorded under this agreement.

As a reminder, Mr. Henri Lachmann, director of CARMAT, is chairman of the board of directors of CCML.
In addition, it is our responsibility, if applicable, to provide you with the information provided for in Article R. 225-31 of the French Commercial Code relating to the execution, during the past financial year, of agreements already approved by the general meeting.

We have performed the due diligence that we have deemed necessary in light of the professional standards of the National Company of Auditors relating to this engagement. These procedures consisted in verifying the concordance of the information given to us with the basic documents from which it came.

**AGREEMENTS SUBMITTED FOR THE APPROVAL OF THE GENERAL MEETING**

We inform you that we have not been given notice of any agreement authorized during the past financial year to be submitted for the approval of the general meeting in application of the provisions of Article L. 225-38 of the Code.

**AGREEMENTS ALREADY APPROVED BY THE GENERAL MEETING**

Agreements approved in previous years

a) with execution during the past financial year

Pursuant to Article R.225-30 of the French Commercial Code, we have been informed of the continuation of the following agreements, which have already been approved by the General Meeting in previous financial years, and which have been enforced during the past financial year.

**RESEARCH COLLABORATION AGREEMENT WITH THE SCIENTIFIC RESEARCH ASSOCIATION OF THE ALAIN CARPENTIER FOUNDATION (ARSFAC)**

A medical collaboration contract had been concluded with ARSFAC as of January 1, 2014, and included animal training trials. Under the terms of this agreement, your company undertakes to reimburse the costs incurred by ARSFAC as described in the appendix to the said contract.

Your company has recognized a charge of €66,364 under this agreement in 2018.

ARSFAC is represented by Alain Carpentier, director of your company.

b) without execution during the past financial year

Pursuant to Article R.225-30 of the French Commercial Code, we have been informed of the continuation of the following agreements, which have already been approved by the General Meeting in previous financial years, and which have not been enforced during the past financial year.

**ROYALTIES AGREEMENT BETWEEN CARMAT («COMPANY»), PROFESSOR ALAIN CARPENTIER AND MATRA DEFENSE**

On June 24, 2008, the Company signed a royalty agreement (hereinafter «the Agreement») with Professor Alain Carpentier and Matra Défense, the founding shareholders of the Company. Under this Contract, the Company undertakes to pay to Professor Alain Carpentier and Matra Défense 2% of the net sales proceeds of the CARMAT artificial heart manufactured and distributed by CARMAT SAS, this amount to be divided between the two beneficiaries in proportion to their respective share in the capital of the Company on the date of its creation. These royalties will be payable every 6 months within thirty days after the end of each six-month period, from the first marketing of the CARMAT Artificial Heart and until the expiry of the patents presented in Appendix 1 of the Contract.

The Company is also authorized to redeem at any time the right to benefit from these royalties for an amount of €30,000,000 reduced by the royalties already paid under this contract, this total amount being divided between the two beneficiaries in proportion to their respective share in the capital of the Company on the date of its creation. This amount of 30,000,000 euros is indexed to the Producer Price Index of the Business Services Industry - Euro-area orthopedic and orthopedic equipment.

The rights thus allocated to Professor Alain Carpentier and Matra Défense are not transferable.

As at December 31, 2018, the marketing of the CARMAT Artificial Heart did not begin, no royalty was paid by the Company under the Contract.

Signed in Neuilly-Sur-Seine and Paris,
Monday, March 11, 2019,

The statutory auditors

PRICEROOKERS COOPERS LISON CHOURAKI
AUDIT AUDIT

THIERRY CHARRON LISON CHOURAKI
Supplementary Information
6.1 AUTHOR OF THE REGISTRATION DOCUMENT

6.1.1 NAME OF THE AUTHOR OF THE REGISTRATION DOCUMENT

Stéphane Piat, CARMAT’s chief executive officer, is the author of the registration document.

6.1.2 DECLARATION OF THE AUTHOR OF THE REGISTRATION DOCUMENT

“Having taken all reasonable steps to verify the contents of this registration document, I affirm that the information contained therein is accurate to the best of my knowledge, and that no material information has been omitted.

I confirm, to the best of my knowledge, that the financial statements have been prepared in accordance with the applicable accounting standards and give a true and fair view of the Company’s financial situation and results, and that the information contained in the management report, for which a cross-reference table appears at paragraph 6.7.2 of this document: “Cross-reference table of the annual financial report”, gives a true and fair picture of changes to the business, results and financial situation of the Company and a description of the principal risks and uncertainties faced by the Company.

I have obtained a completion letter from the Statutory Auditors, in which they state that they have verified the information concerning the financial situation and the financial statements set out in this registration document, and that they have read the entire registration document.”

The financial information for the year ending December 31, 2018 set out in this Document de Référence was the subject of the auditors’ report which appears in paragraph 3.3 of this registration document, and which contains no observations.

The historical financial information as at December 31, 2016 and December 31, 2017 that is incorporated by reference into the present registration document was previously presented in the 2016 registration document and the 2017 registration document, which were filed with the Financial Markets Authority respectively on March 22, 2017 under number D.17-0200 and on March 22, 2018 under number D.18-0169, and was the subject of reports by the statutory auditors which contained no observations.”

Vélizy, Monday March 11, 2019

Stéphane Piat
Chief executive officer, CARMAT

6.2 STATUTORY AUDITORS

6.2.1 STATUTORY AUDITORS IN OFFICE

PricewaterhouseCoopers Audit, member of the Regional Auditors’ Association of Versailles.

Represented by Mr Thierry Charron

63, rue de Villiers – 92200 Neuilly-sur-Seine

Date of commencement of duties: appointed upon the incorporation of the Company on June 25, 2008.

Duration of current term: 6 financial years, following renewal of the mandate at the general meeting of June 24, 2015.

Expiry of current term: at the end of the general shareholders’ meeting to approve the accounts for the year ending December 31, 2020.

Lison Chouraki Audit, member of the Auditors’ Association of Paris

Represented by Ms Lison CHOURAKI

3, rue Anatole de la Forge – 75017 Paris

Date of commencement of duties: Wednesday, June 24, 2015.

Duration of current term: 6 financial years.

Expiry of current term: at the end of the general shareholders’ meeting to approve the accounts for the year ending December 31, 2020.
### 6.2.2 Alternate Auditors

**Mr Jean-Christophe GEORGHIOU**, member of the Regional Auditors’ Association of Versailles

63, rue de Villiers – 92200 Neuilly-sur-Seine

Date of commencement of duties: Wednesday, June 24, 2015.

Duration of current term: 6 financial years.

Expiry of current term: at the end of the general shareholders’ meeting to approve the accounts for the year ending December 31, 2020.

**Ms. Soulika BENZAQUEN**, member of the Auditors’ Association of Paris

5, rue de Prony – 75017 Paris

Date of commencement of duties: October 16, 2008.

Duration of current term: 6 financial years, following renewal of the mandate at the general meeting of June 24, 2015.

Expiry of current term: at the end of the general shareholders’ meeting to approve the accounts for the year ending December 31, 2020.

### 6.2.3 Statutory Auditors Who Resigned, Were Dismissed or Were Not Reinstated

Since their appointment, the statutory auditors and their substitutes have not been dismissed from their positions, nor have they resigned.

### 6.3 Information from Third Parties, Declarations by Experts and Declarations of Interest

None.

### 6.4 Publicly Accessible Documents

Copies of this registration document are available free of charge from the Company and from the Company’s website (www.carmatsa.com) and from the website of the French Financial Markets Authority (www.amf-france.org).

All documents which must be made available to shareholders (such as the articles of association, minutes of general meetings, historical financial information and the valuations and declarations made by an expert at the Company’s request included or referred to in this registration document) may be consulted at the Company’s registered office at 36, avenue de l’Europe – 78140 Vélizy-Villacoublay.

All regulatory information, as defined in Article 221-1 of the General Regulations of the AMF, is available on the Company’s website.
6.5 INFORMATION ON HOLDINGS

As at the date of this registration document, the Company did not have any holdings in the share capital of other companies.

6.6 RECENTS EVENTS

Since the end of the 2018 financial year, the Company has published the following press releases:

- On January 15, 2019, a press release entitled: CARMAT presents positive interim results of the first part of its pivotal study.


The full text of these press releases may be viewed on the Company’s website, http://www.carmatsa.com/fr/investisseurs/documentation/communiques-de-presse.

CARMAT plans to communicate on the overall progress of the CE marking or on the completion of significant milestones in the pivotal study. In accordance with good clinical practice and subject to regulatory requirements or special circumstances, CARMAT will not communicate individually on patient implantations and their health status.
# 6.7 CROSS-REFERENCE TABLES

## 6.7.1 CROSS-REFERENCE TABLE OF THE REGISTRATION DOCUMENT

<table>
<thead>
<tr>
<th>CHAPTER 1</th>
<th>PERSONS RESPONSABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 1.1. Name of the author of the registration document</td>
<td>Paragraph 6.1.1</td>
</tr>
<tr>
<td>• 1.2. Declaration of the author of the registration document</td>
<td>Paragraph 6.1.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 2</th>
<th>STATUTORY AUDITORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 2.1. Statutory auditors in office and alternate auditors</td>
<td>Paragraphs 6.2.1 and 6.2.2</td>
</tr>
<tr>
<td>• 2.2. Statutory auditors who resigned, were dismissed or were not reinstated</td>
<td>Paragraph 6.2.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 3</th>
<th>SELECTED FINANCIAL INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 3.1. Historical financial information</td>
<td>Paragraph 3.1.1</td>
</tr>
<tr>
<td>• 3.2. Interim financial information</td>
<td>Non applicable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 4</th>
<th>RISK FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 4. Risks relating to the Company’s activity</td>
<td>Paragraph 2.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 5</th>
<th>INFORMATION CONCERNING THE ISSUER</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 5.1. History and development of the company</td>
<td>Introduction</td>
</tr>
<tr>
<td>• 5.2. Investments</td>
<td>Paragraph 3.1.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 6</th>
<th>BUSINESS OVERVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 6.1. Main activities</td>
<td>Paragraph 1.3</td>
</tr>
<tr>
<td>• 6.2. Main markets</td>
<td>Paragraphs 1.1 and 1.2</td>
</tr>
<tr>
<td>• 6.3. Exceptional events</td>
<td>Non applicable</td>
</tr>
<tr>
<td>• 6.4. Degree of dependency on patents, licenses, manufacturing, sales or financial contracts or new manufacturing processes</td>
<td>Paragraph 1.5.4</td>
</tr>
<tr>
<td>• 6.5. Competitive position</td>
<td>Paragraph 1.2.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 7</th>
<th>ORGANIZATIONAL STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 7.1. Summary description of the group</td>
<td>Paragraph 5.1.5</td>
</tr>
<tr>
<td>• 7.2. List of major subsidiaries</td>
<td>Non applicable</td>
</tr>
</tbody>
</table>
CHAPTER 8. PROPERTY, PLANT AND EQUIPMENT

- 8.1. Main property, plant and equipment and significant expenses related thereto  Paragraph 3.1.8
- 8.2. Environmental issues that can influence the use of property, plant and equipment  Paragraph 3.1.8

CHAPTER 9. OPERATING AND FINANCIAL REVIEW

- 9.1. Financial condition  Paragraph 3.1.1
- 9.2. Operating result  Paragraph 3.1.1

CHAPTER 10. CAPITAL RESOURCES

- 10.1. Information on the capital  Paragraph 3.2.1
- 10.2. Cash flow  Paragraph 3.2.1
- 10.3. Borrowing conditions and financing structure  Paragraphs 3.1.1 and 3.1.10
- 10.4. Restrictions on the use of capital  Paragraph 3.1.10
- 10.5. Anticipated sources of finance  Paragraph 3.1.1

CHAPTER 11. RESEARCH & DEVELOPMENT, PATENTS AND LICENCES

- 11.1. Research & development  Paragraph 1.5.4
- 11.2. Patents, licences and brands  Paragraph 1.5.4

CHAPTER 12. TREND INFORMATION

- 12.1. Main trends since the end of the previous fiscal year  Paragraph 3.1.4
- 12.2. Known trend or event likely to influence the outlook of the issuer  Paragraph 3.1.4

CHAPTER 13. PROFIT FORECASTS OR ESTIMATES

- 13. Profit forecasts or estimates  Non applicable

CHAPTER 14. ADMINISTRATIVE, MANAGEMENT AND SUPERVISORY BODIES AND SENIOR MANAGEMENT

- 14.1. Administrative bodies  Paragraph 4.1
- 14.2. Conflicts of interest  Paragraph 4.2

CHAPTER 15. REMUNERATION AND BENEFITS

- 15.1. Remuneration and benefits in kind  Paragraph 4.5.1
- 15.2. Total amount of sums provisioned or otherwise booked for payment of pensions, retirement or other benefits  Paragraph 4.5.2

CHAPTER 16. BOARD PRACTICES

- 16.1. Date of expiration of current terms  Paragraphs 4.4.2 to 4.4.5
- 16.2. Service contracts with the members of the administrative, management and supervisory bodies  Non applicable
- 16.3. Audit committee and remuneration committee  Paragraph 4.3
- 16.4. Compliance with the corporate governance recommendations  Paragraph 4.4.1
CHAPTER 17. EMPLOYEES

- 17.1. Number of employees  
  Paragraph 4.6.1
- 17.2. Investment and stock options  
  Paragraph 4.6.2
- 17.3. Employee involvement in issuer’s capital  
  Paragraph 4.6.3

CHAPTER 18. MAJOR SHAREHOLDERS

- 18.1. Shareholders holding as at December 31, 2016  
  Paragraph 5.3.1
- 18.2. Existence of different voting rights  
  Paragraphs 5.3.1 and 5.3.2
- 18.3. Control of the issuer  
  Paragraph 5.3.3
- 18.4. Agreements that could bring about a change in control  
  Paragraphs 5.3.3 and 5.3.4

CHAPTER 19. RELATED PARTY TRANSACTIONS

- 19.1. Related agreements description  
  Paragraph 5.6.1
- 19.2. Special report of the statutory auditors on the regulated agreements  
  Paragraph 5.6.2

CHAPTER 20. FINANCIAL INFORMATION CONCERNING THE ISSUER’S ASSETS AND LIABILITIES, FINANCIAL POSITION AND PROFITS AND LOSSES

- 20.1. Historical financial information  
  Paragraph 3.2
- 20.2. Pro-forma financial information  
  Non applicable
- 20.3. Financial statements  
  Non applicable
- 20.4. Auditing of the annual historical financial information  
  Paragraph 3.3
- 20.5. Age of latest financial information  
  December 31, 2018
- 20.6. Interim and other financial information  
  Non applicable
- 20.7. Dividend policy  
  Paragraph 3.1.7
- 20.8. Legal and arbitration proceedings  
  Paragraph 2.7
- 20.9. Significant changes in the financial or trading position  
  Non applicable

CHAPTER 21. SUPPLEMENTARY INFORMATION

- 21.1. Share capital  
  Paragraph 5.2.1
- 21.2. Memorandum and Articles of Association  
  Paragraph 5.4

CHAPTER 22. IMPORTANTS CONTRACTS

- 22. Important contracts  
  Paragraph 3.1.10

CHAPTER 23. INFORMATION FROM THIRD PARTIES, DECLARATIONS BY EXPERTS AND DECLARATIONS OF INTEREST

- 23. Information from third parties, declarations by experts and declarations of interest  
  Paragraph 6.3

CHAPTER 24. DOCUMENTS ON DISPLAY

- 24. Publicly accessible documents  
  Paragraph 6.4

CHAPTER 25. INFORMATION ON HOLDINGS

- 25.1. Information on holdings  
  Non applicable
6.7.2 CROSS REFERENCE TABLE OF THE ANNUAL FINANCIAL REPORT

DECLARATION OF THE PERSON RESPONSIBLE FOR THE ANNUAL FINANCIAL REPORT

- Declaration of the person responsible for the annual financial report

MANAGEMENT REPORT

- Analysis of the financial situation
- Risks factors
- Information related to share capital and elements likely to have an influence in the case of a public offering
- Acquisition by the Company of its own shares
- Summary table of currently valid delegations made by the shareholders’ general meeting to the board of directors concerning capital increases
- Participation of employees in the capital
- Remuneration of corporate board members and management and list of mandates

FINANCIAL STATEMENTS AND REPORTS

- Corporate financial statements
- Auditors’ report on the corporate financial statements
- Consolidated financial statements
- Auditors’ report on the consolidated financial statements
- Auditors’ fees

6.7.3 CROSS REFERENCE TABLE OF THE CORPORATE GOVERNANCE REPORT

- List of mandates and functions fulfilled by each corporate officer during the financial year
- Regulated agreements
- Share capital authorized by the general meeting
- Choice in terms of the methods of exercise of the general management (Chairman vs Chief Executive)

6.8 GLOSSARY

Accident vasculaire cérébral (AVC)
Sudden neurological deficit of vascular origin caused by an infarctus or a hemorrhage in the brain.

Actuator
A device that controls the movement of a fluid or a solid.

Clinical Trial Authorization (CTA)
Authorization issued by the ANSM. One of two authorizations required to carry out biomedical research on humans in France, the other being that of the Ethics Committee (Comité de Protection des Personnes – CPP: see corresponding entry).

AFSSAPS
French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Aliments et Produits de Santé). This agency judges and monitors the safe use of health products, examines their quality in the laboratory and inspects their production, distribution and testing sites. It
also produces information campaigns to ensure the correct use of health products. It was replaced by the ANSM (see corresponding entry) through law n° 2011-2012 of December 29, 2011.

**Annuloplasty**
Intervention with the aim of correcting a mitral insufficiency linked to an expansion of the mitral annulus.

**ANSM**
French National Agency for Medicines and Health Products Safety (Agence nationale de sécurité du médicament et des produits de santé – ANSM). This is a French public institution whose objective is to evaluate the health risks of health products for humans. It has authority over the regulation of biomedical research.

**Platelet antiaggregant**
Drug preventing the blood platelets, which are partly responsible for the coagulation phenomenon (see corresponding entry) of blood, from sticking together and forming the beginning of a clot. The most well known is aspirin.

**Anticoagulant**
Drug limiting blood-clotting to avoid the formation of clots by acting on coagulation factors other than platelets (see previous entry). Their dosing is complicated: too much risks hemorrhages, not enough risks thromboembolic accidents. Their use at high doses is required for all implantable metallic or plastic devices which are not hemocompatible and are the source of many complications.

**Aorta**
The aorta is the largest artery of the body and allows oxygenated blood to be supplied from the left ventricle to all parts of the body.

**Pulmonary artery**
Arteries that carry blood from the heart to the lungs.

**Betablockers**
Drugs which reduce the cardiac rhythm and output to decrease blood pressure.

**Bioprosthetic (valve) or bioprosthesis**
Artificial valve manufactured from animal tissues in order to replace a failing heart valve. By extension, it refers to a medical device containing biological components.

**Bpifrance**
French public investment bank – Banque Publique d’Investissement française (which has incorporated the activities of Oseo Innovation, e.g. ANVAR, aiming to promote innovation through financial guarantees and partnerships).

**Coagulation (blood)**
Phenomenon of blood clot formation. It is the body’s normal reaction to stop a hemorrhage. Nevertheless, when clots form in the heart, a blood vessel or in a device, they may obstruct a blood vessel and can cause a pulmonary embolism or cerebrovascular accident.

**Total orthotopic artificial heart**
Artificial cardiac prosthesis (or total artificial heart – TAH) intended to completely replace the natural heart. It is different from ventricular assistance which functions in parallel to the diseased heart.

**Critical Event Committee (CEC)**
Committee consisting of members who are totally independent of the sponsor and study investigators, established as part of the ISO 13485 standard and the Good Clinical Practice (GCP) guidelines: its role is to review all adverse events, serious or otherwise, and to determine their causal link with the device under investigation.

**Ethics Committee (Comité de Protection des Personnes – CPP)**
Ethics committee whose role is to ensure that all biomedical research projects on humans carried out in France complies with the various considerations (medical, ethical and legal) aimed at ensuring the protection of the persons participating in the research.

**Safety Committee (DSMB)**
DSMB: Data Safety and Monitoring Board. Committee consisting of members who are totally independent of the sponsor and study investigators, established as part of the ISO 13485 standard and the Good Clinical Practice (GCP) guidelines: its role is to review all study data and to issue an opinion to the sponsor on whether to continue with inclusions in the clinical study.

**Compliance**
In medical terms, the ability of an organic cavity to change volume under the influence of a variation in pressure.

**Research Tax Credit (RTC)**
Financial aid created to encourage research and development efforts in companies.

**Diastole**
Relaxation phase of the muscle of a cardiac cavity that allows it to be filled.

**Diuretic**
Drug to remove excess fluids and, in this way, lighten the load on the heart and prevent pulmonary edema.

**Pulmonary embolism**
Situation where a blood clot blocks a pulmonary artery.

**Ex vivo**
Refers to tests which are performed on cadavers (see In
**Etiology**
Medical field which studies and analyses the causes of diseases.

**FDA – Food & Drug Administration.**
American regulatory agency that authorizes the marketing of drugs and medical devices in the United States.

**Altered ejection fraction:**
is termed terminal chronic heart failure affecting a patient whose ejection capacities are reduced to less than 40%.

**HDE – Humanitarian Device Exemption**
FDA approval process allowing a device to be marketed without evidence of effectiveness (only data relating to the safety of the device are required). The FDA calls a device approved in this way an HUD (Humanitarian Use Device : Device for compassionate use). This approval limits the number of devices that can be released on the US market to 4,000 per year.

**Red blood corpuscles**
Red blood cells.

**Hemocompatibility**
The biological compatibility quality of non-living materials used in a medical device in contact with blood and other biological organs.

**Hemolysis**
Destruction of red corpuscles with the release of hemoglobin into the blood plasma, thus reducing the capacity to transport oxygen.

**HUD**
See HDE.

**Hyperlipidemia**
Pathology referring to the dysfunctions caused by an increased level of fat in the blood.

**High blood pressure**
Cardiovascular disease characterized by an arterial pressure greater than the norm and causing an increase in the left ventricular volume.

**Hypertrophy**
Excessive growth of an organ or an element of the body.

**IDE – Investigational Device Exemption**
Approval process allowing a device to be used during a clinical study with the aim of generating the safety and efficacy data required to obtain a PMA.

**Immunosuppressant**
An agent that limits the immune reactions of the organism in order to reduce the rejection risks following the transplantation of a graft. The most well known is cyclosporin.

**Incidence**
The number of new cases of a disease observed during a given period and in a determined population. It differs from the prevalence, which is a status measurement which counts all the cases (new or not) at a given time.

**Myocardial infarction**
Necrosis (death) of part of the cardiac muscle. In plain language, heart attack. It occurs when one or more coronary arteries become blocked so that the cells of the myocardium (the muscle that makes up the heart), irrigated by this artery (or these arteries), are no longer oxygenated, thereby causing them to suffer (pain felt) and possibly resulting in their death.

**Angiotensin-converting enzyme (ACE) inhibitors**
Drugs reducing vascular resistance.

**Inotropic**
Drug increasing the contractility of the cardiac muscle. Dependence on inotropes marks the terminal phase of heart failure.

**In silico**
Refers to tests which are performed on computers and/or by digital simulation.

**Acute cardiac insufficiency**
Sudden incapacity of the heart to provide a sufficient blood flow to deal with the oxygen needs of the various organs. The symptoms are severe. It occurs either following a heart attack (see myocardial infarction) that caused lesions to an area of the heart, or following a sudden incapacity of the body to compensate for chronic cardiac insufficiency (see decompensation).

**Chronic cardiac insufficiency**
The incapacity of the heart to provide sufficient blood flow to deal with the oxygen needs of the various organs. The main causes of chronic cardiac insufficiency are angina and myocardial infarction, high blood pressure, valvular disease and degenerative diseases of the myocardium. In each of these cases, the result is the progressive destruction of the cardiac muscle with loss of its contractile power.

**In vitro**
Refers to tests which take place outside of the organism, in the laboratory or on a test bench. Originally, these tests were carried out in glass tubes.

**In vivo**
Refers to tests which are performed in living organisms. (also see ex vivo)

**Ischemia**
Decrease of the arterial blood flow to an organ.
Coronary disease
Decrease in the power of one or more arteries of the heart (or coronary arteries) and brings about angina and myocardial infarction (or heart attack).

CE marking
A declaration from the manufacturer certifying that the product complies with the applicable legal requirements and with the European directives (meeting a number of safety, efficacy and traceability of manufacture, etc. conditions).

Mitral (valve)
Cardiac valve which separates the left auricle from the left ventricle.

New York Heart Association (NYHA)
A scale based on symptoms that aims to quantify and monitor the functional impact (on activity) of cardiac insufficiency for an individual.

ISO standard
Standard created by the International Organization for Standardization (ISO) in order to guarantee reliable and good quality products and services.

Pulmonary edema
Invasion of the pulmonary alveoli by blood plasma that has passed through the wall of the capillaries (small vessels). Acute pulmonary edema (APE) is an absolute emergency and the common consequence of cardiac decompression.

Medical Board
Professional, administrative and legal body for the defense and regulation of the medical profession in France.

Auricle (atrium)
One of two small upper cavities in the heart which receives blood before passing it into the corresponding ventricle. Each auricle communicates with the corresponding ventricle through an atrioventricular valve, the tricuspid valve on the right and the mitral valve on the left.

Orthotopic
Refers to the transplantation of an organ to its normal anatomical location.

Chemically treated animal pericardium
A double-walled sack that contains the heart and the roots of the large blood vessels of animal origin (bovine, porcine or equine) treated with a sterilizing fixative, glutaraldehyde. It is known to be the least thrombogenic biomaterial and does not bring about the rejection phenomenon.

Fuel cell
Cell in which electricity is produced through the oxidation on an electrode of a reduction fuel (for example hydrogen) coupled with the reduction on the other electrode of an oxidant, such as oxygen from the air.

PMA – Post Market Approval
FDA approval process before the marketing of a device. It requires exhaustive safety and effectiveness data, notably by means of a clinical study (IDE).

Prevalence
Measurement of the state of health of a population at a given time which can be expressed as a percentage. For a given pathology, the prevalence is obtained by dividing the number of people affected at a given time by the size of the total population.

Product Lifecycle Management (PLM)
The software used to create and maintain the definition of products throughout their life cycle, from the issuing of the quotation until the end of its life. PLM covers the management of the definition of products, including configuration management, development management and project management.

Polyetheretherketone (PEEK)
A high performance plastic with a unique combination of properties, used for its strength in the medical, aeronautical, automobile, electronics, food and industrial sectors.

Polyurethane
A plastic material used in varnishes, paints and synthetic rubbers obtained by polymerization.

Proteinic Concerning proteins.

Pulsatile Animated by rhythmic pulsations of the heart beat.

Clean room
Room or suite of rooms where the concentration of particles is controlled in order to minimize the introduction, generation and retention of particles inside, generally with a specific industrial or research aim. Parameters such as temperature, humidity and relative pressure are also maintained at a precise level.

Whole human blood
This is blood with all its constituents, in particular plasma, red corpuscles, white corpuscles and platelets.

Septicemia
Serious generalized infection of an organism due to the discharges of pathogenic bacteria in the blood.

HIL simulator
A real time simulator that makes the computers believe they are navigating the actual system (Hardware in the Loop test principle).

Stasis
In medical terms, this refers to the abnormal stagnation of blood in an organ.

Systole
Phase of contraction of the muscle of a cardiac cavity
allowing ejection of the blood it contains.

**Telemetry**
Means of monitoring certain biological, particularly cardio-respiratory, parameters or technical parameters, at a distance.

**Thrombosis**
Obturation, through the formation of a clot (thrombus), of an arterial or venous blood vessel or of a cardiac cavity (embolism). The blood no longer flows and the organs are no longer supplied with it.

**Thromboembolic**
Ailment characterized by the formation of coagulated blood clots in veins (thrombus) which, upon detaching, risk causing embolisms (sudden blockages of blood vessels).

**Thrombogenic, thrombogenicity**
Refers to causing a thrombus (blood clot).

**Destination therapy**
Definitive implantation – Destination Therapy, as opposed to the pending transplantation indication (Bridged Therapy) Transplantation Surgical operation consisting of replacing a diseased organ with a healthy one.

**Vasodilator**
Drug which relaxes the blood vessels to increase the blood and oxygen flow to the heart without increasing its workload.